Glucose Tolerance by unknown
Glucose Tolerance
Edited by Sureka Chackrewarthy
Edited by Sureka Chackrewarthy
The progression from normal glucose tolerance (NGT) to type 2 diabetes involves 
intermediate stages of impaired fasting glucose (IFG) and impaired glucose tolerance 
(IGT), also known as prediabetes. The pathophysiology underlying the development 
of these glucose metabolic alterations is multifactorial, leading to an alteration in 
the balance between insulin sensitivity and insulin secretion. Our knowledge of the 
molecular basis of the signaling pathways mediating the various physiologic effects 
of insulin is steadily advancing. New substrates and signaling molecules have been 
identified and potential mechanisms involved in the pathophysiology of type 2 
diabetes have been revealed. This book summarises the current state of knowledge 
on the pathophysiology underlying the progression from normal glucose tolerance to 
type 2 diabetes and therapeutic advances in the improvement of glycaemic control in 
prediabetic and diabetic states.
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With the rapidly rising rates of diabetes has come refreshed research efforts to 
understand the biological process impacting glucose tolerance. Glucose tolerance 
depends on a complex interaction among insulin secretion from the β-cells, clearance 
of the hormone, and the actions of insulin to accelerate glucose disappearance and 
inhibit endogenous glucose production. The research approaches the topic  from 
several directions including insights into mechanisms of action, development of 
screening methods and novel therapeutic targets and the effectiveness of lifestyle and 
pharmacologic interventions in improving glucose tolerance. This book summarises 
the recent advances in research relating to glucose tolerance.  
The book is divided into four sections and each section subdivided into individual 
chapters contributed by experts in that particular field. The progression from normal 
glucose tolerance to impaired glucose tolerance known as a prediabetic state, and then 
to overt diabetes is reviewed in the first section of this book. Usefulness of the oral 
glucose tolerance test in basic and clinical investigations and the effectiveness of 
interventions to prevent or delay the progression from a prediabetic to a diabetic state 
as demonstrated by findings of clinical trials are included in this section. 
The second section reviews the potential mechanisms associated with insulin 
resistance leading to impaired glucose tolerance and type 2 diabetes. Our knowledge 
of the molecular basis of the signaling pathways mediating the various physiologic 
effects of insulin is steadily advancing. New substrates and signaling molecules have 
been identified and potential mechanisms involved in the pathophysiology of type II 
diabetes have been revealed. Each chapter in this section is an updated account of the 
advances in this field of research. 
Third section reviews current evidence on the role of dietary constituents on insulin 
resistance and glycaemic control. Type of dietary fat and fatty acid composition in the 
modern diets contributing to the development of obesity and altered insulin action are 
reviewed. Further, research findings which demonstrate the effects of dietary sugars 
on postprandial glucose uptake and insulin secretion are included in this section. 
Therapy of type 2 diabetes is also advancing and many new avenues of research have 
developed and established areas have taken new directions. The fourth section of this 
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book includes several reviews on selected novel pharmacologic compounds with 
antidiabetic potential from natural sources. Their effectiveness in potentiating insulin 
action and improving glucose tolerance are discussed.  In addition a review on 
experimental animal models extensively used in type 2 diabetes research and a 
mechanistic model of insulin dynamics with relevance to identifying new therapies is 
included to allow the reader to gain insights into potential new therapeutic targets. 
This book is a team product, combining input from many individuals whose 
contributions are much appreciated. Each chapter is written as a focused review 
accompanied by extensive and updated reference lists providing a resource for further 
in-depth researching of the area of interest. All the contributing authors and co-
authors are acknowledged for their scholarly approach and willingness to participate 
in this endeavor. Without their contributions this book could not have been 
successfully completed.   
 
Sureka Chackrewarthy, PhD 
Department of Biochemistry & Clinical Chemistry 
Faculty of Medicine, 
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1. Introduction 
Metabolic syndrome is a cluster of abnormalities that are often associated with prediabetes, 
a condition present prior to the onset of diabetes (1). The hallmark of both metabolic 
syndrome and prediabetes is insulin resistance, an impairment of insulin action within 
tissues at the level of the insulin receptor and subsequent cellular events. Insulin resistance 
resides mainly within muscle, liver and adipose tissues (2). Type 2 diabetes arises from a 
combination of insulin resistance and a relative impairment of insulin secretion in response 
to meal ingestion. Type 2 diabetics differ in the relative contributions of insulin resistance 
and impaired insulin secretion to the development of hyperglycemia (3). Some diabetic 
patients predominantly have a secretory defect, while others may have normal or even 
excessive insulin secretion. The latter subgroup of diabetics has insulin resistance as the 
primary defect in their glucose homeostasis. Hyperglycemia by itself does not indicate 
whether there is an insufficiency of insulin secretion or a deficit in insulin action. Type 2 
diabetics lie along a continuum between these two extremes, with a variable mix of 
secretory and cell signaling deficits. During the progression from normal glucose tolerance 
to impaired glucose tolerance to prediabetes to diabetes to severe diabetes over a number of 
years, individuals show a progressive decline in pancreatic insulin secretion in response to a 
glucose load(3). Insulin resistance may show progressive deterioration, but generally insulin 
resistance is the major defect early in the development of diabetes whereas late in the course 
of the disease pancreatic islet cell failure is more notable. 
In Type 2 diabetes, determining the relative contribution of insulin secretion versus action 
has clinical implications. Knowledge of the predominant abnormalities in glucose 
homeostasis may well affect the choice of therapeutic agent for the treatment of diabetes. For 
example, metformin acts to reduce insulin resistance, particularly within the liver (4), and 
therefore is of considerable utility in early stages of Type 2 diabetes where insulin resistance 
 The Author(s). Licensee InTech. This chapter is d tributed under the terms of he Cr ative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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is predominant. Sulfonylureas such as glyburide, in contrast, promote the secretion of 
endogenous insulin in response to a meal (5) and might therefore be more useful when 
insulin secretion is declining.  
However, some have alleged that sulfonylureas may accelerate beta cell exhaustion over 
time and thereby accelerate the deterioration of diabetes (5). The incretin mimetic agents 
such as exendin and the DPP-IV inhibitors also promote insulin release from pancreatic 
islets but may also be cytoprotective within pancreatic islets and thereby delay the 
progression of diabetes (6). As shown in the Results section below, DPP-IV inhibitors are 
also effective in reversing metabolic syndrome prior to the onset of diabetes. 
Diabetes typically manifests itself in the context of other abnormalities, especially the 
principal components of metabolic syndrome, namely hypertension and hyperlipidemia (2). 
The SHROB or Koletsky rat is a leading animal model of metabolic syndrome (7;8), as 
summarized in Table 1.  
 
Trait SHR(7) SHROB(7) Human Metabolic 
Syndrome(9) 
Hypertension SBP = 195 SBP = 185 SBP > 130 
Insulin resistance Absent Profound Present 
Fasting glucose Normal Normal to slightly 
high 
Normal to slightly 
high 
Glucose tolerance Normal Impaired Impaired 
Triglycerides Absent >200 mg/dL >150 mg/dL 
Total Cholesterol Normal Slightly elevated >200 mg/dL 
Visceral obesity Absent Present Present 
Fasting insulin Normal Elevated 20-fold Elevated 
Fasting glucagon Normal(10) Elevated 2-fold(10) Elevated(11;12) 
Table 1. Characteristics of human metabolic syndrome compared with the SHROB model 
Each of the primary abnormalities expressed in human metabolic syndrome are present in 
the SHROB rat. Other obese rodents fail to show these characteristics. In particular, the 
SHROB is only rodent model that incorporates hypertension and related cardiovascular 
changes together with insulin resistance and abnormal glucose homeostasis. The SHROB 
has marked hyperinsulinemia without hyperglycemia. Other rodent models show diabetes 
that ranges from mild (Zucker fatty rat) to fulminant Type 2 diabetes (db/db mouse) (8;13).  
In contrast, the SHROB is a model for the prediabetic state accompanied by hypertension 
and hyperlipidemia as well as obesity. Prediabetes can lead to secondary disease 
complications even in the absence of fasting hyperglycemia (14). The SHROB model can be 
used to understand the complex physiologic processes that contribute to metabolic 
syndrome. Dietary and pharmacologic interventions in this model may help identify the 
best prevention strategies and treatment combinations for metabolic syndrome as well. 
 
The Glucose Tolerance Test as a Laboratory Tool with Clinical Implications 5 
Premise: The oral glucose tolerance test (OGTT) is vital for the characterization of metabolic 
syndrome, the natural progression from prediabetes to Type 2 diabetes, and characterization 
of the metabolic actions of cardiovascular and metabolic drugs. Although the OGTT is 
seldom used as a diagnostic test for Type 2 diabetes (15), it is extensively used as a sensitive 
indicator of gestational diabetes (16). As we demonstrate in the present work, the OGTT is 
an important laboratory tool in preclinical studies. In both humans and animals, the OGTT 
provides an indication of the relative roles of insulin secretion and insulin resistance in the 
progression of glucose intolerance. The impact of diet composition and pharmacologic 
interventions can be tested and possible target tissues identified. This in vivo, real time, 
whole body test can be used to identify the best treatments and possibly delay or prevent 
development of Type 2 diabetes. 
Insulin release in response to a glucose load occurs in two phases in humans and in rodents. 
The early phase peaks within the first 15-30 min and is responsible for limiting the initial 
rise in glucose upon meal ingestion. The late phase of insulin secretion occurs later than 30 
min after a meal, and may persist for several hours. This delayed burst of insulin secretion is 
responsible for returning glucose to baseline fasting levels. In the face of insulin resistance, 
the late phase of insulin secretion persists for an extended period and contributes to 
excessive insulin levels even after a return to the fasted state, resulting in fasting 
hyperinsulinemia (2). 
Insulin and glucagon, derived from beta and alpha pancreatic islet cells, respectively, are the 
two most important hormones involved in glucose homeostasis. Together they determine 
whether food is utilized immediately for energy or put into storage for later use. 
Abnormalities in the release or actions of either or both of these hormones can be involved 
in the development of hyperglycemia and diabetes. Glucagon levels may influence glucose 
tolerance (11), although this hormone is seldom considered in the context of oral glucose 
tolerance. Glucagon raises glucose levels, and a higher level of insulin is needed to control 
glucose in the presence of glucagon (10). 
 The phases of insulin secretion in response to the oral ingestion of glucose are cephalic, 
gastric and intestinal. The cephalic phase begins with the sight of food and is strongly 
triggered by sweet taste receptors on the tongue (17). The cephalic and gastric phases are 
considered part of the early response, while the intestinal response is later. Interestingly, 
sweet taste receptors are also present in the small intestine and may shape the physiological 
response to carbohydrates (18;19). Sweet taste receptors in the small intestine not only 
regulate the rate of glucose absorption through glucose transporters (19), but also trigger the 
release of GLP-1 and cholecystokinin (18). GLP-1 and gastric inhibitory peptide (GIP) are 
incretins, gut hormones secreted from enteroendocrine cells into the blood in response to 
meal ingestion. Importantly, incretin secretion only occurs with oral ingestion of nutrients. 
Incretin secretion is not triggered in response to intravenous feeding, as the intestinal 
receptors are not activated when glucose is delivered through the circulation. Indeed, 
incretins were discovered as a result of the observation that the insulin stimulation and 
glucagon suppression by glucose was much greater when glucose was delivered orally or 
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into the gut rather than by any other route (20). Thus, the normal physiological response to 
food ingestion can only be elicited through the oral route of administration. 
Both incretins are rapidly deactivated by a degradative enzyme called dipeptidyl peptidase 
4 (DPP4) (21). Since 2005, two new classes of drugs based on incretin action have been 
approved for Type 2 diabetes therapy: incretin analogs and incretin enhancers, which inhibit 
DPP4. DPP4 inhibitors act by slowing the breakdown of endogenous incretin peptides, thus 
extending their actions. 
An OGTT is used clinically to diagnose impaired glucose tolerance and as a standardized 
test of carbohydrate metabolism and insulin secretion. The test is based on oral 
administration of glucose and subsequently following plasma glucose and insulin levels 
over time. A prolonged elevation (>120min) in both plasma glucose and insulin constitutes 
impaired glucose tolerance and insulin resistance and can be used in conjunction with 
fasting hyperglycemia in diagnosing Type 2 diabetes. A prolonged elevation in glucose with 
minimal changes in insulin secretion would be suggestive of impaired glucose stimulated 
insulin secretion. This procedure is directly applicable to rats and mice. 
The OGTT was introduced first as a diagnostic tool for diabetes. Later studies focused on 
identifying patterns of the glucose curve during the OGTT that predicted the onset of 
diabetes years later. An OGTT profile during pregnancy can accurately predict which 
women will later develop Type 2 diabetes when they reach middle age (22). Clinically, the 
use of OGTT has fallen off because of the need for glucose loading, which many patients 
perceive as unpleasant. Furthermore, 4 to 6 separate blood samples are necessary. In the 
modern clinic, the OGTT has generally been supplanted by measuring fasting blood 
glucose, random post prandial blood glucose and glycosylated hemoglobin values. 
The OGTT is influenced by many factors including age, diet, state of health, GI function, 
medications and emotional state. As age increases, the excursion of glucose during the 
OGTT progressively increases as a consequence of declining insulin sensitivity of target 
tissues, such as in muscle, fat and liver. The dose of glucose and standardization of 
measured responses including glucose levels and insulin have been debated over the years. 
When used in large population studies the OGTT test overestimates the prevalence of 
diabetes. In other words, it has a high false positive rate. 
The intravenous glucose tolerance test is not sensitive for the diagnosis of diabetes and is 
used mainly as an assessment purely of glucose disposal i.e. the time required for glucose to 
clear circulation. It can be used as an index of residual beta cell function as well. The test 
bypasses the GI tract and eliminates the influence of intestinal hormones, especially 
incretins, on insulin and glucagon levels and subsequent glucose disposal. The endocrine 
system of the small intestine is important in the development of diabetes and has spawned 
new drugs to treat diabetes. The relative advantages of OGTT over other methods of 
assessing glucose homeostasis in the laboratory are summarized in Table 2. 
The hyperinsulemic clamp has been described by some authors as “the gold standard” yet 
has a number of limitations. Indwelling catheters are required, necessitating some trauma. 
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Even with time for recovery, glucose homeostasis can be altered by ongoing wound healing 
and pain. For highly insulin resistant individuals, insulin must be elevated to very high 
levels. For example, insulin levels in SHROB rats must be raised to levels that would result 
in convulsions and death from hypoglycemia in a lean animal (results not shown). The 
OGTT allows all of the normal stages of insulin secretion and glucose processing to take 
place in sequence without causing stress or trauma to the subject. 
 
 OGTT IVGTT Hyperinsulinemic 
Clamp 
Incorporates cephalic phase Yes No No 
Incorporates gut-pancreatic axis Yes No No 
First pass through liver and portal circulation Yes No No 
Raises insulin to nonphysiologic levels No No Yes 
Requires surgery No Yes Yes 
Table 2. Advantages of OGTT over IVGTT and hyperinsulinemic clamps 
2. Methods  
Special diets are fed for 30 to 90d prior to the OGTT. Antihypertensive or antidiabetic 
medications are given in the drinking water or incorporated into the food and given for 42 
to 90d. We carry out the OGTT by fasting animals for 18h, taking a baseline 200 µL blood 
sample from the tail under local anesthesia, and then gavaging with 12 mL/kg of a 50% 
glucose solution, which delivers 6g of glucose per kg of body weight. Blood samples are 
taken 30, 60, 120, 180, 240 and 360 minutes after the glucose meal and analyzed for blood 
glucose with a clinical meter. Plasma samples are frozen for later analysis of rat insulin by 
ELISA. The 240 and 360 minute time points are not typically used in OGTT, but the SHROB 
is so profoundly glucose intolerant that extended sampling is required to reliably establish 
the area under the curve. Area under the curve is determined for each subject using curve 
fitting software (Prism 5.0, GraphPad software, San Diego, CA).  
Procedures: 
1. Weigh the rats to the nearest 0.5g and place them into clean cages with new bedding. 
Rodents are copraphagic, so new cages will assure true fasting conditions over the next 
18h.  
2. Dextrose (D-glucose) solution: A 50% dextrose solution is made by weighing out the 
needed amount of dextrose and heating and stirring with water (be sure not to overheat 
solution or caramelization will take place). For example, if you need 50mL of workable 
solution, you would weigh out 25g of dextrose and add that to approximately 28mL of 
water then stir and heat until dextrose is in solution. Once in solution, pour into a 
graduated cylinder and dilute up to 50mL and allow cooling at room temperature prior 
to using. 
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3. Dose: We administer a 6g/kg body weight of a 50% dextrose solution for our studies to 
assure a significant challenge to glucose metabolism, but 2-4g/kg body weight is 
frequently reported by others. 
4. Oral gavaging: Discharge rate should be slow so as not to cause a pressure induced 
“dumping syndrome”. This will be apparent about 30-60min after gavaging with the 
presence of diarrhea.  
5. Blood Collection: This is done by tail bleed. We recommend that blood be collected at 
least five times: 0, 30, 60, 120 and 180 min. However, we collect additional time points 
of 240 and 360 min in our SHROB rats, as this represents the delayed insulin peak 
response and allows an accurate estimate of the area under the curve for glucose, as 
glucose returns to fasting levels only very slowly. We also dip the cut tail tip into the 
local anesthetic, bupivacaine (Marcaine, 0.5%), after the first tail bleed and after each 
sample thereafter to minimize pain associated with the procedure. 
6. Glucose measurement: A clinical glucose meter (One Touch Ultra, Lifescan) is used 
with 5 µL of whole blood. 
7. Insulin and glucagon ELISA: Rodent-specific kits are available from several suppliers, 
including ALPCO (Salem, NH). The coefficient of variation is less than 10% in repeat 
measures and the sensitivity is 0.1 ng/mL. Plasma samples from our insulin resistant 
rats must be diluted 1:10 in assay buffer before addition to the assay plate. 
8. Statistical analysis: Glucose and insulin data are processed through an analysis of 
variance with repeated measures to determine treatment effects, time effects, and 
treatment by time interaction terms by using the Prism 5.0 statistical and graphing 
program (GraphPad Software, Sand Diego, CA). Newman-Keuls post-hoc tests are used 
to determine significance of individual comparisons. Area under the curve 
measurement are also determined for each animal, expressed as mg*min/dL for glucose 
and ng*min/mL for insulin, and analyzed as a single datum. 
3. Results 
We review data from several contrasting interventions in SHROB rats, which includes diets 
and drug treatments with both beneficial and harmful effects on glucose tolerance. We 
contrast the use of OGTT with other measures such as fasting glucose and glucose to insulin 
ratios.  
A relatively normal OGTT profile is illustrated by the data from lean SHR. Glucose starts at 
a low fasting level and rises only to a maximum of about 100 mg/dL at 60 min. Insulin levels 
are low in the fasted state and show a maximum 4-fold rise around 60 min and then return 
to baseline by 240 min. Not shown is the profile for normotensive Wistar or Sprague-
Dawley control rats, which would show a similar profile but with even lower levels of 
insulin owing to a small amount of insulin resistance associated with hypertension (23).  
SHROB on a control diet show a normal fasting level of glucose, but glucose ascends to a 
much higher peak around 60 min and takes much longer to return to baseline. Fasting 
insulin levels in the SHROB are 40-fold elevated compared to lean SHR littermates, and the 
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further rise in insulin in response to a glucose load is delayed and prolonged. Dietary obese 
genetically lean SHR rats are only about 25% overweight compared to lean SHR on normal 
chow, in contrast to genetically obese SHROB which are about 100% overweight compared 
to lean SHR on normal chow (24). Despite the lesser degree of obesity, the dietary obese 
genetically lean SHR showed about the same degree of glucose intolerance as SHROB. 
Insulin levels at fasting and after the glucose load were unchanged relative to the SHR fed 
control diet. SHROB fed a high sucrose diet showed unchanged glucose tolerance. In 
contrast, the insulin response to a glucose load was greatly increased and prolonged beyond 
that observed for SHROB on a control diet. To our knowledge, the insulin levels in sucrose-
fed SHROB during the OGTT, which exceed 100 ng/mL, are the highest ever recorded in a 
rodent. The data in Figure 1 illustrate the value of the OGTT. High sucrose input affected 
glucose levels in genetically lean animals without affecting insulin. In contrast, in genetically 
obese SHROB rats, high sucrose affected insulin without affecting glucose levels. None of 
this could be learned by obtaining fasting levels alone. 
 
Figure 1. Glucose tolerance test: SHR versus SHROB on normal versus high sucrose diets. A: Glucose. 
B: Insulin. SHR were fed a supplementary sweet drink to induce dietary obesity in these genetically 
lean rats. SHROB were fed a high sucrose diet (70% sucrose by weight).  
Figure 2 includes only the genetically obese SHROB fed a control diet, which were given 
vehicle or drug in their drinking water. Two oral antihyperglycemic agents, the insulin 
secretagogue glyburide (mg/kg) and the DPP4 inhibitor sitagliptin (mg/kg), were contrasted 
with the widely used antihypertensive hydrochlorothiazide (50 mg/kg). None of the agents 
had any effect on fasting glucose. The two antihyperglycemic agents, as expected, lowered 
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the excursion of glucose in response to an oral load. The antihypertensive agent 
dramatically increased glucose levels following the oral load, with glucose rising to levels 
associated with frank diabetes (>400 mg/dL).  
 
Figure 2. Glucose tolerance test: untreated SHROB versus SHROB treated with antihyperglycemic 
agents and one antihypertensive agent. A: Glucose. B: Insulin 
Fasting insulin levels in vehicle controls (Figure 2) were very high, similar to those observed 
before in Figure 1. The oral antihyperglycemic drugs both reduced fasting insulin levels, 
although not to levels seen in lean SHR. Remarkably, hydrochlorothiazide further elevated 
fasting insulin. The post-load insulin curve in glyburide treated SHROB closely paralleled 
vehicle treated controls, but at a lower level. The insulin curve for the sitagliptin treated 
group showed a higher net response to the glucose load, especially at 30 min. This is 
consistent with the hypothesized role of incretin hormones in facilitating the insulin 
response to glucose. Hydrochlorothiazide greatly increased insulin levels, reminiscent of the 
effect of dietary sucrose in Figure 1.  
Other hormones and metabolites can be measured during OGTT, not just glucose and 
insulin. Figure 3 illustrates changes in plasma glucagon during the first hour after an oral 
glucose load. Homeostasis predicts that glucagon would be high in the fasting state and 
decline when the fed state is restored. Glucagon levels are unchanged in SHR animals, 
possibly because the fall in glucagon is mainly mediated by gut hormones such as GLP-1 
and GIP which are secreted later after the load has reached the distal small intestine where 
the L-cells that secrete these hormones reside. Remarkably, SHROB rats show a dramatic 
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increase in glucagon from already high fasting levels. This paradoxical increase in glucagon 
in response to a glucose meal has been reported in humans with Type 2 diabetes (12). 
 
Figure 3. Changes in plasma glucagon level during an OGTT in SHROB and lean SHR littermates.  
Besides glucose, another plasma substrate that can be assayed is the level of free fatty acids. 
We found that free fatty acids fall after glucose load in lean SHR, indicating reduced 
lipolysis when an abundant supply of glucose is present (10). Remarkably, the level of free 
fatty acids in SHROB rats stayed at the elevated level found in fasting (data not shown). This 
finding illustrates the multiple abnormalities in the whole body handling of metabolic fuels 
that can be uncovered in an OGTT.  
4. Discussion 
These data show that OGTT is much more sensitive than are other measures in identifying 
the loci of insulin resistance and its modulation by different interventions. Moreover, the 
results of OGTT testing in the SHROB model tracks closely with efficacy against metabolic 
syndrome and Type 2 diabetes in clinical trials. Thus, the OGTT yields laboratory data with 
greater relevance to the prevention and treatment of human disease. 
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The glucose tolerance test determines the rate at which glucose is cleared from blood. 
Glucose is administered either orally or intravenously and serial samples of glucose, insulin 
and glucagon are measured over time. Hypoglycemic medications used to treat diabetes 
have been developed that modify the actions of glucagon and insulin directly. Medications 
that are used to treat high blood pressure and lipid disturbances can also modify the 
responses to these hormones, sometimes improving the clearance of glucose and sometimes 
making it worse. Comparisons of the responses of glucose, insulin and glucagon levels 
during glucose tolerance testing with and without medications used to treat metabolic 
syndrome will lead to a better understanding of what combinations of these medications are 
the most beneficial and least toxic. 
The current literature has many examples of inadequate assessments of glucose metabolism. 
Many authors report only on “random glucose” values, taken without regard to whether the 
animal had just eaten or had voluntarily fasted for several hours. If food is available ad 
libitum, then some animals may be postprandial and others will be fasted as a result of their 
sleep cycle. The glucose and insulin values obtained under these circumstances are highly 
variable and often irreproducible. A somewhat better approach is to determine fasting 
glucose and insulin levels. Various ratios between glucose and insulin can be calculated, 
with the most popular being the Homeostasis Model Assessment (HOMA). The 
mathematical derivation of the HOMA equation is sophisticated, but it is still based on only 
two numbers: fasting glucose and fasting insulin. The OGTT, by contrast, reflects the in vivo 
physiological response to a glucose meal and integrates the homeostatic response to a meal 
over time. Thus, the OGTT more accurately mirrors daily life. 
The OGTT is useful as a research tool. It does allow for a more physiologic assessment of 
metabolism as it assesses a global response to the disposition of a meal. Neurologic and 
hormonal responses that influence the function of the gastric tract, absorption, 
transportation and processing of food in the liver and transport to and from storage tissue 
can be assessed. These include newly recognized hormones secreted from the GI tract in the 
presence of food known as incretins and previously recognized hormones such as insulin 
and glucagon. The OGTT is particularly useful in characterizing the actions of drugs which 
can be either beneficial or detrimental to glucose homeostasis. 
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1. Introduction 
Type 2 diabetes results from the interaction between genetic predisposition, behavioral and 
environmental risk factors (1). There is strong evidence that modifiable risk factors such as 
obesity and physical inactivity are the main non-genetic determinants of the disease(2). New 
figures indicate that the number of people living with diabetes is expected to rise from 366 
million to 552 million by 2030, if no urgent action is taken (3).  
Impaired glucose tolerance (IGT) is an intermediate category between normal glucose 
tolerance and overt diabetes, and it can be identified by glucose tolerance test. Subjects with 
IGT have an increased risk of type 2 diabetes (4), and consequently many trials of 
interventions for the prevention of type 2 diabetes have focused on such individuals. By 
2025, the number of people with IGT is projected to increase to 418 million, or 8.1% of the 
adult population (5).  
Interventions to delay or even to prevent type 2 diabetes have a potential to improve the 
health of the population and reduce the burden of healthcare costs. The interventions 
assessed have been diverse and include pharmacological and lifestyle changes.  
Abnormal glucose tolerance is also a well-known risk factor of incident diabetes (6). The 
main known predictor of incident diabetes is the presence of insulin resistance. Direct 
measures of insulin sensitivity can be laborious, complicated, and expensive to be applicable 
for routine use in the general population as a screening tool. Markers like HOMA-IR index 
or 2-hour post-challenge glucose levels are being used to diagnose insulin resistance. 
IGT when compared to impaired fasting glucose (IFG) is a stronger risk factor in predicting 
the onset of diabetes (7). Diagnosing of IGT requires oral glucose tolerance test (OGTT), a 
test of high specificity (92%) but low sensitivity (52%) in the prediction of diabetes (8). The 
World Health Organization (WHO) criteria including either IFG (≥6.1 mmol/L and <7.0 
mmol/L and 2-h plasma glucose concentration <11.1 mmol/L during the oral glucose 
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tolerance test) or IGT test (<7.0 mmol/L and 2-h plasma glucose concentration ≥7.8 mmol/L 
and <11.1mmol/L) are used to diagnose people with IGT (9).  
The clinical characteristics associated with type 2 diabetes risk include obesity and 
overweight, age (the risk rises steadily from puberty into geriatric years), a history of 
gestational diabetes, polycystic ovary syndrome, a family history of type 2 diabetes, and 
membership in certain high-risk minority groups: African American, Hispanic, Native 
American, and Asian-Pacific Islanders (6). The ADA recommends screening youth and 
adults with multiple risk factors for type 2 diabetes; fasting plasma glucose is the preferred 
first-line test (10, 11). 
People with metabolic syndrome are at a high risk to develop diabetes and ischemic 
atherosclerotic diseases (7). Several studies have shown that metabolic syndrome is a strong 
predictor of incident diabetes (12-14). 
The Insulin Resistance Atherosclerosis Study (IRAS) assessed a series of risk factors and 
identified five significant risk factors for the development of type 2 diabetes including high 
plasminogen activator inhibitor 1 (PAI-1), hypertension (HTN), high triglycerides (TG), low 
high-density lipoprotein (HDL), and IGT. The incidence of type 2 diabetes increases with the 
increasing number of risk factors, 5% with 0 risk factors to 50% when all 5 risk factors are 
present (p<0.001) (15). 
Every year about 5%-10% of people with IGT will develop diabetes and acquire the disease 
burden related to its diagnosis symptoms, need for surveillance for chronic consequences 
and associated costs, and increased risk of several chronic diseases (16).  
The purpose of this article is to review available evidence on lifestyle and pharmacological 
intervention on the prevention or delay of the onset of type 2 diabetes and adapting these 
lessons from clinical trials to clinical practice. 
2. How we can prevent type 2 diabetes? 
The high economic and social costs of type 2 diabetes mellitus and its rising prevalence 
make a compelling case for its prevention (17). The most vulnerable groups to have diabetes 
are people with IFG and IGT and in the mean time they present the potent groups of 
preventing or delaying the progression to type 2 diabetes mellitus. These two groups are 
recognized as prediabetic states by the ADA (11). 
3. Non pharmacological intervention  
Four large prospective studies demonstrated that a treatment regimen using diet plus 
exercise reduces IGT progression to type 2 diabetes (18-21). Factor analysis showed that both 
insulin resistance and insulin secretion had a significant association with the development 
of diabetes, and lifestyle intervention was more effective in subjects with lower insulin 
resistance and higher insulin secretion (13).  
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3.1. Lifestyle trials - diet and physical activity 
Overweight, obesity and physical inactivity are the major risk factors for developing type 2 
diabetes mainly through insulin resistance. Therefore, interventions in  weight reduction 
were shown to enhance insulin sensitivity and improve glucose tolerance in nondiabetic and 
diabetic subjects.  
In the DaQing study, 577 subjects with IGT as defined by the WHO criteria were followed 
over 6 years. They were randomized into diet-only, exercise only, diet plus exercise groups, 
and a control group, which were associated with a 31% (p≤0.03), 46% (p≤0.0005) and 42% 
(p≤0.005) reduction in the risk of developing diabetes, respectively, when compared to the 
control group. Factor analysis showed that both insulin resistance and insulin secretion had 
a significant association with the development of diabetes, and lifestyle intervention was 
more effective in subjects with lower insulin resistance and higher insulin secretion 
(15,21,22). 
The Swedish Diabetes Prevention Study was the first individually randomized clinical trial, 
where 522 middle-aged overweight subjects (body mass index/BMI >25) with IGT were 
randomized to the control group or intervention group and followed over a mean of 3.2 
years. The intervention group received individual counseling regarding diet and exercise 
and lost 4.2±5.1 kg versus 0.8±3.7 kg in the control group, which translated to a 58% (p≤0.001) 
reduction in the risk of developing diabetes and was directly associated with changes in 
lifestyle (18,23). 
The Diabetes Prevention Program (DPP) study was a double-blind randomized controlled 
trial (RCT) involving a larger number of subjects, 3234 with IGT or IFG with BMI >24 kg/m2 
(>22 in Asian population) followed over 2.8 years. They were randomized to standard 
lifestyle recommendations with placebo or with metformin or to an intensive program of 
lifestyle modifications (19). The incidence of developing diabetes was 4.8 cases versus 11 
cases per 100 person years for 3 years in the intensive lifestyle and placebo groups, 
respectively, which was a 58% lower incidence of developing diabetes in the intensive 
lifestyle group. In this study these changes were observed in all of the various ethnic and 
racial subgroups, and at least 50% of the lifestyle group had achieved the goal of >7% of 
weight reduction. 
The Look AHEAD trial, which, like DPP, demonstrated impressive weight loss at year 1, 
was also followed by significant weight regain over the subsequent 3 years despite 
continued intensive intervention and follow-up (24). 
In a recent community study in Finland, 2,797 high-risk individuals were enrolled in a 
diabetes prevention program designed to achieve 5–7% body weight loss. Only 
approximately one-third of participants were able to successfully decrease body weight by 
2.5% (25). 
From above mention studies it is obvious that successful weight reduction alone is not 
sufficient to prevent diabetes in a large percentage of individuals. The main issues is that it 
is difficult to maintain weight without an intervention program.  
 
Glucose Tolerance 16 
tolerance test) or IGT test (<7.0 mmol/L and 2-h plasma glucose concentration ≥7.8 mmol/L 
and <11.1mmol/L) are used to diagnose people with IGT (9).  
The clinical characteristics associated with type 2 diabetes risk include obesity and 
overweight, age (the risk rises steadily from puberty into geriatric years), a history of 
gestational diabetes, polycystic ovary syndrome, a family history of type 2 diabetes, and 
membership in certain high-risk minority groups: African American, Hispanic, Native 
American, and Asian-Pacific Islanders (6). The ADA recommends screening youth and 
adults with multiple risk factors for type 2 diabetes; fasting plasma glucose is the preferred 
first-line test (10, 11). 
People with metabolic syndrome are at a high risk to develop diabetes and ischemic 
atherosclerotic diseases (7). Several studies have shown that metabolic syndrome is a strong 
predictor of incident diabetes (12-14). 
The Insulin Resistance Atherosclerosis Study (IRAS) assessed a series of risk factors and 
identified five significant risk factors for the development of type 2 diabetes including high 
plasminogen activator inhibitor 1 (PAI-1), hypertension (HTN), high triglycerides (TG), low 
high-density lipoprotein (HDL), and IGT. The incidence of type 2 diabetes increases with the 
increasing number of risk factors, 5% with 0 risk factors to 50% when all 5 risk factors are 
present (p<0.001) (15). 
Every year about 5%-10% of people with IGT will develop diabetes and acquire the disease 
burden related to its diagnosis symptoms, need for surveillance for chronic consequences 
and associated costs, and increased risk of several chronic diseases (16).  
The purpose of this article is to review available evidence on lifestyle and pharmacological 
intervention on the prevention or delay of the onset of type 2 diabetes and adapting these 
lessons from clinical trials to clinical practice. 
2. How we can prevent type 2 diabetes? 
The high economic and social costs of type 2 diabetes mellitus and its rising prevalence 
make a compelling case for its prevention (17). The most vulnerable groups to have diabetes 
are people with IFG and IGT and in the mean time they present the potent groups of 
preventing or delaying the progression to type 2 diabetes mellitus. These two groups are 
recognized as prediabetic states by the ADA (11). 
3. Non pharmacological intervention  
Four large prospective studies demonstrated that a treatment regimen using diet plus 
exercise reduces IGT progression to type 2 diabetes (18-21). Factor analysis showed that both 
insulin resistance and insulin secretion had a significant association with the development 
of diabetes, and lifestyle intervention was more effective in subjects with lower insulin 
resistance and higher insulin secretion (13).  
 
Can We Prevent or Delay Type 2 Diabetes? 17 
3.1. Lifestyle trials - diet and physical activity 
Overweight, obesity and physical inactivity are the major risk factors for developing type 2 
diabetes mainly through insulin resistance. Therefore, interventions in  weight reduction 
were shown to enhance insulin sensitivity and improve glucose tolerance in nondiabetic and 
diabetic subjects.  
In the DaQing study, 577 subjects with IGT as defined by the WHO criteria were followed 
over 6 years. They were randomized into diet-only, exercise only, diet plus exercise groups, 
and a control group, which were associated with a 31% (p≤0.03), 46% (p≤0.0005) and 42% 
(p≤0.005) reduction in the risk of developing diabetes, respectively, when compared to the 
control group. Factor analysis showed that both insulin resistance and insulin secretion had 
a significant association with the development of diabetes, and lifestyle intervention was 
more effective in subjects with lower insulin resistance and higher insulin secretion 
(15,21,22). 
The Swedish Diabetes Prevention Study was the first individually randomized clinical trial, 
where 522 middle-aged overweight subjects (body mass index/BMI >25) with IGT were 
randomized to the control group or intervention group and followed over a mean of 3.2 
years. The intervention group received individual counseling regarding diet and exercise 
and lost 4.2±5.1 kg versus 0.8±3.7 kg in the control group, which translated to a 58% (p≤0.001) 
reduction in the risk of developing diabetes and was directly associated with changes in 
lifestyle (18,23). 
The Diabetes Prevention Program (DPP) study was a double-blind randomized controlled 
trial (RCT) involving a larger number of subjects, 3234 with IGT or IFG with BMI >24 kg/m2 
(>22 in Asian population) followed over 2.8 years. They were randomized to standard 
lifestyle recommendations with placebo or with metformin or to an intensive program of 
lifestyle modifications (19). The incidence of developing diabetes was 4.8 cases versus 11 
cases per 100 person years for 3 years in the intensive lifestyle and placebo groups, 
respectively, which was a 58% lower incidence of developing diabetes in the intensive 
lifestyle group. In this study these changes were observed in all of the various ethnic and 
racial subgroups, and at least 50% of the lifestyle group had achieved the goal of >7% of 
weight reduction. 
The Look AHEAD trial, which, like DPP, demonstrated impressive weight loss at year 1, 
was also followed by significant weight regain over the subsequent 3 years despite 
continued intensive intervention and follow-up (24). 
In a recent community study in Finland, 2,797 high-risk individuals were enrolled in a 
diabetes prevention program designed to achieve 5–7% body weight loss. Only 
approximately one-third of participants were able to successfully decrease body weight by 
2.5% (25). 
From above mention studies it is obvious that successful weight reduction alone is not 
sufficient to prevent diabetes in a large percentage of individuals. The main issues is that it 
is difficult to maintain weight without an intervention program.  
 
Glucose Tolerance 18 
The key components of lifestyle interventions in clinical practice based on the studies 
analyzed by Burnet et al. (37) were as follows: the staff included were medical doctors, 
nurses, technicians, dietitians and physiotherapists. Trainings with patients were focused on 
nutrition, physical activity and behavioral self-management four times during the year in 
individualized sessions (in Diabetes Prevention Study) or small group counseling sessions 
weekly for one month, then monthly for three months (32). Physical activities were 
organized 2 times during the week as brisk walking (in Diabetes Prevention Program and 
Malmo Feasibility Study). Smokers were advised to stop or reduce smoking. It was a useful 
follow up session every 2 months with phone calls to patients between visits. In DPS study, 
if weight goal was not achieved in 6 to 12 months, a very low calorie diet was considered. 
As for social support, spouses were invited to join sessions. 
The overall goal for diabetes prevention is to reach and maintain an active, healthy weight 
with a tendency toward a hypocaloric diet. Evidence supports limiting total calories and fat 
(25% of caloric intake) and increasing dietary fiber (20 to 30 g/day). Essential skills include 
understanding portion sizes and reading food labels (37). 
4. Pharmacological interventions  
Weight regain is a characteristic feature of most weight reduction programs, irrespective of 
the type of dietary intervention and similarly, weight loss achieved with pharmacological 
intervention is associated with major weight regain once medication is discontinued.  
As shown above, lifestyle modification is the best strategy to prevent the progression of 
metabolic risk factors and to prevent cardiovascular events and the onset of diabetes. 
However, pharmacological trials have shown important results. 
4.1. Metformin 
Metformin (MF) 850 mg was used in one arm of the DPP study along with standard lifestyle 
recommendations. Subjects in this study had a decrease in their calorie intake by a mean of 
296±23 kcal compared to 249±27 kcal in the placebo group; their average fat intake decreased 
by 0.8±0.2% in both the MF and the placebo group (p=NS).  
The DPP demonstrated a 31% reduction in IGT conversion to type 2 diabetes in subjects 
receiving metformin, 850 mg twice daily (15,21). 
4.2. α-Glucosidase inhibitors  
Both acarbose (STOP-NIDDM) (26) and voglibose (27) have been shown to decrease 
conversion of IGT to type 2 diabetes. Although this preventive effect initially was believed 
to result from inhibition of carbohydrate absorption, α-glucosidases augment incretin 
hormone secretion; thus, enhanced b-cell function could, in part, explain their beneficial 
effects on glucose homeostasis (28). Subjects on acarbose were by 25% less likely to develop 
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diabetes compared to placebo at the end of 1 year, and this continued to the end of the 
study. The reduced risk was present even after adjusting for change in weight, age, sex, or 
BMI (p=0.0063) (26). 
4.3. Thiazolidinediones 
Thiazolidinediones (TZD) are insulin sensitizers that act by facilitating glucose transport 
into the muscle and by acting on Perioxisome Proliferator Activated Receptor (PPAR)-γ 
receptors in the adipose cells to shift fat from visceral to less active subcutaneous fat 
compartment thus reducing insulin resistance. The TRIPOD was a single-center, placebo-
controlled randomized controlled trials, which enrolled Mexican-American women with 
prior gestational diabetes mellitus (GDM) randomized to either placebo or troglitazone 400 
mg/day. The mean annual incidence of diabetes was 5.4% in the troglitazone group versus 
12.1% in the placebo group (p=0.009), which was a >50% reduction with troglitazone use 
(29). Analysis done 8 months after troglitazone had been stopped showed that the mean 
annual incidence of diabetes was 21.2% and 3.1% in the placebo and troglitazone group, 
respectively. This indicated that the protection by the drug persisted even after it had been 
stopped. The study was continued in the same group of women using pioglitazone called 
the Pioglitazone In the Prevention of Diabetes (PIPOD) study and the results published 
indicated that the benefit in terms of β-cell function achieved with troglitazone was 
maintained with the use of pioglitazone, indicating that it could be a class effect (30). Also, a 
report appeared on diabetes reduction assessment in the Ramipril and Rosiglitazone 
medication (DREAM) trial (16). This trial reported only combined results for individuals 
with either IGT or IFG. Briefly, it was found that the ACE inhibitor ramipril did not 
significantly reduce the incidence of diabetes (hazard ratio 0.91, 0.80 to 1.03) but 
rosiglitazone, an oral diabetes drug, did (0.38, 0.33 to 0.44). 
In another study ACT NOW, pioglitazone (45 mg/day) decreased by 72% (P <0.00001) IGT 
conversion to type 2 diabetes (31). 
4.4. Orlistat 
Orlistat is another pharmacological agent used in the prevention of diabetes. Orlistat is a 
weight-reduction agent that inhibits the activity of intestinal lipase and thus decreases the 
amount of fat (triglycerides) absorbed. After 4 years' treatment, the cumulative incidence of 
diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 
37.3% (P = 0.0032). Exploratory analyses indicated that the preventive effect was explained 
by the difference in subjects with IGT. Mean weight loss after 4 years was significantly 
greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat 
recipients with impaired (5.7 kg) or normal glucose tolerance (NGT) (5.8 kg) at baseline. A 
second analysis in which the baseline weights of subjects who dropped out of the study was 
carried forward also demonstrated greater weight loss in the orlistat group (3.6 vs. 1.4 kg; P 
< 0.001)(32). 
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indicated that the benefit in terms of β-cell function achieved with troglitazone was 
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rosiglitazone, an oral diabetes drug, did (0.38, 0.33 to 0.44). 
In another study ACT NOW, pioglitazone (45 mg/day) decreased by 72% (P <0.00001) IGT 
conversion to type 2 diabetes (31). 
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amount of fat (triglycerides) absorbed. After 4 years' treatment, the cumulative incidence of 
diabetes was 9.0% with placebo and 6.2% with orlistat, corresponding to a risk reduction of 
37.3% (P = 0.0032). Exploratory analyses indicated that the preventive effect was explained 
by the difference in subjects with IGT. Mean weight loss after 4 years was significantly 
greater with orlistat (5.8 vs. 3.0 kg with placebo; P < 0.001) and similar between orlistat 
recipients with impaired (5.7 kg) or normal glucose tolerance (NGT) (5.8 kg) at baseline. A 
second analysis in which the baseline weights of subjects who dropped out of the study was 
carried forward also demonstrated greater weight loss in the orlistat group (3.6 vs. 1.4 kg; P 
< 0.001)(32). 
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4.5. GLP-1 analogs 
Liraglutide and exenatide are GLP-1 receptor agonists that mimic the actions of GLP-1 and 
are resistant to dipeptidyl peptidase-4 degradation. GLP-1 analogs represent a logical 
therapeutic intervention for treatment of IGT. Moreover, the stimulatory effect of GLP-1 and 
GLP-1 analogs on insulin secretion is glucose dependent, minimizing risk for hypoglycemia 
(33). Once-daily liraglutide also reduces body weight and decreases IGT conversion to type 
2 diabetes in obese nondiabetic subjects (34). 
4.6. Angiotensin converting enzyme inhibitor (ACEI)/angiotensinogen receptor 
blocker (ARB) 
In addition to the beneficial effects on hypertension, the kidneys and the heart, both ACEI 
and ARBs have been shown to improve insulin sensitivity and glycemic control. Therapy 
with ACEI, like captopril and ramipril, and ARBs, like losartan and valsartan has been 
shown to reduce the incidence of new-onset diabetes anywhere by 14% to 34% (18). 
Although the exact mechanism how these agents reduce the incidence of diabetes is not 
known, it is well established that ACEI increases glucose uptake in skeletal muscle through 
increased synthesis of GLUT- 4 transporter protein secondary to up-regulation of insulin 
receptor substrate 1 (IRS 1) activity, enhanced bradykinin and nitric oxide (NO) activity (35). 
4.7. Statins 
The West of Scotland Coronary Prevention Study (WOSCOPS) examined the effect of 
pravastatin on cardiovascular (CV) events and observed that these pharmacological 
interventions were associated with a 30% reduction in the incidence of diabetes as 
secondary outcome (36). Therapeutic agents used to treat other coexisting conditions like 
hypertension and dyslipidemia with agents like ACEI/ARB/statins can also help with the 
prevention of diabetes and CV disease (15). 
5. Conclusions and recommendations 
From the trials discussed it was shown that both non pharmacological and pharmacological 
intervention can reduce the risk of type 2 diabetes in people with IGT, but lifestyle 
intervention seems to be more effective than pharmacological interventions. Lifestyle 
intervention, which aims to reduce obesity and increase physical activity, helps in 
addressing directly these risk factors. In the mean time lifestyle interventions incur fewer 
and less serious side effects than drug treatment. Like in pharmacological interventions, 
lifestyle interventions may not be permanent and advice on diet and exercise needs to be 
regularly reinforced by professional staff. For pharmacological interventions, adverse effects 
need to be fully understood to enable the potential harms and benefits to be assessed. 
In lifestyle intervention, clinicians should recommend behavior changes for asymptomatic 
patients at a high risk of diabetes such as IGT. High-risk patients can be identified through 
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clinical characteristics augmented with careful screening by fasting glucose. Although the 
diabetes prevention trials used intensive strategies for effecting lifestyle change, clinicians 
can translate key elements from those strategies into brief, office-based counseling on 
physical activity and dietary change. As it was proved by different trials in clinical practice, 
lifestyle changes should be made better through structured programs. These programs, 
proved to be successful in clinical practices from different countries, should emphasize goal 
setting, practice and motivational interviewing with patients, education and skills 
development, self-monitoring, behavior change (cognitive restructuring), physical activity, 
problem solving,  stress and stimulus control, the importance of social support, and the 
utilization of community resources. 
Multidisciplinary care teams consisting of nurses, clinicians, dietitians, psychologist 
physiotherapists and health educators may provide more intensive counseling and increase 
the motivation to continue and achieve the targets. Other forms of awareness rising as 
printed materials or if possible interactive computer programs in offices can reinforce 
counseling efforts. Implementing diabetes prevention will require significant changes for 
both patients and clinicians. Every health system that provide these special services need to 
educate clinicians in training and in practice about the potential benefits of diabetes 
prevention. Appropriate programs on the prevention or delay of type 2 diabetes have to be 
culturally adaptive for office-based counseling considering the better results planned to 
achieve. Besides office bases counseling with patients and family members, successful 
diabetes prevention efforts through lifestyle changes will likely require involvement broader 
societal entities such as schools, communities and workplaces. 
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1. Introduction 
1.1. Plasma glucose levels and prediction of future type 2 diabetes 
Prediabetes (PD) is a dysmetabolic state of glucose level between diabetes mellitus and 
normal glucose tolerance (NGT) which includes basically impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT). All these conditions are becoming a considerable public 
health problem worldwide [1]. Measurement of glucose in plasma of fasting subjects is 
widely accepted as a diagnostic criterion for diabetes. Oral glucose tolerance test (OGTT) 
evaluates the efficiency of the body to metabolize glucose. For many years, fasting plasma 
glucose (FPG) test and OGTT have been used as “gold standards” for diagnosis of glucose 
metabolism disorders [2]. In addition hemoglobin A1C (HbA1C) measurement has also 
become the focus of considerable attention for diagnosis of diabetes. HbA1C is formed by 
the nonenzymatic attachment of glucose to the N-terminal valin of the beta chain of 
hemoglobin and its normal range is between 4% and 6% [2-4]. Because of the long life span 
of erythrocytes, HbA1C reflects long-term glycemic exposure, representing the average 
glucose concentration over the preceding 8-12 weeks [2].  
The hyperglycemic diagnostic criteria defined by American Diabetes Association (ADA) is 
widely used for the evaluation of glucose metabolism disorders [1]. Fasting plasma glucose 
(FPG) is less than 100 mg/dl and 2-hour postprandial plasma glucose (2hPG) [75g glucose 
OGTT) level is less than 140 mg/dl in normal glucose tolerance (NGT). If the FPG level is 
between 100 and 125 mg/ dl, but the 2hPG level is less than 140 mg/dl, this situation is 
defined as IFG. In IGT, the FPG level is between 100 and 125 mg/ dl, the 2hPG level is 
between 140 and 200 mg/dl. If 2hPG level is more than 200 mg/dl, it is termed as diabetes 
according to the ADA’s criteria [1,2]. Similarly, the glycated hemoglobin (HbA1c) level is 
found more than 6.5% in type 2 diabetes [1,2].  
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metabolism disorders [2]. In addition hemoglobin A1C (HbA1C) measurement has also 
become the focus of considerable attention for diagnosis of diabetes. HbA1C is formed by 
the nonenzymatic attachment of glucose to the N-terminal valin of the beta chain of 
hemoglobin and its normal range is between 4% and 6% [2-4]. Because of the long life span 
of erythrocytes, HbA1C reflects long-term glycemic exposure, representing the average 
glucose concentration over the preceding 8-12 weeks [2].  
The hyperglycemic diagnostic criteria defined by American Diabetes Association (ADA) is 
widely used for the evaluation of glucose metabolism disorders [1]. Fasting plasma glucose 
(FPG) is less than 100 mg/dl and 2-hour postprandial plasma glucose (2hPG) [75g glucose 
OGTT) level is less than 140 mg/dl in normal glucose tolerance (NGT). If the FPG level is 
between 100 and 125 mg/ dl, but the 2hPG level is less than 140 mg/dl, this situation is 
defined as IFG. In IGT, the FPG level is between 100 and 125 mg/ dl, the 2hPG level is 
between 140 and 200 mg/dl. If 2hPG level is more than 200 mg/dl, it is termed as diabetes 
according to the ADA’s criteria [1,2]. Similarly, the glycated hemoglobin (HbA1c) level is 
found more than 6.5% in type 2 diabetes [1,2].  
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There are some fundamental problems in using IGT and IFG to characterize abnormal 
glucose metabolism. These problems can be classified as; the best means of identifying 
at-risk populations, whether they characterize the same degree of risk, and whether IFG 
and IGT represent manifestations of the same process or fundamentally different 
mechanisms [5].  
The results of recent studies demonstrate that, although both IFG and IGT are characterized 
by ß-cell dysfunction, the defects in insulin secretion in IFG and IGT are very distinct [6]. 
Subjects with IGT have impaired late-phase insulin secretion and increased insulin 
resistance (IR) in skeletal muscle. In contrasts, subjects with IFG have impaired early –phase 
insulin secretion and increased IR in liver [6-8]. Similarly there are some discrepancies 
between the clinical features of IFG and IGT. Subjects with isolated IFG are more insulin 
resistant, and subjects with isolated IGT exhibits a more severe deficit in insulin secretion 
[8]. IFG and IGT have been associated with other features of insulin resistance, including 
dyslipidaemia, hypertension, abdominal obesity, microalbuminuria, endothelial 
dysfunction, and markers of inflammation and hypercoagulability [5]. Combinations of 
these components have also been associated with progression to type 2 diabetes mellitus 
(T2DM), cardiovascular disease and increased mortality [10].  
Impaired ß-cell function and increased IR in several peripheral tissues are both present in 
type 2 diabetes mellitus (T2DM) [9]. Currently it is understood that T2DM is also associated 
with obesity, hypertension and combined hyperlipidemia [10-12]. Populations at high risk 
for development of T2DM and atherosclerosis can be identified using markers of abnormal 
glucose metabolism, and recent studies have demonstrated that lifestyle modification and 
some pharmacological therapies have a favorable effect on reducing the risk for 
development of T2DM and increased mortality [5,10].  
2. Relationship between obesity and glucose metabolism  
Obesity is associated with an array of health problems including IR and T2DM, fatty liver 
disease, atherosclerosis, airway diseases, degenerative disorders, and various types of 
cancer [11,12]. IR is determined by impaired insulin sensitivity of its main target organs, 
such as adipose tissue, liver, and muscle. Insulin regulates glucose uptake and circulating 
free fatty acid (FFA) concentrations. Insulin decreases lipolysis in adipose tissue and inhibits 
gluconeogenesis in liver. Insulin resistance leads to increased circulating FFA concentrations 
and ectopic fat accumulation that impede insulin mediated glucose uptake in skeletal 
muscle and elevated glucose production in liver [13]. Finally, IR together with abnormalities 
in insulin secretion leads to T2DM [13].  
Obesity is defined as abnormal or excessive fat accumulation and it is measured with body 
mass index (BMI) [10]. The conceptual transformation of adipose tissue from a passive 
organ to an active participant of homeostasis, has emerged relatively recently [12,14]. In 
1994, adipose tissue was identified as the source of the hormone leptin, opening the door for 
a new area of research focused on adipocyte endocrinology [14]. Our understanding of the 
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pathogenesis of obesity and its metabolic disturbances have advanced significantly over the 
past decades [11-14]. The growing evidence on obesity and associated pathologies has led to 
understand the role of adipose tissue as an active potential participant in controlling the 
physiological and pathological processes [11-15]. For many years, adipose tissue was 
regarded merely as a heat insulator and a store of excess FFAs that could be released when 
needed [14]. To date, the adipose tissue is considered as an endocrine organ able to mediate 
biological effects on metabolism and inflammation, contributing to the maintenance of 
energy homeostasis and, probably, pathogenesis of obesity-related metabolic and 
inflammatory complications [10-16]. Nowadays, worldwide increased obesity prevalence 
has been accompanied by a parallel rise in the glucose metabolism disorders [11,17]. There is 
evidence that IR and T2DM is also related to a chronic low-grade inflammatory state [17]. 
Therefore weight loss is associated both with an improvement of the inflammatory profile 
and a decreased risk of glucose metabolism disorders [9-11,13-15]. 
3. Effects of inflammatory mediators on glucose metabolism 
Many complex signaling pathways regulate chronic low-grade inflammation associated 
with both the metabolism and immune systems [18]. Pro- inflammatory cytokines are 
mediators of these pathways and they enter the circulation as a result of lipolysis [10]. 
Recent data indicates that macrophages in adipose tissue are a major source of them [10-18]. 
Especially in obesity, adipose tissue is characterized by an increased production and 
secretion of a wide range of pro- inflammatory molecules which have been recognized as an 
active participant in numerous immunologic processes [13-16]. Cytokines play the crucial 
roles in many physiological and pathological processes such as hematopoiesis, angiogenesis, 
inflammation, atherosclerosis, allergy and autoimmunity [18]. The increased concentrations 
of circulatory cytokines are commonly determined in cardiovascular disease (CVD), the 
metabolic syndrome and T2DM. These cytokines are produced by different cell types and 
are secreted into circulation where they regulate different tissues through their local, central 
or peripheral action [19]. 
It is demonstrated that increases of these cytokines effect through intracellular signaling 
pathways which involve the nuclear factor kappa B (NF- κB) and c- Jun N-terminal 
kinase (JNK) systems [10]. Leptin also impairs glucose-stimulated insulin production of 
human β cells through activation of JNK. Moreover, hyperglycemia induces IL-1β 
production by pancreatic β-cells, which putatively contributes to glucotoxicity in human 
pancreatic islets [13]. 
The name of adipokine is nowadays generally given to any protein or cytokine that can be 
synthesized and secreted by adipocytes [11]. Several studies have shown that adipokine 
production is altered in obesity [11]. The first link between obesity and elevation of Tumor 
Necrosis Factor- Alpha (TNF-α) came from a study almost 20 years ago and this finding led 
to the concept of inflammation in obesity and demonstrated that adipocytes express TNF-α 
[17-23]. TNF-alpha is a pro- inflammatory cytokine, overproduced in adipose tissue of 
several rodent models of obesity and has an important role in the pathogenesis of IR in these 
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species [21]. Interleukin-1 (IL-1) is one of the first identified cytokines and exert strong pro-
inflammatory functions [10,20]. IL-1α has been demonstrated to be involved in the 
pathogenesis of glucose metabolism disorders in mice [18]. IL-1β is able to reduce IRS-1 
expression at a transcriptional level through a mechanism that is ERK dependent and at a 
posttranscriptional level independent of ERK activation [18]. By targeting IRS-1, IL-1β is 
capable of impairing insulin signaling and action and could thus participate, in the 
development of IR, in concert with other cytokines [18-21]. IL-6 is also among the first 
identified cytokines and acts on the liver to stimulate the production of a number of acute-
phase proteins [10]. It is implicated as a pathogenetic marker of IR and CVD. IL-1ß together 
with IL-6 concentration is suggested as a predictor for T2DM in humans better than either 
cytokine alone [9,19,23-28].  
Similarly interleukin 8 (IL-8) is a pro- inflammatory cytokine, overproduced in adipose 
tissue of several rodent models of obesity and has an important role in the pathogenesis of 
IR in these species [12,21,29,30]. However, IL-8 is basically evaluated as a cytokine with 
atherogenic properties and its actual involvement in glucose metabolism disorders remains 
controversial in humans [29-31]. Through its multiple actions, IL-8 might promote intimal 
thickening and atherosclerosis. This cytokine is also able to increase the instability of 
atherosclerotic plaque [29-31]. Elevated circulating IL-8 levels were also reported in type 1 
and type 2 diabetic patients. It was hypothesized that this cytokine could be involved in the 
pathogenesis of diabetic macroangiopathy. Especially T2DM is associated with accelerated 
atherogenesis and it is recognized as an independent risk factor for CVD. Precise 
mechanisms linking those conditions are not fully understood [18,19]. In recent years, 
theories about the role of chronic low-grade inflammation in the pathogenesis of both 
glucose metabolism disorders and atherosclerosis have been developed. Some 
investigations reported that elevated plasma IL-8 concentrations are related to obesity and 
hyperlipidemia [12].  
C-reactive protein (CRP) is an acute-phase reactant, the elevation of which is indicative of 
acute or chronic inflammation [32,33]. CRP is produced solely by the liver [19]. An 
etiologic role for chronic inflammation in the development of IR has been hypothesized 
[32,33]. It has been recognized that elevation of CRP concentrations is an independent 
predictive parameter of T2DM, which is also associated with various components of the 
metabolic syndrome such as obesity, IR, and dyslipidemia [20-24]. A number of previous 
study have reported that high sensitivity (hs) CRP is also related to circulating IL-6 levels 
[24,32,33] and IL-6 is a powerful inducer of CRP production in the liver [18]. In addition, 
abdominal obesity is associated with elevated plasma hs-CRP concentration and it has 
shown that elevation of hs-CRP concentration is an independent predictive parameter of 
T2DM [32,33] Actually CRP is a most sensitive marker of inflammation and it is associated 
with features of IR [15,16].  
More recently, hormone leptin has also been linked to inflammation in human. Leptin, is the 
product of the ob gene. It is involved in the regulation of energy homeostasis and is almost 
exclusively expressed and produced by white adipose tissue (WAT) and more particularly 
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by differentiated mature adipocytes [11]. Circulating levels and adipose tissue mRNA 
expression of leptin are strongly associated with BMI and fat mass in obesity. Therefore, 
leptin appears as a real marker of adipose tissue mass in humans [11]. Leptin acts mainly at 
the level of the central nervous system to regulate food intake and energy expenditure. In 
addition, there is a relationship between leptin and the low-grade inflammatory state in 
obesity. It was suggested that leptin could exert peripheral biological effects as a function of 
its cytokine-like structure. It is similar to the IL-2 and receptors of leptin belong to the 
cytokine class I receptor family [14]. Some works have reported that there is an increased 
inflammatory response associated with the presence of hyperleptinemia without obesity. 
Leptin-deficient mice or humans display an altered immune status . The reduction in leptin 
levels could be responsible for fat-associated immunosuppression [11]. Leptin is able to 
control TNF-α production and activation by macrophages, however, the underlying 
mechanisms have not been clearly identified [11,14].  
Adiponectin is an adipokine mainly produced by the adipose tissue and it is induced by 
activity of the nuclear peroxisome- proliferator–activated receptor (PPAR) γ. It exists both as 
a full-length protein as well as a proteolytic cleavage fragment, also known as globular 
adiponectin. Adiponectin circulates at high concentrations in human serum [5 to 10 μg/mL) 
and has a wide spectrum of biological activities. Adiponectin is unique that, unlike other 
adipokines, circulating concentrations are reduced with obesity. Serum levels of adiponectin 
are reduced in individuals with visceral obesity and states of IR. TNF-α suppresses the 
transcription of adiponectin in adipocytes, which might explain the lower adiponectin levels 
in serum in individuals who are obese. Weight loss induces adiponectin synthesis, as 
activation of PPARγ by its ligands thiazolidinediones (TZDs), which are used in the 
treatment of T2DM [19,21]  
Data from epidemiological studies indicate that circulating adiponectin is reduced in 
patients with CVD and T2DM. Importantly, low adiponectin concentrations are strongly 
correlated with IR. In addition, adiponectin reduces glucose production in the liver by 
directly inhibiting the gluconeogenic enzymes phosphoenolpyruvate carboxykinase and 
glucose 6 phosphate , improving glycemic control and insulin sensitivity .The reduction in 
adiponectin with obesity and diabetes most likely arises from increased adipose tissue 
macrophage infiltration resulting in inflammation. In contrast, high concentrations of 
adiponectin are related to higher insulin sensitivity and decreased risk for CVD. The 
proinflammatory cytokines TNFα and IL-6 reduce adiponectin expression. Conversely, 
adiponectin has an antiinflammatory effect, inhibiting activation of NFκB by TNFα [19].  
Resistin, also called FIZZ3 (found in inflammatory zones) or adipocyte secreted factor 
(ADSF) has been discovered in 2001 while looking for new molecular targets of TZDs in 
adipocytes [11,33]. It was shown that resistin levels were increased in obese rodents and 
resistin knock-out mice have lower fasting glycaemia, increased glucose tolerance and 
insulin sensitivity associated with a reduced liver glucose production [11]. Resistin is also 
expressed in the WAT, especially in the WAT of abdominal region and female gonadal 
adipose tissue [33]. Resistin has been linked with many facets of the metabolic syndrome, 
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principally, obesity, insulin resistance and hyperlipidemia. The effect of resistin upon 
insulin resistance is mediated through increased expression of suppressor of cytokine 
signaling-3 (SOCS-3], which is a known inhibitor of insulin signaling [33]. Mice injected with 
resistin showed insulin resistance. Resistin was thus found to attend endocrine functions 
that led to insulin resistance. Increased expression of resistin was found to be associated 
with dyslipidemia and non-alcoholic fatty liver disease (NAFLD) in a few medical ranks. In 
patients with NAFLD, serum resistin levels were higher than those in control cases. The 
presence of metabolic syndrome with elevated levels of plasma resistin is associated with 
increased cardiovascular risk [33-35]. 
Osteopontin (OPN) actually is a secreted matrix glycoprotein and pro-inflammatory 
cytokine playing an important role in cell-mediated immunity. Its ability to interact with 
integrin surface molecules through an Arg-Gly-Asp sequence and with the CD44 receptor 
has established this mediator as an important signaling molecule [34]. Indeed, tissue 
infiltration of macrophages as observed in obesity is dependent on the expression of OPN, 
which promotes monocyte chemotaxis and motility. Obese mice lacking OPN showed 
improved insulin sensitivity and decreased macrophage infiltration into adipose tissue. 
These experiments add OPN to a long list of pro-inflammatory pathways involved in the 
development of IR [21] 
However, actual involvement of all these mediators in glucose metabolism disorders in 
humans remains controversial. It is suggested that these mediators may alter insulin 
sensitivity by triggering different key steps in the insulin signaling pathway and 
overproduction of them is associated with the glucose metabolism disorders [36-40]. Many 
mediators contribute to the pathogenesis of impaired glucose homeostasis and most of them 
are overproduced during obesity. It now appears that obesity is associated with a low- 
grade inflammation of adipose tissue, resulting from activation of innate immune system. 
Especially in obesity, adipose tissue is characterized by an increased production and 
secretion of a wide range of pro- inflammatory molecules including IL-1ß, IL-6, IL-8, TNF-α, 
CRP, leptin, resistin and so on [23-35]. Recent data indicate that macrophages in obese 
adipose tissue are major source of most mediators. Therefore weight loss is associated with a 
reduction in the macrophage infiltration of adipose tissue and an improvement of the 
inflammatory profile [39-45].  
4. Conclusion 
During the last decades, understanding of the biology of adipose tissue and especially its 
secretory functions, have dramatically improved. This development has completely 
modified the understanding of the pathogenesis of obesity, glucose metabolism disorders 
and inflammation. Several cytokines attracted considerable attention as potential effectors in 
the pathology and physiology of insulin resistance associated with type 2 diabetes mellitus 
(T2DM) and obesity. Recent studies have implicated a number of inflammatory mediators 
including cytokines and adipokines in the inflammatory responses that accompany the 
glucose metabolism disorders. Therefore measurement of serum levels of inflammatory 
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mediator is important in determining glucose regulation disorders and provides an 
improvement in therapeutic approaches to modulate the inflammatory responses and 
thereby alter disease progression. Elucidation of the mechanisms that link obesity with 
inflammation and glucose metabolism will contribute to the understanding of the 
physiopathology of obesity. As well as it will be probably provide the new strategies in the 
development of new therapeutic approaches.  
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principally, obesity, insulin resistance and hyperlipidemia. The effect of resistin upon 
insulin resistance is mediated through increased expression of suppressor of cytokine 
signaling-3 (SOCS-3], which is a known inhibitor of insulin signaling [33]. Mice injected with 
resistin showed insulin resistance. Resistin was thus found to attend endocrine functions 
that led to insulin resistance. Increased expression of resistin was found to be associated 
with dyslipidemia and non-alcoholic fatty liver disease (NAFLD) in a few medical ranks. In 
patients with NAFLD, serum resistin levels were higher than those in control cases. The 
presence of metabolic syndrome with elevated levels of plasma resistin is associated with 
increased cardiovascular risk [33-35]. 
Osteopontin (OPN) actually is a secreted matrix glycoprotein and pro-inflammatory 
cytokine playing an important role in cell-mediated immunity. Its ability to interact with 
integrin surface molecules through an Arg-Gly-Asp sequence and with the CD44 receptor 
has established this mediator as an important signaling molecule [34]. Indeed, tissue 
infiltration of macrophages as observed in obesity is dependent on the expression of OPN, 
which promotes monocyte chemotaxis and motility. Obese mice lacking OPN showed 
improved insulin sensitivity and decreased macrophage infiltration into adipose tissue. 
These experiments add OPN to a long list of pro-inflammatory pathways involved in the 
development of IR [21] 
However, actual involvement of all these mediators in glucose metabolism disorders in 
humans remains controversial. It is suggested that these mediators may alter insulin 
sensitivity by triggering different key steps in the insulin signaling pathway and 
overproduction of them is associated with the glucose metabolism disorders [36-40]. Many 
mediators contribute to the pathogenesis of impaired glucose homeostasis and most of them 
are overproduced during obesity. It now appears that obesity is associated with a low- 
grade inflammation of adipose tissue, resulting from activation of innate immune system. 
Especially in obesity, adipose tissue is characterized by an increased production and 
secretion of a wide range of pro- inflammatory molecules including IL-1ß, IL-6, IL-8, TNF-α, 
CRP, leptin, resistin and so on [23-35]. Recent data indicate that macrophages in obese 
adipose tissue are major source of most mediators. Therefore weight loss is associated with a 
reduction in the macrophage infiltration of adipose tissue and an improvement of the 
inflammatory profile [39-45].  
4. Conclusion 
During the last decades, understanding of the biology of adipose tissue and especially its 
secretory functions, have dramatically improved. This development has completely 
modified the understanding of the pathogenesis of obesity, glucose metabolism disorders 
and inflammation. Several cytokines attracted considerable attention as potential effectors in 
the pathology and physiology of insulin resistance associated with type 2 diabetes mellitus 
(T2DM) and obesity. Recent studies have implicated a number of inflammatory mediators 
including cytokines and adipokines in the inflammatory responses that accompany the 
glucose metabolism disorders. Therefore measurement of serum levels of inflammatory 
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mediator is important in determining glucose regulation disorders and provides an 
improvement in therapeutic approaches to modulate the inflammatory responses and 
thereby alter disease progression. Elucidation of the mechanisms that link obesity with 
inflammation and glucose metabolism will contribute to the understanding of the 
physiopathology of obesity. As well as it will be probably provide the new strategies in the 
development of new therapeutic approaches.  
Author details 
Ayfer Colak 
Izmir Tepecik Research Hospital, Biochemistry Department, Turkey 
Gulden Diniz 
Izmir Dr.Behcet Uz Children’s Hospital, Pathology Department, Turkey 
5. References 
[1] Lu Q, Tong N, Liu Y, Li N, Tang X, Zhao J, et al. Community-based population data 
indicates the significant alterations of insulin resistance, chronic inflammation and 
urine ACR in IFG combined IGT group among prediabetic population.Diabetes Res 
Clin Pract 2009;84(3):319-24.  
[2] Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011; 34(2):518-23.  
[3] Kumar PR, Bhansali A, Ravikiran M, Bhansali S, Dutta P, Thakur JS, Sachdeva N, 
Bhadada SK, Walia R . Utility of glycated hemoglobin in diagnosing type 2 diabetes 
mellitus: a community-based study. J Clin Endocrinol Metab 2010;95(6):2832-5.  
[4] Malkani S, DeSilva T. Controversies on how diabetes is diagnosed. Curr Opin 
Endocrinol Diabetes Obes 2012;19(2):97-103.  
[5] Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose − a 
review of diagnosis, clinical implications and management Diabetes and Vascular 
Disease Research 2005 2: 9. 
[6] Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA. 
Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. 
Diabetes 2012; 61(2):447-53.  
[7] Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future 
risk of type 2 diabetes. Diabetes Care 2009;32 Suppl 2:S194-8. 
[8] Oka R, Yagi K, Sakurai M, Nakamura K, Moriuchi T, Miyamoto S, Oka R, Yagi K, 
Sakurai M, Nakamura K, Moriuchi T, Miyamoto. Insulin secretion and insulin 
sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese. Endocr J 
2012;59(1):55-64.  
[9] Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J. 
Different mechanisms for impaired fasting glucose and impaired postprandial glucose 
tolerance in humans. Diabetes Care 2006; 29(8):1909-14. A29. 
 
Glucose Tolerance 34 
[10] Colak A, Coker I, Diniz G, Karademirci I, Turkon H, Ergonen F, Hanci T, Bozkurt U et 
al. Interleukin 6 and Tumor Necrosis Factor-alpha Levels in Women with and without 
Glucose Metabolism Disorders. Turk J Biochem 2010; 35(3): 190- 194.  
[11] Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H,et al. Recent advances in 
the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine 
Netw 2006;17(1): 4-12.  
[12] Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 
2010;17(4):332-41.  
[13] Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance. Gerontology 
2009;55: 379-86. 
[14] Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic 
disorders linked to obesity. J Am Soc Nephrol 2004;15(11):2792-800. 
[15] Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J 
Physiol Gastrointest Liver Physiol 2011;300(5):G697-702. 
[16] Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in 
obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010:802078. 1. 
[17] Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and Insulin Resistance. Mol 
Med 2008; 14(11-12): 741–751.  
[18] Rosa MS, Pinto AM. Cytokines. In: Tietz Textbook of Clinical Chemistry and Molecular 
Diagnostics. Burtis CA, Ashwood ER, Bruns MD DE (eds) 5th ed, Elsevier, Philadelphia 
2005; Vol 1, p 645-723.  
[19] Puglisi MJ, Fernandez ML. Modulation of C-reactive protein, tumor necrosis factor-
alpha, and adiponectin by diet, exercise, and weight loss. J Nutr 2008;138(12):2293-6. 
[20] Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 
in insulin-dependent diabetic children. Mediators Inflamm 2006;2006(1):59206.  
[21] Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. 
Mol Med 2008; 14(3-4):222-231. 
[22] Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha 
in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. 
J Lipid Res 2007;48(4):751-62.  
[23] Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and 
insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 
2003;27(1):88-94. 
[24] Payette C, Blackburn P, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Després JP, 
Couillard C. Sex differences in postprandial plasma tumor necrosis factor-alpha, 
interleukin-6, and C-reactive protein concentrations. Metabolism 2009;58(11):1593-601.  
[25] Konukoglu D, Hatemi H, Bayer H, Bagriacik N. Relationship between serum 
concentrations of interleukin-6 and tumor necrosis factor alpha in female Turkish 
subjects with normal and impaired glucose tolerance. Horm Metab Res 2006, 38(1):34-
37. 
[26] Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, 
Barroso MC, Lankisch M.. Elevated plasma levels of TNF-alpha and interleukin-6 in 
 
Impaired Glucose Tolerance, Obesity and Inflammatory Mediators 35 
patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc 
Diabetol 2009;8:58.  
[27] Yeste D, Vendrell J, Tomasini R, Broch M, Gussinye M, Megia A, Carrascosa A. 
Interleukin-6 in obese children and adolescents with and without glucose intolerance. 
Diabetes Care 2007; 30(7):1892-1894. 
[28] Cardellini M, Andreozzi F, Laratta E, Marini MA, Lauro R, Hribal ML, Perticone F, Sesti 
G.. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance 
but not in those with impaired fasting glucose in a cohort of Italian Caucasians.Diabetes 
Metab Res Rev 2007;23(2):141-5. 1.  
[29] Ruotsalainen E, Stancáková A, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen 
K, Laakso M. Changes in cytokine levels during acute hyperinsulinemia in offspring of 
type 2 diabetic subjects. Atherosclerosis 2010;210(2):536-41. 
[30] Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K, et al. Inhibitory effect of 
IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm (Lond) 
2009;6:25.  
[31] Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Szelachowska M, 
Kinalska I. Plasma interleukin 8 concentrations in obese subjects with impaired glucose 
tolerance. Cardiovasc Diabetol 2003; 2: 5. 
[32] Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. 
Curr Opin Lipidol 2009;20(3):182-9.  
[33] Gandhi H, Upaganlawar A, Balaraman R. Adipocytokines: The pied pipers. J 
Pharmacol Pharmacother 2010;1(1):9-17. 
[34] Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, Hong J, Gu Y, Li X, Ning G, Chen M. 
Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and 
impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. 
Diabetes Res Clin Pract 2006;72(3):244-50.  
[35] Ma K, Jin X, Liang X, Zhao Q, Zhang X. Inflammatory mediators involved in the 
progression of the metabolic syndrome. Diabetes Metab Res Rev 2012; 28(5):388-94.  
[36] Fève B, Bastard JP .The role of interleukins in insulin resistance and type 2 diabetes 
mellitus. Nature Reviews Endocrinology 2009; 5, 305-311. | 
[37] Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C. 
Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008:639803.  
[38] Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, Caruso C. 
Innate immunity and inflammation in ageing: a key for understanding age-related 
diseases. Immun Ageing 2005; 2:8. 
[39] Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, 
Otziomek E, et al. Insulin resistance, serum adiponectin, and proinflammatory markers 
in young subjects with the metabolic syndrome. Metabolism 2008; 57(11): 1539-1544. 
[40] Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets 
promote insulin resistance through cytokine gene expression in growing female rats. J 
Nutr Biochem 2008; 19(8):505-513. 
 
Glucose Tolerance 34 
[10] Colak A, Coker I, Diniz G, Karademirci I, Turkon H, Ergonen F, Hanci T, Bozkurt U et 
al. Interleukin 6 and Tumor Necrosis Factor-alpha Levels in Women with and without 
Glucose Metabolism Disorders. Turk J Biochem 2010; 35(3): 190- 194.  
[11] Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H,et al. Recent advances in 
the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine 
Netw 2006;17(1): 4-12.  
[12] Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 
2010;17(4):332-41.  
[13] Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance. Gerontology 
2009;55: 379-86. 
[14] Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic 
disorders linked to obesity. J Am Soc Nephrol 2004;15(11):2792-800. 
[15] Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J 
Physiol Gastrointest Liver Physiol 2011;300(5):G697-702. 
[16] Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in 
obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010:802078. 1. 
[17] Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and Insulin Resistance. Mol 
Med 2008; 14(11-12): 741–751.  
[18] Rosa MS, Pinto AM. Cytokines. In: Tietz Textbook of Clinical Chemistry and Molecular 
Diagnostics. Burtis CA, Ashwood ER, Bruns MD DE (eds) 5th ed, Elsevier, Philadelphia 
2005; Vol 1, p 645-723.  
[19] Puglisi MJ, Fernandez ML. Modulation of C-reactive protein, tumor necrosis factor-
alpha, and adiponectin by diet, exercise, and weight loss. J Nutr 2008;138(12):2293-6. 
[20] Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 
in insulin-dependent diabetic children. Mediators Inflamm 2006;2006(1):59206.  
[21] Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. 
Mol Med 2008; 14(3-4):222-231. 
[22] Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha 
in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. 
J Lipid Res 2007;48(4):751-62.  
[23] Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and 
insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord 
2003;27(1):88-94. 
[24] Payette C, Blackburn P, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Després JP, 
Couillard C. Sex differences in postprandial plasma tumor necrosis factor-alpha, 
interleukin-6, and C-reactive protein concentrations. Metabolism 2009;58(11):1593-601.  
[25] Konukoglu D, Hatemi H, Bayer H, Bagriacik N. Relationship between serum 
concentrations of interleukin-6 and tumor necrosis factor alpha in female Turkish 
subjects with normal and impaired glucose tolerance. Horm Metab Res 2006, 38(1):34-
37. 
[26] Dinh W, Füth R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, 
Barroso MC, Lankisch M.. Elevated plasma levels of TNF-alpha and interleukin-6 in 
 
Impaired Glucose Tolerance, Obesity and Inflammatory Mediators 35 
patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc 
Diabetol 2009;8:58.  
[27] Yeste D, Vendrell J, Tomasini R, Broch M, Gussinye M, Megia A, Carrascosa A. 
Interleukin-6 in obese children and adolescents with and without glucose intolerance. 
Diabetes Care 2007; 30(7):1892-1894. 
[28] Cardellini M, Andreozzi F, Laratta E, Marini MA, Lauro R, Hribal ML, Perticone F, Sesti 
G.. Plasma interleukin-6 levels are increased in subjects with impaired glucose tolerance 
but not in those with impaired fasting glucose in a cohort of Italian Caucasians.Diabetes 
Metab Res Rev 2007;23(2):141-5. 1.  
[29] Ruotsalainen E, Stancáková A, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen 
K, Laakso M. Changes in cytokine levels during acute hyperinsulinemia in offspring of 
type 2 diabetic subjects. Atherosclerosis 2010;210(2):536-41. 
[30] Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K, et al. Inhibitory effect of 
IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm (Lond) 
2009;6:25.  
[31] Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Szelachowska M, 
Kinalska I. Plasma interleukin 8 concentrations in obese subjects with impaired glucose 
tolerance. Cardiovasc Diabetol 2003; 2: 5. 
[32] Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. 
Curr Opin Lipidol 2009;20(3):182-9.  
[33] Gandhi H, Upaganlawar A, Balaraman R. Adipocytokines: The pied pipers. J 
Pharmacol Pharmacother 2010;1(1):9-17. 
[34] Yuan G, Zhou L, Tang J, Yang Y, Gu W, Li F, Hong J, Gu Y, Li X, Ning G, Chen M. 
Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and 
impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. 
Diabetes Res Clin Pract 2006;72(3):244-50.  
[35] Ma K, Jin X, Liang X, Zhao Q, Zhang X. Inflammatory mediators involved in the 
progression of the metabolic syndrome. Diabetes Metab Res Rev 2012; 28(5):388-94.  
[36] Fève B, Bastard JP .The role of interleukins in insulin resistance and type 2 diabetes 
mellitus. Nature Reviews Endocrinology 2009; 5, 305-311. | 
[37] Wolowczuk I, Verwaerde C, Viltart O, Delanoye A, Delacre M, Pot B, Grangette C. 
Feeding our immune system: impact on metabolism. Clin Dev Immunol 2008:639803.  
[38] Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, Caruso C. 
Innate immunity and inflammation in ageing: a key for understanding age-related 
diseases. Immun Ageing 2005; 2:8. 
[39] Kowalska I, Straczkowski M, Nikolajuk A, Adamska A, Karczewska-Kupczewska M, 
Otziomek E, et al. Insulin resistance, serum adiponectin, and proinflammatory markers 
in young subjects with the metabolic syndrome. Metabolism 2008; 57(11): 1539-1544. 
[40] Flanagan AM, Brown JL, Santiago CA, Aad PY, Spicer LJ, Spicer MT. High-fat diets 
promote insulin resistance through cytokine gene expression in growing female rats. J 
Nutr Biochem 2008; 19(8):505-513. 
 
Glucose Tolerance 36 
[41] Goldberg RB.Cytokine and cytokine-like inflammation markers, endothelial 
dysfunction, and imbalanced coagulation in development of diabetes and its 
complications. J Clin Endocrinol Metab 2009;94(9):3171-82. 
[42] Azar Sharabiani MT, Vermeulen R, Scoccianti C, Hosnijeh FS, Minelli L, Sacerdote C, 
Palli D, Krogh V, Tumino R, Chiodini P, Panico S, Vineis P . Immunologic profile of 
excessive body weight. Biomarkers 2011;16(3):243-51. 
[43] Lamb RE, Goldstein BJ. Modulating an oxidative-inflammatory cascade: potential new 
treatment strategy for improving glucose metabolism, insulin resistance, and vascular 
function. Int J Clin Pract 2008;62(7):1087-95.  
[44] de Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, Kritchevsky SB, Kuller 
LH, Strotmeyer ES, Schwartz AV, Vellas B, Harris TB. Diabetes, hyperglycemia, and 
inflammation in older individuals: the health, aging and body composition study. 
Diabetes Care 2006;29(8):1902-8.  
[45] Kopp HP, Krzyzanowska K, Möhlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects 
of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical 







© 2012 Shi and Kumar, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Sex Differences in Obesity-Related Glucose 
Intolerance and Insulin Resistance 
Haifei Shi and Shiva Priya Dharshan Senthil Kumar 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/52972 
1. Introduction 
The prevalence of obesity has increased dramatically over the past decade (1) along with 
several health risks it encompasses, including non-insulin dependent type 2 diabetes, 
cardiovascular disease, fatty liver, dyslipidemia, and some types of cancer (2). The economic 
costs of caring for patients with obesity and diabetic complications are enormously high (3). 
There are important sex differences in the prevalence of these metabolic diseases. 
Premenopausal women have much less metabolic disorders than men; however, the 
prevalence of obesity and diabetes increases dramatically in postmenopausal women (4). 
Sex steroid hormone estrogen may be protective against the metabolic syndrome and may 
contribute to the maintenance of insulin sensitivity, and its deficiency leads to development 
of type 2 diabetes and insulin resistance. This has resulted in the use of estrogen hormone 
replacement therapy for the treatment of insulin resistance in postmenopausal women (5) 
and in men with congenital aromatase deficiency (6). Thus, estrogen has enormous potential 
as a therapeutic agent for use in the prevention or treatment of type 2 diabetes with glucose 
intolerance and insulin resistance. 
1.1. Sex differences in genetic polymorphisms on the development of diabetes 
The development and etiology of obesity and related diseases such as type 2 diabetes stems 
from a conflict between genes which allowed our ancestors to survive extended periods of 
famine and physiological responses to caloric excess and sedentary lifestyle of the modern 
world. Some studies have evaluated potential genetic components and reported sex 
differences in the effects of certain polymorphisms of several enzymes and genes on the 
development and etiology of diabetes. Several examples are listed below. 
First example is protein tyrosine phosphatase, an enzyme involving signal transduction of T 
cell and insulin receptors. The activity of this enzyme, affected by certain genotypes, is 
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1. Introduction 
The prevalence of obesity has increased dramatically over the past decade (1) along with 
several health risks it encompasses, including non-insulin dependent type 2 diabetes, 
cardiovascular disease, fatty liver, dyslipidemia, and some types of cancer (2). The economic 
costs of caring for patients with obesity and diabetic complications are enormously high (3). 
There are important sex differences in the prevalence of these metabolic diseases. 
Premenopausal women have much less metabolic disorders than men; however, the 
prevalence of obesity and diabetes increases dramatically in postmenopausal women (4). 
Sex steroid hormone estrogen may be protective against the metabolic syndrome and may 
contribute to the maintenance of insulin sensitivity, and its deficiency leads to development 
of type 2 diabetes and insulin resistance. This has resulted in the use of estrogen hormone 
replacement therapy for the treatment of insulin resistance in postmenopausal women (5) 
and in men with congenital aromatase deficiency (6). Thus, estrogen has enormous potential 
as a therapeutic agent for use in the prevention or treatment of type 2 diabetes with glucose 
intolerance and insulin resistance. 
1.1. Sex differences in genetic polymorphisms on the development of diabetes 
The development and etiology of obesity and related diseases such as type 2 diabetes stems 
from a conflict between genes which allowed our ancestors to survive extended periods of 
famine and physiological responses to caloric excess and sedentary lifestyle of the modern 
world. Some studies have evaluated potential genetic components and reported sex 
differences in the effects of certain polymorphisms of several enzymes and genes on the 
development and etiology of diabetes. Several examples are listed below. 
First example is protein tyrosine phosphatase, an enzyme involving signal transduction of T 
cell and insulin receptors. The activity of this enzyme, affected by certain genotypes, is 
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related to age of onset of type 1 diabetes in a sex-specific manner (7). Specifically, genotypes 
associated with medium to high enzyme activity are correlated with younger age of onset in 
females but not in males, whereas low activity genotypes do not display sex differences. 
Second example is peroxisome proliferator-activated receptor y2 (PPARy2), whose 
polymorphism is correlated with increased insulin sensitivity and reduced risk for type 2 
diabetes. Interestingly, in males, a more efficient shift from lipid oxidation in the basal state 
to carbohydrate oxidation during insulin stimulation has been observed in lean, glucose 
tolerant males with the polymorphism compared to wild-type males; whereas this 
difference has not been observed in females (8). Therefore, the PPARy2 polymorphism 
protects individuals from insulin insensitivity by promoting better suppression of lipid 
oxidation leading to more glucose disposal in males but not females. Another example is the 
3’ untranslated region of the PPP1R3A gene, a gene involved in glycogen synthase activity 
and associated with development of type 2 diabetes (9). Males homozygous for the 
polymorphism of PPP1R3A gene are significantly younger at diagnosis than female carriers 
(10). Additionally, a polymorphism in the promoter region of uncoupling protein (UCP)-2, a 
mitochondrial inner membrane protein, may be involved in obesity and development of 
type 2 diabetes (11). In a study of 100 obese subjects, the genotype that causes increased 
transcription of UCP-2 mRNA is more prevalent in diabetic women than in nondiabetic 
women. However no difference in distribution of this genotype is detected in men (12). To 
summarize, sex differences in genetic polymorphisms exist in the development and etiology 
of diabetes.  
1.2. Sex differences in physiologic mechanism on the development of diabetes 
Obesity has been recognized as a major and an independent diabetes risk factor. The 
increase in type 2 diabetes is closely associated with the epidemic of obesity. Body 
composition is very closely associated with glucose tolerance and insulin sensitivity (13). 
Development of adverse metabolic complications has been attributed to increased body fat, 
not just body weight, and the fat distributed particularly in the abdominal visceral 
compartment, a source of bioactive mediators that directly contribute to insulin resistance 
(14). To be more specific, intra-abdominal visceral adipose tissue carries a stronger risk for 
the development of metabolic disorders, such as glucose intolerance and insulin resistance 
related type 2 diabetes, than subcutaneous adipose tissue. Therefore, risk for diabetes 
incidence is particularly high in individuals with large amounts of abdominal visceral fat.  
Sex differences in the regional fat distribution exist. Males and females differ in terms of 
how and where they store body fat. In humans, premenopausal women usually have more 
subcutaneous fat, whereas men have more intra-abdominal visceral fat. Consequently, 
obesity-related metabolic disorders are much lower in premenopausal women than men 
(15). In addition, estrogens are responsible for body weight homeostasis in women. The 
prevalence of obesity is particularly high among middle-aged women. Symptoms of the 
metabolic syndrome, including increased visceral obesity and shifts in body fat distribution, 
as well as glucose intolerance and insulin resistance begin appearing in many women 
experiencing menopause and developing estrogen deficiency (16). Even in women who do 
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not gain weight after menopause, fat shifts from a subcutaneous location into the abdomen. 
Women are at an increased risk to develop visceral obesity due to the loss of endogenous 
ovarian hormone production. The increased visceral obesity in menopausal women can be 
altered by exogenous hormone replacement therapy (17, 18). Researches using animal 
models have provided important insights into the pathogenesis of human diseases and new 
therapeutic approaches. Peripheral metabolic signals and hormones are not only involved in 
regulating adiposity and body fat distribution, but also involved in regulating glucose 
metabolism and glucose tolerance. In experimental rodent models, reductions in circulating 
estrogens, which occurs following removal of ovaries (i.e., ovariectomy), results in increased 
body adiposity. Such increase in body adiposity can be ameliorated by exogenous 17β –
estradiol administration (19).  
In addition, sex hormones are directly involved in the regulation of glucose tolerance (20, 
21). In a prospective study that included over 500 women and men who did not have 
diabetes upon study entry, development of diabetes was associated with low levels of total 
testosterone in men and high levels of bioavailable testosterone in women (22). Therefore, 
differences in the regulation of glucose tolerance may be under the influence of sex 
hormones indirectly through their influence of body fat content and distribution or directly 
through their influence in the glucose metabolism and insulin signaling.  
This chapter discusses the sex differences in regulation of glucose homeostasis, focusing on 
the roles of female sex hormone estrogens as determinants mediating body adiposity levels 
and body fat distribution as well as glucose metabolism and insulin sensitivity. We will use 
the term “sex difference” instead of “gender difference” throughout this chapter. The term 
“sex” refers to differences between males and females that result from the chromosomal 
complement and the effects of hormones; whereas the term “gender” refers to an 
individual’s identity as a man or a woman, and the cultural and behavioral expectations 
associated with being a man or a woman. With regard to the regulation of glucose 
homeostasis and energy metabolism, little is known about gender differences, thus this 
chapter focuses primarily on sex differences. 
2. Sex differences in body adiposity and fat distribution 
The prevalence of obesity is higher in women than in men in many areas around the world 
(www.iaso.org). In addition there is a sex difference in body fat distribution. These sex 
differences in obesity incidence and fat distribution can be explained in part by the influence 
of gonadal steroids, as well as behavioral, socio-cultural and genetic factors. Several factors 
may play important roles to drive greater propensity for excess body fat in females than in 
males. It has been suggested that evolutionary pressures predispose females to store excess 
fat for reproduction and lactation. In contrast, evolutionary pressures predispose males to 
burn stored fuels in gathering and hunting. Adipose tissue plays a major role in the 
regulation of glucose homeostasis and insulin sensitivity, thus total body adiposity is closely 
associated with insulin sensitivity. Increased body fat is a risk factor for developing type 2 
diabetes mellitus. A line of research has focused on behavioral and social differences 
between men and women that relate to eating or activity behaviors. Sex differences in body 
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related to age of onset of type 1 diabetes in a sex-specific manner (7). Specifically, genotypes 
associated with medium to high enzyme activity are correlated with younger age of onset in 
females but not in males, whereas low activity genotypes do not display sex differences. 
Second example is peroxisome proliferator-activated receptor y2 (PPARy2), whose 
polymorphism is correlated with increased insulin sensitivity and reduced risk for type 2 
diabetes. Interestingly, in males, a more efficient shift from lipid oxidation in the basal state 
to carbohydrate oxidation during insulin stimulation has been observed in lean, glucose 
tolerant males with the polymorphism compared to wild-type males; whereas this 
difference has not been observed in females (8). Therefore, the PPARy2 polymorphism 
protects individuals from insulin insensitivity by promoting better suppression of lipid 
oxidation leading to more glucose disposal in males but not females. Another example is the 
3’ untranslated region of the PPP1R3A gene, a gene involved in glycogen synthase activity 
and associated with development of type 2 diabetes (9). Males homozygous for the 
polymorphism of PPP1R3A gene are significantly younger at diagnosis than female carriers 
(10). Additionally, a polymorphism in the promoter region of uncoupling protein (UCP)-2, a 
mitochondrial inner membrane protein, may be involved in obesity and development of 
type 2 diabetes (11). In a study of 100 obese subjects, the genotype that causes increased 
transcription of UCP-2 mRNA is more prevalent in diabetic women than in nondiabetic 
women. However no difference in distribution of this genotype is detected in men (12). To 
summarize, sex differences in genetic polymorphisms exist in the development and etiology 
of diabetes.  
1.2. Sex differences in physiologic mechanism on the development of diabetes 
Obesity has been recognized as a major and an independent diabetes risk factor. The 
increase in type 2 diabetes is closely associated with the epidemic of obesity. Body 
composition is very closely associated with glucose tolerance and insulin sensitivity (13). 
Development of adverse metabolic complications has been attributed to increased body fat, 
not just body weight, and the fat distributed particularly in the abdominal visceral 
compartment, a source of bioactive mediators that directly contribute to insulin resistance 
(14). To be more specific, intra-abdominal visceral adipose tissue carries a stronger risk for 
the development of metabolic disorders, such as glucose intolerance and insulin resistance 
related type 2 diabetes, than subcutaneous adipose tissue. Therefore, risk for diabetes 
incidence is particularly high in individuals with large amounts of abdominal visceral fat.  
Sex differences in the regional fat distribution exist. Males and females differ in terms of 
how and where they store body fat. In humans, premenopausal women usually have more 
subcutaneous fat, whereas men have more intra-abdominal visceral fat. Consequently, 
obesity-related metabolic disorders are much lower in premenopausal women than men 
(15). In addition, estrogens are responsible for body weight homeostasis in women. The 
prevalence of obesity is particularly high among middle-aged women. Symptoms of the 
metabolic syndrome, including increased visceral obesity and shifts in body fat distribution, 
as well as glucose intolerance and insulin resistance begin appearing in many women 
experiencing menopause and developing estrogen deficiency (16). Even in women who do 
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not gain weight after menopause, fat shifts from a subcutaneous location into the abdomen. 
Women are at an increased risk to develop visceral obesity due to the loss of endogenous 
ovarian hormone production. The increased visceral obesity in menopausal women can be 
altered by exogenous hormone replacement therapy (17, 18). Researches using animal 
models have provided important insights into the pathogenesis of human diseases and new 
therapeutic approaches. Peripheral metabolic signals and hormones are not only involved in 
regulating adiposity and body fat distribution, but also involved in regulating glucose 
metabolism and glucose tolerance. In experimental rodent models, reductions in circulating 
estrogens, which occurs following removal of ovaries (i.e., ovariectomy), results in increased 
body adiposity. Such increase in body adiposity can be ameliorated by exogenous 17β –
estradiol administration (19).  
In addition, sex hormones are directly involved in the regulation of glucose tolerance (20, 
21). In a prospective study that included over 500 women and men who did not have 
diabetes upon study entry, development of diabetes was associated with low levels of total 
testosterone in men and high levels of bioavailable testosterone in women (22). Therefore, 
differences in the regulation of glucose tolerance may be under the influence of sex 
hormones indirectly through their influence of body fat content and distribution or directly 
through their influence in the glucose metabolism and insulin signaling.  
This chapter discusses the sex differences in regulation of glucose homeostasis, focusing on 
the roles of female sex hormone estrogens as determinants mediating body adiposity levels 
and body fat distribution as well as glucose metabolism and insulin sensitivity. We will use 
the term “sex difference” instead of “gender difference” throughout this chapter. The term 
“sex” refers to differences between males and females that result from the chromosomal 
complement and the effects of hormones; whereas the term “gender” refers to an 
individual’s identity as a man or a woman, and the cultural and behavioral expectations 
associated with being a man or a woman. With regard to the regulation of glucose 
homeostasis and energy metabolism, little is known about gender differences, thus this 
chapter focuses primarily on sex differences. 
2. Sex differences in body adiposity and fat distribution 
The prevalence of obesity is higher in women than in men in many areas around the world 
(www.iaso.org). In addition there is a sex difference in body fat distribution. These sex 
differences in obesity incidence and fat distribution can be explained in part by the influence 
of gonadal steroids, as well as behavioral, socio-cultural and genetic factors. Several factors 
may play important roles to drive greater propensity for excess body fat in females than in 
males. It has been suggested that evolutionary pressures predispose females to store excess 
fat for reproduction and lactation. In contrast, evolutionary pressures predispose males to 
burn stored fuels in gathering and hunting. Adipose tissue plays a major role in the 
regulation of glucose homeostasis and insulin sensitivity, thus total body adiposity is closely 
associated with insulin sensitivity. Increased body fat is a risk factor for developing type 2 
diabetes mellitus. A line of research has focused on behavioral and social differences 
between men and women that relate to eating or activity behaviors. Sex differences in body 
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composition and insulin sensitivity are evident in humans throughout the lifespan. 
Pregnancy and menopause also have physiological and behavioral consequences on 
appetite and weight regulation that confer elevated obesity risk in many women. There is a 
sex difference in the regional fat distribution. Men and premenopausal women differ in their 
fat distribution. Females have “gynoid” or female-pattern fat distribution with more 
subcutaneous fat, whereas males have “android” or male-pattern body fat distribution with 
more abdominal visceral fat (15). Fat deposition in the subcutaneous depot is important for 
females during lactation. Despite the higher level of body fat, obesity-related metabolic 
disorders, such as type 2 diabetes, are much lower in premenopausal women and female 
animals than males. The role of estrogen in mediating body fat distribution and glucose 
homeostasis will be discussed in this chapter. 
2.1. Difference between subcutaneous and abdominal adipose tissues 
Body fat distribution is a more appropriate indicator than total adiposity for metabolic 
disorders, as obesity is not only a condition characterized by homogenous distribution of 
adipose tissue, but that the regional distribution of adipose tissue is more important in 
understanding the relationship between obesity and various metabolic diseases. Adipose 
tissue, which is distributed in the abdominal viscera, carries a greater risk for glucose 
intolerance and insulin resistance than adipose tissue subcutaneously. Specifically, 
abdominal adipose tissues contribute to the development of insulin resistance, glucose 
intolerance, hypertension, dyslipidemia, and atherosclerosis (23). Metabolites and secretions 
of visceral adipose tissue drain through the hepatic portal system, partially at least, to the 
liver. Insulin effect is lower and catecholamine effect is higher in visceral than subcutaneous 
adipose tissue. Specifically,  visceral fat have higher rates of catecholamine-induced lipolysis 
(24, 25), express higher numbers of beta-1, -2 and -3 adrenergic receptors and are more 
sensitive to catecholamine-induced lipolysis  (26, 27), and are less responsive to the cAMP-
lowering effects of alpha-adrenergic agonists (28). In addition, visceral fat cells express 
higher levels of glucocorticoid receptor (29, 30) and have greater glucocorticoid response 
with lipoprotein lipase activation (31), produce more angiotensinogen (32, 33), and secrete 
more interleukin-6 and plasminogen activator inhibitor-1 (34) than subcutaneous adipose 
tissue. Accumulation of intra-abdominal/visceral adipose tissue carries a much greater risk 
for metabolic disorders than does adipose tissue distributed subcutaneously (35-37). In 
contrast, subcutaneous fat distribution is poorly correlated with risks for these metabolic 
disorders (23). Therefore, the elevated health risks in diabetes associated with obesity 
depend on the localization of the adipose tissue in the body, as the distribution of fat is more 
directly associated with glucose tolerance and insulin sensitivity than the total body 
adiposity. Consequently, there is a sex-based difference in the prevalence and incidence of 
metabolic complications associated with obesity. Males have an increased incidence of 
obesity-related metabolic diseases than females aged 12 to 18 years (38, 39). In 
premenopausal women, there is a lower incidence of metabolic disorders associated with 
obesity (38). The prevalence of the metabolic syndrome increases with age, and the 
prevalence of the metabolic syndrome is similar in middle-aged men and women (40). 
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There are noted functional differences between subcutaneous and abdominal adipose 
tissues. Subcutaneous tissue is poorly innervated compared to the abdominal adipose tissue 
(35). Consequently, subcutaneous adipose tissue takes up free fatty acids and stores the 
excess calories more readily than abdominal adipose tissue in both males and females. 
Lipoprotein lipase (LPL) is the major enzyme involved in the fatty acid uptake and is the 
key regulator of fat accumulation in adipose tissues. Estrogens decrease adipose tissue LPL 
activity (41-43), and thus males have a higher level of LPL activity and thus fat accumulation 
than females with higher levels of estrogens. The lipolytic pathway involves the breakdown of 
energy stored in the form of triglycerides and is initiated when the energy supply from the 
metabolic fuels is depleted. The lipolytic activity of the abdominal fat is higher compared to 
the lipolytic activity of the subcutaneous fat in premenopausal women; a phenomenon not 
observed in post-menopausal women lacking endogenous estrogen (24, 44, 45).  
Recent evidence suggests that great subcutaneous fat accumulation may be protective 
against development of metabolic disorders. First, epidemiological studies indicate 
association of a high waist-to-hip ratio, instead of a large waist circumference alone, with 
the incidence of type 2 diabetes and other metabolic diseases (46-48). Indeed, a larger hip 
circumference has been shown to be protective against metabolic risk in multiple ethnic 
groups, independent of waist circumference or abdominal fat accumulation(49). Second, 
several animal studies reported that mice with transplantation of subcutaneous fat from the 
inguinal region of male donors into the intra-abdominal compartment of male recipient 
mice resulted in significantly protective effects on adiposity, insulin sensitivity and glucose 
tolerance (50-53). Since protective effect of a large hip circumference with regard to 
cardiovascular disease morbidity and mortality is significant in women but not in men (54), 
it would be expected that transplanting female subcutaneous adipose tissue might have 
greater protective effects.  
2.2. Sex hormone estrogens and estrogen receptors regulate adiposity 
Obesity development is accelerated after menopause in women; factors such as loss of 
estrogens, the ageing process and changes in lifestyle may all be contributors (Shi & Clegg 
2009, Barton 2010). The effect of menopause is supported by animal models showing that a 
reduction in circulating estrogen levels following ovariectomy results in increased body 
adiposity (55). Body fat increases in several conditions associated with estrogen deficiency 
such as ovariectomy, polycystic ovary syndrome (PCOS), and the lack of a functional 
aromatase gene; all can be corrected and reversed by exogenous administration of 17β-
estradiol, the active form of estrogens (56-61).  
The classical nuclear estrogen receptors (ER) include estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ).Genomic activation of ERs results from estrogens binding to 
estrogen response elements (EREs) in promoter regions of target genes (62, 63). Increased 
visceral adiposity is associated with the XbaI polymorphism of the human ERα gene when 
guanidine is substituted for adenine in exon one (64). Additionally, pre-menopausal women 
with increased of visceral adiposity, indicated by higher waist-hip ratios, have the XbaI 
polymorphism compared to the control cohort of women with the normal genotype (64). 
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composition and insulin sensitivity are evident in humans throughout the lifespan. 
Pregnancy and menopause also have physiological and behavioral consequences on 
appetite and weight regulation that confer elevated obesity risk in many women. There is a 
sex difference in the regional fat distribution. Men and premenopausal women differ in their 
fat distribution. Females have “gynoid” or female-pattern fat distribution with more 
subcutaneous fat, whereas males have “android” or male-pattern body fat distribution with 
more abdominal visceral fat (15). Fat deposition in the subcutaneous depot is important for 
females during lactation. Despite the higher level of body fat, obesity-related metabolic 
disorders, such as type 2 diabetes, are much lower in premenopausal women and female 
animals than males. The role of estrogen in mediating body fat distribution and glucose 
homeostasis will be discussed in this chapter. 
2.1. Difference between subcutaneous and abdominal adipose tissues 
Body fat distribution is a more appropriate indicator than total adiposity for metabolic 
disorders, as obesity is not only a condition characterized by homogenous distribution of 
adipose tissue, but that the regional distribution of adipose tissue is more important in 
understanding the relationship between obesity and various metabolic diseases. Adipose 
tissue, which is distributed in the abdominal viscera, carries a greater risk for glucose 
intolerance and insulin resistance than adipose tissue subcutaneously. Specifically, 
abdominal adipose tissues contribute to the development of insulin resistance, glucose 
intolerance, hypertension, dyslipidemia, and atherosclerosis (23). Metabolites and secretions 
of visceral adipose tissue drain through the hepatic portal system, partially at least, to the 
liver. Insulin effect is lower and catecholamine effect is higher in visceral than subcutaneous 
adipose tissue. Specifically,  visceral fat have higher rates of catecholamine-induced lipolysis 
(24, 25), express higher numbers of beta-1, -2 and -3 adrenergic receptors and are more 
sensitive to catecholamine-induced lipolysis  (26, 27), and are less responsive to the cAMP-
lowering effects of alpha-adrenergic agonists (28). In addition, visceral fat cells express 
higher levels of glucocorticoid receptor (29, 30) and have greater glucocorticoid response 
with lipoprotein lipase activation (31), produce more angiotensinogen (32, 33), and secrete 
more interleukin-6 and plasminogen activator inhibitor-1 (34) than subcutaneous adipose 
tissue. Accumulation of intra-abdominal/visceral adipose tissue carries a much greater risk 
for metabolic disorders than does adipose tissue distributed subcutaneously (35-37). In 
contrast, subcutaneous fat distribution is poorly correlated with risks for these metabolic 
disorders (23). Therefore, the elevated health risks in diabetes associated with obesity 
depend on the localization of the adipose tissue in the body, as the distribution of fat is more 
directly associated with glucose tolerance and insulin sensitivity than the total body 
adiposity. Consequently, there is a sex-based difference in the prevalence and incidence of 
metabolic complications associated with obesity. Males have an increased incidence of 
obesity-related metabolic diseases than females aged 12 to 18 years (38, 39). In 
premenopausal women, there is a lower incidence of metabolic disorders associated with 
obesity (38). The prevalence of the metabolic syndrome increases with age, and the 
prevalence of the metabolic syndrome is similar in middle-aged men and women (40). 
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There are noted functional differences between subcutaneous and abdominal adipose 
tissues. Subcutaneous tissue is poorly innervated compared to the abdominal adipose tissue 
(35). Consequently, subcutaneous adipose tissue takes up free fatty acids and stores the 
excess calories more readily than abdominal adipose tissue in both males and females. 
Lipoprotein lipase (LPL) is the major enzyme involved in the fatty acid uptake and is the 
key regulator of fat accumulation in adipose tissues. Estrogens decrease adipose tissue LPL 
activity (41-43), and thus males have a higher level of LPL activity and thus fat accumulation 
than females with higher levels of estrogens. The lipolytic pathway involves the breakdown of 
energy stored in the form of triglycerides and is initiated when the energy supply from the 
metabolic fuels is depleted. The lipolytic activity of the abdominal fat is higher compared to 
the lipolytic activity of the subcutaneous fat in premenopausal women; a phenomenon not 
observed in post-menopausal women lacking endogenous estrogen (24, 44, 45).  
Recent evidence suggests that great subcutaneous fat accumulation may be protective 
against development of metabolic disorders. First, epidemiological studies indicate 
association of a high waist-to-hip ratio, instead of a large waist circumference alone, with 
the incidence of type 2 diabetes and other metabolic diseases (46-48). Indeed, a larger hip 
circumference has been shown to be protective against metabolic risk in multiple ethnic 
groups, independent of waist circumference or abdominal fat accumulation(49). Second, 
several animal studies reported that mice with transplantation of subcutaneous fat from the 
inguinal region of male donors into the intra-abdominal compartment of male recipient 
mice resulted in significantly protective effects on adiposity, insulin sensitivity and glucose 
tolerance (50-53). Since protective effect of a large hip circumference with regard to 
cardiovascular disease morbidity and mortality is significant in women but not in men (54), 
it would be expected that transplanting female subcutaneous adipose tissue might have 
greater protective effects.  
2.2. Sex hormone estrogens and estrogen receptors regulate adiposity 
Obesity development is accelerated after menopause in women; factors such as loss of 
estrogens, the ageing process and changes in lifestyle may all be contributors (Shi & Clegg 
2009, Barton 2010). The effect of menopause is supported by animal models showing that a 
reduction in circulating estrogen levels following ovariectomy results in increased body 
adiposity (55). Body fat increases in several conditions associated with estrogen deficiency 
such as ovariectomy, polycystic ovary syndrome (PCOS), and the lack of a functional 
aromatase gene; all can be corrected and reversed by exogenous administration of 17β-
estradiol, the active form of estrogens (56-61).  
The classical nuclear estrogen receptors (ER) include estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ).Genomic activation of ERs results from estrogens binding to 
estrogen response elements (EREs) in promoter regions of target genes (62, 63). Increased 
visceral adiposity is associated with the XbaI polymorphism of the human ERα gene when 
guanidine is substituted for adenine in exon one (64). Additionally, pre-menopausal women 
with increased of visceral adiposity, indicated by higher waist-hip ratios, have the XbaI 
polymorphism compared to the control cohort of women with the normal genotype (64). 
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Interestingly such polymorphism does not affect adiposity in postmenopausal women or in 
men(64). ERα gene expression in subcutaneous adipose tissue is reduced in obese pre-
menopausal women, but increases after weight reduction (65). Furthermore several ERα 
single nucleotide polymorphisms have been associated with obesity phenotypes in women 
and men (64, 66, 67). Thus, polymorphisms of the human ERα gene may impair estrogen 
signaling and lead to increased visceral adiposity and its attendant health risks. In humans, 
polymorphisms in the ERβ gene have been associated with lower BMI although other 
investigators found no correlations (68, 69). 
Utilizing targeted deletions in the ERα gene or both ERα and ERβ genes of male and female 
mice indicate increase in adiposity (70, 71). ERβ inhibits food intake and reduces body 
weight through effects in the central nervous system in rats (72). In addition, one study 
investigated the effect of estrogens on adipose tissue development using ERα knockout 
mice. Loss of estrogen following ovariectomy in ERα knockout mice resulted in decreased 
body fat and adipocyte size, which was reversed by 17β-estradiol treatment (73), suggesting 
that regulation of body adiposity is mediated by an ER other than ERα, possibly by ERβ. In 
contrast, mice lacking both ERα and ERβ develop obesity but increased adiposity is not 
observed in ERβ-knockout mice (71), questioning a role for ERβ and suggesting that the 
obesity-promoting effect of estrogen deficiency is mediated specifically through ERα. These 
findings support a substantial physiological role for ERα in mediating the effects of 
estrogens in the control of body adiposity. Replacement of 17β-estradiol prevents 
ovariectomized wild-type mice from developing obesity, such protective effects are not 
observed in ovariectomized ERα deficient mice (74). Therefore, estrogens, together with its 
ERα, play important roles to regulate total adiposity. 
To summarize, the metabolic effects of estrogens appear to be largely mediated by ERα 
whereas the role of ERβ and possible cross-talk with other ERs is currently unclear. Indeed, 
ERβ inhibits ERα-mediated gene expression in certain cell types and often opposes the 
action of ERα (75), an interaction that might be also important for the regulation of body fat. 
Finally, it should be noted that compensatory developmental changes in both animal models 
and humans may alter hormone responsiveness in ways that are different from the inherent 
biology in healthy individuals or wild-type animals respectively.  
2.3. Sex hormone estrogens regulate fat distribution 
Because there are differential effects on health risk between subcutaneous and abdominal 
adipose tissues, it is important to understand mechanisms that determine not only total fat 
accumulation but also where fat is accumulated, and how fat distribution is regulated in 
males and females. Recent research using molecular approaches and animal models has 
provided greater understanding of the role of sex hormones and other molecules on fat 
partitioning. 
The question of sex differences in fat distribution have been examined using animal models. 
Several animal species, including pigs and rodents, show sex-specific differences in fat 
distribution, with males having more abdominal fat and less subcutaneous fat than females. 
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Ovarian hormone estrogen appears to be a key regulator in mediating the sex-specific 
adipose tissue distribution pattern. Estrogens promote the accumulation of subcutaneous fat 
(76). In contrast, abdominal fat varies inversely with levels of estrogens (77). During the 
peri-menopausal period, depletion of ovarian follicles leads to a steady decline in 17β-
estradiol production in post-menopausal women (78). Loss of estrogens with menopause is 
associated with an increase in abdominal fat accrual (36). Indeed, changes in body fat mass 
are positively correlated with serum 17β-estradiol concentration in post-menopausal women 
(79-81), although this association varies with time from the onset of menopause and may 
take up to 6 years to develop (81). In premenopausal women, there is a lower incidence of 
metabolic disorders associated with obesity. However, after menopause when there is a very 
low level of estrogen in the circulation, an increased risk of obesity-related metabolic 
disorders is reported (38). Therefore ovarian hormones might play a vital role in protecting 
the body against metabolic diseases via the sex-based differences seen in adipose tissue 
deposition.  
The sexual dimorphism in adipose tissue distribution may partially explain the greater risk 
for the metabolic syndrome in men compared with premenopausal women. Estrogens are 
known to regulate body fat distribution in animals and humans. As being discussed earlier 
in this chapter, females tend to accumulate more fat in their subcutaneous depots whereas 
males tend to accumulate more fat in their visceral depots (82). Additionally, after the loss of 
endogenous estrogens as a result of menopause, a shift towards visceral adiposity occurs, 
which is sensitive to estrogen therapy (55).  
Studies in ovariectomized rodent models have elucidated possible mechanisms by which 
changes in estrogen levels may impact fat distribution. Ovariectomized female rats gain fat, 
specifically visceral fat with a loss of subcutaneous fat (19, 83). Additionally peripheral or 
central administration of 17β-estradiol to OVX rats changes their body fat distribution to 
mirror that of intact females with normal estrous cycles. administration of exogenous 
estradiol reverses this increased visceral fat distribution pattern (19). Furthermore, altering 
the sex hormone milieu in males with exogenous 17β-estradiol administration to male rats 
decreases visceral fat and increases subcutaneous fat relative to males not given estrogen 
(19). An important implication from these findings is that estrogens are critical determinates 
of body fat distribution. Estrogen may influence fat distribution centrally by modulating 
leptin responsiveness, as leptin not only influences total body fat in rodents but also favors 
loss of visceral fat via Stat3 signaling in the hypothalamus (84). Female mice are more 
responsive than male mice to the effects of centrally administered leptin to decrease food 
intake and body weight and to increase c-fos and Stat3 expression in the arcuate nucleus 
(85). In addition, research has shown that both male and female aromatase-knockout mice, 
which are estrogen-deficient and have elevated testosterone, accumulate more abdominal 
adipose tissue with increased adipocyte size in the gonadal and intra-renal fat depots (57). 
Male aromatase-knockout mice also develop fatty liver, as do aromatase-deficient men, and 
this is reversible with estradiol treatment (86). 
Sex hormones play important roles in adipose tissue lipolysis and fat uptake. Sex differences 
exist for regulation of lipolysis by alpha-2 adrenergic receptor(87). Estrogen treatment 
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Interestingly such polymorphism does not affect adiposity in postmenopausal women or in 
men(64). ERα gene expression in subcutaneous adipose tissue is reduced in obese pre-
menopausal women, but increases after weight reduction (65). Furthermore several ERα 
single nucleotide polymorphisms have been associated with obesity phenotypes in women 
and men (64, 66, 67). Thus, polymorphisms of the human ERα gene may impair estrogen 
signaling and lead to increased visceral adiposity and its attendant health risks. In humans, 
polymorphisms in the ERβ gene have been associated with lower BMI although other 
investigators found no correlations (68, 69). 
Utilizing targeted deletions in the ERα gene or both ERα and ERβ genes of male and female 
mice indicate increase in adiposity (70, 71). ERβ inhibits food intake and reduces body 
weight through effects in the central nervous system in rats (72). In addition, one study 
investigated the effect of estrogens on adipose tissue development using ERα knockout 
mice. Loss of estrogen following ovariectomy in ERα knockout mice resulted in decreased 
body fat and adipocyte size, which was reversed by 17β-estradiol treatment (73), suggesting 
that regulation of body adiposity is mediated by an ER other than ERα, possibly by ERβ. In 
contrast, mice lacking both ERα and ERβ develop obesity but increased adiposity is not 
observed in ERβ-knockout mice (71), questioning a role for ERβ and suggesting that the 
obesity-promoting effect of estrogen deficiency is mediated specifically through ERα. These 
findings support a substantial physiological role for ERα in mediating the effects of 
estrogens in the control of body adiposity. Replacement of 17β-estradiol prevents 
ovariectomized wild-type mice from developing obesity, such protective effects are not 
observed in ovariectomized ERα deficient mice (74). Therefore, estrogens, together with its 
ERα, play important roles to regulate total adiposity. 
To summarize, the metabolic effects of estrogens appear to be largely mediated by ERα 
whereas the role of ERβ and possible cross-talk with other ERs is currently unclear. Indeed, 
ERβ inhibits ERα-mediated gene expression in certain cell types and often opposes the 
action of ERα (75), an interaction that might be also important for the regulation of body fat. 
Finally, it should be noted that compensatory developmental changes in both animal models 
and humans may alter hormone responsiveness in ways that are different from the inherent 
biology in healthy individuals or wild-type animals respectively.  
2.3. Sex hormone estrogens regulate fat distribution 
Because there are differential effects on health risk between subcutaneous and abdominal 
adipose tissues, it is important to understand mechanisms that determine not only total fat 
accumulation but also where fat is accumulated, and how fat distribution is regulated in 
males and females. Recent research using molecular approaches and animal models has 
provided greater understanding of the role of sex hormones and other molecules on fat 
partitioning. 
The question of sex differences in fat distribution have been examined using animal models. 
Several animal species, including pigs and rodents, show sex-specific differences in fat 
distribution, with males having more abdominal fat and less subcutaneous fat than females. 
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Ovarian hormone estrogen appears to be a key regulator in mediating the sex-specific 
adipose tissue distribution pattern. Estrogens promote the accumulation of subcutaneous fat 
(76). In contrast, abdominal fat varies inversely with levels of estrogens (77). During the 
peri-menopausal period, depletion of ovarian follicles leads to a steady decline in 17β-
estradiol production in post-menopausal women (78). Loss of estrogens with menopause is 
associated with an increase in abdominal fat accrual (36). Indeed, changes in body fat mass 
are positively correlated with serum 17β-estradiol concentration in post-menopausal women 
(79-81), although this association varies with time from the onset of menopause and may 
take up to 6 years to develop (81). In premenopausal women, there is a lower incidence of 
metabolic disorders associated with obesity. However, after menopause when there is a very 
low level of estrogen in the circulation, an increased risk of obesity-related metabolic 
disorders is reported (38). Therefore ovarian hormones might play a vital role in protecting 
the body against metabolic diseases via the sex-based differences seen in adipose tissue 
deposition.  
The sexual dimorphism in adipose tissue distribution may partially explain the greater risk 
for the metabolic syndrome in men compared with premenopausal women. Estrogens are 
known to regulate body fat distribution in animals and humans. As being discussed earlier 
in this chapter, females tend to accumulate more fat in their subcutaneous depots whereas 
males tend to accumulate more fat in their visceral depots (82). Additionally, after the loss of 
endogenous estrogens as a result of menopause, a shift towards visceral adiposity occurs, 
which is sensitive to estrogen therapy (55).  
Studies in ovariectomized rodent models have elucidated possible mechanisms by which 
changes in estrogen levels may impact fat distribution. Ovariectomized female rats gain fat, 
specifically visceral fat with a loss of subcutaneous fat (19, 83). Additionally peripheral or 
central administration of 17β-estradiol to OVX rats changes their body fat distribution to 
mirror that of intact females with normal estrous cycles. administration of exogenous 
estradiol reverses this increased visceral fat distribution pattern (19). Furthermore, altering 
the sex hormone milieu in males with exogenous 17β-estradiol administration to male rats 
decreases visceral fat and increases subcutaneous fat relative to males not given estrogen 
(19). An important implication from these findings is that estrogens are critical determinates 
of body fat distribution. Estrogen may influence fat distribution centrally by modulating 
leptin responsiveness, as leptin not only influences total body fat in rodents but also favors 
loss of visceral fat via Stat3 signaling in the hypothalamus (84). Female mice are more 
responsive than male mice to the effects of centrally administered leptin to decrease food 
intake and body weight and to increase c-fos and Stat3 expression in the arcuate nucleus 
(85). In addition, research has shown that both male and female aromatase-knockout mice, 
which are estrogen-deficient and have elevated testosterone, accumulate more abdominal 
adipose tissue with increased adipocyte size in the gonadal and intra-renal fat depots (57). 
Male aromatase-knockout mice also develop fatty liver, as do aromatase-deficient men, and 
this is reversible with estradiol treatment (86). 
Sex hormones play important roles in adipose tissue lipolysis and fat uptake. Sex differences 
exist for regulation of lipolysis by alpha-2 adrenergic receptor(87). Estrogen treatment 
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increases lipolysis in abdominal fat cells in mice(88). Lactation and menopausal status also 
impact the lipolytic responsiveness and lipoprotein lipase activity of fat cells. Higher 
adipose tissue lipoprotein lipase activity (promoting fat storage) occurs in subcutaneous 
femoral adipocytes compared with abdominal adipocytes in premenopausal women but not 
in postmenopausal, estrogen-deficient women(89). Additionally lipolysis increases in 
subcutaneous femoral fat during lactation but not in abdominal fat(89). Furthermore, 
estrogen treatment in postmenopausal women restores the lipoprotein lipase activity of the 
femoral adipocytes and attenuates lipolytic response in subcutaneous adipocytes but not in 
abdominal adipocytes (90). Subcutaneous gluteal adipocytes from premenopausal women 
are more sensitive to the antilipolytic effects of insulin than abdominal adipocytes (91). 
Testosterone, male androgens also impact body fat distribution. Testosterone deficiency 
aggravates the development of obesity and hyperinsulinemia, which in turn will suppress 
testicular androgen synthesis even further and result in a vicious cycle (92). In ‘andropause’ 
men, gradual decline in circulating androgens with aging is accompanied by increased total 
and abdominal fat (93). Administration of aromatizable androgens such as testosterone (94, 
95), but not nonaromatizable dihydrotestostone (94), reduces total and abdominal fat in 
older men. In contrast, androgen administration to ovariectomized female mice significantly 
increases body adiposity and abdominal fat (96). Such obesity development is associated 
with reduced fatty acid oxidation, indicated by decreased phosphorylation of adenosine 
monophosphate (AMP)-activated protein kinase and acetyl-CoA carboxylase in abdominal 
visceral fat (96). In humans, women with higher circulating androgen levels (97) or 
exogenous androgen administration (98, 99) increase abdominal fat. These findings raise 
significant clinical concern about the use of testosterone as a hormone replacement therapy 
in postmenopausal women.  
In summary, sex differences in body fat distribution appear to be largely a result of 
differences in sex hormones between men and women. Estrogens reduce visceral fat in men 
and women, an effect that is likely mediated by both central and peripheral mechanisms. In 
contrast, opposite effects of androgens on fat distribution in men and women are seen, with 
aromatizable androgens decreasing visceral fat in men but increasing it in women. 
2.4. Estrogen receptors regulate fat distribution 
Gonadal hormones, including estrogen, progesterone and androgen, have their receptors 
expressed in the visceral and the subcutaneous adipose tissue depots (100). Subcutaneous 
adipose tissues have higher concentrations of estrogen receptors and progesterone receptors 
than androgen receptors in females, and estrogens down-regulates AR expression in 
subcutaneous fat (101). In contrast, visceral adipose tissue has higher concentrations of 
androgen receptors (102, 103). In visceral adipose tissue, there is an increase in the 
expression of androgen receptors in males relative to estrogen receptors. The development 
of knockout animals has provided a powerful tool to examine the role of individual 
receptors for estrogen, progesterone and androgen in the regulation of adipose tissue. 
Adipose tissue-specific androgen receptor knockout mice have increased intra-adipose 
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tissue estradiol levels, which precedes increased subcutaneous obesity and hyperleptinemia 
(104). Additionally, androgens can be converted to estrogens through activation of the 
aromatase enzyme. Aromatase knockout mice have elevated testosterone and accumulate 
more abdominal adipose tissue with increased adipocyte size in the visceral fat depot. 
Hence, in adipose tissue, there is a counteracting effect between estrogen and androgen, 
which may lead to differences in fat distribution.  
Estradiol regulates body fat distribution either directly at the level of the adipocyte or 
through augmenting the efficacy of the adiposity signals in the CNS. Subcutaneous and 
abdominal adipose tissues express both ERα and ERβ, but ERα is predominantly expressed 
in abdominal adipose tissue (105) and ERβ are higher in subcutaneous adipose tissue (106). 
ERα gene polymorphisms predict abdominal obesity in women, but not in men, suggesting 
a possible sexual dimorphism in the ERα effects (64). Female and male mice lacking ERα 
develop central obesity with increases in abdominal adipose tissue, which is reflected by 
increased adipocyte number and size (70). ERα is ubiquitously expressed in rodent brains, 
but the physiologically relevant sites of ERα in the regulation of food intake and energy 
expenditure have not been identified. ERα is expressed in the ventrolateral portion of the 
VMN, the ARC, the medial preoptic area (MPOA), and the paraventricular nuclei (PVN) 
(107-109). ERβ is found in the same hypothalamic nuclei as ERα, but ERβ expression is 
significantly reduced relative to ERα. Site-specific knock-down of ERα in bilateral 
ventromedial nucleus of the hypothalamus in mice using siRNA result in increased 
adiposity, no change in food intake, and suppression of energy expenditure, increased 
visceral adiposity, and decreased leptin sensitivity, implicating ventromedial hypothalamic 
ERα in energy homeostasis (110).  
Both short-term and long-term castration in males resulted in increased insulin sensitivity and 
increased lipogenesis in both abdominal and subcutaneous adipose tissues, an event that is 
independent of changes in the fat pad weights (102). Thus, in contrast to the preferential effect 
of estrogen in females on the abdominal adipocytes, testosterone exerts an inhibitory effect on 
lipogenesis and insulin sensitivity in both abdominal and subcutaneous adipocytes. 
3. Sex difference in glucose metabolism 
Glucose challenge test is important in terms of understanding the pathophysiology of 
individuals at risk of progressing to type 2 diabetes. As recommended by the World Health 
Organization, the standardized, 75-g oral glucose tolerance test is used for diagnosis of 
impaired fasting glucose and impaired glucose tolerance. Plasma glucose at fasting and 2 
hours after oral glucose tolerance test are measured to indicate glucose tolerance in 
individuals. Fasting glucose is the glucose concentration after an overnight fast and mostly 
reflects endogenous glucose production, whereas glucose level 2 hours after oral glucose 
tolerance test, i.e. post-load hyperglycemia, reflects the acute increase in blood glucose after 
a glucose challenge. 
Several epidemiological investigations from European countries (111-113), Australia (114-
116), Asian countries (117), and Mauritius (118) report that men have higher fasting plasma 
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increases lipolysis in abdominal fat cells in mice(88). Lactation and menopausal status also 
impact the lipolytic responsiveness and lipoprotein lipase activity of fat cells. Higher 
adipose tissue lipoprotein lipase activity (promoting fat storage) occurs in subcutaneous 
femoral adipocytes compared with abdominal adipocytes in premenopausal women but not 
in postmenopausal, estrogen-deficient women(89). Additionally lipolysis increases in 
subcutaneous femoral fat during lactation but not in abdominal fat(89). Furthermore, 
estrogen treatment in postmenopausal women restores the lipoprotein lipase activity of the 
femoral adipocytes and attenuates lipolytic response in subcutaneous adipocytes but not in 
abdominal adipocytes (90). Subcutaneous gluteal adipocytes from premenopausal women 
are more sensitive to the antilipolytic effects of insulin than abdominal adipocytes (91). 
Testosterone, male androgens also impact body fat distribution. Testosterone deficiency 
aggravates the development of obesity and hyperinsulinemia, which in turn will suppress 
testicular androgen synthesis even further and result in a vicious cycle (92). In ‘andropause’ 
men, gradual decline in circulating androgens with aging is accompanied by increased total 
and abdominal fat (93). Administration of aromatizable androgens such as testosterone (94, 
95), but not nonaromatizable dihydrotestostone (94), reduces total and abdominal fat in 
older men. In contrast, androgen administration to ovariectomized female mice significantly 
increases body adiposity and abdominal fat (96). Such obesity development is associated 
with reduced fatty acid oxidation, indicated by decreased phosphorylation of adenosine 
monophosphate (AMP)-activated protein kinase and acetyl-CoA carboxylase in abdominal 
visceral fat (96). In humans, women with higher circulating androgen levels (97) or 
exogenous androgen administration (98, 99) increase abdominal fat. These findings raise 
significant clinical concern about the use of testosterone as a hormone replacement therapy 
in postmenopausal women.  
In summary, sex differences in body fat distribution appear to be largely a result of 
differences in sex hormones between men and women. Estrogens reduce visceral fat in men 
and women, an effect that is likely mediated by both central and peripheral mechanisms. In 
contrast, opposite effects of androgens on fat distribution in men and women are seen, with 
aromatizable androgens decreasing visceral fat in men but increasing it in women. 
2.4. Estrogen receptors regulate fat distribution 
Gonadal hormones, including estrogen, progesterone and androgen, have their receptors 
expressed in the visceral and the subcutaneous adipose tissue depots (100). Subcutaneous 
adipose tissues have higher concentrations of estrogen receptors and progesterone receptors 
than androgen receptors in females, and estrogens down-regulates AR expression in 
subcutaneous fat (101). In contrast, visceral adipose tissue has higher concentrations of 
androgen receptors (102, 103). In visceral adipose tissue, there is an increase in the 
expression of androgen receptors in males relative to estrogen receptors. The development 
of knockout animals has provided a powerful tool to examine the role of individual 
receptors for estrogen, progesterone and androgen in the regulation of adipose tissue. 
Adipose tissue-specific androgen receptor knockout mice have increased intra-adipose 
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tissue estradiol levels, which precedes increased subcutaneous obesity and hyperleptinemia 
(104). Additionally, androgens can be converted to estrogens through activation of the 
aromatase enzyme. Aromatase knockout mice have elevated testosterone and accumulate 
more abdominal adipose tissue with increased adipocyte size in the visceral fat depot. 
Hence, in adipose tissue, there is a counteracting effect between estrogen and androgen, 
which may lead to differences in fat distribution.  
Estradiol regulates body fat distribution either directly at the level of the adipocyte or 
through augmenting the efficacy of the adiposity signals in the CNS. Subcutaneous and 
abdominal adipose tissues express both ERα and ERβ, but ERα is predominantly expressed 
in abdominal adipose tissue (105) and ERβ are higher in subcutaneous adipose tissue (106). 
ERα gene polymorphisms predict abdominal obesity in women, but not in men, suggesting 
a possible sexual dimorphism in the ERα effects (64). Female and male mice lacking ERα 
develop central obesity with increases in abdominal adipose tissue, which is reflected by 
increased adipocyte number and size (70). ERα is ubiquitously expressed in rodent brains, 
but the physiologically relevant sites of ERα in the regulation of food intake and energy 
expenditure have not been identified. ERα is expressed in the ventrolateral portion of the 
VMN, the ARC, the medial preoptic area (MPOA), and the paraventricular nuclei (PVN) 
(107-109). ERβ is found in the same hypothalamic nuclei as ERα, but ERβ expression is 
significantly reduced relative to ERα. Site-specific knock-down of ERα in bilateral 
ventromedial nucleus of the hypothalamus in mice using siRNA result in increased 
adiposity, no change in food intake, and suppression of energy expenditure, increased 
visceral adiposity, and decreased leptin sensitivity, implicating ventromedial hypothalamic 
ERα in energy homeostasis (110).  
Both short-term and long-term castration in males resulted in increased insulin sensitivity and 
increased lipogenesis in both abdominal and subcutaneous adipose tissues, an event that is 
independent of changes in the fat pad weights (102). Thus, in contrast to the preferential effect 
of estrogen in females on the abdominal adipocytes, testosterone exerts an inhibitory effect on 
lipogenesis and insulin sensitivity in both abdominal and subcutaneous adipocytes. 
3. Sex difference in glucose metabolism 
Glucose challenge test is important in terms of understanding the pathophysiology of 
individuals at risk of progressing to type 2 diabetes. As recommended by the World Health 
Organization, the standardized, 75-g oral glucose tolerance test is used for diagnosis of 
impaired fasting glucose and impaired glucose tolerance. Plasma glucose at fasting and 2 
hours after oral glucose tolerance test are measured to indicate glucose tolerance in 
individuals. Fasting glucose is the glucose concentration after an overnight fast and mostly 
reflects endogenous glucose production, whereas glucose level 2 hours after oral glucose 
tolerance test, i.e. post-load hyperglycemia, reflects the acute increase in blood glucose after 
a glucose challenge. 
Several epidemiological investigations from European countries (111-113), Australia (114-
116), Asian countries (117), and Mauritius (118) report that men have higher fasting plasma 
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glucose levels and plasma glucose levels during the early course of the oral glucose tests 
than women, indicating that the prevalence of impaired fasting glycaemia is higher in men 
than in women; and  women have higher plasma glucose levels 2 hours after oral glucose 
tolerance tests than men, suggesting that the prevalence of impaired glucose tolerance is 
higher in women than in men. The pre-diabetic condition of impaired fasting glycaemia is 
characterized by hepatic insulin resistance, elevated hepatic glucose production and beta 
cell dysfunction.  
3.1. Sex difference in glucose tolerance  
Men and women are given the same amount of glucose during a standard oral glucose 
tolerance test. In all ethnic groups throughout the world, women are on average shorter by 
approximately 15 cm and thus have smaller body sizes than men (119). Additionally, 
women generally have less absolute amount of fat-free muscle mass than men, which is the 
major metabolically active tissue involved in glucose uptake, and thus women are less able 
to metabolize the fixed amount of glucose (111, 115, 118). The higher prevalence of impaired 
glucose tolerance in women may be an artifact caused by the fact that individuals of 
different body sizes and lean muscle masses receive the same amount of glucose during 
glucose challenge test. This notion is supported by the observation that the increments of 
glucose, insulin and the incretin hormones glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide after an glucose challenge test are significantly higher in women 
than in men (120), indicating that the same amount of glucose represents a larger stimulus in 
women than in men when seen in relation to their body sizes. 
Further analysis using anthropometric measures (e.g., weights, heights and waist-hip 
circumferences) indicated that the differences in plasma glucose levels 2 hours after oral 
glucose tolerance tests, but not  fasting plasma glucose levels, could be explained by 
differences in body size and/or body composition between men and women (113, 115, 118, 
121). Consequently, women are more commonly diagnosed with diabetes on the basis of 
glucose level 2-hour post glucose tolerance test compared with fasting plasma glucose levels 
(112, 115).The risk of gestational diabetes is also higher in shorter compared with taller 
women (122). Women do not have higher glucose levels following glucose test than men 
when differences in height and high-waist circumference (113) or absolute amount of fat-
free mass (121) are taken into account. This notion is supported by the observation that there 
is a higher risk of developing type 2 diabetes in men than in women with impaired glucose 
tolerance (123), suggesting that women with impaired glucose tolerance may be healthier 
than their male counterparts. In summary, sex difference in glucose tolerance without taking 
into account of body size is probably not related to sex-specific differences in the physiology 
of glucose regulation. 
3.2. Sex difference in fasting plasma glucose 
In contrast to the sex difference in glucose tolerance, sex difference in fasting plasma glucose 
levels is not related to differences in anthropometry and could not be explained by 
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differences in body size and/or body composition between men and women. Indeed, higher 
fasting plasma glucose in men compared with women reflects differences in insulin 
sensitivity and pancreatic β cell function between men and women (113), suggesting that the 
sex difference in fasting plasma glucose has a true physiological basis.  
During fasting females have decreased liver enzymes, lower creatinine and uric acid 
concentrations with a trend toward reduced triglycerides, but higher HDL cholesterol and 
body fat mass, which are generally seen as gender-related differences because of the direct 
effects by sex hormones (124, 125). There is an association between elevated FFA and 
increased endogenous glucose production (126). Interestingly, females displayed lower 
fasting endogenous glucose production than males, despite higher fasting plasma FFA 
concentrations (116). Study using laboratory rodent models indicate that there is no direct 
effect by FFA on hepatic glucose production in isolated perfused rat liver (127).  
The possible physiological mechanism that is responsible for the higher fasting plasma 
glucose levels observed in men compared with women could be related to large waist 
circumference in men (128), suggesting that sex differences in body fat distribution 
contribute to the sex difference in fasting plasma glucose levels. Indeed, high waist 
circumference and hip circumference are associated with impaired glucose tolerance in both 
men and women (113), suggesting that obesity contributes and is related to disturbances of 
glucose metabolism. Visceral component of abdominal fat is strongly associated with insulin 
resistance (129). Abdominal adipose tissue has a reduced ability to metabolize the glucose 
load of a glucose challenge test (102). Homeostasis model assessment of insulin resistance 
(HOMA-IR), predominantly reflecting hepatic insulin resistance, is lower in men than in 
women in general (113). Homeostasis model assessment of β cell function (HOMA-β) is also 
slightly lower in men than in women.  
In summary, sex differences in fasting plasma glucose levels are caused by underlying 
physiological differences in both insulin sensitivity and β cell function.  
3.3. Sex difference in glucose absorption 
Sex difference in carbohydrate metabolism may contribute to sex-specific glucose 
regulation. A glucose infusion at fasting and during hyperinsulinemia is used to measure 
whole-body insulin sensitivity and endogenous glucose production using hyperinsulinemic 
clamp technique. Healthy glucose-tolerant women have slower glucose absorption rates and 
slower liquid emptying from the stomach (130), and thus longer gut glucose half-life 
compared with glucose-tolerant men(116).Furthermore, there is an association between 
glucose absorption velocity and body size, with body tallness having strong influence on the 
glucose absorption velocity. This notion is supported by a recent study showing that, for 
both sexes, although people with different heights have similar fasting glucose levels, those 
in the shortest height quartile do have significantly higher 2 h glucose levels following oral 
glucose tolerance test compared with those in the tallest height quartile (115). As it is 
mentioned earlier in this section, women are on average shorter by approximately 15 cm 
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glucose levels and plasma glucose levels during the early course of the oral glucose tests 
than women, indicating that the prevalence of impaired fasting glycaemia is higher in men 
than in women; and  women have higher plasma glucose levels 2 hours after oral glucose 
tolerance tests than men, suggesting that the prevalence of impaired glucose tolerance is 
higher in women than in men. The pre-diabetic condition of impaired fasting glycaemia is 
characterized by hepatic insulin resistance, elevated hepatic glucose production and beta 
cell dysfunction.  
3.1. Sex difference in glucose tolerance  
Men and women are given the same amount of glucose during a standard oral glucose 
tolerance test. In all ethnic groups throughout the world, women are on average shorter by 
approximately 15 cm and thus have smaller body sizes than men (119). Additionally, 
women generally have less absolute amount of fat-free muscle mass than men, which is the 
major metabolically active tissue involved in glucose uptake, and thus women are less able 
to metabolize the fixed amount of glucose (111, 115, 118). The higher prevalence of impaired 
glucose tolerance in women may be an artifact caused by the fact that individuals of 
different body sizes and lean muscle masses receive the same amount of glucose during 
glucose challenge test. This notion is supported by the observation that the increments of 
glucose, insulin and the incretin hormones glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide after an glucose challenge test are significantly higher in women 
than in men (120), indicating that the same amount of glucose represents a larger stimulus in 
women than in men when seen in relation to their body sizes. 
Further analysis using anthropometric measures (e.g., weights, heights and waist-hip 
circumferences) indicated that the differences in plasma glucose levels 2 hours after oral 
glucose tolerance tests, but not  fasting plasma glucose levels, could be explained by 
differences in body size and/or body composition between men and women (113, 115, 118, 
121). Consequently, women are more commonly diagnosed with diabetes on the basis of 
glucose level 2-hour post glucose tolerance test compared with fasting plasma glucose levels 
(112, 115).The risk of gestational diabetes is also higher in shorter compared with taller 
women (122). Women do not have higher glucose levels following glucose test than men 
when differences in height and high-waist circumference (113) or absolute amount of fat-
free mass (121) are taken into account. This notion is supported by the observation that there 
is a higher risk of developing type 2 diabetes in men than in women with impaired glucose 
tolerance (123), suggesting that women with impaired glucose tolerance may be healthier 
than their male counterparts. In summary, sex difference in glucose tolerance without taking 
into account of body size is probably not related to sex-specific differences in the physiology 
of glucose regulation. 
3.2. Sex difference in fasting plasma glucose 
In contrast to the sex difference in glucose tolerance, sex difference in fasting plasma glucose 
levels is not related to differences in anthropometry and could not be explained by 
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differences in body size and/or body composition between men and women. Indeed, higher 
fasting plasma glucose in men compared with women reflects differences in insulin 
sensitivity and pancreatic β cell function between men and women (113), suggesting that the 
sex difference in fasting plasma glucose has a true physiological basis.  
During fasting females have decreased liver enzymes, lower creatinine and uric acid 
concentrations with a trend toward reduced triglycerides, but higher HDL cholesterol and 
body fat mass, which are generally seen as gender-related differences because of the direct 
effects by sex hormones (124, 125). There is an association between elevated FFA and 
increased endogenous glucose production (126). Interestingly, females displayed lower 
fasting endogenous glucose production than males, despite higher fasting plasma FFA 
concentrations (116). Study using laboratory rodent models indicate that there is no direct 
effect by FFA on hepatic glucose production in isolated perfused rat liver (127).  
The possible physiological mechanism that is responsible for the higher fasting plasma 
glucose levels observed in men compared with women could be related to large waist 
circumference in men (128), suggesting that sex differences in body fat distribution 
contribute to the sex difference in fasting plasma glucose levels. Indeed, high waist 
circumference and hip circumference are associated with impaired glucose tolerance in both 
men and women (113), suggesting that obesity contributes and is related to disturbances of 
glucose metabolism. Visceral component of abdominal fat is strongly associated with insulin 
resistance (129). Abdominal adipose tissue has a reduced ability to metabolize the glucose 
load of a glucose challenge test (102). Homeostasis model assessment of insulin resistance 
(HOMA-IR), predominantly reflecting hepatic insulin resistance, is lower in men than in 
women in general (113). Homeostasis model assessment of β cell function (HOMA-β) is also 
slightly lower in men than in women.  
In summary, sex differences in fasting plasma glucose levels are caused by underlying 
physiological differences in both insulin sensitivity and β cell function.  
3.3. Sex difference in glucose absorption 
Sex difference in carbohydrate metabolism may contribute to sex-specific glucose 
regulation. A glucose infusion at fasting and during hyperinsulinemia is used to measure 
whole-body insulin sensitivity and endogenous glucose production using hyperinsulinemic 
clamp technique. Healthy glucose-tolerant women have slower glucose absorption rates and 
slower liquid emptying from the stomach (130), and thus longer gut glucose half-life 
compared with glucose-tolerant men(116).Furthermore, there is an association between 
glucose absorption velocity and body size, with body tallness having strong influence on the 
glucose absorption velocity. This notion is supported by a recent study showing that, for 
both sexes, although people with different heights have similar fasting glucose levels, those 
in the shortest height quartile do have significantly higher 2 h glucose levels following oral 
glucose tolerance test compared with those in the tallest height quartile (115). As it is 
mentioned earlier in this section, women are on average shorter by approximately 15 cm 
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than men (119). Consequently, women generally have lower glucose absorption rates and 
have higher plasma glucose levels 2 hours after oral glucose tolerance test than men (115).  
Glucose absorption rates are higher in males in the initial phase and elevate in females in the 
end of the of the oral glucose tolerance tests three hours after oral glucose intake (116). The 
best-suited value to describe of glucose absorption velocity is glucose half-life in the gut. In 
all participants, glucose half-life is negatively related to body height and fat-free mass (116, 
131), thus glucose half-life is prolonged in females in comparison with males. When 
adjusted for total fat-free body mass, females with similar gut absorption as males are 
slightly more insulin sensitive than males(116). The alterations of plasma glucose 
concentrations during glucose tolerance test in females and males are not only due to 
different glucose clearance rates but also due to  different absorption rates from the 
gastrointestinal tract between sexes (116), which could serve to explain higher glucose 
concentrations at the end of the glucose challenge test in females. Additionally, postprandial 
insulin secretion affects glucose disappearance rate and glucose concentrations. One study 
has reported that females have greater peripheral insulin release and thus higher 
concentration during the first hour of oral glucose tolerance test (132). A separate study has 
reported that insulin secretion is comparable between young males and females following a 
high-carbohydrate mixed meal (133). Therefore, these available data from previous human 
studies suggest that the disturbance in insulin secretion does not contribute to the higher 
postprandial glucose concentrations in women. This notion is supported by animal studies 
using rodents, which have reported no sex associated difference in glucose-stimulated 
insulin secretion (134).  
To summarize, sex difference in glucose absorption and concomitant effect of insulin 
release, but not insulin-induced glucose uptake or glucose metabolism, contributes to the 
higher prevalence of glucose intolerance in females diagnosed from oral glucose tolerance 
tests as observed in several epidemiological studies worldwide. 
4. Sex differences in insulin sensitivity 
Glucose homeostasis is maintained in a narrow range via glucose output by the liver and 
glucose uptake by tissues. Insulin, secreted by the pancreatic β cells in response to increased 
circulating levels of glucose, is the major anabolic hormone whose action is essential for 
maintenance of glucose homeostasis. Insulin regulates glucose homeostasis by reducing 
hepatic glucose production via decreased gluconeogenesis (de novo glucose synthesis) and 
glycogenolysis (glycogen breakdown), and increasing the rate of glucose uptake, primarily 
into skeletal muscle and adipose tissue (135). Insulin's actions are brought about by 
intracellular events following the binding of insulin to insulin receptor and the activation of 
its tyrosine kinase, which phosphorylates tyrosine residues of target proteins such as insulin 
receptor substrates (136). The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is 
activated by the IRS proteins to trigger the stimulation of glucose uptake (135). Insulin 
resistance, defined as a state of decreased responsiveness of target tissues to insulin, plays a 
major role in the development of type 2 diabetes. Increased plasma free fatty acid 
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concentrations due to high-fat diet feeding are typically associated with many insulin-
resistant states (135).Abnormalities in fatty acid metabolism result in inappropriate 
accumulation of lipids in myocytes and hepatocytes, thus impairing their function and 
leading to insulin resistance (135). 
4.1. Female human and animals are more insulin sensitive 
There is evidence indicating that insulin sensitivity differs between males and females (137). 
Premenopausal women have better glucose tolerance and insulin sensitivity compared with 
men in general. Despite having lower fat mass, the prevalence of diabetes and early 
abnormalities of glucose metabolism is three times higher in men than in women (138). 
Moreover, women have decreased susceptibility to fatty acid–induced peripheral insulin 
resistance (124, 139, 140). Female humans and rodents are more insulin-sensitive than their 
male counterparts.  
In many different laboratory rodent models of glucose intolerance, insulin resistance, and 
diabetes, the different insulin sensitivity of female versus male mice can be detected by 
glucose tolerance tests and insulin tolerance tests. When various strains of mice are 
subjected to glucose tolerance tests, female mice have lower glucose levels than male mice at 
different time point throughout the tests (141-143). Additionally, female mice show a  
greater fall in blood glucose in response to insulin as compared with male mice during 
insulin tolerance tests (141-143). These data from our lab suggest that female animals are 
more insulin sensitive than males. Furthermore, female rodents are less prone to diet-
induced insulin resistance, and many genetically induced forms of insulin resistance have a 
milder phenotype in females compared with males (141, 142, 144, 145).  
4.2. Female fat cells are more insulin sensitive 
Adipocytes in different fat depots appear to have a distinct impact in insulin sensitivity. As 
it is mentioned previously in this chapter, accumulation of visceral fat, but not subcutaneous 
fat, is linked to the development of metabolic complications. Fat accumulation in different 
depots is sexually dimorphic, i.e., men accumulate more visceral fat, whereas women 
accumulate more subcutaneous fat and have a higher percentage of body fat compared with 
men. These sex-related differences in insulin sensitivity and adipose tissue development and 
function could be attributable in part to actions of estrogen and testosterone. For example, 
decreases in estrogen and increases in testosterone levels that occur during menopause are 
associated with loss of subcutaneous and gain of visceral fat and increase in insulin 
resistance (146).  
Female adipocytes have increased insulin sensitivity compared with male adipocytes, which 
is particularly true for abdominal adipocytes (102, 147). A recent study analyzed insulin 
sensitivity and glucose metabolism of adipocytes from abdominal and subcutaneous 
adipose tissue from normal, castrated, or steroid-implanted mice (102). The authors reported 
that both abdominal and subcutaneous adipocytes of females have greater lipogenic rates 
than those from males. Additionally, female abdominal adipocytes are more insulin 
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than men (119). Consequently, women generally have lower glucose absorption rates and 
have higher plasma glucose levels 2 hours after oral glucose tolerance test than men (115).  
Glucose absorption rates are higher in males in the initial phase and elevate in females in the 
end of the of the oral glucose tolerance tests three hours after oral glucose intake (116). The 
best-suited value to describe of glucose absorption velocity is glucose half-life in the gut. In 
all participants, glucose half-life is negatively related to body height and fat-free mass (116, 
131), thus glucose half-life is prolonged in females in comparison with males. When 
adjusted for total fat-free body mass, females with similar gut absorption as males are 
slightly more insulin sensitive than males(116). The alterations of plasma glucose 
concentrations during glucose tolerance test in females and males are not only due to 
different glucose clearance rates but also due to  different absorption rates from the 
gastrointestinal tract between sexes (116), which could serve to explain higher glucose 
concentrations at the end of the glucose challenge test in females. Additionally, postprandial 
insulin secretion affects glucose disappearance rate and glucose concentrations. One study 
has reported that females have greater peripheral insulin release and thus higher 
concentration during the first hour of oral glucose tolerance test (132). A separate study has 
reported that insulin secretion is comparable between young males and females following a 
high-carbohydrate mixed meal (133). Therefore, these available data from previous human 
studies suggest that the disturbance in insulin secretion does not contribute to the higher 
postprandial glucose concentrations in women. This notion is supported by animal studies 
using rodents, which have reported no sex associated difference in glucose-stimulated 
insulin secretion (134).  
To summarize, sex difference in glucose absorption and concomitant effect of insulin 
release, but not insulin-induced glucose uptake or glucose metabolism, contributes to the 
higher prevalence of glucose intolerance in females diagnosed from oral glucose tolerance 
tests as observed in several epidemiological studies worldwide. 
4. Sex differences in insulin sensitivity 
Glucose homeostasis is maintained in a narrow range via glucose output by the liver and 
glucose uptake by tissues. Insulin, secreted by the pancreatic β cells in response to increased 
circulating levels of glucose, is the major anabolic hormone whose action is essential for 
maintenance of glucose homeostasis. Insulin regulates glucose homeostasis by reducing 
hepatic glucose production via decreased gluconeogenesis (de novo glucose synthesis) and 
glycogenolysis (glycogen breakdown), and increasing the rate of glucose uptake, primarily 
into skeletal muscle and adipose tissue (135). Insulin's actions are brought about by 
intracellular events following the binding of insulin to insulin receptor and the activation of 
its tyrosine kinase, which phosphorylates tyrosine residues of target proteins such as insulin 
receptor substrates (136). The phosphatidylinositol 3-kinase (PI3K)/Akt signaling cascade is 
activated by the IRS proteins to trigger the stimulation of glucose uptake (135). Insulin 
resistance, defined as a state of decreased responsiveness of target tissues to insulin, plays a 
major role in the development of type 2 diabetes. Increased plasma free fatty acid 
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concentrations due to high-fat diet feeding are typically associated with many insulin-
resistant states (135).Abnormalities in fatty acid metabolism result in inappropriate 
accumulation of lipids in myocytes and hepatocytes, thus impairing their function and 
leading to insulin resistance (135). 
4.1. Female human and animals are more insulin sensitive 
There is evidence indicating that insulin sensitivity differs between males and females (137). 
Premenopausal women have better glucose tolerance and insulin sensitivity compared with 
men in general. Despite having lower fat mass, the prevalence of diabetes and early 
abnormalities of glucose metabolism is three times higher in men than in women (138). 
Moreover, women have decreased susceptibility to fatty acid–induced peripheral insulin 
resistance (124, 139, 140). Female humans and rodents are more insulin-sensitive than their 
male counterparts.  
In many different laboratory rodent models of glucose intolerance, insulin resistance, and 
diabetes, the different insulin sensitivity of female versus male mice can be detected by 
glucose tolerance tests and insulin tolerance tests. When various strains of mice are 
subjected to glucose tolerance tests, female mice have lower glucose levels than male mice at 
different time point throughout the tests (141-143). Additionally, female mice show a  
greater fall in blood glucose in response to insulin as compared with male mice during 
insulin tolerance tests (141-143). These data from our lab suggest that female animals are 
more insulin sensitive than males. Furthermore, female rodents are less prone to diet-
induced insulin resistance, and many genetically induced forms of insulin resistance have a 
milder phenotype in females compared with males (141, 142, 144, 145).  
4.2. Female fat cells are more insulin sensitive 
Adipocytes in different fat depots appear to have a distinct impact in insulin sensitivity. As 
it is mentioned previously in this chapter, accumulation of visceral fat, but not subcutaneous 
fat, is linked to the development of metabolic complications. Fat accumulation in different 
depots is sexually dimorphic, i.e., men accumulate more visceral fat, whereas women 
accumulate more subcutaneous fat and have a higher percentage of body fat compared with 
men. These sex-related differences in insulin sensitivity and adipose tissue development and 
function could be attributable in part to actions of estrogen and testosterone. For example, 
decreases in estrogen and increases in testosterone levels that occur during menopause are 
associated with loss of subcutaneous and gain of visceral fat and increase in insulin 
resistance (146).  
Female adipocytes have increased insulin sensitivity compared with male adipocytes, which 
is particularly true for abdominal adipocytes (102, 147). A recent study analyzed insulin 
sensitivity and glucose metabolism of adipocytes from abdominal and subcutaneous 
adipose tissue from normal, castrated, or steroid-implanted mice (102). The authors reported 
that both abdominal and subcutaneous adipocytes of females have greater lipogenic rates 
than those from males. Additionally, female abdominal adipocytes are more insulin 
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sensitive than subcutaneous adipocytes and more insulin-sensitive than male adipocytes 
from either depot, with female abdominal adipocytes showing a robust increase in insulin-
induced lipogenesis and insulin signaling, including downstream targets Akt and 
extracellular signal–related kinase phosphorylation, when stimulated by low physiological 
concentrations of insulin. In contrast, male adipocytes show activation only at much higher 
insulin concentrations (102). Furthermore, adipocytes from females have higher mRNA and 
protein levels of several genes involved in glucose and lipid metabolism, including glucose 
transporters and key lipogenic enzymes fatty acid synthase and acetyl CoA carboxylase 
(102), suggesting that the sex difference in insulin sensitivity at adipocyte level is 
attributable at least partially to increased glucose transporters and lipogenic enzyme levels. 
In summary, sex-specific differences in insulin action in adipocytes may contribute to the 
sexual dimorphism of insulin resistance.  
Despite a higher lipogenic rates female adipocytes are smaller than male adipocytes, 
especially those from the abdominal adipose depot. This is because adipocytes of females 
also has a higher lipolytic capacity than those of males (148, 149), suggesting a higher 
metabolic turnover of female abdominal adipocytes leading to decreased fat accumulation 
in visceral depots in females compared with males. As a result, in humans, females have 
higher serum levels of free fatty acid than males (124, 139) but appear to be protected 
against insulin resistance induced by elevated free fatty acid (139).  
Sex steroids are known to play a role in the regulation of adipose tissue development and 
function as well as whole body insulin sensitivity (146). These sex differences in insulin 
sensitivity in adipose tissue are regulated by physiological levels of sex steroids. Adipocytes 
of castrated male mice have increased insulin sensitivity and increased lipogenic rates, 
whereas adipocytes of ovariectomized females have lowered insulin sensitivity and reduced 
lipogenic capacity (102). The increased sensitivity to insulin and lipogenesis observed in 
adipocytes from females may account for their lower level of insulin resistance and diabetes 
risk despite similar or higher fat content than in male mice (102), indicating a positive role of 
estrogen in insulin sensitivity and lipogenesis in females. Therefore, gonadal hormones 
estrogen and testosterone contribute to the sexual dimorphism of lipogenesis and insulin 
sensitivity, lipogenic capacity of adipocytes.  
4.3. Estrogens regulate insulin sensitivity  
Gonadal hormones play critical roles in the regulation of glucose metabolism and 
maintenance of insulin sensitivity. Disturbances and changes in the relationship between 
estrogens and androgen metabolism seem to adversely affect fat metabolism and insulin 
sensitivity independent of sex (see below). Deficiency of estrogen leads to development of 
insulin resistance. Animals and humans lacking endogenous estrogen synthesis exhibit 
insulin resistance, which can be treated by estrogen supplementation (57, 61, 150). In 
humans, postmenopausal women with deficiency in endogenous estrogen have increased 
risk of insulin resistance and developing type 2 diabetes (4), while hormone replacement 
therapy or treatment with estradiol, the major bioactive form of estrogen, improves insulin 
sensitivity and lowers blood glucose levels (151, 152) and reduce incidence of diabetes (153, 
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154). Insulin resistance in a man with a homozygous inactivating mutation of the aromatase 
gene has been reported (60, 155). Estrogen deficiency also contributes to the development of 
insulin resistance and type 2 diabetes in rodent models (Louet et al 2004). Ovariectomized 
rodents with low level of endogenous estrogen have elevated basal glucose levels and 
impaired glucose tolerance (Bailey et al 1980). Aromatase knockout mice with a genetic 
impairment in endogenous estrogen synthesis exhibit decreased glucose tolerance and 
insulin resistance (Jones et al 2000; Takeda et al 2003).  
The mechanism of regulation of estrogens on insulin sensitivity is not clear. Estrogens may 
increase hepatic insulin sensitivity by decreasing gluconeogenesis and glycogenolysis and 
increasing insulin release in islets of Langerhans (156). Estrogens also prevent β-cell 
apoptosis (157). Additionally, estrogens reduce pro-inflammatory adipokines and their 
signaling and therefore decrease inflammation (158, 159). Changes in the level of sex 
steroids had variable effects on levels of circulating adipokines, as ovariectomized females 
have lower level of adiponectin and females implanted with estradiol have higher 
adiponectin levels (102). It is increasingly evident that chronic activation of pro-
inflammatory pathways may be at least partly responsible for obesity-induced insulin 
resistance and diabetes (25, 160). ERs are expressed in monocytes and macrophages, and 
estrogens activate these cells (161, 162). Female rats and mice are relatively protected from 
high-fat diet induced obesity, insulin resistance and inflammatory responses (141-143, 163-
165). Recent studies have shown that 17β -estradiol may play a role in reducing the 
inflammatory response in adipose, cardiovascular, and neural systems (146). Suppression of 
pro-inflammatory responses with estrogens may represent a promising strategy to combat 
obesity and associated metabolic disorders. Furthermore estrogens may improve insulin 
action (166). Therefore, the greater amount of abdominal visceral adipose tissue in 
conjunction with lower endogenous estrogen levels found in men may be related to the 
higher insulin resistance when compared with pre-menopausal women.  
4.4. Estrogen receptor regulates insulin sensitivity  
Estrogen’s action is via its classic nuclear receptors and non-classic membrane receptors (63, 
167-172).Both ERα and ERβ are expressed in the liver, muscle, and adipose tissue, as well as 
in several key regions of the hypothalamus of the central nervous system that have been 
linked to the control of peripheral glucose homeostasis. In particular, recent evidence points 
to neurons in the arcuate nucleus as critical regulators of glucose homeostasis (173). ER 
subtype-specific ligands have been used to clarify the specific roles of ERα and ERβ, such as 
the selective ERα ligand propyl pyrazoletriol (PPT) and the selective ERβagonist (2,3-bis(4-
hydroxyphenyl)-propionitrile (DPN). PPT has similar effects as estradiol, including increase 
of uterine weight, and prevention of increased body weight following ovariectomy (174). In 
addition, estrogen acts through other extranuclear pathways after ligands bind to the ERα or 
ERβ associated to the plasma membrane, as well as to ERs located at the plasma membrane, 
in the cytosol, or in the mitochondria (167, 171, 175) to regulate energy balance and glucose 
homeostasis (167). Estrogen may trigger its actions after binding to membrane ERs, such as 
GPR30 (176, 177), binding to receptors for other ligands, or binding to ion channels (167, 178, 
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sensitive than subcutaneous adipocytes and more insulin-sensitive than male adipocytes 
from either depot, with female abdominal adipocytes showing a robust increase in insulin-
induced lipogenesis and insulin signaling, including downstream targets Akt and 
extracellular signal–related kinase phosphorylation, when stimulated by low physiological 
concentrations of insulin. In contrast, male adipocytes show activation only at much higher 
insulin concentrations (102). Furthermore, adipocytes from females have higher mRNA and 
protein levels of several genes involved in glucose and lipid metabolism, including glucose 
transporters and key lipogenic enzymes fatty acid synthase and acetyl CoA carboxylase 
(102), suggesting that the sex difference in insulin sensitivity at adipocyte level is 
attributable at least partially to increased glucose transporters and lipogenic enzyme levels. 
In summary, sex-specific differences in insulin action in adipocytes may contribute to the 
sexual dimorphism of insulin resistance.  
Despite a higher lipogenic rates female adipocytes are smaller than male adipocytes, 
especially those from the abdominal adipose depot. This is because adipocytes of females 
also has a higher lipolytic capacity than those of males (148, 149), suggesting a higher 
metabolic turnover of female abdominal adipocytes leading to decreased fat accumulation 
in visceral depots in females compared with males. As a result, in humans, females have 
higher serum levels of free fatty acid than males (124, 139) but appear to be protected 
against insulin resistance induced by elevated free fatty acid (139).  
Sex steroids are known to play a role in the regulation of adipose tissue development and 
function as well as whole body insulin sensitivity (146). These sex differences in insulin 
sensitivity in adipose tissue are regulated by physiological levels of sex steroids. Adipocytes 
of castrated male mice have increased insulin sensitivity and increased lipogenic rates, 
whereas adipocytes of ovariectomized females have lowered insulin sensitivity and reduced 
lipogenic capacity (102). The increased sensitivity to insulin and lipogenesis observed in 
adipocytes from females may account for their lower level of insulin resistance and diabetes 
risk despite similar or higher fat content than in male mice (102), indicating a positive role of 
estrogen in insulin sensitivity and lipogenesis in females. Therefore, gonadal hormones 
estrogen and testosterone contribute to the sexual dimorphism of lipogenesis and insulin 
sensitivity, lipogenic capacity of adipocytes.  
4.3. Estrogens regulate insulin sensitivity  
Gonadal hormones play critical roles in the regulation of glucose metabolism and 
maintenance of insulin sensitivity. Disturbances and changes in the relationship between 
estrogens and androgen metabolism seem to adversely affect fat metabolism and insulin 
sensitivity independent of sex (see below). Deficiency of estrogen leads to development of 
insulin resistance. Animals and humans lacking endogenous estrogen synthesis exhibit 
insulin resistance, which can be treated by estrogen supplementation (57, 61, 150). In 
humans, postmenopausal women with deficiency in endogenous estrogen have increased 
risk of insulin resistance and developing type 2 diabetes (4), while hormone replacement 
therapy or treatment with estradiol, the major bioactive form of estrogen, improves insulin 
sensitivity and lowers blood glucose levels (151, 152) and reduce incidence of diabetes (153, 
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154). Insulin resistance in a man with a homozygous inactivating mutation of the aromatase 
gene has been reported (60, 155). Estrogen deficiency also contributes to the development of 
insulin resistance and type 2 diabetes in rodent models (Louet et al 2004). Ovariectomized 
rodents with low level of endogenous estrogen have elevated basal glucose levels and 
impaired glucose tolerance (Bailey et al 1980). Aromatase knockout mice with a genetic 
impairment in endogenous estrogen synthesis exhibit decreased glucose tolerance and 
insulin resistance (Jones et al 2000; Takeda et al 2003).  
The mechanism of regulation of estrogens on insulin sensitivity is not clear. Estrogens may 
increase hepatic insulin sensitivity by decreasing gluconeogenesis and glycogenolysis and 
increasing insulin release in islets of Langerhans (156). Estrogens also prevent β-cell 
apoptosis (157). Additionally, estrogens reduce pro-inflammatory adipokines and their 
signaling and therefore decrease inflammation (158, 159). Changes in the level of sex 
steroids had variable effects on levels of circulating adipokines, as ovariectomized females 
have lower level of adiponectin and females implanted with estradiol have higher 
adiponectin levels (102). It is increasingly evident that chronic activation of pro-
inflammatory pathways may be at least partly responsible for obesity-induced insulin 
resistance and diabetes (25, 160). ERs are expressed in monocytes and macrophages, and 
estrogens activate these cells (161, 162). Female rats and mice are relatively protected from 
high-fat diet induced obesity, insulin resistance and inflammatory responses (141-143, 163-
165). Recent studies have shown that 17β -estradiol may play a role in reducing the 
inflammatory response in adipose, cardiovascular, and neural systems (146). Suppression of 
pro-inflammatory responses with estrogens may represent a promising strategy to combat 
obesity and associated metabolic disorders. Furthermore estrogens may improve insulin 
action (166). Therefore, the greater amount of abdominal visceral adipose tissue in 
conjunction with lower endogenous estrogen levels found in men may be related to the 
higher insulin resistance when compared with pre-menopausal women.  
4.4. Estrogen receptor regulates insulin sensitivity  
Estrogen’s action is via its classic nuclear receptors and non-classic membrane receptors (63, 
167-172).Both ERα and ERβ are expressed in the liver, muscle, and adipose tissue, as well as 
in several key regions of the hypothalamus of the central nervous system that have been 
linked to the control of peripheral glucose homeostasis. In particular, recent evidence points 
to neurons in the arcuate nucleus as critical regulators of glucose homeostasis (173). ER 
subtype-specific ligands have been used to clarify the specific roles of ERα and ERβ, such as 
the selective ERα ligand propyl pyrazoletriol (PPT) and the selective ERβagonist (2,3-bis(4-
hydroxyphenyl)-propionitrile (DPN). PPT has similar effects as estradiol, including increase 
of uterine weight, and prevention of increased body weight following ovariectomy (174). In 
addition, estrogen acts through other extranuclear pathways after ligands bind to the ERα or 
ERβ associated to the plasma membrane, as well as to ERs located at the plasma membrane, 
in the cytosol, or in the mitochondria (167, 171, 175) to regulate energy balance and glucose 
homeostasis (167). Estrogen may trigger its actions after binding to membrane ERs, such as 
GPR30 (176, 177), binding to receptors for other ligands, or binding to ion channels (167, 178, 
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179). The membrane ERs are characterized by a completely different pharmacological profile 
when compared to nuclear ERα and ERβ. They do not bind the antiestrogen ICI182,780 (167). 
These extranuclear actions of estrogen are the rapid activation of signaling cascades resulting 
in the activation of transcription factors and therefore in the regulation of gene expression.  
Both animal and human studies suggest that ERα may play a critical role to regulate glucose 
tolerance and insulin sensitivity (see below). Impaired insulin sensitivity, glucose 
intolerance, and hyperinsulinemia in a man with a mutation of ERα and thus lacking 
functional ERα has been reported (180). Estrogen-dependent effects on glucose homeostasis 
through both ERα and ERβ, whereas glucose tolerance is normal in ERβ-knockout mice (70, 
73, 181, 182). Additionally, ERα deficiency increases fasting insulin levels, impairs glucose 
tolerance, and results in skeletal muscle insulin resistance (182), suggesting that ERα may 
have a direct anti-diabetic role. Insulin sensitivity is preserved in mice lacking ERβ although 
these animals become obese following a high-fat diet (183). In addition, ERβ acts as an 
inhibitor of peroxisome proliferators-activated receptor gamma activity, a major inhibitory 
regulator of glucose and lipid metabolism (183). Therefore, previous studies argue in favor 
of an estrogen-dependent regulation of glucose tolerance and insulin sensitivity by ERα. 
Several mechanisms of metabolic function of ERs involved in the regulation of estrogen-
mediated insulin sensitivity have been suggested by animal studies.  
First, estrogen’s action helps to sustain insulin production. In the absence of ERα, 17β-estradiol 
only partially protects pancreatic β-cells from apoptosis in diabetic male and female mice 
(157), suggesting that this effect is at least in part ERα dependent. A recent study from the 
same group of investigators has demonstrated that estradiol stimulates islet insulin synthesis 
in an ERα independent manner, through interactions between non-classic extranuclear / 
membrane ERα and the tyrosine kinase Src, which activates ERK1/2 MAPK (184).  
Second, estrogen’s action facilitates insulin release. Glucose- and arginine-stimulated insulin 
release in pancreatic islets is similar in mice lacking either ERα or ERβ when compared with 
control animals (181).17β-estradiol does not increase insulin levels in isolated islets from 
ERαknockout animals compared to controls or to ERβ-knockout mice (156).  
Third, estrogen’s action regulates insulin sensitivity in liver and muscle. The development of 
ERα and ERβ knockout mice (185) has demonstrated the participation of these receptors in 
the regulation of many processes related to glucose metabolism, including insulin sensitivity 
in the liver and muscle. Impaired insulin sensitivity and glucose tolerance as determined by 
the hyperinsulinemic clamp technique in ERα deficient animals is attributed to either 
inadequate suppression of hepatic glucose production by insulin or impaired insulin action 
in skeletal muscle (181, 182).Furthermore, insulin-stimulated glucose uptake in skeletal 
muscle, mediated by the glucose transporter isoform GLUT4, is suppressed in the absence of 
ERα (181), however GLUT4 expression is not affected in mice lacking ERβ (186).  
Fourth, estrogen’s action mediates inflammation associated with insulin resistance. In both 
healthy and diabetic mice lacking ERβ, 17β-estradiol reduces inflammatory nitric oxide 
synthase expression in the aorta. This inhibitory effect is absent in ERα knockout animals 
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(187), indicating that the protective effects of estrogens on inflammatory responses in the 
vessel wall are mediated by ERα (187). In addition, adiponectin, an adipokine associated 
with suppression of insulin resistance and inflammation, is decreased in the absence of ERα 
whereas plasminogen activator inhibitor-1, a surrogate marker of systemic inflammation is 
increased (182). Increased inflammation-associated changes following streptozotocin-
induced injury of pancreatic islets have been described in ERα-deficient mice (Le May et al. 
2006). Moreover, enhanced inflammatory signaling and impaired fatty acid oxidation are 
found in the skeletal muscle of ERα-knockout mice (182), further indicating an ERα 
dependent regulation in inflammation which affects insulin resistance. In vitro studies have 
demonstrated 17β -estradiol-activated ERα decreases the number of pro-inflammatory 
cytokines (161). The anti-inflammatory properties of 17β-estradiol can be partially explained 
by the ability of ERs to act as transcriptional repressors by inhibiting the activity of nuclear 
factor kappa B (NFκB) through protein–protein interactions between agonist-bound ERs and 
activated NFκB subunits (188-190). Estrogens' inhibitory effect on NFκB function is not fully 
understood and may be target selective (189, 191). The PI3K pathway is also implicated in 
the anti-inflammatory effects of estrogens. For example, 17β-estradiol blocks LPS-induced 
NFκB nuclear translocation in macrophages, an effect that involves the activation of PI3K 
(188). Similarly, estradiol-17β decreases vascular leukocyte accumulation after an ischemia–
reperfusion injury, and these effects are blocked by PI3K inhibitors (192) 
In summary, previous studies not only support that estrogens and their cellular targets are 
important for the maintenance of glucose homeostasis, but also indicate an important role of 
ERα in the regulation of insulin sensitivity.  
5. Conclusion 
Sex differences and the role of gonadal hormones in modulating insulin sensitivity and 
glucose tolerance are of increasing interest and importance because of the increasing 
prevalence of type 2 diabetes mellitus and the metabolic abnormalities. Body composition is 
closely associated with insulin sensitivity, and increased body fat, particularly in the visceral 
compartment, is a risk factor for developing type 2 diabetes mellitus. Sex differences in body 
composition and/or insulin sensitivity are evident in humans and many non-human animal 
models. 
Gonadal hormones estrogens and androgens are important, sex-independent regulators of 
body weight, body fat distribution, glucose metabolism and insulin resistance. When 
women enter menopause, they have a dramatically increased risk for developing obesity, 
type 2 diabetes and the metabolic syndrome. Although conventional hormone replacement 
therapy might beneficially to affect adiposity and to reduce diabetes risk, its previous use in 
women is associated with adverse effects including an increased risk for breast cancer and 
heart disease (i.e. thromboembolism). This increased risk may partly due to non-selective 
activation of ERs, which are ubiquitously expressed in the human body, especially in 
peripheral tissues, and due to complex intracellular events coupled to ERs genomic and 
non-genomic actions.  
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179). The membrane ERs are characterized by a completely different pharmacological profile 
when compared to nuclear ERα and ERβ. They do not bind the antiestrogen ICI182,780 (167). 
These extranuclear actions of estrogen are the rapid activation of signaling cascades resulting 
in the activation of transcription factors and therefore in the regulation of gene expression.  
Both animal and human studies suggest that ERα may play a critical role to regulate glucose 
tolerance and insulin sensitivity (see below). Impaired insulin sensitivity, glucose 
intolerance, and hyperinsulinemia in a man with a mutation of ERα and thus lacking 
functional ERα has been reported (180). Estrogen-dependent effects on glucose homeostasis 
through both ERα and ERβ, whereas glucose tolerance is normal in ERβ-knockout mice (70, 
73, 181, 182). Additionally, ERα deficiency increases fasting insulin levels, impairs glucose 
tolerance, and results in skeletal muscle insulin resistance (182), suggesting that ERα may 
have a direct anti-diabetic role. Insulin sensitivity is preserved in mice lacking ERβ although 
these animals become obese following a high-fat diet (183). In addition, ERβ acts as an 
inhibitor of peroxisome proliferators-activated receptor gamma activity, a major inhibitory 
regulator of glucose and lipid metabolism (183). Therefore, previous studies argue in favor 
of an estrogen-dependent regulation of glucose tolerance and insulin sensitivity by ERα. 
Several mechanisms of metabolic function of ERs involved in the regulation of estrogen-
mediated insulin sensitivity have been suggested by animal studies.  
First, estrogen’s action helps to sustain insulin production. In the absence of ERα, 17β-estradiol 
only partially protects pancreatic β-cells from apoptosis in diabetic male and female mice 
(157), suggesting that this effect is at least in part ERα dependent. A recent study from the 
same group of investigators has demonstrated that estradiol stimulates islet insulin synthesis 
in an ERα independent manner, through interactions between non-classic extranuclear / 
membrane ERα and the tyrosine kinase Src, which activates ERK1/2 MAPK (184).  
Second, estrogen’s action facilitates insulin release. Glucose- and arginine-stimulated insulin 
release in pancreatic islets is similar in mice lacking either ERα or ERβ when compared with 
control animals (181).17β-estradiol does not increase insulin levels in isolated islets from 
ERαknockout animals compared to controls or to ERβ-knockout mice (156).  
Third, estrogen’s action regulates insulin sensitivity in liver and muscle. The development of 
ERα and ERβ knockout mice (185) has demonstrated the participation of these receptors in 
the regulation of many processes related to glucose metabolism, including insulin sensitivity 
in the liver and muscle. Impaired insulin sensitivity and glucose tolerance as determined by 
the hyperinsulinemic clamp technique in ERα deficient animals is attributed to either 
inadequate suppression of hepatic glucose production by insulin or impaired insulin action 
in skeletal muscle (181, 182).Furthermore, insulin-stimulated glucose uptake in skeletal 
muscle, mediated by the glucose transporter isoform GLUT4, is suppressed in the absence of 
ERα (181), however GLUT4 expression is not affected in mice lacking ERβ (186).  
Fourth, estrogen’s action mediates inflammation associated with insulin resistance. In both 
healthy and diabetic mice lacking ERβ, 17β-estradiol reduces inflammatory nitric oxide 
synthase expression in the aorta. This inhibitory effect is absent in ERα knockout animals 
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(187), indicating that the protective effects of estrogens on inflammatory responses in the 
vessel wall are mediated by ERα (187). In addition, adiponectin, an adipokine associated 
with suppression of insulin resistance and inflammation, is decreased in the absence of ERα 
whereas plasminogen activator inhibitor-1, a surrogate marker of systemic inflammation is 
increased (182). Increased inflammation-associated changes following streptozotocin-
induced injury of pancreatic islets have been described in ERα-deficient mice (Le May et al. 
2006). Moreover, enhanced inflammatory signaling and impaired fatty acid oxidation are 
found in the skeletal muscle of ERα-knockout mice (182), further indicating an ERα 
dependent regulation in inflammation which affects insulin resistance. In vitro studies have 
demonstrated 17β -estradiol-activated ERα decreases the number of pro-inflammatory 
cytokines (161). The anti-inflammatory properties of 17β-estradiol can be partially explained 
by the ability of ERs to act as transcriptional repressors by inhibiting the activity of nuclear 
factor kappa B (NFκB) through protein–protein interactions between agonist-bound ERs and 
activated NFκB subunits (188-190). Estrogens' inhibitory effect on NFκB function is not fully 
understood and may be target selective (189, 191). The PI3K pathway is also implicated in 
the anti-inflammatory effects of estrogens. For example, 17β-estradiol blocks LPS-induced 
NFκB nuclear translocation in macrophages, an effect that involves the activation of PI3K 
(188). Similarly, estradiol-17β decreases vascular leukocyte accumulation after an ischemia–
reperfusion injury, and these effects are blocked by PI3K inhibitors (192) 
In summary, previous studies not only support that estrogens and their cellular targets are 
important for the maintenance of glucose homeostasis, but also indicate an important role of 
ERα in the regulation of insulin sensitivity.  
5. Conclusion 
Sex differences and the role of gonadal hormones in modulating insulin sensitivity and 
glucose tolerance are of increasing interest and importance because of the increasing 
prevalence of type 2 diabetes mellitus and the metabolic abnormalities. Body composition is 
closely associated with insulin sensitivity, and increased body fat, particularly in the visceral 
compartment, is a risk factor for developing type 2 diabetes mellitus. Sex differences in body 
composition and/or insulin sensitivity are evident in humans and many non-human animal 
models. 
Gonadal hormones estrogens and androgens are important, sex-independent regulators of 
body weight, body fat distribution, glucose metabolism and insulin resistance. When 
women enter menopause, they have a dramatically increased risk for developing obesity, 
type 2 diabetes and the metabolic syndrome. Although conventional hormone replacement 
therapy might beneficially to affect adiposity and to reduce diabetes risk, its previous use in 
women is associated with adverse effects including an increased risk for breast cancer and 
heart disease (i.e. thromboembolism). This increased risk may partly due to non-selective 
activation of ERs, which are ubiquitously expressed in the human body, especially in 
peripheral tissues, and due to complex intracellular events coupled to ERs genomic and 
non-genomic actions.  
 
Glucose Tolerance 54 
Future basic science investigations should therefore lead to a better understanding of the 
molecular mechanisms whereby different ERs regulate body weight, body fat, and insulin 
sensitivity in both females and males. Important gaps in the research need to be identified. 
In particular, potential interactions and cross-talk between ERα and G-protein-coupled 
estrogen receptor, which seem to mediate most beneficial effects, critical brain sites where 
ERs regulate glucose homeostasis, and intracellular signaling pathways that are required for 
estrogens' actions, need to be identified. Consequently only the ERs involved in energy 
homeostasis and glucose metabolism will be targeted. This identification would help to 
define novel pharmacological targets selectively associated with fat metabolism and glucose 
homeostasis and help to develop estrogen-like drugs that only initiate intracellular events 
that produce metabolically beneficial actions without deleterious side effects. Such an 
approach would also imply a therapeutic potential in men bypassing the unwanted effects 
of estrogens. 
Author details 
Haifei Shi and Shiva Priya Dharshan Senthil Kumar 
Cellular, Molecular and Structural Biology, Miami University, Oxford, Ohio, USA 
6. References 
[1] James WPT 2008 The epidemiology of obesity: the size of the problem. J Intern Med 
263:336-352 
[2] Cummings DE, Schwartz MW 2003 Genetics and Pathophysiology of Human Obesity. 
Annual Review of Medicine 54:453-471 
[3] Alberti K, Zimmet P, Shaw J 2005 IDF epidemiology task force consensus group: the 
metabolic syndrome - a worldwide definition. Lancet 366:1059 - 1062 
[4] Ford ES 2005 Prevalence of the metabolic syndrome defined by the International 
Diabetes Federation among adults in the U.S. Diabetes Care 28:2745-2749 
[5] Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE 2006 Meta-
analysis: effect of hormone-replacement therapy on components of the metabolic 
syndrome in postmenopausal women. Diabetes Obes Metab 8:538-554 
[6] Rochira V, Madeo B, Zirilli L, Caffagni G, Maffei L, Carani C 2007 Oestradiol 
replacement treatment and glucose homeostasis in two men with congenital aromatase 
deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin 
sensitivity in men. Diabetic Medicine 24:1491-1495 
[7] Bottini N, Meloni GF, Borgiani P, Giorgini A, Buzzetti R, Pozzilli P, Lucarelli P, Gloria-
Bottini F 2002 Genotypes of cytosolic low-molecular-weight protein-tyrosine-
phosphatase correlate with age at onset of type 1 diabetes in a sex-specific manner. 
Metabolism 51:419-422 
[8] Thamer C, Haap M, Volk A, Maerker E, Becker R, Bachmann O, Machicao F, Häring 
HU, Stumvoll M 2002 Evidence for Greater Oxidative Substrate Flexibility in Male 
Carriers of the Pro 12 Ala Polymorphism in PPARγ2. Horm Metab Res 34:132,136 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 55 
[9] Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJH, Cohen PTW 2003 
Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein 
phosphatase 1 leads to increased weight gain, fat deposition, and development of 
insulin resistance. Diabetes 52:596-604 
[10] Doney A, Fischer B, Cecil J, Cohen P, Boyle D, Leese G, Morris A, Palmer C 2003 Male 
preponderance in early diagnosed type 2 diabetes is associated with the ARE 
insertion/deletion polymorphism in the PPP1R3A locus. BMC Genet 4:11 
[11] Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC 2004 Uncoupling protein-2 
polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol 
Endocrinol Metab 286:E1-E7 
[12] D’Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, 
Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, 
Sesti G 2004 The −866A/A Genotype in the Promoter of the Human Uncoupling Protein 
2 Gene Is Associated With Insulin Resistance and Increased Risk of Type 2 Diabetes. 
Diabetes 53:1905-1910 
[13] Björntorp P 1991 Metabolic implications of body fat distribution. Diabetes Care 14:1132-
1143 
[14] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia 
LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J Clin Invest 112:1821-1830 
[15] Shi H, Seeley RJ, Clegg DJ 2009 Sexual differences in the control of energy homeostasis. 
Front Neuroendocrinol 30:396-404 
[16] Pokrywka GS 2007 Diagnosis and Treatment of Metabolic Syndrome in Menopausal 
Women. Menopause Management 16:16-25  
[17] Ryan AS, Nicklas BJ, Berman DM 2002 Hormone replacement therapy, insulin 
sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25:127-133 
[18] Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV 1999 Effects of 
postmenopausal hormone replacement therapy on central abdominal fat, glycemic 
control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. 
Diabetes Care 22:1401-1407 
[19] Clegg DJ, Brown LM, Woods SC, Benoit SC 2006 Gonadal hormones determine 
sensitivity to central leptin and insulin. Diabetes 55:978-987 
[20] Livingstone C, Collison M 2002 Sex steroids and insulin resistance. Clin Sci (Lond) 
102:151-166 
[21] Bruns CM, Kemnitz JW 2004 Sex hormones, insulin sensitivity, and diabetes mellitus. 
ILAR J 45:160-169 
[22] Oh J-Y, Barrett-Connor E, Wedick NM, Wingard DL 2002 Endogenous Sex Hormones 
and the Development of Type 2 Diabetes in Older Men and Women: the Rancho 
Bernardo Study. Diabetes Care 25:55-60 
[23] Björntorp P 1992 Abdominal obesity and the metabolic syndrome. Ann Med 24:465-468 
[24] Rebuffé-Scrive M, Andersson B, Olbe L, Björntorp P 1989 Metabolism of adipose tissue 
in intraabdominal depots of nonobese men and women. Metabolism 38:453-458 
[25] Kahn BB, Flier JS 2000 Obesity and insulin resistance. The Journal of Clinical 
Investigation 106:473-481 
 
Glucose Tolerance 54 
Future basic science investigations should therefore lead to a better understanding of the 
molecular mechanisms whereby different ERs regulate body weight, body fat, and insulin 
sensitivity in both females and males. Important gaps in the research need to be identified. 
In particular, potential interactions and cross-talk between ERα and G-protein-coupled 
estrogen receptor, which seem to mediate most beneficial effects, critical brain sites where 
ERs regulate glucose homeostasis, and intracellular signaling pathways that are required for 
estrogens' actions, need to be identified. Consequently only the ERs involved in energy 
homeostasis and glucose metabolism will be targeted. This identification would help to 
define novel pharmacological targets selectively associated with fat metabolism and glucose 
homeostasis and help to develop estrogen-like drugs that only initiate intracellular events 
that produce metabolically beneficial actions without deleterious side effects. Such an 
approach would also imply a therapeutic potential in men bypassing the unwanted effects 
of estrogens. 
Author details 
Haifei Shi and Shiva Priya Dharshan Senthil Kumar 
Cellular, Molecular and Structural Biology, Miami University, Oxford, Ohio, USA 
6. References 
[1] James WPT 2008 The epidemiology of obesity: the size of the problem. J Intern Med 
263:336-352 
[2] Cummings DE, Schwartz MW 2003 Genetics and Pathophysiology of Human Obesity. 
Annual Review of Medicine 54:453-471 
[3] Alberti K, Zimmet P, Shaw J 2005 IDF epidemiology task force consensus group: the 
metabolic syndrome - a worldwide definition. Lancet 366:1059 - 1062 
[4] Ford ES 2005 Prevalence of the metabolic syndrome defined by the International 
Diabetes Federation among adults in the U.S. Diabetes Care 28:2745-2749 
[5] Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE 2006 Meta-
analysis: effect of hormone-replacement therapy on components of the metabolic 
syndrome in postmenopausal women. Diabetes Obes Metab 8:538-554 
[6] Rochira V, Madeo B, Zirilli L, Caffagni G, Maffei L, Carani C 2007 Oestradiol 
replacement treatment and glucose homeostasis in two men with congenital aromatase 
deficiency: evidence for a role of oestradiol and sex steroids imbalance on insulin 
sensitivity in men. Diabetic Medicine 24:1491-1495 
[7] Bottini N, Meloni GF, Borgiani P, Giorgini A, Buzzetti R, Pozzilli P, Lucarelli P, Gloria-
Bottini F 2002 Genotypes of cytosolic low-molecular-weight protein-tyrosine-
phosphatase correlate with age at onset of type 1 diabetes in a sex-specific manner. 
Metabolism 51:419-422 
[8] Thamer C, Haap M, Volk A, Maerker E, Becker R, Bachmann O, Machicao F, Häring 
HU, Stumvoll M 2002 Evidence for Greater Oxidative Substrate Flexibility in Male 
Carriers of the Pro 12 Ala Polymorphism in PPARγ2. Horm Metab Res 34:132,136 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 55 
[9] Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJH, Cohen PTW 2003 
Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein 
phosphatase 1 leads to increased weight gain, fat deposition, and development of 
insulin resistance. Diabetes 52:596-604 
[10] Doney A, Fischer B, Cecil J, Cohen P, Boyle D, Leese G, Morris A, Palmer C 2003 Male 
preponderance in early diagnosed type 2 diabetes is associated with the ARE 
insertion/deletion polymorphism in the PPP1R3A locus. BMC Genet 4:11 
[11] Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC 2004 Uncoupling protein-2 
polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol 
Endocrinol Metab 286:E1-E7 
[12] D’Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, 
Lauro D, Sbraccia P, Federici M, Paganelli M, Pontiroli AE, Lauro R, Perticone F, Folli F, 
Sesti G 2004 The −866A/A Genotype in the Promoter of the Human Uncoupling Protein 
2 Gene Is Associated With Insulin Resistance and Increased Risk of Type 2 Diabetes. 
Diabetes 53:1905-1910 
[13] Björntorp P 1991 Metabolic implications of body fat distribution. Diabetes Care 14:1132-
1143 
[14] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia 
LA, Chen H 2003 Chronic inflammation in fat plays a crucial role in the development of 
obesity-related insulin resistance. J Clin Invest 112:1821-1830 
[15] Shi H, Seeley RJ, Clegg DJ 2009 Sexual differences in the control of energy homeostasis. 
Front Neuroendocrinol 30:396-404 
[16] Pokrywka GS 2007 Diagnosis and Treatment of Metabolic Syndrome in Menopausal 
Women. Menopause Management 16:16-25  
[17] Ryan AS, Nicklas BJ, Berman DM 2002 Hormone replacement therapy, insulin 
sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25:127-133 
[18] Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV 1999 Effects of 
postmenopausal hormone replacement therapy on central abdominal fat, glycemic 
control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. 
Diabetes Care 22:1401-1407 
[19] Clegg DJ, Brown LM, Woods SC, Benoit SC 2006 Gonadal hormones determine 
sensitivity to central leptin and insulin. Diabetes 55:978-987 
[20] Livingstone C, Collison M 2002 Sex steroids and insulin resistance. Clin Sci (Lond) 
102:151-166 
[21] Bruns CM, Kemnitz JW 2004 Sex hormones, insulin sensitivity, and diabetes mellitus. 
ILAR J 45:160-169 
[22] Oh J-Y, Barrett-Connor E, Wedick NM, Wingard DL 2002 Endogenous Sex Hormones 
and the Development of Type 2 Diabetes in Older Men and Women: the Rancho 
Bernardo Study. Diabetes Care 25:55-60 
[23] Björntorp P 1992 Abdominal obesity and the metabolic syndrome. Ann Med 24:465-468 
[24] Rebuffé-Scrive M, Andersson B, Olbe L, Björntorp P 1989 Metabolism of adipose tissue 
in intraabdominal depots of nonobese men and women. Metabolism 38:453-458 
[25] Kahn BB, Flier JS 2000 Obesity and insulin resistance. The Journal of Clinical 
Investigation 106:473-481 
 
Glucose Tolerance 56 
[26] Hellmer J, Marcus C, Sonnenfeld T, Arner P 1992 Mechanisms for differences in 
lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 
75:15-20 
[27] Arner P, Hellström L, Wahrenberg H, Brönnegård M 1990 Beta-adrenoceptor 
expression in human fat cells from different regions. J Clin Invest 86:1595-1600 
[28] Vikman HL, Savola JM, Raasmaja A, Ohisalo JJ 1996 Alpha 2A-adrenergic regulation of 
cyclic AMP accumulation and lipolysis in human omental and subcutaneous 
adipocytes. Int J Obes Relat Metab Disord 20:185-189 
[29] Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson J-A, Björntorp P 1990 
Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 71:1215-
1219 
[30] Lundholm K, Rebuffe-Scrive M, Bjc-Rntorp P 1985 Glucocorticoid hormone binding to 
human adipose tissue. Eur J Clin Invest 15:267-271 
[31] Fried SK, Russell CD, Grauso NL, Brolin RE 1993 Lipoprotein lipase regulation by 
insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese 
women and men. J Clin Invest 92:2191-2198 
[32] Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LMS 1998 Human 
adipose tissue expresses angiotensinogen and enzymes required for its conversion to 
angiotensin II. J Clin Endocrinol Metab 83:3925-3929 
[33] Dusserre E, Moulin P, Vidal H 2000 Differences in mRNA expression of the proteins 
secreted by the adipocytes in human subcutaneous and visceral adipose tissues. 
Biochim Biophys Acta 1500:88-96 
[34] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 2003 Obesity 
is associated with macrophage accumulation in adipose tissue. The Journal of Clinical 
Investigation 112:1796-1808 
[35] Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: Their relation to the 
metabolic syndrome. Endocr Rev 21:697-738 
[36] Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, Chandler WL, 
Boyko EJ, Brunzell JD 2009 Adipokines, Inflammation, and Visceral Adiposity across 
the Menopausal Transition: A Prospective Study. J Clin Endocrinol Metab 94:1104-1110 
[37] Björntorp P 1997 Body fat distribution, insulin resistance, and metabolic diseases. 
Nutrition 13:795-803 
[38] Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH 2008 Prevalence of the metabolic 
syndrome among U.S. adolescents using the definition from the International Diabetes 
Federation. Diabetes Care 31:587-589 
[39] O'Dea JA 2008 Gender, ethnicity, culture and social class influences on childhood 
obesity among Australian schoolchildren: implications for treatment, prevention and 
community education. Health Soc Care Community 16:282-290 
[40] Villegas R, Perry IJ, Creagh D, Hinchion R, O’Halloran D 2003 Prevalence of the 
metabolic syndrome in middle-aged men and women. Diabetes Care 26:3198-3199 
[41] Dark J, Wade GN, Zucker I 1984 Ovarian modulation of lipoprotein lipase activity in 
white adipose tissue of ground squirrels. Physiol Behav 32:75-78 
[42] Gray JM, Greenwood MR 1983 Uterine and adipose lipoprotein lipase activity in 
hormone-treated and pregnant rats. Am J Physiol 245:E132-E137 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 57 
[43] Ramirez I 1981 Estradiol-induced changes in lipoprotein lipase, eating, and body 
weight in rats. Am J Physiol 240:E533-E538 
[44] Llado I, Rodriguez-Cuenca S, Pujol E, Monjo M, Estrany ME, Roca P, Palou A 2002 
Gender effects on adrenergic receptor expression and lipolysis in white adipose tissue 
of rats. Obesity 10:296-305 
[45] Rebuffé-Scrive M, Enk L, Crona N, Lönnroth P, Abrahamsson L, Smith U, Björntorp P 
1985 Fat cell metabolism in different regions in women. Effect of menstrual cycle, 
pregnancy, and lactation. J Clin Invest 75:1973-1976 
[46] Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan I, Day N, 
Khaw K-T 2007 Body fat distribution and risk of coronary heart disease in men and 
women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk 
cohort: : a population-based prospective study. Circulation 116:2933-2943 
[47] Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, 
Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai Jr P, Razak F, Sharma AM, 
Anand SS 2005 Obesity and the risk of myocardial infarction in 27 000 participants from 
52 countries: a case-control study. The Lancet 366:1640-1649 
[48] Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, Yudkin JS, 
Heine RJ, Nijpels G, Seidell JC 2003 Associations of hip and thigh circumferences 
independent of waist circumference with the incidence of type 2 diabetes: the Hoorn 
Study. Am J Clin Nutr 77:1192-1197 
[49] Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE 2004 Independent 
association of hip circumference with metabolic profile in different ethnic groups. 
Obesity 12:1370-1374 
[50] Foster M, Shi H, Softic S, Kohli R, Seeley R, Woods S 2011 Transplantation of non-
visceral fat to the visceral cavity improves glucose tolerance in mice: investigation of 
hepatic lipids and insulin sensitivity. Diabetologia 54:2890-2899 
[51] Foster MT, Shi H, Seeley RJ, Woods SC 2010 Transplantation or removal of intra-
abdominal adipose tissue prevents age-induced glucose insensitivity. Physiol Behav 
101:282-288 
[52] Hocking S, Chisholm D, James D 2008 Studies of regional adipose transplantation 
reveal a unique and beneficial interaction between subcutaneous adipose tissue and the 
intra-abdominal compartment. Diabetologia 51:900-902 
[53] Tran TT, Yamamoto Y, Gesta S, Kahn CR 2008 Beneficial effects of subcutaneous fat 
transplantation on metabolism. Cell Metabolism 7:410-420 
[54] Heitmann BL, Frederiksen P, Lissner L 2004 Hip circumference and cardiovascular 
morbidity and mortality in men and women. Obesity 12:482-487 
[55] Shi H, Clegg DJ 2009 Sex differences in the regulation of body weight. Physiol Behav 
97:199-204 
[56] Asarian L, Geary N 1999 Cyclic estradiol treatment phasically potentiates endogenous 
cholecystokinin's satiating action in ovariectomized rats. Peptides 20:445-450 
[57] Jones MEE, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury 
BJ, Robertson KM, Yao S, Simpson ER 2000 Aromatase-deficient (ArKO) mice have a 
phenotype of increased adiposity. Proc Natl Acad Sci U S A 97:12735-12740 
[58] Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R 2002 Obesity and the 
polycystic ovary syndrome. Int J Obes Relat Metab Disord 26:883-896 
 
Glucose Tolerance 56 
[26] Hellmer J, Marcus C, Sonnenfeld T, Arner P 1992 Mechanisms for differences in 
lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab 
75:15-20 
[27] Arner P, Hellström L, Wahrenberg H, Brönnegård M 1990 Beta-adrenoceptor 
expression in human fat cells from different regions. J Clin Invest 86:1595-1600 
[28] Vikman HL, Savola JM, Raasmaja A, Ohisalo JJ 1996 Alpha 2A-adrenergic regulation of 
cyclic AMP accumulation and lipolysis in human omental and subcutaneous 
adipocytes. Int J Obes Relat Metab Disord 20:185-189 
[29] Rebuffé-Scrive M, Brönnegard M, Nilsson A, Eldh J, Gustafsson J-A, Björntorp P 1990 
Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab 71:1215-
1219 
[30] Lundholm K, Rebuffe-Scrive M, Bjc-Rntorp P 1985 Glucocorticoid hormone binding to 
human adipose tissue. Eur J Clin Invest 15:267-271 
[31] Fried SK, Russell CD, Grauso NL, Brolin RE 1993 Lipoprotein lipase regulation by 
insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese 
women and men. J Clin Invest 92:2191-2198 
[32] Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson LMS 1998 Human 
adipose tissue expresses angiotensinogen and enzymes required for its conversion to 
angiotensin II. J Clin Endocrinol Metab 83:3925-3929 
[33] Dusserre E, Moulin P, Vidal H 2000 Differences in mRNA expression of the proteins 
secreted by the adipocytes in human subcutaneous and visceral adipose tissues. 
Biochim Biophys Acta 1500:88-96 
[34] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW 2003 Obesity 
is associated with macrophage accumulation in adipose tissue. The Journal of Clinical 
Investigation 112:1796-1808 
[35] Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: Their relation to the 
metabolic syndrome. Endocr Rev 21:697-738 
[36] Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, Chandler WL, 
Boyko EJ, Brunzell JD 2009 Adipokines, Inflammation, and Visceral Adiposity across 
the Menopausal Transition: A Prospective Study. J Clin Endocrinol Metab 94:1104-1110 
[37] Björntorp P 1997 Body fat distribution, insulin resistance, and metabolic diseases. 
Nutrition 13:795-803 
[38] Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH 2008 Prevalence of the metabolic 
syndrome among U.S. adolescents using the definition from the International Diabetes 
Federation. Diabetes Care 31:587-589 
[39] O'Dea JA 2008 Gender, ethnicity, culture and social class influences on childhood 
obesity among Australian schoolchildren: implications for treatment, prevention and 
community education. Health Soc Care Community 16:282-290 
[40] Villegas R, Perry IJ, Creagh D, Hinchion R, O’Halloran D 2003 Prevalence of the 
metabolic syndrome in middle-aged men and women. Diabetes Care 26:3198-3199 
[41] Dark J, Wade GN, Zucker I 1984 Ovarian modulation of lipoprotein lipase activity in 
white adipose tissue of ground squirrels. Physiol Behav 32:75-78 
[42] Gray JM, Greenwood MR 1983 Uterine and adipose lipoprotein lipase activity in 
hormone-treated and pregnant rats. Am J Physiol 245:E132-E137 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 57 
[43] Ramirez I 1981 Estradiol-induced changes in lipoprotein lipase, eating, and body 
weight in rats. Am J Physiol 240:E533-E538 
[44] Llado I, Rodriguez-Cuenca S, Pujol E, Monjo M, Estrany ME, Roca P, Palou A 2002 
Gender effects on adrenergic receptor expression and lipolysis in white adipose tissue 
of rats. Obesity 10:296-305 
[45] Rebuffé-Scrive M, Enk L, Crona N, Lönnroth P, Abrahamsson L, Smith U, Björntorp P 
1985 Fat cell metabolism in different regions in women. Effect of menstrual cycle, 
pregnancy, and lactation. J Clin Invest 75:1973-1976 
[46] Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan I, Day N, 
Khaw K-T 2007 Body fat distribution and risk of coronary heart disease in men and 
women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk 
cohort: : a population-based prospective study. Circulation 116:2933-2943 
[47] Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, 
Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai Jr P, Razak F, Sharma AM, 
Anand SS 2005 Obesity and the risk of myocardial infarction in 27 000 participants from 
52 countries: a case-control study. The Lancet 366:1640-1649 
[48] Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, Yudkin JS, 
Heine RJ, Nijpels G, Seidell JC 2003 Associations of hip and thigh circumferences 
independent of waist circumference with the incidence of type 2 diabetes: the Hoorn 
Study. Am J Clin Nutr 77:1192-1197 
[49] Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE 2004 Independent 
association of hip circumference with metabolic profile in different ethnic groups. 
Obesity 12:1370-1374 
[50] Foster M, Shi H, Softic S, Kohli R, Seeley R, Woods S 2011 Transplantation of non-
visceral fat to the visceral cavity improves glucose tolerance in mice: investigation of 
hepatic lipids and insulin sensitivity. Diabetologia 54:2890-2899 
[51] Foster MT, Shi H, Seeley RJ, Woods SC 2010 Transplantation or removal of intra-
abdominal adipose tissue prevents age-induced glucose insensitivity. Physiol Behav 
101:282-288 
[52] Hocking S, Chisholm D, James D 2008 Studies of regional adipose transplantation 
reveal a unique and beneficial interaction between subcutaneous adipose tissue and the 
intra-abdominal compartment. Diabetologia 51:900-902 
[53] Tran TT, Yamamoto Y, Gesta S, Kahn CR 2008 Beneficial effects of subcutaneous fat 
transplantation on metabolism. Cell Metabolism 7:410-420 
[54] Heitmann BL, Frederiksen P, Lissner L 2004 Hip circumference and cardiovascular 
morbidity and mortality in men and women. Obesity 12:482-487 
[55] Shi H, Clegg DJ 2009 Sex differences in the regulation of body weight. Physiol Behav 
97:199-204 
[56] Asarian L, Geary N 1999 Cyclic estradiol treatment phasically potentiates endogenous 
cholecystokinin's satiating action in ovariectomized rats. Peptides 20:445-450 
[57] Jones MEE, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury 
BJ, Robertson KM, Yao S, Simpson ER 2000 Aromatase-deficient (ArKO) mice have a 
phenotype of increased adiposity. Proc Natl Acad Sci U S A 97:12735-12740 
[58] Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R 2002 Obesity and the 
polycystic ovary syndrome. Int J Obes Relat Metab Disord 26:883-896 
 
Glucose Tolerance 58 
[59] Misso ML, Murata Y, Boon WC, Jones MEE, Britt KL, Simpson ER 2003 Cellular and 
molecular characterization of the adipose phenotype of the aromatase-deficient mouse. 
Endocrinology 144:1474-1480 
[60] Maffei L, Rochira V, Zirilli L, Antunez P, Aranda C, Fabre B, Simone ML, Pignatti E, 
Simpson ER, Houssami S, Clyne CD, Carani C 2007 A novel compound heterozygous 
mutation of the aromatase gene in an adult man: reinforced evidence on the 
relationship between congenital oestrogen deficiency, adiposity and the metabolic 
syndrome. Clin Endocrinol (Oxf) 67:218-224 
[61] Takeda K, Toda K, Saibara T, Nakagawa M, Saika K, Onishi T, Sugiura T, Shizuta Y 
2003 Progressive development of insulin resistance phenotype in male mice with 
complete aromatase (CYP19) deficiency. J Endocrinol 176:237-246 
[62] Razandi M, Pedram A, Greene GL, Levin ER 1999 Cell membrane and nuclear estrogen 
receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in 
Chinese hamster ovary cells. Mol Endocrinol 13:307-319 
[63] Pappas T, Gametchu B, Watson C 1995 Membrane estrogen receptors identified by 
multiple antibody labeling and impeded-ligand binding. FASEB J 9:404-410 
[64] Okura T, Koda M, Ando F, Niino N, Ohta S, Shimokata H 2003 Association of 
polymorphisms in the estrogen receptor [alpha] gene with body fat distribution. Int J 
Obes Relat Metab Disord 27:1020-1027 
[65] Nilsson M, Dahlman I, Ryden M, Nordstrom EA, Gustafsson JA, Arner P, Dahlman-
Wright K 2007 Oestrogen receptor alpha gene expression levels are reduced in obese 
compared to normal weight females. Int J Obes 31:900-907 
[66] Deng H-W, Li J, Li J-L, Dowd R, Davies KM, Johnson M, Gong G, Deng H, Recker RR 
2000 Association of estrogen receptor-alpha genotypes with body mass index in normal 
healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 85:2748-2751 
[67] Fox CS, Yang Q, Cupples LA, Guo C-Y, Atwood LD, Murabito JM, Levy D, Mendelsohn 
ME, Housman DE, Shearman AM 2005 Sex-specific association between estrogen 
receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. 
J Clini Endocrinol Metab 90:6257-6262 
[68] Goulart AC, Zee RYL, Rexrode KM 2009 Association of estrogen receptor 2 gene 
polymorphisms with obesity in women (obesity and estrogen receptor 2 gene). 
Maturitas 62:179-183 
[69] Saltiki K, Mantzou E, Doukas C, Kanakakis I, Zotos P, Lazaros L, Georgiou I, Alevizaki 
M 2009 Estrogen receptor beta gene variants may be associated with more favorable 
metabolic profile in postmenopausal women undergoing coronary angiography. Exp 
Clin Endocrinol Diabetes 117:610-615 
[70] Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS 2000 Increased adipose tissue 
in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci U S A 
97:12729-12734 
[71] Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly M, Rudling M, Lindberg MK, 
Warner M, Angelin B, Gustafsson J-Å 2000 Obesity and disturbed lipoprotein profile in 
estrogen receptor-α-deficient male mice. Biochem Biophys Res Commun 278:640-645 
[72] Liang YQ, Akishita M, Kim S, Ako J, Hashimoto M, Iijima K, Ohike Y, Watanabe T, 
Sudoh N, Toba K, Yoshizumi M, Ouchi Y 2002 Estrogen receptor beta is involved in the 
anorectic action of estrogen. Int J Obes Relat Metab Disord 26:1103-1109 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 59 
[73] Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cooke PS 2002 
Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor 
alpha (ERα): a potential role for estrogen receptor beta (ERβ). Horm Metab Res 
34:758,763 
[74] Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S 2001 Deficits in E2-dependent 
control of feeding, weight gain, and cholecystokinin satiation in ER-α null mice. 
Endocrinology 142:4751-4757 
[75] Matthews J, Gustafsson J-Å 2003 Estrogen signaling: a subtle balance between ER alpha 
and ER beta. Mol Interv 3:281-292 
[76] Krotkiewski M, Björntorp P, Sjöström L, Smith U 1983 Impact of obesity on metabolism 
in men and women. Importance of regional adipose tissue distribution. J Clin Invest 
72:1150-1162 
[77] Bouchard C, Despres, JEAN-PIERRE, Mauriege P 1993 Genetic and nongenetic 
determinants of regional fat distribution. Endocr Rev 14:72-93 
[78] Gruber CJ, Tschugguel W, Schneeberger C, Huber JC 2002 Production and actions of 
estrogens. N Engl J Med 346:340-352 
[79] Haffner SM, Katz MS, Dunn JF 1991 Increased upper body and overall adiposity is 
associated with decreased sex hormone binding globulin in postmenopausal women. 
Int J Obes 15:471-478 
[80] Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD 1991 Associations of body mass and 
fat distribution with sex hormone concentrations in postmenopausal women. Int J 
Epidemiol 20:151-156 
[81] Baglietto L, English D, Hopper J, MacInnis R, Morris H, Tilley W, Krishnan K, Giles G 
2009 Circulating steroid hormone concentrations in postmenopausal women in relation 
to body size and composition. Breast Cancer Res Treat 115:171-179 
[82] Enzi G, Gasparo M, Biondetti P, Fiore D, Semisa M, Zurlo F 1986 Subcutaneous and 
visceral fat distribution according to sex, age, and overweight, evaluated by computed 
tomography. Am J Clin Nutr 44:739-746 
[83] Asarian L, Geary N 2006 Modulation of appetite by gonadal steroid hormones. Philos T 
Roy Soc B 361:1251-1263 
[84] Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L 1997 Leptin 
selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 
100:3105-3110 
[85] Clegg DJ, Riedy CA, Smith KAB, Benoit SC, Woods SC 2003 Differential sensitivity to 
central leptin and insulin in male and female rats. Diabetes 52:682-687 
[86] Simpson ER, Jones ME 2007 Of mice and men: the many guises of estrogens. In: Korach 
KS, Wintermantel T eds. Tissue-specific estrogen action: Springer Berlin Heidelberg; 45-
68 
[87] Wahrenberg H, Lönnqvist F, Arner P 1989 Mechanisms underlying regional differences 
in lipolysis in human adipose tissue. The Journal of Clinical Investigation 84:458-467 
[88] D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS 2005 Estrogen 
regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic 
regulation of lipogenic and oxidative pathways. J Biol Chem 280:35983-35991 
 
Glucose Tolerance 58 
[59] Misso ML, Murata Y, Boon WC, Jones MEE, Britt KL, Simpson ER 2003 Cellular and 
molecular characterization of the adipose phenotype of the aromatase-deficient mouse. 
Endocrinology 144:1474-1480 
[60] Maffei L, Rochira V, Zirilli L, Antunez P, Aranda C, Fabre B, Simone ML, Pignatti E, 
Simpson ER, Houssami S, Clyne CD, Carani C 2007 A novel compound heterozygous 
mutation of the aromatase gene in an adult man: reinforced evidence on the 
relationship between congenital oestrogen deficiency, adiposity and the metabolic 
syndrome. Clin Endocrinol (Oxf) 67:218-224 
[61] Takeda K, Toda K, Saibara T, Nakagawa M, Saika K, Onishi T, Sugiura T, Shizuta Y 
2003 Progressive development of insulin resistance phenotype in male mice with 
complete aromatase (CYP19) deficiency. J Endocrinol 176:237-246 
[62] Razandi M, Pedram A, Greene GL, Levin ER 1999 Cell membrane and nuclear estrogen 
receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in 
Chinese hamster ovary cells. Mol Endocrinol 13:307-319 
[63] Pappas T, Gametchu B, Watson C 1995 Membrane estrogen receptors identified by 
multiple antibody labeling and impeded-ligand binding. FASEB J 9:404-410 
[64] Okura T, Koda M, Ando F, Niino N, Ohta S, Shimokata H 2003 Association of 
polymorphisms in the estrogen receptor [alpha] gene with body fat distribution. Int J 
Obes Relat Metab Disord 27:1020-1027 
[65] Nilsson M, Dahlman I, Ryden M, Nordstrom EA, Gustafsson JA, Arner P, Dahlman-
Wright K 2007 Oestrogen receptor alpha gene expression levels are reduced in obese 
compared to normal weight females. Int J Obes 31:900-907 
[66] Deng H-W, Li J, Li J-L, Dowd R, Davies KM, Johnson M, Gong G, Deng H, Recker RR 
2000 Association of estrogen receptor-alpha genotypes with body mass index in normal 
healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 85:2748-2751 
[67] Fox CS, Yang Q, Cupples LA, Guo C-Y, Atwood LD, Murabito JM, Levy D, Mendelsohn 
ME, Housman DE, Shearman AM 2005 Sex-specific association between estrogen 
receptor-alpha gene variation and measures of adiposity: the Framingham Heart Study. 
J Clini Endocrinol Metab 90:6257-6262 
[68] Goulart AC, Zee RYL, Rexrode KM 2009 Association of estrogen receptor 2 gene 
polymorphisms with obesity in women (obesity and estrogen receptor 2 gene). 
Maturitas 62:179-183 
[69] Saltiki K, Mantzou E, Doukas C, Kanakakis I, Zotos P, Lazaros L, Georgiou I, Alevizaki 
M 2009 Estrogen receptor beta gene variants may be associated with more favorable 
metabolic profile in postmenopausal women undergoing coronary angiography. Exp 
Clin Endocrinol Diabetes 117:610-615 
[70] Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS 2000 Increased adipose tissue 
in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci U S A 
97:12729-12734 
[71] Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly M, Rudling M, Lindberg MK, 
Warner M, Angelin B, Gustafsson J-Å 2000 Obesity and disturbed lipoprotein profile in 
estrogen receptor-α-deficient male mice. Biochem Biophys Res Commun 278:640-645 
[72] Liang YQ, Akishita M, Kim S, Ako J, Hashimoto M, Iijima K, Ohike Y, Watanabe T, 
Sudoh N, Toba K, Yoshizumi M, Ouchi Y 2002 Estrogen receptor beta is involved in the 
anorectic action of estrogen. Int J Obes Relat Metab Disord 26:1103-1109 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 59 
[73] Naaz A, Zakroczymski M, Heine P, Taylor J, Saunders P, Lubahn D, Cooke PS 2002 
Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor 
alpha (ERα): a potential role for estrogen receptor beta (ERβ). Horm Metab Res 
34:758,763 
[74] Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S 2001 Deficits in E2-dependent 
control of feeding, weight gain, and cholecystokinin satiation in ER-α null mice. 
Endocrinology 142:4751-4757 
[75] Matthews J, Gustafsson J-Å 2003 Estrogen signaling: a subtle balance between ER alpha 
and ER beta. Mol Interv 3:281-292 
[76] Krotkiewski M, Björntorp P, Sjöström L, Smith U 1983 Impact of obesity on metabolism 
in men and women. Importance of regional adipose tissue distribution. J Clin Invest 
72:1150-1162 
[77] Bouchard C, Despres, JEAN-PIERRE, Mauriege P 1993 Genetic and nongenetic 
determinants of regional fat distribution. Endocr Rev 14:72-93 
[78] Gruber CJ, Tschugguel W, Schneeberger C, Huber JC 2002 Production and actions of 
estrogens. N Engl J Med 346:340-352 
[79] Haffner SM, Katz MS, Dunn JF 1991 Increased upper body and overall adiposity is 
associated with decreased sex hormone binding globulin in postmenopausal women. 
Int J Obes 15:471-478 
[80] Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD 1991 Associations of body mass and 
fat distribution with sex hormone concentrations in postmenopausal women. Int J 
Epidemiol 20:151-156 
[81] Baglietto L, English D, Hopper J, MacInnis R, Morris H, Tilley W, Krishnan K, Giles G 
2009 Circulating steroid hormone concentrations in postmenopausal women in relation 
to body size and composition. Breast Cancer Res Treat 115:171-179 
[82] Enzi G, Gasparo M, Biondetti P, Fiore D, Semisa M, Zurlo F 1986 Subcutaneous and 
visceral fat distribution according to sex, age, and overweight, evaluated by computed 
tomography. Am J Clin Nutr 44:739-746 
[83] Asarian L, Geary N 2006 Modulation of appetite by gonadal steroid hormones. Philos T 
Roy Soc B 361:1251-1263 
[84] Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L 1997 Leptin 
selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 
100:3105-3110 
[85] Clegg DJ, Riedy CA, Smith KAB, Benoit SC, Woods SC 2003 Differential sensitivity to 
central leptin and insulin in male and female rats. Diabetes 52:682-687 
[86] Simpson ER, Jones ME 2007 Of mice and men: the many guises of estrogens. In: Korach 
KS, Wintermantel T eds. Tissue-specific estrogen action: Springer Berlin Heidelberg; 45-
68 
[87] Wahrenberg H, Lönnqvist F, Arner P 1989 Mechanisms underlying regional differences 
in lipolysis in human adipose tissue. The Journal of Clinical Investigation 84:458-467 
[88] D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS 2005 Estrogen 
regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic 
regulation of lipogenic and oxidative pathways. J Biol Chem 280:35983-35991 
 
Glucose Tolerance 60 
[89] Rebuffé-Scrive M, Eldh J, Hafström L-O, Björntorp P 1986 Metabolism of mammary, 
abdominal, and femoral adipocytes in women before and after menopause. Metabolism 
35:792-797 
[90] Lindberg U-B, Crona N, Silfverstolpe G, Björntorp P, Rebuffé-Scrive M 1990 Regional 
adipose tissue metabolism in postmenopausal women after treatment with exogenous 
sex steroids. Horm Metab Res 22:345,351 
[91] Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB 2001 Impaired insulin action in 
subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol 
Metab 280:E40-E49 
[92] Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic 
syndrome. Nat Rev Endocrinol 5:673-681 
[93] Blouin K, Després J-P, Couillard C, Tremblay A, Prud'homme D, Bouchard C, Tchernof 
A 2005 Contribution of age and declining androgen levels to features of the metabolic 
syndrome in men. Metabolism 54:1034-1040 
[94] Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, Sjostrom L, 
Holm G, Bjorntorp P 1993 Androgen treatment of abdominally obese men. Obes Res 
1:245-251 
[95] Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R 1995 
Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases 
abdominal fat in obese, older men. Int J Obes Relat Metab Disord 19:614-624 
[96] McInnes KJ, Corbould A, Simpson ER, Jones ME 2006 Regulation of adenosine 
5',monophosphate-activated protein kinase and lipogenesis by androgens contributes to 
visceral obesity in an estrogen-deficient state. Endocrinology 147:5907-5913 
[97] Pasquali R, Casimirri F, Cantobelli S, Morselli Labate AM, Venturoli S, Paradisi R, 
Zannarini L 1993 Insulin and androgen relationships with abdominal body fat 
distribution in women with and without hyperandrogenism. Horm Res 39:179-187 
[98] Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C, Partington C 
1996 Exogenous androgens influence body composition and regional body fat 
distribution in obese postmenopausal women--a clinical research center study. J Clin 
Endocrinol Metab 81:2198-2203 
[99] Elbers JMH, Asscheman H, Seidell JC, Megens JAJ, Gooren LJG 1997 Long-term 
testosterone administration increases visceral fat in female to male transsexuals. J Clin 
Endocrinol Metab 82:2044-2047 
[100] Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG 1998 Identification of estrogen 
receptor β RNA in human breast and abdominal subcutaneous adipose tissue. Biochem 
Biophys Res Commun 248:523-526 
[101] Björntorp P 1997 Hormonal control of regional fat distribution. Hum Reprod 12:21-25 
[102] Macotela Y, Boucher J, Tran TT, Kahn CR 2009 Sex and depot differences in adipocyte 
insulin sensitivity and glucose metabolism. Diabetes 58:803-812 
[103] Lu S-f, McKenna SE, Cologer-Clifford A, Nau EA, Simon NG 1998 Androgen receptor 
in mouse brain: sex differences and similarities in autoregulation. Endocrinology 
139:1594-1601 
[104] Yu I-C, Lin H-Y, Liu N-C, Wang R-S, Sparks JD, Yeh S, Chang C 2008 Hyperleptinemia 
without obesity in male mice lacking androgen receptor in adipose tissue. 
Endocrinology 149:2361-2368 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 61 
[105] Dieudonné MN, Leneveu MC, Giudicelli Y, Pecquery R 2004 Evidence for functional 
estrogen receptors α and β in human adipose cells: regional specificities and regulation 
by estrogens. Am J Physiol Cell Physiol 286:C655-C661 
[106] Mayes JS, Watson GH 2004 Direct effects of sex steroid hormones on adipose tissues 
and obesity. Obes Rev 5:197-216 
[107] Österlund M, G.J.M. Kuiper G, Gustafsson J-Å, Hurd YL 1998 Differential distribution 
and regulation of estrogen receptor-α and -β mRNA within the female rat brain. Mol 
Brain Res 54:175-180 
[108] Merchenthaler I, Lane MV, Numan S, Dellovade TL 2004 Distribution of estrogen 
receptor α and β in the mouse central nervous system: In vivo autoradiographic and 
immunocytochemical analyses. J Comp Neurol 473:270-291 
[109] Simerly RB, Swanson LW, Chang C, Muramatsu M 1990 Distribution of androgen and 
estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization 
study. J Comp Neurol 294:76-95 
[110] Musatov S, Chen W, Pfaff DW, Mobbs CV, Yang X-J, Clegg DJ, Kaplitt MG, Ogawa S 
2007 Silencing of estrogen receptor α in the ventromedial nucleus of hypothalamus 
leads to metabolic syndrome. Proc Natl Acad Sci U S A 104:2501-2506 
[111] Glümer C, Jørgensen T, Borch-Johnsen K 2003 Prevalences of diabetes and impaired 
glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335-
2340 
[112] Group tDS 2003 Age- and sex-specific prevalences of diabetes and impaired glucose 
regulation in 13 European cohorts. Diabetes Care 26:61-69 
[113] Færch K, Borch-Johnsen K, Vaag A, Jørgensen T, Witte D 2010 Sex differences in 
glucose levels: a consequence of physiology or methodological convenience? The 
Inter99 study. Diabetologia 53:858-865 
[114] Dunstan DW, Zimmet PZ, Welborn TA, de Courten MP, Cameron AJ, Sicree RA, 
Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE 2002 The rising 
prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity 
and Lifestyle Study. Diabetes Care 25:829-834 
[115] Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE 2008 
Differences in height explain gender differences in the response to the oral glucose 
tolerance test— the AusDiab study. Diabet Med 25:296-302 
[116] Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer 
A, Stadler M, DeFronzo RA, Pacini G, Bischof MG 2011 Mechanism and effects of 
glucose absorption during an oral glucose tolerance test among females and males. J 
Clini Endocrinol Metab 96:515-524 
[117] Group EHBCC 2003 Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk 
in Postmenopausal Women. J Natl Cancer Inst 95:1218-1226 
[118] Williams JW, Zimmet PZ, Shaw JE, De Courten MP, Cameron AJ, Chitson P, 
Tuomilehto J, Alberti KGMM 2003 Gender differences in the prevalence of impaired 
fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet 
Med 20:915-920 
[119] Nettle D 2002 Women's height, reproductive success and the evolution of sexual 
dimorphism in modern humans. Proc Biol Sci 269:1919-1923 
 
Glucose Tolerance 60 
[89] Rebuffé-Scrive M, Eldh J, Hafström L-O, Björntorp P 1986 Metabolism of mammary, 
abdominal, and femoral adipocytes in women before and after menopause. Metabolism 
35:792-797 
[90] Lindberg U-B, Crona N, Silfverstolpe G, Björntorp P, Rebuffé-Scrive M 1990 Regional 
adipose tissue metabolism in postmenopausal women after treatment with exogenous 
sex steroids. Horm Metab Res 22:345,351 
[91] Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB 2001 Impaired insulin action in 
subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol 
Metab 280:E40-E49 
[92] Zitzmann M 2009 Testosterone deficiency, insulin resistance and the metabolic 
syndrome. Nat Rev Endocrinol 5:673-681 
[93] Blouin K, Després J-P, Couillard C, Tremblay A, Prud'homme D, Bouchard C, Tchernof 
A 2005 Contribution of age and declining androgen levels to features of the metabolic 
syndrome in men. Metabolism 54:1034-1040 
[94] Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, Sjostrom L, 
Holm G, Bjorntorp P 1993 Androgen treatment of abdominally obese men. Obes Res 
1:245-251 
[95] Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R 1995 
Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases 
abdominal fat in obese, older men. Int J Obes Relat Metab Disord 19:614-624 
[96] McInnes KJ, Corbould A, Simpson ER, Jones ME 2006 Regulation of adenosine 
5',monophosphate-activated protein kinase and lipogenesis by androgens contributes to 
visceral obesity in an estrogen-deficient state. Endocrinology 147:5907-5913 
[97] Pasquali R, Casimirri F, Cantobelli S, Morselli Labate AM, Venturoli S, Paradisi R, 
Zannarini L 1993 Insulin and androgen relationships with abdominal body fat 
distribution in women with and without hyperandrogenism. Horm Res 39:179-187 
[98] Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C, Partington C 
1996 Exogenous androgens influence body composition and regional body fat 
distribution in obese postmenopausal women--a clinical research center study. J Clin 
Endocrinol Metab 81:2198-2203 
[99] Elbers JMH, Asscheman H, Seidell JC, Megens JAJ, Gooren LJG 1997 Long-term 
testosterone administration increases visceral fat in female to male transsexuals. J Clin 
Endocrinol Metab 82:2044-2047 
[100] Crandall DL, Busler DE, Novak TJ, Weber RV, Kral JG 1998 Identification of estrogen 
receptor β RNA in human breast and abdominal subcutaneous adipose tissue. Biochem 
Biophys Res Commun 248:523-526 
[101] Björntorp P 1997 Hormonal control of regional fat distribution. Hum Reprod 12:21-25 
[102] Macotela Y, Boucher J, Tran TT, Kahn CR 2009 Sex and depot differences in adipocyte 
insulin sensitivity and glucose metabolism. Diabetes 58:803-812 
[103] Lu S-f, McKenna SE, Cologer-Clifford A, Nau EA, Simon NG 1998 Androgen receptor 
in mouse brain: sex differences and similarities in autoregulation. Endocrinology 
139:1594-1601 
[104] Yu I-C, Lin H-Y, Liu N-C, Wang R-S, Sparks JD, Yeh S, Chang C 2008 Hyperleptinemia 
without obesity in male mice lacking androgen receptor in adipose tissue. 
Endocrinology 149:2361-2368 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 61 
[105] Dieudonné MN, Leneveu MC, Giudicelli Y, Pecquery R 2004 Evidence for functional 
estrogen receptors α and β in human adipose cells: regional specificities and regulation 
by estrogens. Am J Physiol Cell Physiol 286:C655-C661 
[106] Mayes JS, Watson GH 2004 Direct effects of sex steroid hormones on adipose tissues 
and obesity. Obes Rev 5:197-216 
[107] Österlund M, G.J.M. Kuiper G, Gustafsson J-Å, Hurd YL 1998 Differential distribution 
and regulation of estrogen receptor-α and -β mRNA within the female rat brain. Mol 
Brain Res 54:175-180 
[108] Merchenthaler I, Lane MV, Numan S, Dellovade TL 2004 Distribution of estrogen 
receptor α and β in the mouse central nervous system: In vivo autoradiographic and 
immunocytochemical analyses. J Comp Neurol 473:270-291 
[109] Simerly RB, Swanson LW, Chang C, Muramatsu M 1990 Distribution of androgen and 
estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization 
study. J Comp Neurol 294:76-95 
[110] Musatov S, Chen W, Pfaff DW, Mobbs CV, Yang X-J, Clegg DJ, Kaplitt MG, Ogawa S 
2007 Silencing of estrogen receptor α in the ventromedial nucleus of hypothalamus 
leads to metabolic syndrome. Proc Natl Acad Sci U S A 104:2501-2506 
[111] Glümer C, Jørgensen T, Borch-Johnsen K 2003 Prevalences of diabetes and impaired 
glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335-
2340 
[112] Group tDS 2003 Age- and sex-specific prevalences of diabetes and impaired glucose 
regulation in 13 European cohorts. Diabetes Care 26:61-69 
[113] Færch K, Borch-Johnsen K, Vaag A, Jørgensen T, Witte D 2010 Sex differences in 
glucose levels: a consequence of physiology or methodological convenience? The 
Inter99 study. Diabetologia 53:858-865 
[114] Dunstan DW, Zimmet PZ, Welborn TA, de Courten MP, Cameron AJ, Sicree RA, 
Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE 2002 The rising 
prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity 
and Lifestyle Study. Diabetes Care 25:829-834 
[115] Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE 2008 
Differences in height explain gender differences in the response to the oral glucose 
tolerance test— the AusDiab study. Diabet Med 25:296-302 
[116] Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer 
A, Stadler M, DeFronzo RA, Pacini G, Bischof MG 2011 Mechanism and effects of 
glucose absorption during an oral glucose tolerance test among females and males. J 
Clini Endocrinol Metab 96:515-524 
[117] Group EHBCC 2003 Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk 
in Postmenopausal Women. J Natl Cancer Inst 95:1218-1226 
[118] Williams JW, Zimmet PZ, Shaw JE, De Courten MP, Cameron AJ, Chitson P, 
Tuomilehto J, Alberti KGMM 2003 Gender differences in the prevalence of impaired 
fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet 
Med 20:915-920 
[119] Nettle D 2002 Women's height, reproductive success and the evolution of sexual 
dimorphism in modern humans. Proc Biol Sci 269:1919-1923 
 
Glucose Tolerance 62 
[120] Vaag AA, Holst JJ, Vølund A, Beck-Nielsen H 1996 Gut incretin hormones in identical 
twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for 
decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM 
twins. Eur J Endocrinol 135:425-432 
[121] Rathmann W, Strassburger K, Giani G, Döring A, Meisinger C 2008 Differences in 
height explain gender differences in the response to the oral glucose tolerance test. 
Diabet Med 25:1374-1375 
[122] Anastasiou E, Alevizaki M, Grigorakis SJ, Philippou G, Kyprianou M, Souvatzoglou A 
1998 Decreased stature in gestational diabetes mellitus. Diabetologia 41:997-1001 
[123] Magliano DJ, Barr ELM, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S, Jolley D, 
Owen N, Phillips P, Tapp RJ, Welborn TA, Shaw JE 2008 Glucose indices, health 
behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and 
Lifestyle Study. Diabetes Care 31:267-272 
[124] Soeters MR, Sauerwein HP, Groener JE, Aerts JM, Ackermans MT, Glatz JFC, Fliers E, 
Serlie MJ 2007 Gender-related differences in the metabolic response to fasting. J Clin 
Endocrinol Metab 92:3646-3652 
[125] Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ 
1996 Effects of gender and menopausal status on plasma lipoprotein subspecies and 
particle sizes. J Lipid Res 37:1886-1896 
[126] Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D 1984 Relationships between 
insulin secretion, insulin action, and fasting plasma glucose concentration in 
nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-1246 
[127] Anderwald C, Brunmair B, Stadlbauer K, Krebs M, Fürnsinn C, Roden M 2007 Effects 
of free fatty acids on carbohydrate metabolism and insulin signalling in perfused rat 
liver. Eur J Clin Invest 37:774-782 
[128] Færch K, Vaag A, Witte DR, Jørgensen T, Pedersen O, Borch-Johnsen K 2009 Predictors 
of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and 
women—the Inter99 study. Diabet Med 26:377-383 
[129] Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, 
Bergman RN 2003 Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin 
Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52:2490-2496 
[130] Datz FL, Christian PE, Moore J 1987 Gender-related differences in gastric emptying. J 
Nucl Med 28:1204-1207 
[131] Anderwald C, Tura A, Winhofer Y, Krebs M, Winzer C, Bischof MG, Luger A, Pacini 
G, Kautzky-Willer A 2011 Glucose absorption in gestational diabetes mellitus during an 
oral glucose tolerance test. Diabetes Care 34:1475-1480 
[132] Flanagan DE, Holt RIG, Owens PC, Cockington RJ, Moore VM, Robinson JS, Godsland 
IF, Phillips DIW 2006 Gender differences in the insulin-like growth factor axis response 
to a glucose load. Acta Physiol (Oxf) 187:371-378 
[133] Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G, Cobelli C, Rizza RA 
2006 Effects of age and sex on postprandial glucose metabolism: differences in glucose 
turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 
55:2001-2014 
[134] Sugden M, Holness M 2002 Gender-specific programming of insulin secretion and 
action. J Endocrinol 175:757-767 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 63 
[135] Shulman GI 2000 Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176 
[136] Saltiel AR, Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 414:799-806 
[137] Mittendorfer B 2005 Insulin resistance: sex matters. Current Opinion in Clinical 
Nutrition & Metabolic Care 8:367-372 
[138] Kuhl J, Hilding A, Östenson CG, Grill V, Efendic S, Båvenholm P 2005 
Characterisation of subjects with early abnormalities of glucose tolerance in the 
Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes 
heredity. Diabetologia 48:35-40 
[139] Frias JP, Macaraeg GB, Ofrecio J, Yu JG, Olefsky JM, Kruszynska YT 2001 Decreased 
susceptibility to fatty acid-induced peripheral tissue insulin resistance in women. 
Diabetes 50:1344-1350 
[140] Hevener A, Reichart D, Janez A, Olefsky J 2002 Female rats do not exhibit free fatty 
acid-induced insulin resistance. Diabetes 51:1907-1912 
[141] Shi H, Sorrell JE, Clegg DJ, Woods SC, Seeley RJ 2010 The roles of leptin receptors on 
POMC neurons in the regulation of sex-specific energy homeostasis. Physiol Behav 
100:165-172 
[142] Shi H, Strader AD, Sorrell JE, Chambers JB, Woods SC, Seeley RJ 2008 Sexually 
different actions of leptin in proopiomelanocortin neurons to regulate glucose 
homeostasis. Am J Physiol Endocrinol Metab 294:E630-639 
[143] Shi H, Strader AD, Woods SC, Seeley RJ 2007 The effect of fat removal on glucose 
tolerance is depot specific in male and female mice. Am J Physiol Endocrinol Metab 
293:E1012-1020 
[144] Trevaskis JL, Meyer EA, Galgani JE, Butler AA 2008 Counterintuitive effects of double-
heterozygous null melanocortin-4 receptor and leptin genes on diet-induced obesity 
and insulin resistance in C57BL/6J mice. Endocrinology 149:174-184 
[145] Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome 
proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL 
receptor–deficient mice. J Clin Invest 106:523-531 
[146] Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM 2006 Complex actions of 
sex steroids in adipose tissue, the cardiovascular system, and train: Insights from basic 
science and clinical studies. Endocr Rev 27:575-605 
[147] Guerre-Millo M, Leturque A, Girard J, Lavau M 1985 Increased insulin sensitivity and 
responsiveness of glucose metabolism in adipocytes from female versus male rats. J 
Clin Invest 76:109-116 
[148] Pujol E, Rodríguez-Cuenca S, Frontera M, Justo R, Lladó I, Kraemer FB, Gianotti M, 
Roca P 2003 Gender- and site-related effects on lipolytic capacity of rat white adipose 
tissue. Cellular and Molecular Life Sciences 60:1982-1989 
[149] Mittendorfer B, Horowitz JF, Klein S 2001 Gender differences in lipid and glucose 
kinetics during short-term fasting. Am J Physiol Endocrinol Metab 281:E1333-1339 
[150] Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase 
deficiency in male and female siblings caused by a novel mutation and the 
physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698 
[151] Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE 2002 Hormone replacement 
therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic 
 
Glucose Tolerance 62 
[120] Vaag AA, Holst JJ, Vølund A, Beck-Nielsen H 1996 Gut incretin hormones in identical 
twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for 
decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM 
twins. Eur J Endocrinol 135:425-432 
[121] Rathmann W, Strassburger K, Giani G, Döring A, Meisinger C 2008 Differences in 
height explain gender differences in the response to the oral glucose tolerance test. 
Diabet Med 25:1374-1375 
[122] Anastasiou E, Alevizaki M, Grigorakis SJ, Philippou G, Kyprianou M, Souvatzoglou A 
1998 Decreased stature in gestational diabetes mellitus. Diabetologia 41:997-1001 
[123] Magliano DJ, Barr ELM, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S, Jolley D, 
Owen N, Phillips P, Tapp RJ, Welborn TA, Shaw JE 2008 Glucose indices, health 
behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and 
Lifestyle Study. Diabetes Care 31:267-272 
[124] Soeters MR, Sauerwein HP, Groener JE, Aerts JM, Ackermans MT, Glatz JFC, Fliers E, 
Serlie MJ 2007 Gender-related differences in the metabolic response to fasting. J Clin 
Endocrinol Metab 92:3646-3652 
[125] Li Z, McNamara JR, Fruchart JC, Luc G, Bard JM, Ordovas JM, Wilson PW, Schaefer EJ 
1996 Effects of gender and menopausal status on plasma lipoprotein subspecies and 
particle sizes. J Lipid Res 37:1886-1896 
[126] Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D 1984 Relationships between 
insulin secretion, insulin action, and fasting plasma glucose concentration in 
nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-1246 
[127] Anderwald C, Brunmair B, Stadlbauer K, Krebs M, Fürnsinn C, Roden M 2007 Effects 
of free fatty acids on carbohydrate metabolism and insulin signalling in perfused rat 
liver. Eur J Clin Invest 37:774-782 
[128] Færch K, Vaag A, Witte DR, Jørgensen T, Pedersen O, Borch-Johnsen K 2009 Predictors 
of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and 
women—the Inter99 study. Diabet Med 26:377-383 
[129] Wagenknecht LE, Langefeld CD, Scherzinger AL, Norris JM, Haffner SM, Saad MF, 
Bergman RN 2003 Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin 
Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52:2490-2496 
[130] Datz FL, Christian PE, Moore J 1987 Gender-related differences in gastric emptying. J 
Nucl Med 28:1204-1207 
[131] Anderwald C, Tura A, Winhofer Y, Krebs M, Winzer C, Bischof MG, Luger A, Pacini 
G, Kautzky-Willer A 2011 Glucose absorption in gestational diabetes mellitus during an 
oral glucose tolerance test. Diabetes Care 34:1475-1480 
[132] Flanagan DE, Holt RIG, Owens PC, Cockington RJ, Moore VM, Robinson JS, Godsland 
IF, Phillips DIW 2006 Gender differences in the insulin-like growth factor axis response 
to a glucose load. Acta Physiol (Oxf) 187:371-378 
[133] Basu R, Dalla Man C, Campioni M, Basu A, Klee G, Toffolo G, Cobelli C, Rizza RA 
2006 Effects of age and sex on postprandial glucose metabolism: differences in glucose 
turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes 
55:2001-2014 
[134] Sugden M, Holness M 2002 Gender-specific programming of insulin secretion and 
action. J Endocrinol 175:757-767 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 63 
[135] Shulman GI 2000 Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176 
[136] Saltiel AR, Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature 414:799-806 
[137] Mittendorfer B 2005 Insulin resistance: sex matters. Current Opinion in Clinical 
Nutrition & Metabolic Care 8:367-372 
[138] Kuhl J, Hilding A, Östenson CG, Grill V, Efendic S, Båvenholm P 2005 
Characterisation of subjects with early abnormalities of glucose tolerance in the 
Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes 
heredity. Diabetologia 48:35-40 
[139] Frias JP, Macaraeg GB, Ofrecio J, Yu JG, Olefsky JM, Kruszynska YT 2001 Decreased 
susceptibility to fatty acid-induced peripheral tissue insulin resistance in women. 
Diabetes 50:1344-1350 
[140] Hevener A, Reichart D, Janez A, Olefsky J 2002 Female rats do not exhibit free fatty 
acid-induced insulin resistance. Diabetes 51:1907-1912 
[141] Shi H, Sorrell JE, Clegg DJ, Woods SC, Seeley RJ 2010 The roles of leptin receptors on 
POMC neurons in the regulation of sex-specific energy homeostasis. Physiol Behav 
100:165-172 
[142] Shi H, Strader AD, Sorrell JE, Chambers JB, Woods SC, Seeley RJ 2008 Sexually 
different actions of leptin in proopiomelanocortin neurons to regulate glucose 
homeostasis. Am J Physiol Endocrinol Metab 294:E630-639 
[143] Shi H, Strader AD, Woods SC, Seeley RJ 2007 The effect of fat removal on glucose 
tolerance is depot specific in male and female mice. Am J Physiol Endocrinol Metab 
293:E1012-1020 
[144] Trevaskis JL, Meyer EA, Galgani JE, Butler AA 2008 Counterintuitive effects of double-
heterozygous null melanocortin-4 receptor and leptin genes on diet-induced obesity 
and insulin resistance in C57BL/6J mice. Endocrinology 149:174-184 
[145] Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome 
proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL 
receptor–deficient mice. J Clin Invest 106:523-531 
[146] Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM 2006 Complex actions of 
sex steroids in adipose tissue, the cardiovascular system, and train: Insights from basic 
science and clinical studies. Endocr Rev 27:575-605 
[147] Guerre-Millo M, Leturque A, Girard J, Lavau M 1985 Increased insulin sensitivity and 
responsiveness of glucose metabolism in adipocytes from female versus male rats. J 
Clin Invest 76:109-116 
[148] Pujol E, Rodríguez-Cuenca S, Frontera M, Justo R, Lladó I, Kraemer FB, Gianotti M, 
Roca P 2003 Gender- and site-related effects on lipolytic capacity of rat white adipose 
tissue. Cellular and Molecular Life Sciences 60:1982-1989 
[149] Mittendorfer B, Horowitz JF, Klein S 2001 Gender differences in lipid and glucose 
kinetics during short-term fasting. Am J Physiol Endocrinol Metab 281:E1333-1339 
[150] Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase 
deficiency in male and female siblings caused by a novel mutation and the 
physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698 
[151] Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE 2002 Hormone replacement 
therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic 
 
Glucose Tolerance 64 
postmenopausal women: results from the Third National Health and Nutrition 
Examination Survey (NHANES III). Diabetes Care 25:1675-1680 
[152] Saglam K, Polat Z, Yilmaz M, Gulec M, Akinci S 2002 Effects of postmenopausal 
hormone replacement therapy on insulin resistance. Endocrine 18:211-214 
[153] Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson 
KC, Margolis KL 2006 Risk of fracture in women with type 2 diabetes: the Women's 
Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-3410 
[154] Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, 
Burke G, Torrens J, Howard BV, for the Women’s Health Initiative I 2004 Effect of 
oestrogen plus progestin on the incidence of diabetes in postmenopausal women: 
results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175-1187 
[155] Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, 
Simpson ER, Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of 
the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin 
Endocrinol Metab 89:61-70 
[156] Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquié M, Gauthier BR, 
Nef S, Stefani E, Nadal A 2008 Pancreatic insulin content regulation by the estrogen 
receptor ER alpha. PLoS One 3:e2069 
[157] Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai M-J, Mauvais-Jarvis 
F 2006 Estrogens protect pancreatic β-cells from apoptosis and prevent insulin-deficient 
diabetes mellitus in mice. Proc Natl Acad Sci U S A 103:9232-9237 
[158] Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC 2001 Reciprocal antagonism 
between estrogen receptor and NF-kappaB activity in vivo. Circ Res 89:823-830 
[159] Evans MJ, Lai K, Shaw LJ, Harnish DC, Chadwick CC 2002 Estrogen receptor alpha 
inhibits IL-1beta induction of gene expression in the mouse liver. Endocrinology 
143:2559-2570 
[160] Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 
115:1111-1119 
[161] Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, 
Ciana P, Chambon P, Maggi A 2003 Estrogen receptor-α mediates the brain 
antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 100:9614-9619 
[162] Pozzi S, Benedusi V, Maggi A, Vegeto E 2006 Estrogen action in neuroprotection and 
brain inflammation. Ann N Y Acad Sci 1089:302-323 
[163] Payette C, Blackburn P, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Després J-P, 
Couillard C 2009 Sex differences in postprandial plasma tumor necrosis factor–α, 
interleukin-6, and C-reactive protein concentrations. Metabolism 58:1593-1601 
[164] Gallou-Kabani C, Vigé A, Gross M-S, Boileau C, Rabes J-P, Fruchart-Najib J, Jais J-P, 
Junien C 2007 Resistance to high-fat diet in the female progeny of obese mice fed a 
control diet during the periconceptual, gestation, and lactation periods. Am J Physiol 
Endocrinol Metab 292:E1095-E1100 
[165] Dhar MS, Sommardahl CS, Kirkland T, Nelson S, Donnell R, Johnson DK, Castellani 
LW 2004 Mice heterozygous for Atp10c, a putative amphipath, represent a novel model 
of obesity and type 2 diabetes. J Nutr 134:799-805 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 65 
[166] Brussaard HE, Leuven JAG, Frölich M, Kluft C, Krans HMJ 1997 Short-term oestrogen 
replacement therapy improves insulin resistance, lipids and fibrinolysis in 
postmenopausal women with NIDDM. Diabetologia 40:843-849 
[167] Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B 2000 Nongenomic actions 
of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to 
estrogen receptor α and estrogen receptor β. Proc Natl Acad Sci U S A 97:11603-11608 
[168] Beato M, Klug J 2000 Steroid hormone receptors: an update. Hum Reprod Update 
6:225-236 
[169] Monje P, Boland R 2001 Subcellular distribution of native estrogen receptor α and β 
isoforms in rabbit uterus and ovary. J Cell Biochem 82:467-479 
[170] Yang S-H, Liu R, Perez EJ, Wen Y, Stevens SM, Valencia T, Brun-Zinkernagel A-M, 
Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW 2004 Mitochondrial localization of 
estrogen receptor β. Proc Natl Acad Sci U S A 101:4130-4135 
[171] Pedram A, Razandi M, Wallace DC, Levin ER 2006 Functional estrogen receptors in 
the mitochondria of breast cancer cells. Mol Biol Cell 17:2125-2137 
[172] Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L, Stefani E 2006 Heart estrogen 
receptor alpha: distinct membrane and nuclear distribution patterns and regulation by 
estrogen. J Mol Cell Cardiol 41:496-510 
[173] Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ 2008 Arcuate glucagon-
like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 
57:2046-2054 
[174] Harris HA, Katzenellenbogen JA, Katzenellenbogen BS 2002 Characterization of the 
biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues 
in vivo through the use of an ERalpha-selective ligand. Endocrinology 143:4172-4177 
[175] Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. 
Trends Endocrinol Metab 12:152-156 
[176] Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER 2005 A 
transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 
307:1625-1630 
[177] Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P 2007 Activation of 
the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma 
membrane. Endocrinology 148:3236-3245 
[178] Ropero AB, Soria B, Nadal A 2002 A Nonclassical Estrogen Membrane Receptor 
Triggers Rapid Differential Actions in the Endocrine Pancreas. Molecular 
Endocrinology 16:497-505 
[179] Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, Mann GE, 
Vergara C, Latorre R 1999 Acute activation of Maxi-K channels (hSlo) by estradiol 
binding to the beta subunit. Science 285:1929-1931 
[180] Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, 
Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-
receptor gene in a man. N Engl J Med 331:1056-1061 
[181] Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, Steiler TL, Dahlman-Wright K, 
Nilsson S, Gustafsson JÅ, Efendic S, Khan A 2006 Evidence that oestrogen receptor-α 
plays an important role in the regulation of glucose homeostasis in mice: insulin 
sensitivity in the liver. Diabetologia 49:588-597 
 
Glucose Tolerance 64 
postmenopausal women: results from the Third National Health and Nutrition 
Examination Survey (NHANES III). Diabetes Care 25:1675-1680 
[152] Saglam K, Polat Z, Yilmaz M, Gulec M, Akinci S 2002 Effects of postmenopausal 
hormone replacement therapy on insulin resistance. Endocrine 18:211-214 
[153] Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson 
KC, Margolis KL 2006 Risk of fracture in women with type 2 diabetes: the Women's 
Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-3410 
[154] Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, 
Burke G, Torrens J, Howard BV, for the Women’s Health Initiative I 2004 Effect of 
oestrogen plus progestin on the incidence of diabetes in postmenopausal women: 
results from the Women’s Health Initiative Hormone Trial. Diabetologia 47:1175-1187 
[155] Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, 
Simpson ER, Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of 
the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin 
Endocrinol Metab 89:61-70 
[156] Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquié M, Gauthier BR, 
Nef S, Stefani E, Nadal A 2008 Pancreatic insulin content regulation by the estrogen 
receptor ER alpha. PLoS One 3:e2069 
[157] Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai M-J, Mauvais-Jarvis 
F 2006 Estrogens protect pancreatic β-cells from apoptosis and prevent insulin-deficient 
diabetes mellitus in mice. Proc Natl Acad Sci U S A 103:9232-9237 
[158] Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC 2001 Reciprocal antagonism 
between estrogen receptor and NF-kappaB activity in vivo. Circ Res 89:823-830 
[159] Evans MJ, Lai K, Shaw LJ, Harnish DC, Chadwick CC 2002 Estrogen receptor alpha 
inhibits IL-1beta induction of gene expression in the mouse liver. Endocrinology 
143:2559-2570 
[160] Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 
115:1111-1119 
[161] Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, 
Ciana P, Chambon P, Maggi A 2003 Estrogen receptor-α mediates the brain 
antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A 100:9614-9619 
[162] Pozzi S, Benedusi V, Maggi A, Vegeto E 2006 Estrogen action in neuroprotection and 
brain inflammation. Ann N Y Acad Sci 1089:302-323 
[163] Payette C, Blackburn P, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Després J-P, 
Couillard C 2009 Sex differences in postprandial plasma tumor necrosis factor–α, 
interleukin-6, and C-reactive protein concentrations. Metabolism 58:1593-1601 
[164] Gallou-Kabani C, Vigé A, Gross M-S, Boileau C, Rabes J-P, Fruchart-Najib J, Jais J-P, 
Junien C 2007 Resistance to high-fat diet in the female progeny of obese mice fed a 
control diet during the periconceptual, gestation, and lactation periods. Am J Physiol 
Endocrinol Metab 292:E1095-E1100 
[165] Dhar MS, Sommardahl CS, Kirkland T, Nelson S, Donnell R, Johnson DK, Castellani 
LW 2004 Mice heterozygous for Atp10c, a putative amphipath, represent a novel model 
of obesity and type 2 diabetes. J Nutr 134:799-805 
 
Sex Differences in Obesity-Related Glucose Intolerance and Insulin Resistance 65 
[166] Brussaard HE, Leuven JAG, Frölich M, Kluft C, Krans HMJ 1997 Short-term oestrogen 
replacement therapy improves insulin resistance, lipids and fibrinolysis in 
postmenopausal women with NIDDM. Diabetologia 40:843-849 
[167] Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B 2000 Nongenomic actions 
of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to 
estrogen receptor α and estrogen receptor β. Proc Natl Acad Sci U S A 97:11603-11608 
[168] Beato M, Klug J 2000 Steroid hormone receptors: an update. Hum Reprod Update 
6:225-236 
[169] Monje P, Boland R 2001 Subcellular distribution of native estrogen receptor α and β 
isoforms in rabbit uterus and ovary. J Cell Biochem 82:467-479 
[170] Yang S-H, Liu R, Perez EJ, Wen Y, Stevens SM, Valencia T, Brun-Zinkernagel A-M, 
Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW 2004 Mitochondrial localization of 
estrogen receptor β. Proc Natl Acad Sci U S A 101:4130-4135 
[171] Pedram A, Razandi M, Wallace DC, Levin ER 2006 Functional estrogen receptors in 
the mitochondria of breast cancer cells. Mol Biol Cell 17:2125-2137 
[172] Ropero AB, Eghbali M, Minosyan TY, Tang G, Toro L, Stefani E 2006 Heart estrogen 
receptor alpha: distinct membrane and nuclear distribution patterns and regulation by 
estrogen. J Mol Cell Cardiol 41:496-510 
[173] Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ 2008 Arcuate glucagon-
like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 
57:2046-2054 
[174] Harris HA, Katzenellenbogen JA, Katzenellenbogen BS 2002 Characterization of the 
biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues 
in vivo through the use of an ERalpha-selective ligand. Endocrinology 143:4172-4177 
[175] Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. 
Trends Endocrinol Metab 12:152-156 
[176] Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER 2005 A 
transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 
307:1625-1630 
[177] Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, Thomas P 2007 Activation of 
the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma 
membrane. Endocrinology 148:3236-3245 
[178] Ropero AB, Soria B, Nadal A 2002 A Nonclassical Estrogen Membrane Receptor 
Triggers Rapid Differential Actions in the Endocrine Pancreas. Molecular 
Endocrinology 16:497-505 
[179] Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, Mann GE, 
Vergara C, Latorre R 1999 Acute activation of Maxi-K channels (hSlo) by estradiol 
binding to the beta subunit. Science 285:1929-1931 
[180] Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, 
Lubahn DB, Korach KS 1994 Estrogen resistance caused by a mutation in the estrogen-
receptor gene in a man. N Engl J Med 331:1056-1061 
[181] Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, Steiler TL, Dahlman-Wright K, 
Nilsson S, Gustafsson JÅ, Efendic S, Khan A 2006 Evidence that oestrogen receptor-α 
plays an important role in the regulation of glucose homeostasis in mice: insulin 
sensitivity in the liver. Diabetologia 49:588-597 
 
Glucose Tolerance 66 
[182] Ribas V, Nguyen MTA, Henstridge DC, Nguyen A-K, Beaven SW, Watt MJ, Hevener 
AL 2010 Impaired oxidative metabolism and inflammation are associated with insulin 
resistance in ERα-deficient mice. Am J Physiol Endocrinol Metab 298:E304-E319 
[183] Foryst-Ludwig A, Clemenz M, Hohmann S, Hartge M, Sprang C, Frost N, Krikov M, 
Bhanot S, Barros R, Morani A, Gustafsson J-Å, Unger T, Kintscher U 2008 Metabolic 
actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with 
PPARγ. PLoS Genet 4:e1000108 
[184] Wong WPS, Tiano JP, Liu S, Hewitt SC, Le May C, Dalle S, Katzenellenbogen JA, 
Katzenellenbogen BS, Korach KS, Mauvais-Jarvis F 2010 Extranuclear estrogen receptor-
α stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. 
Proc Natl Acad Sci U S A 107:13057-13062 
[185] Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M 2000 Effect of 
single and compound knockouts of estrogen receptors alpha (ERalpha) and beta 
(ERbeta) on mouse reproductive phenotypes. Development 127:4277-4291 
[186] Barros RPA, Machado UF, Warner M, Gustafsson J-Å 2006 Muscle GLUT4 regulation 
by estrogen receptors ERβ and ERα. Proc Natl Acad Sci U S A 103:1605-1608 
[187] Cignarella A, Bolego C, Pelosi V, Meda C, Krust A, Pinna C, Gaion RM, Vegeto E, 
Maggi A 2009 Distinct roles of estrogen receptor-alpha and beta in the modulation of 
vascular inducible nitric-oxide synthase in diabetes. J Pharmacol Exp Ther 328:174-182 
[188] Ghisletti S, Meda C, Maggi A, Vegeto E 2005 17beta-estradiol inhibits inflammatory 
gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 
25:2957-2968 
[189] Kalaitzidis D, Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor 
and NF-κB. Trends Endocrinol Metab 16:46-52 
[190] Stein B, Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor 
is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15:4971-4979 
[191] Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith JC, Albert 
LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, 
Adelman SJ, Steffan RJ, Harnish DC 2005 Identification of pathway-selective estrogen 
receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci U S A 
102:2543-2548 
[192] Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-






© 2012 Suastika et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Age is an Important Risk Factor for Type 2 
Diabetes Mellitus and Cardiovascular Diseases 
Ketut Suastika, Pande Dwipayana,  
Made Siswadi Semadi and R.A. Tuty Kuswardhani 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/52397 
1. Introduction 
A field study by World Health Organization (WHO), World Bank and Harvard University 
in 1990 found a changing pattern of diseases caused by unhealthy lifestyle changes that may 
eventually lead to metabolic syndrome, type 2 diabetes mellitus, coronary arterial diseases, 
depression, and traffic accidents (Kinsella and Phillips, 2005). The study also predicted that 
cerebrovascular diseases would become the most prevalent disease, whereas human HIV 
infection would sharply increase in the year 2020 (Kinsella and Phillips, 2005). The lifestyle-
related and degenerative diseases are significant problems in the old aged population 
group. 
The number of elderly population has increased worldwide, and recently it has been 
increasing sharply in the developing countries. The projection of the number of elderly 
population in Indonesia by the year 2010 is 23,992. The Indonesian Central Bureau for 
Statistics (Badan Pusat Statistik) has reported that Indonesia is the world’s fourth in the 
number of elderly population after China, India, and USA (Komala et al., 2005). US Bureau 
of Census predicted that from 1990 to 2020, the Indonesian elderly population would 
increase to 41.4%. The predicted increased number of elderly was ascribed to the success of 
health promotion and improvement of social and economic status (Kinsella and Taeuber, 
1993).  
Metabolic disorders including type 2 diabetes mellitus (T2DM) and cardiovascular diseases  
are closely related with the aging process. Central obesity and insulin resistance as the initial 
preconditions and its consequences related to  metabolic diseases and cardiovascular 
diseases are frequently found among the elderly. Decline in lean body mass and increase in 
body fat, particularly visceral adiposity that often accompanies aging, may contribute to the 
development of insulin resistance. As for the mechanism of T2DM, it is known that aging 
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1. Introduction 
A field study by World Health Organization (WHO), World Bank and Harvard University 
in 1990 found a changing pattern of diseases caused by unhealthy lifestyle changes that may 
eventually lead to metabolic syndrome, type 2 diabetes mellitus, coronary arterial diseases, 
depression, and traffic accidents (Kinsella and Phillips, 2005). The study also predicted that 
cerebrovascular diseases would become the most prevalent disease, whereas human HIV 
infection would sharply increase in the year 2020 (Kinsella and Phillips, 2005). The lifestyle-
related and degenerative diseases are significant problems in the old aged population 
group. 
The number of elderly population has increased worldwide, and recently it has been 
increasing sharply in the developing countries. The projection of the number of elderly 
population in Indonesia by the year 2010 is 23,992. The Indonesian Central Bureau for 
Statistics (Badan Pusat Statistik) has reported that Indonesia is the world’s fourth in the 
number of elderly population after China, India, and USA (Komala et al., 2005). US Bureau 
of Census predicted that from 1990 to 2020, the Indonesian elderly population would 
increase to 41.4%. The predicted increased number of elderly was ascribed to the success of 
health promotion and improvement of social and economic status (Kinsella and Taeuber, 
1993).  
Metabolic disorders including type 2 diabetes mellitus (T2DM) and cardiovascular diseases  
are closely related with the aging process. Central obesity and insulin resistance as the initial 
preconditions and its consequences related to  metabolic diseases and cardiovascular 
diseases are frequently found among the elderly. Decline in lean body mass and increase in 
body fat, particularly visceral adiposity that often accompanies aging, may contribute to the 
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induces a decrease of insulin sensitivity and alteration or insufficient compensation of beta 
cell functional mass in the face of increasing insulin resistance (Meneilly and Elliot, 1999). 
Related to beta cell functions, aging correlates with a decrease of beta cell proliferation 
capacity and enhances sensitivity to apoptosis (Maedler et al., 2006). It has recently been 
proposed that an age-associated decline in mitochondrial function contributes to insulin 
resistance in the elderly (Petersen et al., 2003). Other metabolic diseases are also frequently 
related with aging such as coronary arterial disease, malignancies, cognitive disorders, and 
vitamin D deficiency (Yaffe et al., 200; Lu et al., 2009).  
2. Age and related risk factors for type 2 diabetes mellitus and 
cardiovascular diseases  
2.1. Age, mitochondrial dysfunction and inflammation 
Mitochondria, a membrane-enclosed organelle found in most eukaryotic cells, generate most 
of the cell's supply of adenosine triphosphate (ATP), are used as a source of chemical 
energy, and are involved in a range of other processes such as signaling, cellular 
differentiation, cell death, as well as the control of the cell cycle and cell growth. 
Mitochondria have been implicated in several human diseases, including mitochondrial 
disorders, aging process and cardiac dysfunction. Mitochondrial dysfunction is central to 
the theories of aging because age-related changes of mitochondria are likely to impair a host 
of cellular physiological functions in parallel and thus contribute to the development of all 
the common age-related diseases (Dai et al., 2012).  Rising cellular oxidative stress due to any 
cause induces mtDNA and mitochondria damage and culminates in a mitochondria 
function crisis, cell death and aging. Otherwise, aging itself causes abnormal mitochondrial 
morphology and cell death or apoptosis (Seo et al., 2010). Judge et al. (2005) in their study on 
rats found that accumulation of oxidant-induced damage in interfibrillar mitochondria 
might be a major contributing factor to the age-related alterations in myocardial function. 
How old age can be a major risk factor for CVD via mitochondrial dysfunction has been 
completely reviewed by Dai et al. (2012). 
Chronic inflammation is a characteristic feature of aging. A study by Sarkar et al. (2004) 
showed that human polynuleotide phosphrylase might play a significant role in producing 
pathological changes associated with aging by generating proinflammatory cytokines via 
reactive oxidative stress (reactive oxygen species(ROS) and NF-B. The role of NF-B in 
bridging the explanation of how aging is associated with inflammation and endothelial 
dysfunction is reviewed well by Csiszar et al. (2008). Another study has shown that 
depletion of cellular (GSH) during aging plays an important role in regulating the hepatic 
response to IL-1 (Rutkute et al., 2007). At rest, skeletal muscles of elderly people showed a 
lower number of macrophages, higher gene expression of several cytokines, and activation 
of stress signaling proteins, compared with skeletal muscles of young people (Peake et al., 
2010). Human aging is associated with the development of insulin resistance, -cell 
dysfunction and glucose intolerance.   The level of suppression of the TNF- production 
was observed and found to be significantly correlated with insulin action. Reduced 
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suppression of TNF- production in the elderly may in part contribute to the decline in 
insulin sensitivity (Kirwan et al., 2001). Hyperglycemia in patients with prediabetes and 
diabetes is associated with inflammation (de Rekeneire et al., 2006). 
2.2. Age and lipid metabolism 
Aging and age are often associated with lipid metabolism disorders. Lipid metabolism 
disorders that are associated with aging process constitute the early stage in the emergence 
of a constellation of risk factors for metabolic disorders (Sawabe et al., 2009; Gobal and 
Metha, 2010). After the age of 20 years, low-density lipoprotein cholesterol (LDL-C) 
increases significantly in both men and women. LDL-C does not increase or is in a flat state  
between the age of 50-60 years (male) and 60-70 years (female) (Gobal and Mehta, 2010). On 
the other hand, high–density lipoprotein cholesterol (HDL-C) levels decrease during 
puberty to young adulthood (in males). Throughout their lives women have lower total 
cholesterol compared to men, but the levels will rise sharply after menopause and will be 
higher in the age >60 years as compared to men. Concentrations of triglyceride (TG) increase 
sharply in males, reaching a peak at the age 40-50 years and decline gradually thereafter. TG 
levels increase in women throughout their lives, especially in women taking estrogen 
replacement therapy (Gobal and Mehta, 2010).  
With the increase of age the composition of body fat also increases, which especially 
accumulates in the abdomen triggering the incidence of central obesity. TG composition in 
the muscle and liver are higher in older age compared with younger age groups (Cree et al., 
2004). Increased body fat composition is associated with reduced fat oxidation both at rest 
and in activity (Nagy et al., 1996). Aging (age) affects the release of fatty acids (FFA),from fat 
tissue (adipose), and the capacity of peripheral tissues such as muscles, to oxidize fat. These 
are some of the changes in lipid metabolism influenced by age and aging, which decreases 
lipolysis response and capacity of fat oxidation. 
Lipolysis is modulated by various hormones such as catecholamines, glucagon, 
adrenocorticotropic hormone, growth hormone, prostaglandin, and thyroid hormone (Toth 
and Tchernof, 2000). Lipolysis response regulated by these hormones will decrease with 
aging. Decreased ability of catecholamines to stimulate lipolysis in the elderly is caused by 
decreased fat tissue response to adrenergic stimulation (Dillon et al., 1984). This response 
involves reduced role of protein kinase A, G-protein complex adenylil cyclase, or the stages in 
the cyclic AMP signaling cascade (Toth and Tchernof, 2000). Effects of insulin on plasma FFA 
was different between in the elderly compared with in younger subjects. Insulin infusions 
showed that plasma FFA, turnover and oxidation, and total lipid oxidation were higher 
significantly in the elderly than in the younger group (Bonadonna et al., 1994). Aging is also 
associated with decreased sensitivity to antilipolysis effects of insulin (Toth and Tchernof, 
2000). Hence this will also increase the release of free fatty acids to the blood in the elderly. 
Age is associated with decline in fat oxidation during activity, after meal and in resting 
condition (Robert et al., 1996). In principle, the capacity of metabolically active tissues such 
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induces a decrease of insulin sensitivity and alteration or insufficient compensation of beta 
cell functional mass in the face of increasing insulin resistance (Meneilly and Elliot, 1999). 
Related to beta cell functions, aging correlates with a decrease of beta cell proliferation 
capacity and enhances sensitivity to apoptosis (Maedler et al., 2006). It has recently been 
proposed that an age-associated decline in mitochondrial function contributes to insulin 
resistance in the elderly (Petersen et al., 2003). Other metabolic diseases are also frequently 
related with aging such as coronary arterial disease, malignancies, cognitive disorders, and 
vitamin D deficiency (Yaffe et al., 200; Lu et al., 2009).  
2. Age and related risk factors for type 2 diabetes mellitus and 
cardiovascular diseases  
2.1. Age, mitochondrial dysfunction and inflammation 
Mitochondria, a membrane-enclosed organelle found in most eukaryotic cells, generate most 
of the cell's supply of adenosine triphosphate (ATP), are used as a source of chemical 
energy, and are involved in a range of other processes such as signaling, cellular 
differentiation, cell death, as well as the control of the cell cycle and cell growth. 
Mitochondria have been implicated in several human diseases, including mitochondrial 
disorders, aging process and cardiac dysfunction. Mitochondrial dysfunction is central to 
the theories of aging because age-related changes of mitochondria are likely to impair a host 
of cellular physiological functions in parallel and thus contribute to the development of all 
the common age-related diseases (Dai et al., 2012).  Rising cellular oxidative stress due to any 
cause induces mtDNA and mitochondria damage and culminates in a mitochondria 
function crisis, cell death and aging. Otherwise, aging itself causes abnormal mitochondrial 
morphology and cell death or apoptosis (Seo et al., 2010). Judge et al. (2005) in their study on 
rats found that accumulation of oxidant-induced damage in interfibrillar mitochondria 
might be a major contributing factor to the age-related alterations in myocardial function. 
How old age can be a major risk factor for CVD via mitochondrial dysfunction has been 
completely reviewed by Dai et al. (2012). 
Chronic inflammation is a characteristic feature of aging. A study by Sarkar et al. (2004) 
showed that human polynuleotide phosphrylase might play a significant role in producing 
pathological changes associated with aging by generating proinflammatory cytokines via 
reactive oxidative stress (reactive oxygen species(ROS) and NF-B. The role of NF-B in 
bridging the explanation of how aging is associated with inflammation and endothelial 
dysfunction is reviewed well by Csiszar et al. (2008). Another study has shown that 
depletion of cellular (GSH) during aging plays an important role in regulating the hepatic 
response to IL-1 (Rutkute et al., 2007). At rest, skeletal muscles of elderly people showed a 
lower number of macrophages, higher gene expression of several cytokines, and activation 
of stress signaling proteins, compared with skeletal muscles of young people (Peake et al., 
2010). Human aging is associated with the development of insulin resistance, -cell 
dysfunction and glucose intolerance.   The level of suppression of the TNF- production 
was observed and found to be significantly correlated with insulin action. Reduced 
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suppression of TNF- production in the elderly may in part contribute to the decline in 
insulin sensitivity (Kirwan et al., 2001). Hyperglycemia in patients with prediabetes and 
diabetes is associated with inflammation (de Rekeneire et al., 2006). 
2.2. Age and lipid metabolism 
Aging and age are often associated with lipid metabolism disorders. Lipid metabolism 
disorders that are associated with aging process constitute the early stage in the emergence 
of a constellation of risk factors for metabolic disorders (Sawabe et al., 2009; Gobal and 
Metha, 2010). After the age of 20 years, low-density lipoprotein cholesterol (LDL-C) 
increases significantly in both men and women. LDL-C does not increase or is in a flat state  
between the age of 50-60 years (male) and 60-70 years (female) (Gobal and Mehta, 2010). On 
the other hand, high–density lipoprotein cholesterol (HDL-C) levels decrease during 
puberty to young adulthood (in males). Throughout their lives women have lower total 
cholesterol compared to men, but the levels will rise sharply after menopause and will be 
higher in the age >60 years as compared to men. Concentrations of triglyceride (TG) increase 
sharply in males, reaching a peak at the age 40-50 years and decline gradually thereafter. TG 
levels increase in women throughout their lives, especially in women taking estrogen 
replacement therapy (Gobal and Mehta, 2010).  
With the increase of age the composition of body fat also increases, which especially 
accumulates in the abdomen triggering the incidence of central obesity. TG composition in 
the muscle and liver are higher in older age compared with younger age groups (Cree et al., 
2004). Increased body fat composition is associated with reduced fat oxidation both at rest 
and in activity (Nagy et al., 1996). Aging (age) affects the release of fatty acids (FFA),from fat 
tissue (adipose), and the capacity of peripheral tissues such as muscles, to oxidize fat. These 
are some of the changes in lipid metabolism influenced by age and aging, which decreases 
lipolysis response and capacity of fat oxidation. 
Lipolysis is modulated by various hormones such as catecholamines, glucagon, 
adrenocorticotropic hormone, growth hormone, prostaglandin, and thyroid hormone (Toth 
and Tchernof, 2000). Lipolysis response regulated by these hormones will decrease with 
aging. Decreased ability of catecholamines to stimulate lipolysis in the elderly is caused by 
decreased fat tissue response to adrenergic stimulation (Dillon et al., 1984). This response 
involves reduced role of protein kinase A, G-protein complex adenylil cyclase, or the stages in 
the cyclic AMP signaling cascade (Toth and Tchernof, 2000). Effects of insulin on plasma FFA 
was different between in the elderly compared with in younger subjects. Insulin infusions 
showed that plasma FFA, turnover and oxidation, and total lipid oxidation were higher 
significantly in the elderly than in the younger group (Bonadonna et al., 1994). Aging is also 
associated with decreased sensitivity to antilipolysis effects of insulin (Toth and Tchernof, 
2000). Hence this will also increase the release of free fatty acids to the blood in the elderly. 
Age is associated with decline in fat oxidation during activity, after meal and in resting 
condition (Robert et al., 1996). In principle, the capacity of metabolically active tissues such 
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as the muscles to oxidize fat represents a combination of the tissue mass and oxidative 
capacity of the tissue. Fat free mass decreases with age (Poehlman et al., 1992) and in resting 
condition fat oxidation tends to be influenced by the size of fat free mass itself. Changes in 
lipid metabolism in the aging process are associated with dysfunction of endothelial cells 
pseudocapillarization of the liver sinusoid. This change causes decreased endocytosis, 
increased leukocyte adhesion, decreased hepatic perfusion and will potentially reduce the 
passage of chylomicron remnants into hepatocytes (Denke and Grundy, 1990). After activity 
or after meal, fat oxidation rate is more influenced by the oxidative capacity of muscle 
tissue. Decreased muscle oxidative capacity with aging is associated with reduced activity of 
enzymes involved in oxidative metabolic processes (such as succinate dehydrogenase; 
citrate synthase; cytrochrome c oxidase) and β-oxidation of fatty acids (such as H-3-CoA 
dehydrogenase Hydroacyl) (Coggan et al., 1992; Rooyackers et al., 1996).   
Changes in lipid metabolism due to aging will lead to increased accumulation of body fat, 
resulting in increased concentrations of free fatty acids in the blood/plasma, and disposal of 
non-oxidative or free fatty acids. Increased concentrations of free fatty acids in blood 
increases glucose production, and this will inhibit insulin-stimulated glucose uptake and 
decrease hepatic insulin extraction (Fanelli et al., 1993; Toth and Tchernof, 2000). The 
changes will be followed by insulin resistance and hyperinsulinemia. Disposal of non-
oxidative free fatty acids into the liver will increase the formation of triglyceride-rich very 
low-density lipoprotein (VLDL) that plays a role in the formation of atherogenic 
dyslipidemia. Increased levels of TG and decrease HDL-C are features of atherogenic 
dyslipidemia  in people with central obesity, hypertension and insulin resistance (Linblad et 
al, 2001). In relation to BMI, although older age correlates with lower BMI and higher fat 
mass, dramatically decreased insulin sensitivity and lack of physical activity are the most 
important risk factors for metabolic disorders in the elderly (Gobal and Metha, 2010; Linbald 
et al., 2001). Insulin resistance itself is associated with decreased glucose carrier protein in 
the muscle (Sawabe et al., 2009). 
The incidence of heart attacks is higher in the elderly compared to middle age group with 
high cholesterol levels. Van der Meer et al. (2008) studied the association of myocardial TG 
content with diastolic function. They found that myocardial TG content was significantly 
associated with age (r = 0.57, p <0.05) and TG was negatively related to left ventricular 
diastolic function (r = 0.68, p <0.05). Multivariate analysis showed that myocardial TG 
content was an independent predictor (p <0.05) for decreased diastolic function associated 
with age. Lower HDL cholesterol is an important risk factor for not only ischemic heart 
disease but also for cerebrovascular disease, especially in diabetic elderly individuals 
(Hayashi et al., 2009).  
2.3. Age, insulin resistance and metabolic syndrome  
Metabolic syndrome is a group of  metabolic abnormalities of which central obesity and 
insulin resistance are believed  to be the primary backgrounds. The diagnostic criteria for 
metabolic syndrome have been proposed by several organizations  and associations, all of 
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which are based on five parameters i.e. central obesity, high blood pressure, high fasting 
blood glucose levels, high TG levels and low levels of HDL-C. The pathogenesis of how 
central obesity causes insulin resistance and metabolic syndrome has been explained in 
many publications. Decreased insulin sensitivity, reduced muscle mass, and increased body 
fat mass, especially visceral fat that accompanies aging contribute to insulin resistance in the 
elderly. Aging process is also associated with reduced compensatory beta cell mass function 
of the pancreas and to insulin resistance (Maneilly and Elliott, 1999) as well as with 
decreased mitochondrial function that contributes to insulin resistance (Petersen et al., 2003). 
A study by Gupta et al. (2000)  showed that hepatic insulin resistant was related to body fat 
and its distribution, and hepatic insulin action could be preserved by caloric restriction in 
aging caloric restriction rat. 
A study conducted in the metropolitan area of St. Louis on 100 women aged ≥ 65 years 
found higher fasting blood sugar levels in subjects with insulin resistance (94.1 ± 8.1 vs. 87.9 
± 8.2 mg/dl, p <0.05) (Banks et al., 2007). A study by Kuusisto et al. (2001) showed that the 
insulin resistance syndrome is a risk factor for coronary heart disease (CHD) in the elderly 
with a hazard ratio of 1.71. Insulin resistance as risk factor for cardiovascular disease (CVD) 
is associated with increase of acute phase protein response and inflammatory markers. The 
Rotterdam study that enrolled 574 non-diabetic elderly population showed that insulin 
correlated strongly and significantly with C-reactive protein (CRP), α-1-antichymotrypsin, 
interleukin (IL)-6 and soluble intercellular adhesion molecule-1, indicating that insulin 
resistance is an integral part of inflammation (Hak et al., 2001). A study by Suastika et al. 
(2011) on the population of Bali, Indonesia, has showed a tendency of increasing frequency 
of metabolic syndrome and its components with increasing age (Table 1). A study on the 
elderly by Zambon et al. (2009) found that metabolic syndrome was associated with increased 
mortality by various causes (HR 1:41) and mortality from CVD (HR 1.60). The association of 
metabolic syndrome and increased frequency of carotid plaque and thickening of the carotid 
artery intima media in elderly subjects (aged 65-85 years) was noted in a study by Empana et 
al. (2007). Subjects with metabolic syndrome have two-fold higher levels of oxidized LDL-C 
than those without Metabolic syndrome, and they are associated with increased risk of 
myocardial infarction with relative risk of 2.25 (Holvoet et al., 2004). Metabolic syndrome in the 
elderly was associated with two-times increase of CRP levels (3.1 vs. 1.5 mg/l), compared with 
the elderly without metabolic syndrome (Hassinen, 2006). 
Decreased physical activity/less exercise in the elderly has also contributed to the occurrence 
of obesity and metabolic syndrome. A study by Hahn et al. (2009) on subjects aged 55-74 
years found that regular exercise at least ≤1 hour per week reduced the risk of metabolic 
syndrome. Sports activities >2 hours per week would be effective in lowering the risk of 
metabolic syndrome.   
3. Age and type 2 diabetes mellitus  
Similar to metabolic syndrome, the prevalence of impaired fasting glycemia (IFG) and 
T2DM increase with rising age. In the United States, the estimated percentage of people 
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as the muscles to oxidize fat represents a combination of the tissue mass and oxidative 
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passage of chylomicron remnants into hepatocytes (Denke and Grundy, 1990). After activity 
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changes will be followed by insulin resistance and hyperinsulinemia. Disposal of non-
oxidative free fatty acids into the liver will increase the formation of triglyceride-rich very 
low-density lipoprotein (VLDL) that plays a role in the formation of atherogenic 
dyslipidemia. Increased levels of TG and decrease HDL-C are features of atherogenic 
dyslipidemia  in people with central obesity, hypertension and insulin resistance (Linblad et 
al, 2001). In relation to BMI, although older age correlates with lower BMI and higher fat 
mass, dramatically decreased insulin sensitivity and lack of physical activity are the most 
important risk factors for metabolic disorders in the elderly (Gobal and Metha, 2010; Linbald 
et al., 2001). Insulin resistance itself is associated with decreased glucose carrier protein in 
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The incidence of heart attacks is higher in the elderly compared to middle age group with 
high cholesterol levels. Van der Meer et al. (2008) studied the association of myocardial TG 
content with diastolic function. They found that myocardial TG content was significantly 
associated with age (r = 0.57, p <0.05) and TG was negatively related to left ventricular 
diastolic function (r = 0.68, p <0.05). Multivariate analysis showed that myocardial TG 
content was an independent predictor (p <0.05) for decreased diastolic function associated 
with age. Lower HDL cholesterol is an important risk factor for not only ischemic heart 
disease but also for cerebrovascular disease, especially in diabetic elderly individuals 
(Hayashi et al., 2009).  
2.3. Age, insulin resistance and metabolic syndrome  
Metabolic syndrome is a group of  metabolic abnormalities of which central obesity and 
insulin resistance are believed  to be the primary backgrounds. The diagnostic criteria for 
metabolic syndrome have been proposed by several organizations  and associations, all of 
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which are based on five parameters i.e. central obesity, high blood pressure, high fasting 
blood glucose levels, high TG levels and low levels of HDL-C. The pathogenesis of how 
central obesity causes insulin resistance and metabolic syndrome has been explained in 
many publications. Decreased insulin sensitivity, reduced muscle mass, and increased body 
fat mass, especially visceral fat that accompanies aging contribute to insulin resistance in the 
elderly. Aging process is also associated with reduced compensatory beta cell mass function 
of the pancreas and to insulin resistance (Maneilly and Elliott, 1999) as well as with 
decreased mitochondrial function that contributes to insulin resistance (Petersen et al., 2003). 
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aging caloric restriction rat. 
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elderly was associated with two-times increase of CRP levels (3.1 vs. 1.5 mg/l), compared with 
the elderly without metabolic syndrome (Hassinen, 2006). 
Decreased physical activity/less exercise in the elderly has also contributed to the occurrence 
of obesity and metabolic syndrome. A study by Hahn et al. (2009) on subjects aged 55-74 
years found that regular exercise at least ≤1 hour per week reduced the risk of metabolic 
syndrome. Sports activities >2 hours per week would be effective in lowering the risk of 
metabolic syndrome.   
3. Age and type 2 diabetes mellitus  
Similar to metabolic syndrome, the prevalence of impaired fasting glycemia (IFG) and 
T2DM increase with rising age. In the United States, the estimated percentage of people 
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aged 20 years or older having diagnosed or undiagnosed diabetes in 2005-2008 was 
increasing with age. In the age group of 20-44 years, it was estimated about 3.7% people had 
diabetes; while in the age group 45-64 years the number increased to 13.7%; and the highest 
percentage of 26.9% was found in the age group of ≥ 65 years (Centers for Disease Control 
and Prevention, 2011). Similar feature was also observed n England, where the prevalence of 
diabetes was increasing with age. The peak prevalence of diabetes can be found in the age 
group of 65-74 years with 15.7% in men and 10.4% in women (Shelton, 2006). The study by 
Suastika et al. (2011) on Bali population showed that the prevalences of IFG and T2DM were 
higher in the elderly than in the younger age group, i.e. nearly two-fold and more than two 
fold, respectively (Figure 2). There was a tendency of increasing frequency of IFG and T2DM 
with increasing age (Table 2). Data from rural Taiwan showed that prevalence of DM was 
16.9% and that of IFG was 25.5% among elderly Chinese in 2000. During a 5 year follow up, 
cumulative prevalences of DM and IFG were 23.7% and 27.9%, respectively. The 5-years 
cumulative incidence of newly onset diabetes was 6.8%. Hypertension, overt proteinuria, 
IFG and high total cholesterol were independent risk factors for new onset diabetes (Peng et 
al., 2006).  
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Table 1. Frequency of metabolic syndrome and its components, by age (years) 
 
Figure 1. Frequency of metabolic syndrome (MS), impaired fasting glycemia (IFG), and diabetes 
mellitus (DM) in the younger-aged and elderly. Suastika et al. J Clin Gerontol Geriatrics 2011; 2: 47-52. 
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The prevalence of glucose intolerance (pre-diabetes and T2DM) increases with advancing 
age. Some factors involve in the pathophysiology of glucose intolerance in the elderly. The 
main factors are that aging induces decrease insulin sensitivity and alteration or insufficient 
compensation of beta cell functional in the face of increasing insulin resistance (Chang and 
Halter, 2003). Decrease in beta cell proliferation capacity and enhanced sensitivity to 
apoptosis are the states related with aging (Maedler et al., 2006).  A study by Szoke et al. 
(2008) showed that the first and second phase of insulin secretion normally decreases at the 
rate of approximately 0.7% per year with aging, this decrease in β cell function is accelerated 
about two-fold in people with impaired glucose tolerance. But aging per se has no effect on 
insulin sensitivity independent of change in body composition. Decline in lean body mass 
and the increase in body fat particularly visceral adipocytes (“central obesity”) that 
accompanies aging may contribute to insulin resistance. It has recently been proposed that 
an age-associated decline in mitochondrial function contributes to insulin resistance in 
elderly. Mitochondrial oxidative and phosphorylation function was reduced about 40% in 
association with increased intramyocellular and intrahepatocellular lipid content and 
decreased insulin-stimulated glucose uptake (Petersen et al., 2003). The pathophysiological 
basis of sarcopenia (loss of muscle mass with age) has a relationship with oxidative stress, 
reduced neuronal stimulation, subclinical inflammatory and insulin resistant state. Those 
conditions contribute to the development of glucose intolerance and type 2 diabetes 
(Khamseh et al., 2011).  
Minamino et al. (2009) in their study on mice proposed a model in which aging and 
inflammation was initiated in adipose tissue and subsequently induced insulin resistance in 
adipose tissue, liver and muscle. They also proposed that adipose tissue p53 tumor 
suppressor mediated the lipid abnormalities and cardiovascular morbidity associated with 
obesity. The study found that excessive calorie intake caused accumulation of oxidative 
stress in the adipose tissue of mice with type 2 diabetes–like disease and promoted 
senescence-like changes, such as increased activity of senescence-associated β-galactosidase, 
increased expression of p53 and increased production of proinflammatory cytokines. 
Inhibition of p53 activity in adipose tissue decreased the expression of proinflammatory 
cytokines and improved insulin resistance. Conversely, up-regulation of p53 in adipose 
tissue caused an inflammatory response that led to insulin resistance. 
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Table 2. Frequency of glycaemic status (), by age (years) 
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4. Age and cardiovascular diseases  
Cardiovascular disease remains to be the most important cause of death in all countries over 
the world. Although certain reports from some developed countries indicate the incidence 
tends to decrease, from many countries there are reports mentioning that its incidence tends 
to increase. Cardiovascular disease is a complex disease; too many risk factors are involved 
in its pathogenesis. In general, risk factors for CVD can be divided into two main groups, 
namely traditional and non-traditional risk factors. Traditional risk factors include age 
(older than 40 years for men, 45 years for women), male sex, family history of coronary heart 
disease, smoking, hypertension, diabetes, central obesity, unhealthy cholesterol levels (high 
total cholesterol, low high-density lipoprotein [HDL] cholesterol, high low-density 
lipoprotein [LDL] cholesterol, high triglycerides), and low physical activity (Fonseca et al., 
2004; Torpy et al., 2009). In addition, some non-traditional risk factors for CVD are reported 
elsewhere (Fonseca et al., 2004; Vasan, 2006; Helfland et al., 2009).  
Several reviews have stressed that age is the strongest risk factor for CVD (Ref).  Age itself 
may be an independent risk factor or may have other risk factors related to aging or 
exposure to risk factors during their lifetime. In the United States, CVD was the leading 
cause of death for persons 65 years of age and over in 2007, which accounted for 28% of 
deaths in this age group (National Center for Health Statistics, 2011). In Asian population, 
age is also one of the most important determinants of CVD. The studies by Suastika et al. in 
a remote area of Ceningan Island found that coronary heart disease (CHD) prevalence was 
relatively high (11.5%), and older age (male ≥45 years and female ≥55 years) had higher risk 
for CHD than younger age group (OR, 27.0). By logistic regression analysis of all variables 
of the risk factors, age (β=3.937) consistently appeared to be the risk factor for CHD 
(Suastika et al., 2012a). Age in the group with CHD (old myocardial infarction and 
myocardial ischemia) was significantly higher than those without CHD (65.0 vs. 58.5 vs. 40.5 
years) (Suastika et al., 2012b). 
Several changes in cardiovascular system related with aging include changes in vascular 
function (increase wall thickening and arterial stiffening, endothelial dysfunction) and 
cardiac function (heart rate and cardiac output, left ventricular wall function and 
myocardial contraction). The stiffness of arterial walls  increase with age. This increase 
includes luminal enlargement with wall thickening and a reduction of elastic properties at 
the level of large elastic arteries. Long standing arterial pulsation in the central artery has a 
direct effect on the structural matrix proteins, collagen and elastin in the arterial wall, 
disrupting muscular attachments and causing elastin fibers to fatigue and fracture. 
Increased vascular calcification and endothelial dysfunction is also characteristic of arterial 
aging. These changes lead to increased pulse wave velocity, especially along central elastic 
arteries, and increase in systolic blood pressure and pulse pressure (Lee and Oh, 2010). 
Aging cardiovascular tissues are exemplified by pathological alterations including 
hypertrophy, altered left ventricular (LV) diastolic function, and diminished LV systolic 
reverse capacity, increased arterial stiffness, and impaired endothelial function. Study by 
Cheng et al. (2009) revealed that age was associated with a phenotype of LV remodeling 
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marked by increased mass-to-volume ratio and accompanied by systolic as well as diastolic 
myocardial dysfunction that is not reflected by preserved ejection fraction. This pattern of 
ventricular remodeling confers significant cardiovascular risk, particularly when present 
earlier in life.  
Peripheral artery disease (PAD), a marker of systemic atherosclerosis, is frequently related 
with age. It mostly starts at 40 and increases after the age 70 years. PAD is the independent 
risk factor for mortality caused by CVD (Norman et al., 2004). A study by Kuswardhani and 
Suastika (2010) on elderly patients who visited the Geriatric Outpatient Clinic, Sanglah 
Hospital showed that diabetic patients with PAD had higher age (70.7 vs. 65 years, p<0.001) 
and higher homocystein levels (13.4 vs. 11.5 mmol/L, p = 0.023), compared with those 
without PAD. High age (70-80 years) had 7.4 times risk than those with lower age (60-69 
years) and high homocystein levels (≥ 11 mmol/L) had 2.5 times risk than those with lower 
homocystein levels, to develop PAD. By multivariate analysis (logistic regression), it was 
found that only age played a role in PAD event.  
How the age/aging relates to T2DM and CVD based on above review is summarised in   
Figure 2. 
 
Figure 2. Summary of the relationship between  age/aging and type 2 diabetes mellitus and 
cardiovascular diseases. . 
5. Conclusion 
The number of elderly population has increased worldwide, and recently it has been 
increasing sharply in the developing countries. Prolong survival in the elderly  creates an 
impact on the appearance of metabolic diseases and CVD. Increase  in the prevalence of 
metabolic diseases (such as T2DM and CVD) in old age  may be related directly with age or 
aging process itself or indirectly through several other age-related risk factors of  T2DM and 
CVD such as central obesity, mitochondrial dysfunction, FFA and lipid metabolisms 
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disorders, inflammation, -cell dysfunction, insulin resistance, metabolic syndrome, and 
other factors which are not discussed in this review. 
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1. Introduction 
The worsening of glucose metabolism as well as increasing risk for cardiovascular disease 
while aging is documented (Wild S. et al., 2004; Okereke OI. et al., 2008). According to gold 
standard research in diabetes - the United Kingdom Prospective Diabetes Study (UKPDS) 
(Matthews D.R 1999; Turner R.C. et al., 1998) - about 40% of patients with type 2 diabetes 
mellitus (T2DM) suffer from late diabetic complications, including  atherosclerosis, 
hypertension and dyslipidemia and microangiopathies (nephropathy, retinopathy). From 
epidemiological point of view, 40% of dysglycemic patients are 65 years old or over (Barnett 
T. 1998; Harris M. 19962). 
An impaired fasting glycemia (IFG) and an impaired glucose tolerance (IGT) are categories of 
increased risk for type 2 diabetes mellitus (prediabetes) (ADA 2012). There is no separate 
algorithm for dysglycaemia in elders, however glucose concentrations in plasma increases with 
aging (from 30 years old, fasting glycemia about 1-2 mg/dl for the every decade and 
postprandial glycaemia about 2-4 mg/dl for the every decade), and is caused by insulin-
resistance (Winger JM & Hornick T. 1996). Paralleled to glucose concentration glycated 
hemoglobin - HbA1c rise with age – round 0,11 to 0,15 % of HbA1c per decade (Nuttal F.Q.  1999). 
Aging is a universal process that can be determined by genetic, the environment or diseases. 
Biological theories are the most promising in relation to finding answers about aging.  
1.1. Aging theories   
There are many aging theories. From the very easy one, like programmed death theories, to 
the more complicated as concerning mistake accumulation theories (Table 1).  
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THEORIES  
OF PROGRAMED DEATH 
THEORIES 
OF MISTAKE ACCUMULATION 
 
programmed cellular aging theory 
clock theory 
autoimmune theory 
random mistake theory 
free radical theory 
cross-links theory 
calories restriction theory 
glycation theory 
Table 1. Theories of aging (examples) 
The gerontological theories try to explain aging from the biological point of view, and 
explain that not only still dividing cells but also cells that are unable to divide, both can be 
targeted by aging (Kirkwood TBL. & Austad SN. 2000). 
1.1.1. Free radical theory 
The free radicals theory postulates that the aging process is the initiation of free radical 
reactions (Harman D. 2003) and in hyperglycemic patients may rise due to increased free 
radicals production. The theory suggests that most of free radicals are initiated and 
produced by mitochondria and a life span is determined by the rate of free radical damage 
to the mitochondria (Harman D. 1983). 
1.1.2. Glycation theory 
The theory is based on non-enzymatic reaction - glycation. The theory suggests that glucose 
acts a mediator of aging. The cross-links between glucose and proteins lead to stable intra- 
and inter-molecular changes which can influence cells, tissues and organs (Soškić V. et al., 
2008). Thus the glycation may have tremendous cumulative effect during a person's life 
leading to shorter life span in diabetics. 
1.1.3. Caloric restriction 
The theory proposes that life span can be prolonged by lover calorie intake but the 
compounds are the full qualitative (Vitetta L. & Anton B. 2007). Decreases in calorie intake 
reduce free radicals production – lower oxidative stress and decreased inflammatory 
processes (Ungvari Z. et al., 2008).  
Patients with hyperglycemia may present more than one reason of increased aging process. 
1.2. Late complications of hyperglycemia 
As hyperglycemia starts (prediabetes, diabetes mellitus) late metabolic complications, 
caused by glucose toxicity (Robertson RP. & Harmon JS. 2006), oxidative stress (Cumaoğlu 
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A. et al., 2010), dyslipidemia (Gordon L. et al., 2010), increased polyol pathway (Obrosova 
I.G. 2005) and glycation of protein (Xie X. et a., 2010), increase. 
1.3. Protein glycation 
Protein glycation and oxidative stress in a context of aging is widely discussed (Robertson 
RP. 2004; Muller F.L. et al., 2007; Soškić V., et al. 2008). Protein glycation depends on duration 
of hyperglycemia and increase in aging and co-morbidities (Peppa M. & Vlassara H. 2005).  
Non-enzymatic glycation of proteins leads trough Amadori products such as glycated 
albumine (fructosamine), glycated hemoglobine (HbA1c) to Advanced Glycation End 
Products (AGEs) eg. Nε-carboxymethyllysine (CML) (figure 1), bio-active molecules which 
accumulate with age. AGEs are produced in human as a part of normal metabolism, but are 
elevated in diabetic patients, and depends on hyperglycemia duration and level (higher and 
longer hyperglycemia leads to higher AGEs concentration). 
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1.3.1. Fructosamine 
Fructosamine is an Amadori product that is formed as a result of lysine side chain of protein 
modification by glucose and its serum level is reported to increase in diabetes. The product 
serves as short term marker (2-3 weeks) of glycemic control (Armbruster DA.1987; True 
MW. 2009). Fructosamine can undergo oxidative cleavage leading to the formation of 
Avanced Glycation End products (AGEs), which are implicated in long-term complications 
of diabetes mellitus.  
1.3.2. Glycated hemoglobin, HbA1c 
Glycated hemoglobin, HbA1c, is an Amadori product that is now recognized as a marker of 
glycemic control. Glycated hemoglobine, HbA1c measures blood glucose control over a 
period of eight to twelve weeks (Rohlfing CL. et al., 2002). The results from different trials 
(The ACCORD trial (ACCORD Group 2008), the Veterans Affairs Diabetes Trial (VADT 
Investigators 2009), the Action in Diabetes and Vascular Disease—PreterAx and DiamicroN 
Modified Release Controlled Evaluation (ADVANCE) trial (ADVANCE Collaborative 
Group 2009)), have created a debate about the optimal choice of glycated hemoglobine 
target. The International Diabetes Federation recommends a level of less than 6.5% (IDF 
2006) whereas the American Diabetes Association recommends an HbA1c level of less than 
7.0% as the standard of glycemic treatment goal (ADA 2010). the American Diabetes 
Association recommends a HbA1c level of less than 8.0% as the glycemic treatment goal for 
the elderly diabetic persons. Nowadays the HbA1c is also recommended for diagnosis of 
diabetes (ADA 2010). 
1.3.3. Advanced glycation end products - Nε-carboxymethyllysine, CML 
Nε-carboxymethyllysine, {(2S)-2-amino-6-(carboxymethylamino)hexanoic acid}, (CML), 
(figure 2) one of dominant Advanced Glycation End products (AGEs), is formed in vivo by 
oxidative cleavage of the Amadori product threulosyl-lysine (combined non-enzymatic 
glycation and  glycoxidation) and of metal-catalyzed oxidation of LDL or peroxidation of 
polyunsaturated fatty acids in the presence of fructose-lysine (Fu M.X. et al., 1996) (As in 
figure 1). Thus CML may serve as bio-marker of oxidative stress and protein damage in 
aging, diabetes mellitus and atherosclerosis (Southern L. et al., 2007; Semba R. D. et al., 
2009). Excessive formation of CML has been proposed to be an important mechanism for 
accelerated atherogenesis in patients with hyperglycemia.  
There are many evidences indicating that protein glycation and oxidative stress may 
accompany and explain metabolic late diabetic complications. Investigation of glycated 
proteins (fructosamine, HbA1c) and AGEs (i.e. CML), in early stages of glucose metabolism 
problems, may explain metabolic complications in hyperglycemic elderly persons.  
The aim of the study was to analyze fructosamine in plasma, HbA1c in blood and CML 
serum concentrations among elderly patients with increased risk for type 2 diabetes mellitus 
(prediabetes) and normal glucose tolerance. 
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Figure 2. Chemical structure of Nε-carboxymethyllysine, (2S)-2-amino-6-
(carboxymethylamino)hexanoic acid, (CML) – one of the Advanced Glycation End product. 
2. Material and methods 
The study was performed in the Department of Clinical Biochemistry and Laboratory 
Medicine, Chair of Chemistry and Clinical Biochemistry of Poznan University of Medical 
Sciences under the permission from local ethics group in accordance with the Declaration of 
Helsinki of 1975 for Human Research and the study protocol was approved by the Bioethics 
Committee of Poznan University of Medical Sciences in Poznan, Poland. 
Subjects and Settings: This study population consisted of 313 elderly Caucasians (65 and 
older) from Poznan metropolitan area, and after following exclusion criteria (below), 58 of 
them with no acute diseases or severe chronic disorder were enrolled to the study. They were 
performed complete physical examination including the measurement of waist circumference 
(WC) in centimeters, percentage of body fat (FAT) by bioimpedance using BodyStat 
equipment and the calculation of body mass index (BMI=kg/m2). Arterial blood pressure: 
systolic (SBP) and diastolic (DBP) were measured twice by sphyngomanometer MEDEL 
PALM PRO No: 91431 (Novamedica Ltd, Birmingham, United Kingdom) in sitting position, 
after at least 5 minutes rest. The arterial blood pressure was expressed than as mean value.  
The exclusion criteria were the presence of following conditions: a coronary artery disease, a 
history of diabetes, the neoplastic diseases, the inflammatory diseases, a previous therapy, 
use of anti- and oxidant drugs, alcohol use, smoking and electrocardiography findings 
specific for myocardial ischaemia/infarct.  
Additional biochemical exclusion criteria were microalbuminuria and macroalbuminuria as 
albumin/creatinin ratio > 30 mg of albumin/1 g of creatinin in fresh morning urine sample 
and decreased estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/m2 based on 
Modified Diet in Renal Diseases (MDRD) formula: 
eGFR (ml/min/1.75m2) = 
= {186 x [creatynin]-1,154 x [age] -0,203 x 0,742 [for women] x 1,210 [for Afroamerican]} 
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Blood sampling and biochemical analysis: The studied subjects were collected ulnar 
venous blood twice: at 0 minute (fasting) and at 120 minute of the 75,0-g OGTT. Fasting 
plasma samples without hemolysis were used for glucose and lipid determinations. Fasting 
serum samples designated for fructosamine and Nε-carboxymethyllysine measurements 
were frozen and stored at –25o C until assayed, separately. Blood collected at 120 minute of 
OGTT was used for plasma glucose determination. 
Glucose and lipids assay. Oral glucose tolerance test (OGTT) was performed according to 
WHO recommendations (WHO 1999) between 7.00-9.00 am. Glucose concentration was 
determined at 0 min (fasting) and 120 min (postprandial) following a standard dose of 75 g 
glucose load. Glucose and lipid parameters including total cholesterol (T-C), high density 
lipoproteins cholesterol (HDL-C), triacyloglycerydes (TG) concentrations were evaluated by 
enzymatic methods using bioMerieux reagent kit (Marcy-l’Etoile, France) and the UV-160A 
Shimadzu spectrophotometer (Shimadzu Co., Kyoto, Japan). Low density lipoproteins 
cholesterol (LDL-C) was calculated using the Friedewald formula: 
LDL-C [mmol/l]={[(T-C)-(HDL-C)]-(TG/2,2)}  
The reference sera: RANDOX Assayed Human Multi Sera Level 1 (as normal) and 
RANDOX Assayed Human Multi Sera Level 2 (as pathological) (Randox, Crumlin, United 
Kingdom) were used for monitoring the accuracy of the determinations.  
Results of OGTT allowed to classify subjects for normal glucose tolerance (NGT) (n=30, 
mean age 69,5 years) and prediabetic (PRE) (n=20, mean age 70,0 years) categories, while 
newly diagnosed type 2 diabetes mellitus (T2DM) patients were excluded from the study. 
The interpretation of oral glucose tolerance test is presented in Table 2 (ADA 2012). 
 
Categories of glycemia  
during OGTT 
 Plasma glucose concentration 
 Fasting (at 0 min.) at 120 min. 
Normal glucose tolerance (NGT ) < 5,6 mmol/l 
< 100 mg/dl  
< 7,8 mmol/l 
< 140 mg/dl  




Impaired Fasting Glycemia (IFG) 5,6 – 6,9 mmol/l 
100 – 125 mg/dl  
< 7,8 mmol/l 
< 140 mg/dl  
Impaired Glucose Tolerance (IGT) < 7,0 mmol/l 
< 126 mg/dl 
7,8 – 11,0 mmol/l 
140 –199 mg/dl  
Diabetes mellitus (DM) < 7,0 mmol/l 
< 126 mg/dl  
≥ 11,1 mmol/l 
≥ 200 mg/dl  
Table 2. The interpretation of oral glucose tolerance test (OGTT)  
Fructosamine assay. Glycated albumine (fructosamine) was determined using calorymetric 
metod based on the ability of ketoamines to reduce nitrotetrazolium-blue (NBT) to formazan 
in an alkaline solution. The rate of formation of formazan is directly proportional to the 
concentration of fructosamine. The measurement was done by Cobas 400 (Roche 
Diagnostics, Mannheim, Germany).  
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The sensitivity of this assay was 0,14 μmol/l with intra-assay coefficient of variation (CV) 
and inter-assay CV precision at 2,8% and 0,65% respectively.  
HbA1c assay. Glycated hemoglobin, (HbA1c) was determined using ion exchange high 
performance liquid chromatography (HPLC), D-10 (BioRad, Heidelberg, Germany). Using a 
specific standardized measurement set established through the National Glycohemoglobin 
Standardization Program (NGSP). The sensitivity of this assay was 0,05% with intra-assay 
coefficient of variation (CV) and inter-assay coefficient of variation (CV) precision at 2,35% 
and 2,66% respectively.  
Nε-carboxymethyllysine {(2S)-2-amino-6-(carboxymethylamino)hexanoic acid} assay. 
Fasting plasma samples were drown and the concentration of Nε-carboxymethyllysine 
(CML) was measured with a novel competition-based ELISA assay using a CML-specific 
monoclonal antibody ELISA kit (MicroCoat, Bernried am Starnberger See, Germany). 
Absorbance was read using a microtitre ELISA plate reader (SunriseTM, Tecan Group Ltd, 
Männedorf, Switzerland) at 405 nm. CML concentrations were obtained from standard 
curve (linear/linear plot method) and expressed in ng/ml. All samples were run in triplicate. 
The sensitivity of this competitive ELISA assay was 5 ng/ml with intra-assay coefficient of 
variation (CV) and inter-assay CV precision at 5% and 6,8% respectively.  
Statistical Analysis Statistica (version 6.0) for Windows was used for statistical analysis. 
The normality of value distribution was checked by Shapiro-Wilk test. Then, the results with 
a Gaussian distribution were analyzed with Student’s t test, and those with a non-Gaussian 
distribution with a nonparametric Mann-Whitney U test to assess the differences between 
studied groups. The Spearman rank correlation test was used to evaluate the strength of 
association between two variables. A p<0.05 was considered statistically significant.  
Sensitivity, specificity and the highest diagnostic value for the fructosamine, HbA1c, CML 
level we obtain based on ROC curves analysis using MedCalc® v. 9.3.7.0 for Windows. ROC 
curves analyses were used to determine the optimal values of fructosamine, glycated 
hemoglobine (HbA1c) and Nε-carboxymethyllysine (CML) distinguishing between normal 
and disturbed glucose tolerance groups. 
All results are shown as mean ± standard deviation (SD) and median (in brackets). 
3. Results 
In our study group, after ruling out those with any disease, patients were divided into: 
normoglycemic (n=30), prediabetes (n=20) and as newly diagnosed diabetes mellitus type 2 
(n=8) (based on oral glucose tolerance test, see methods). The newly diagnosed diabetes type 
2 were excluded than. All investigated patients were normoalbuminuria staged and eGFR > 
60ml/min/m2.  
3.1. Comparison of normoglycemic (NGT) and prediabetic (PRE) subjects 
Table 3 shows the baseline characteristics and clinical parameters of the elderly normal 
glucose tolerance subjects (NGT) and elderly prediabetes patients (PRE) according to Oral 
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Glucose Tolerance Test (OGTT). The groups by definition were different as far as glucose 
concentration was concerned (both fasting and postprandial) (p=0,0000002 and p=0,000009 
respectively). 
The investigated groups did not differ in clinical parameters such as arterial blood pressure 





Mean  ±  SD 
(Median) 
PRE (n=20) 
Mean  ±  SD 
(Median) 
p 
Age [years] 70,6 ± 8,4 (69,5) 70,2 ± 5,27 (70,0) NS 
BMI [kg/m2] 27,9 ± 4,4 (26,6) 30,8 ± 5,5 (30,0) NS 
Waist [cm] 91,0 ± 7,1 (92,0) 95,5 ± 12,8 (93,0) NS 
FAT [%] 36,1 ± 17,6 (45,0) 38,3 ± 11,8 (41,5) NS 
SBP [mmHg] 136,4 ± 13,8 (135,0) 142,9 ± 11,0 (140,0) NS 
DBP[mmHg] 83,2 ± 8,8 (85,0) 78,2 ± 8,5 (80,0) NS 
G0' [mmol/l] 5,0 ± 0,5 (5,0) 5,8 ± 0,5 (5,8) 
by def.: 
p=0,000002 
G120' [mmol/l] 5,2 ± 1,2 (5,2) 7,2 ± 1,3 (7,2) 
by def.: 
p=0,000009 
Fructosamine [μmol/l] 253,5 ± 26,6 (255,0) 258,3 ± 27,8 (253,5) NS 
HbA1c [%] 5,85 ± 0,40 (5,85) 6,22 ± 0,47 (6,30) p<0,005 
CML [ng/ml] 2248,7 ± 375,9 (2292,4) 
2079,9 ± 418,9 
(1987,0) 
NS 
TC [mmol/l] 4,98 ± 0,72  (5,01) 5,05 ± 0,89 (5,00) NS 
TG [mmol/l] 1,16 ± 0,50 (0,94) 1,54 ± 0,98 (1,24) NS 
HDL-C [mmol/l] 1,65 ± 0,36 (1,66) 1,46 ± 0,30 (1,44) NS 
LDL-C[mmol/l] 2,82 ± 0,71 (2,88) 2,90 ± 0,72 (2,82) NS 
p – the probability of obtaining a test statistic, SD – standard deviation, NS – not significant, by def. - by definition, 
NGT – normoglycemic group, PRE – prediabetic group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood 
pressure, DBP – diastolic blood pressure, G0' – fasting glucose, G120' - postprandial glucose, measured at 120 min after 
75 grams glucose load, HbA1c – glycated hemoglobin, CML – Nε-carboxymethyllysine, TC – total cholesterol, TG – 
triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
Table 3. Baseline characteristics and clinical parameters of the normal glucose tolerance subjects (NGT) 
and prediabetes patients (PRE) according to Oral Glucose Tolerance Test (OGTT). 
The glycated albumin - fructosamine did not differ between investigated groups (Figure 3) 
whereas glycated hemoglobin HbA1c were higher in the prediabetes individuals (p<0,005) 
(Figure 4).   
The CML did not differentiate normoglycemic and prediabetes elderly persons (Figure 5). 
Different correlations between glycated proteins (fructosamine and HbA1c) and metabolic 
parameters were found in analyzed subgroups (table 4 and 5 respectively) at p<0,01. There 
were no correlations in any investigated groups for the CML (table 6). 
ROC curve analysis yielded a fructosamine concentration of the highest diagnostic value in 
distinguishing PRE and NGT (<=237 μmol/l, 29.0% sensitivity and 88,2% specificity, 
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AUC=0,511) based on OGTT (Figure 6). ROC curve analysis yielded a HbA1c percentage of 
the highest diagnostic value in distinguishing PRE and NGT (>6,1 %, 54,8% sensitivity and 
88,2% specificity, AUC=0,679) based on OGTT  (Figure 7). ROC curve analysis yielded a CML 
concentration of the highest diagnostic value in distinguishing PRE and NGT (<=2403,2 
ng/ml, 76.7% sensitivity and 41,2% specificity, AUC=0,548) based on OGTT (Figure 8). 
 
Figure 3. Comparison of fructosamine between normoglycemic subjects (NGT, 0) and prediabetic 
patients (PRE, 1). 
 
Figure 4. Comparison of glycated hemoglobin (HbA1c) between normoglycemic subjects (NGT, 0) and 
prediabetic patients (PRE, 1).  
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Glucose Tolerance Test (OGTT). The groups by definition were different as far as glucose 
concentration was concerned (both fasting and postprandial) (p=0,0000002 and p=0,000009 
respectively). 
The investigated groups did not differ in clinical parameters such as arterial blood pressure 
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75 grams glucose load, HbA1c – glycated hemoglobin, CML – Nε-carboxymethyllysine, TC – total cholesterol, TG – 
triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
Table 3. Baseline characteristics and clinical parameters of the normal glucose tolerance subjects (NGT) 
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Figure 5. Comparison of CML between normoglycemic subjects (NGT, 0) and prediabetic patients 
(PRE, 1). 
 
p<0,01 All persons (n=50) NGT (n=30) PRE (n=20) 
Fructosamine & BMI NS NS NS 
Fructosamne & waist NS NS NS 
Fructosamine & FAT R=0,39 NS NS 
Fructosamine & SBP NS NS NS 
Fructosamine & DBP NS NS NS 
Fructosamine & G0' NS NS NS 
Fructosamine & G120' NS R=0,48 NS 
Fructosamine & TC NS NS NS 
Fructosamine & TG NS NS NS 
Fructosamine & HDL-C NS NS NS 
Fructosamine & LDL-C NS NS NS 
p – the probability of obtaining a test statistic, NS – not significant, NGT – normoglycemic group, PRE – prediabetic 
group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood pressure, DBP – diastolic blood pressure, G0' – 
fasting glucose, G120' (postprandial glucose) measured at 120 min after 75 grams glucose load, TC – total cholesterol, 
TG – triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
 
Table 4. Correlation for fructosamine in all investigated persons, NGT and PRE groups. 


























Glucose Tolerance and Elders – Lessons We Have Learned and Challenges for the Future 91 
 
 
p<0,01 All (n=50) NGT (n=30) PRE (n=20) 
HbA1c  BMI NS NS R=-0,78 
HbA1c  and waist R=0,39 NS NS 
HbA1c  and FAT NS NS NS 
HbA1c  and SBP NS NS NS 
HbA1c  and DBP NS NS NS 
HbA1c and G0' R=0,45 NS NS 
HbA1c and G120' R=0,58 0,51 NS 
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fasting glucose, G120' (postprandial glucose) measured at 120 min after 75 grams glucose load, HbA1c – glycated 
hemoglobin, TC – total cholesterol, TG – triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low 
density lipoproteins cholesterol, 
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Figure 6. Receiver operating characteristic (ROC) curve for fructosamine diagnostic value (sensitivity 
and specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic 




Figure 7. Receiver operating characteristic (ROC) curve for HbA1c diagnostic value (sensitivity and 
specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic patients 
(PRE) classified according to OGGT results. 
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Figure 8. Receiver operating characteristic (ROC) curve for CML diagnostic value (sensitivity and 
specificity) in distinguishing between normal glucose tolerance subjects (NGT) and prediabetic patients 
(PRE) classified according to OGGT results. 
3.2. Comparison of two prediabetic (PRE) subgroups: Impaired Fasting Glucose 
(IFG) and Impaired Glucose Tolerance (IGT) subjects 
Table 7 shows the baseline characteristics and clinical parameters of the Impaired Fasting 
Glucose subjects (IFG) and Impaired Glucose Tolerance subjects (IGT) subgroups of 
prediabetic elderly patients according to Oral Glucose Tolerance Test (OGTT).  The 
subgroups by definition were different as far as glucose concentration was concerned (both 
fasting and postprandial) (p=0,01 and p=0,001 respectively). Otherwise the prediabetic 
subgroups did not differ in clinical parameters as well as biochemical factors. However the 
glycated hemoglobin (HbA1c) had tendency to be higher in the Impaired Glucose Tolerance 
individuals and the glycated albumin - fructosamine and Advanced Glycation End Product 
- Nε-carboxymethyllysine had tendency to be higher in Impaired Fasting Glucose subjects.  
4. Disscusion 
One of the fundamental elements for establishing prevention, treatment and prognosis of 
diabetes mellitus is an assessment of the clinical stage of glucose metabolism problems.  
Dysglycemia population is recognized with increased cardiovascular morbidity and 
mortality [Khaw KT. Et al., 2004; Sung J. et al. 2009). The cumulative effect of many metabolic 
risk factors (clinical and biochemical) in one individual which influenced cardiovascular risk 
are widely discussed (Selvin E. et al., 2005; Gerstein HC. et al., 2005). In our study we 
investigated elderly otherwise healthy persons. We found that in those with the increased 
risk for the type 2 diabetes mellitus (prediabetes) there were more (but not significant) 
indicators for the metabolic syndrome (obesity, abdominal obesity, systolic  hypertension).     
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IFG (n=8) 
Mean  ±  SD 
(Median) 
IGT (n=12) 
Mean  ±  SD 
(Median) 
p 
Age [years] 69,8 ± 3,8 (69,0) 70,2 ± 6,56 (70,0) NS 
BMI [kg/m2] 30,4 ± 6,8 (29,0) 31,7 ± 4,6 (30,5) NS 
Waist [cm] 96,0 ± 13,8 (91,5) 96,5 ± 12,9 (94,0) NS 
FAT [%] 35,3 ± 12,6 (38,8) 39,8 ± 12,2 (44,4) NS 
SBP [mmHg] 141,7 ± 12,1 (142,5) 142,0 ± 10,8 (140,0) NS 
DBP[mmHg] 76,7 ± 8,8 (72,5) 79,0 ± 9,1 (80,0) NS 
G0' [mmol/l] 6,3 ± 0,5 (6,4) 6,3 ± 0,5 (6,8) 
by def.: 
p=0,01 
G120' [mmol/l] 6,6 ± 1,0 (7,0) 8,8 ± 1,0 (9,1) 
by def.: 
p=0,001 
Fructosamine [μmol/l] 261,8 ± 27,5 (267,0) 257,0 ± 30,5 (253,5) NS 
HbA1c [%] 6,04 ± 0,60 (5,90) 6,35 ± 0,37 (6,40) NS 
CML [ng/ml] 2123,9 ± 375,5 (2122,7) 2053,4 ± 443,1 (1987,0) NS 
TC [mmol/l] 4,85 ± 0,86  (4,74) 5,41 ± 0,89 (5,25) NS 
TG [mmol/l] 1,22 ± 0,47 (1,18) 1,73 ± 1,2 (1,14) NS 
HDL-C [mmol/l] 1,53 ± 0,42 (1,50) 1,51 ± 0,32 (1,50) NS 
LDL-C[mmol/l] 2,76 ± 0,83 (2,92) 3,09 ± 0,61 (2,87) NS 
p – the probability of obtaining a test statistic, SD – standard deviation, NS – not significant, by def. - by definition, 
NGT – normoglycemic group, PRE – prediabetic group, BMI – Body  Mass Index, FAT – body fat, SBP – systolic blood 
pressure, DBP – diastolic blood pressure, G0' – fasting glucose, G120' - postprandial glucose, measured at 120 min after 
75 grams glucose load, HbA1c – glycated hemoglobin, CML – Nε-carboxymethyllysine, TC – total cholesterol, TG – 
triglycerides, HDL-C – high density lipoproteins cholesterol, LDL-C – low density lipoproteins cholesterol, 
Table 7. Baseline characteristics and clinical parameters of the prediabetes (PRE) subgroups the 
Impaired Fasting Glucose subjects (IFG) and the Impaired Glucose Tolerance subjects (IGT) according 
to Oral Glucose Tolerance Test (OGTT). 
We had hoped while performing those analysis to find a set of laboratory measures that 
would provide a better indicator of a prediabetic elderly persons for glycemic control than 
any one measure alone. 
The amount of glycated proteins (fructosamine and HbA1c) depend on time-averaged 
glucose concentration. Thus fructosamine and HbA1c reflect the extent of exposure to 
glucose in the 2-4 and 8-12 weeks before testing, respectively. Since 2010, American Diabetes 
Association has added a new recommendation for diagnosis of diabetes mellitus, concerning 
not only based on hyperglycemia (random, fasting or due to OGTT) but also glycated 
hemoglobin HbA1c (ADA 2010).  
The primary aim of the study was to evaluate the blood levels of glycated proteins and CML 
in two clinical situations, normal glucose tolerance and prediabetic state in elderly patients. 
Our study showed that the glycated hemoglobin corresponded better in distinguishing the 
NGT from PRE in the investigated elderly persons than fructosamine or advanced glycation 
end product – Nε-carboxymeethyllysine.   
 
Glucose Tolerance and Elders – Lessons We Have Learned and Challenges for the Future 95 
Hyperglycemia and oxidative stress accelerate not only glycation of proteins such as 
hemoglobin but also leads to Advanced Glycated End Products (AGEs) such as Nε-
carboxymethyllysine (CML). During natural aging AGEs accumulate and the 
concentration of formers depends on time and progressive reduction in the capacity to 
neutralise oxidative stress and may leads to many complications such as atherosclerosis 
and dementia (Hipkiss AR., 2006; Semba RD. et al., 2010). In 2003 Hamelin M. and 
collegues established that CML are increased in the rat serum with aging (Hamelin M. et 
al., 2003). So is CML independent risk factor for aging or rather diseases? Our study 
focused on CML in elderly group at the earliest stages of hyperglycemia. Our investigated 
groups had no known clinical and laboratory complications, in all subgroups CML 
concentration is very high in comparison with others investigators. Ahmed K.A. et al. 
excluded the effect of age on CML concentration in type 2 diabetic patients with ischemic 
heart disease (Ahmed K.A. et al., 2007). They argued that increased CML concentration 
was an independent from other risk factors for the coronary artery disease (CAD) in type 
2 diabetes mellitus and ha significant predictive power to CAD especially in type 2 
diabetes mellitus (Ahmed K.A. et al., 2008). In our investigated groups CML concentration 
were higher in comparison with CML concentration in Ahmed work. Our investigated 
study patients were either with normal glucose metabolism or prediabetes stage, both 
elderly patients with no clinical complications such as CAD or kidney failure. CML 
concentration depends on proteins glycation but also is directly proportional to creatinine 
concentration and inversely proportional to glomerular filtration rate. Hirata K. work 
showed that CML is increased in type 2 diabetes mellitus patients with kidney failure in 
comparison with type 2 diabetes mellitus patients with normo-, micro- or even 
macroalbumnuria (Hirata K. & Kubo K. 2004). While Wagner Z. et collegues 
demonstrated normal levels of CML and AGEs (fluorescence) in patients with type 2 
diabetes mellitus who had normal renal function (Wagner Z. et al., 2001). Since we 
excluded patients with CAD or kidney disturbances, those factors did not influences CML 
concentration, in plasma in our investigated groups. Thus, the determined CML 
concentration in plasma did not follow increased accumulation in the body. Baumann M. 
and colleagues found that CML might be accumulated in tissues, what could lead to 
different metabolic complications (Baumann M., 2009).    
Interesting work showed Dworacka M. et colleagues. Their results revealed significantly 
higher CML in non-diabetic patients with coronary heart disease than in healthy control 
subjects and were comparable to serum CML in patients with type 2 diabetes mellitus 
without late complications and coronary heart disease (Dworacka M. et al., 2002). In our 
study we realized higher (but not significant) CML concentration in subgroup defined as 
normoglycemic. This patients had lower total cholesterol, LDL-C and triglicerydes and 
higher HDL-C in comparison with prediabetics.  Thus it is possible that complications of 
diabetes mellitus are themselves related to pathobiochemical alterations other than protein 
glycation i.e. oxidative stress and lipids peroxidation.  
There is no doubt that elevated CML are closely associated with late complication of 
hyperglycemia in patients with type 2 diabetes mellitus or atherosclerotic angiopathies. 
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were higher in comparison with CML concentration in Ahmed work. Our investigated 
study patients were either with normal glucose metabolism or prediabetes stage, both 
elderly patients with no clinical complications such as CAD or kidney failure. CML 
concentration depends on proteins glycation but also is directly proportional to creatinine 
concentration and inversely proportional to glomerular filtration rate. Hirata K. work 
showed that CML is increased in type 2 diabetes mellitus patients with kidney failure in 
comparison with type 2 diabetes mellitus patients with normo-, micro- or even 
macroalbumnuria (Hirata K. & Kubo K. 2004). While Wagner Z. et collegues 
demonstrated normal levels of CML and AGEs (fluorescence) in patients with type 2 
diabetes mellitus who had normal renal function (Wagner Z. et al., 2001). Since we 
excluded patients with CAD or kidney disturbances, those factors did not influences CML 
concentration, in plasma in our investigated groups. Thus, the determined CML 
concentration in plasma did not follow increased accumulation in the body. Baumann M. 
and colleagues found that CML might be accumulated in tissues, what could lead to 
different metabolic complications (Baumann M., 2009).    
Interesting work showed Dworacka M. et colleagues. Their results revealed significantly 
higher CML in non-diabetic patients with coronary heart disease than in healthy control 
subjects and were comparable to serum CML in patients with type 2 diabetes mellitus 
without late complications and coronary heart disease (Dworacka M. et al., 2002). In our 
study we realized higher (but not significant) CML concentration in subgroup defined as 
normoglycemic. This patients had lower total cholesterol, LDL-C and triglicerydes and 
higher HDL-C in comparison with prediabetics.  Thus it is possible that complications of 
diabetes mellitus are themselves related to pathobiochemical alterations other than protein 
glycation i.e. oxidative stress and lipids peroxidation.  
There is no doubt that elevated CML are closely associated with late complication of 
hyperglycemia in patients with type 2 diabetes mellitus or atherosclerotic angiopathies. 
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Further studies should be performed in patients with the very early stages of dysglycemia to 
find when the pathology starts.  
Different tendencies for HbA1c and fructosamine and CML were observed while IFG or IGT 
were separated (as in table 7). Based on HbA1c IGT group seems to be more advanced on the 
way to diabetes. However IFG individuals tended to present higher fructosamine and CML 
which may reflect not only glycation. There is no literature data concerning different 
metabolic aspect of IFG or IGT in elderly, but in middle aged population Faerch K. et al. 
showed different insulin action and incretin hormone concentration suggesting different 
management according to the prediabitic subgroup diagnosis (Faerch K. et al., 2008). 
Despite some answers our study has brought, that there are some challenges for the future 
investigations that should be coped. What biomarker could predict the increased risk related 
to dysglycemia in elderly patients? Does the kind of prediabetes state matter, in a context of 
metabolic complications, especially in elderly patients?   
5. Conclusions 
There is no doubt that elevated fructosamine, HbA1c and CML are closely associated with late 
complication of hyperglycemia in patients with type 2 diabetes mellitus or atherosclerotic 
angiopathy. The best marker in dysglycemic but not yet diabetic elderly patients seems to be 
only glycated hemoglobin. When Nε-carboxymethyllysine and fructosamine as a single 
marker seem to be not good enough prognostic indicators of dysglycemia. In apparently 
healthy elderly people otherwise with no diagnosed comorbidities but with hyperglycemia, 
clinical assessment and laboratory investigations of hyperglycemia complications may help 
in prevention all global complications. In our opinion CML and/or fructosamine may result 
from different metabolic pathways (i.e. glycation and oxidative stress). 
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1. Introduction 
Appetite regulating peptides, particularly ghrelin and leptin in alcohol dependence are 
significantly related with abnormal glucose tolerance or insulin resistance which contribute to 
Type 2 diabetes mellitus (T2DM) [1-5]. Available evidence consistently indicates that altered 
levels of ghrelin and leptin are linked to overall diabetogentc effects of chronic alcohol 
comsumption, and have important mediating roles in the deteriorated pathophysiology of 
T2DM in alcoholic patients [6]. Moreover, these peptides in the regulation of food seeking 
behavior have a similar mechanism of controlling of alcohol craving behavior [7, 8]. 
Threrefore, alterations of the peptides modulating numerous metabolic processes could 
present an intriguing biological mechanism on the relationship between chronic alcohol 
consumption and risk of T2DM. However, the manner in which the peptides contribute to 
the development or maintenance of T2DM with alcohol dependence is not clear. This review 
describes ghrelin and leptin implicated in the elevated risk of developing T2DM with chronic 
use of alcohol that attributes to the impact of glucose and insulin metabolism. Additionally, 
to identify whether these two peptides are relevant to the increase in the clustering of 
metabolic disturbance and progression of T2DM, the background information on the 
peptides, their role in glucose homeostasis and insulin function in addition to their 
mechanism of action are discussed. This review on the relationship between chronic use of 
alcohol and T2DM may further clarify the role of the peptides and provides an insight into 
the effects of chronic alcohol use in the pathophysiology of T2DM.  
2. Pathophysiology of T2DM 
T2DM, known as “non-insulin-dependent DM,” is a complex, multifactorial metabolic 
disorder. Characteristic features of T2DM include chronic hyperglycemia and declining 
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pancreatic β-cell effectiveness, leading to the absence of a first-phase insulin response to 
nutrient ingestion. Further, slower glucose absorption and higher fasting glucose levels 
occur from factors such as a reduced insulin-mediated glucose uptake in muscle, impaired 
hepatic insulin sensitivity, defective insulin action and/or secretion in liver and a disruption 
of secretary function of adipocytes [9-11]. Glucose levels rise and hyperglycemia develops 
from deteriorated insulin secretion [12]. Mechanistically, the manifestation of T2DM features 
a relative decrease in insulin secretion suggesting that this may be in accordance with a 
decreased β-cell mass failing to compensate for peripheral insulin resistance [13-16]. In the 
last two decades, declining pancreatic β-cell effectiveness has been a criterion for the 
development of hyperglycemia and T2DM; its progressive character also determines the 
course of the disease [17]. Impaired glucose-stimulated insulin secretion, defective β-cell 
gene expression and disrupted mitochondrial ultrastructure is thought to be due to lipid 
accumulation and ‘lipoapoptosis’ is observed in pancreatic β-cells from type 2 diabetic 
animals [18]. This is also supported by reports that chronic, high glucose administration 
generates the combination of hyperglycemia and chronic dislipidemia, termed 
‘glucolipotoxicity,’ driving a vicious cycle by which metabolic abnormalities impair insulin 
secretion, which further aggravates metabolic disturbances in β-cell lines and isolated rat 
islets [19].  
There is mounting evidence that chronically elevated circulating levels of glucose and fatty 
acids, critical characteristics of T2DM, contribute to relentless β-cell function decline, by 
endorsing glucolipotoxicity, which induces endoplasmic reticulum (ER) stress [20, 21], 
oxidative stress [22, 23], mitochondrial dysfunction [23, 24] and islet inflammation [25, 26]. 
Several studies have provided evidence that prolonged exposure to increased 
concentrations of fatty acids is associated with reduction of glucose induced insulin 
secretion [27], impairment of insulin gene expression [28, 29] and induction of β-cells death 
[30, 31]. Importantly, lipoapoptosis only occurs in the presence of concomitant elevation in 
insulin secretion [32, 33]. Thus, hyperglycemia and hyperlipidemia have been postulated to 
conduct to the worsening of insulin secretary capacity and β-cell mass observed in T2DM 
[16]. It is to note, that during feeding, insulin secretion occurs in two phases. An elevation of 
insulin synthesis in pancreatic β-cells following an initial rapid release of insulin (i.e. first 
phase) to nutrient ingestion occurs primarily in response to elevated circulating glucose 
concentrations. The insulin level stimulates glucose uptake into striated muscle tissues 
through glucose transport type 4 (GLUT-4) for utilization as a source of energy and into 
adipose tissues for glycerol synthesis; it also affects liver cells thereby activating glycogen 
formation. Consequently, glucose utilization by these different tissues contributes to a 
decrease in concentrations of glucose in blood. Long term release of insulin occurs in 
response to continuously high glucose concentrations as part of the second phase of insulin 
response. On the other hand, during this period of hypoglycemia there is an altered 
interaction between pancreatic islets and glucagon-producing α cells, causing increased 
plasma glucagon, and residual β-cell function largely preserves the first-line defence against 
hypoglycemia in T2DM [34].  
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3. Interplay between alcohol consumption and T2DM 
Chronic, heavy alcohol consumption, an independent risk factor for T2DM [35-37], disrupts 
glucose homeostasis and is associated with development of insulin resistance [38-40]. 
3.1. Epidemiological evidence 
The association between alcohol consumption and DM was demonstrated early in 1971 by 
Phillips et al. [41]. This study suggested that alcohol with doses of 266 to 513 ml produced 
glucose intolerance and insulin resistance in three of six healthy subjects. Later, this 
relationship was also demonstrated in a cross-sectional health screening survey of 636 
individuals with negative urine glucose, suggesting that alcohol dependence was one of the 
malignant factors in individuals with impaired glucose tolerance diagnosed by performing a 
75-g oral glucose tolerance test (OGTT) [42]. Moreover, alcohol consumption influenced 
fasting plasma glucose levels along with obesity after analysis of 434 pairs of adult female 
nondiabetic twins [43]. These results implied that alcohol might impair fasting and 
postprandial glycemic controls and thus may be a risk factor for T2DM, sharing common 
genetic factors. Indeed, alcohol consumption within the past week appears to be an 
independent risk factor of the development of T2DM after a 10 year, prospective 
population-based study [44]. This significant association was observed only in men and 
remained significant after adjusting for other hazards of T2DM.  
However, there also have been studies with negative or opposite findings explaining the 
relationship between alcohol consumption and the development of T2DM. Alcohol 
consumptions of 5-14.9g/d and more than 15g/d were associated with a decreased relative 
risk of DM in women [45]. In a later study worked on younger women, light to moderate 
drinking (<14.9g/d) was also associated with a lower risk of T2DM compared to lifelong 
abstinence, whereas heavy drinking showed a significantly increased diabetic risk [46]. 
Similarly, moderate amount of alcohol consumption (30.0-49.9 g/d) was associated with 
reduced risk of the development of DM in 41,810 male health professionals [47]. Lowering 
the incidence of T2DM by light to moderate drinking, T2DM was also observed in older 
adults [48]. On the other hand, no effect of alcohol consumption on the development of 
T2DM was reported in large population-based survey [49]. The aforementioned results 
suggest the presence of possible influencing factors, such as gender [44, 50] and amount of 
alcohol consumption [46, 50].  
Regarding drinking patterns, Conigrave et al. [51] found that more frequent drinking is 
more protective against T2DM. A later study [50] also showed that binge drinking for 1-3 
days increased the risk of T2DM compared to non-drinking, while drinking the same 
amount over a week did not increase the risk. Meanwhile, there has been controversy on the 
type of alcoholic beverage and the risk of T2DM. Some studies noted protective effects of 
wine on T2DM than other alcoholic beverages [52]. However, other studies presented no 
significant difference with various alcoholic liquors [48, 51]. In addition, obesity may also 
influence the relationship between alcohol consumption and T2DM. A systematic review of 
studies in Japanese showed that alcohol consumption is a risk factor for DM, whereas 
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moderate drinking is associated with a reduced diabetic risk in higher body mass index 
(BMI) men in some studies [53]. Although the mediating effects of obesity are supported by 
a positive association between alcohol intake, adiponectin levels and insulin sensitivity [54, 
55], more studies will be needed to confirm this issue.  
To date, 3 meta-analyses were performed in an attempt to draw a possible conclusion. 
Carlson et al. [56] analyzed data from 13 cohorts and suggested a U-shaped relationship 
between the amount of alcohol consumption and risk of T2DM. Moderate drinking, 
corresponding to about 5-30g/d was associated with a reduced risk of DM (relative risk: 
RR=0.72, 95% CI=0.67-0.77) in both men and women. This U-shaped relationship in both 
sexes was also demonstrated in a meta-analysis by Koppes et al. [57] in which lowest risk 
was in alcohol drinkers of 6-48g/d. Drinkers of ≥48g/d showed equal RR to that of 
nondrinkers. In their study, adjustment for confounding factors including diagnostic 
measures of T2DM (self-reported versus tested) and BMI (low- versus high-BMI) was 
performed. Results of a self-reported diagnosis were associated with lower RR than using a 
diagnostic test, whereas BMI did not affect the RR of T2DM. A third meta-analysis of 
Bauliunas et al. [58] additionally identified a deleterious effect of heavy drinking (≥60 g/d for 
men and ≥50g/d for women) in addition to the protective effect of moderate drinking in both 
sexes.  
3.2. Alcohol consumption and risk of T2DM 
Along with the epidemiological data on the relationship between alcohol consumption and 
T2DM, studies exploring underlying mechanisms between them have been performed. Most 
directly, alcohol can induce acute and chronic pancreatitis and result in DM as in T1DM 
[59]. However, there is a growing body of evidence suggesting that the diabetogenic effect 
of alcohol does not seem to be mediated by decreased insulin secretion [41]. The priming 
effect of ethanol-enhanced insulin secretion in pancreatic β-cells might be caused by an early 
defence mechanism used to compensate for alcohol-inhibited basal insulin secretion. In 
contrast, a limited number of studies have reported deleterious effects of alcohol on β-cells 
in which alcohol inhibited insulin secretion [60].  
Excessive heavy alcohol use increases ROS production and may be a mechanism of 
pancreatic β-cells dysfunction in T2DM. The reason is that ROS production is one of the 
earliest events in glucose intolerance through mitochondrial dysfunction and β-cells are 
very sensitive to oxidative stress [61]. Previous studies of alcohol dependence have shown 
that alcohol elevated the level of β-cell apoptosis and increased insulin resistance in the liver 
and skeletal muscle, which is among the earliest detectable alterations in humans with 
T2DM [62]. In addition, the mechanisms by which this occurs are often multifactorial and 
quite complex, involving many cell signaling pathways. A common result of DM is 
hyperglycemia, which in turn contributes to the progression and maintenance of an overall 
oxidative environment [63]. In obesity, oxidative stress is now recognized to be an important 
feature in dysregulation of adipokines and inflammation [64].  
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Among potential mediators of alcohol-induced insulin resistance including acetate, lactate, 
acetaldehyde, free fatty acids and triglycerides, hepatic insulin sensitizing substance (HISS) 
and glutathione need to be considered. Alcohol suppresses the release or action of HISS and 
meal-induced insulin sensitization in rats [65]. Moreover, in animal models, acute alcohol 
administration also reduces glutathione [66] which is important for HISS release [67]. As 
with acute alcohol consumption, hepatic glutathione and HISS seem to be involved. In 
contrast to the acute alcohol effect, chronic ethanol consumption increased hepatic 
glutathione levels and HISS release in cases of moderate dose, whereas decreased 
glutathione and HISS were reported at high doses [68].  
On the other hand, results on the effect of chronic ethanol consumption on insulin 
sensitivity showed that insulin sensitivity was improved [66, 69-72] or unchanged [73-75] 
after chronic alcohol consumption. The mechanism by which chronic alcohol consumption 
enhances insulin sensitivity also remains elusive. Alcohol consumption is proposed to 
increase plasma adiponectin levels, which subsequently lowers plasma TNF-α, which 
interferes with insulin signaling [76]. Taken together, alcohol might induce alterations in 
insulin resistance mediated by lipids, inflammation oxidative stress and altered metabolism. 
Moreover, the effect of alcohol on insulin sensitivity may be influenced by periods of and 
amount of alcohol consumption. Impaired suppression of hepatic glucose production by 
insulin is likely due to impaired insulin signaling in liver after chronic alcohol exposure. For 
instance, chronic ethanol consumption decreases tyrosine phosphorylation of insulin 
receptor substrate-1 as well as activities of PI 3-kinase and Akt (protein kinase B) in the liver 
[77].  
3.3. Ghrelin and leptin correlated with risk of T2DM in alcoholic patients 
It has been investigated that ghrelin may be associated with β-cell hypofunction and the 
first-phase insulin secretion defects in T2DM and exert to regulate glucose homeostasis with 
glucagon and insulin [78]. Additionally, abnormal glucose tolerance and insulin resistance, 
which are main characteristics of T2DM, through performing 75g OGTT seemed to be 
affected by leptin as well as, the levels of leptin were higher in diabetic patients 
independently of body fat mass when it compared with healthy control patients [4]. Thus, 
ghrelin and leptin have been regarded to have influence on T2DM. Valuable efficacy of 
plasma ghrelin and leptin levels by the development of T2DM in patients with alcohol 
dependence were changed [6]. The data showed that ghrelin levels did not differ among the 
groups, even though there was a tendency towards decreased ghrelin levels; whereas the 
leptin level increased significantly with development of T2DM (Fig. 1). 
The demographic characteristics of each group were shown in Table 1. The three groups 
exhibited similar values of age, height, weight, BMI and lipid profiles such as HDL-
cholesterol, LDL-cholesterol, and triglyceride. Fasting glucose concentration and hemoglobin 
A1c, HOMA-IR in the DM group had significantly higher levels than NGT and Pre-DM 
groups. 
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Clinical characteristics NGT Pre-DM DM 
Alcohol history    
Alcohol use disorder identification test 21.7 ± 1.09 21.17 ± 1.61 24.3 ± 1.23 
Alcohol dependency scale 42.29 ± 1.38 38.86 ± 1.74 43.83 ± 1.79 
Onset age of problematic drinking (years) 36.58 ± 1.89 37.56 ± 1.68 40.05 ± 2.88 
General characteristics    
Age (years) 47.35 ± 1.37 48.87 ± 1.57 52.77 ± 1.84 
Weight (kg) 66.83 ± 1.46 65.39 ± 1.25 63.96 ± 1.92 
Height (cm) 169.57 ± 0.81 167.76 ± 0.8 167.38 ± 0.85 
BMI (kg/m2) 23.19 ± 0.42 23.2 ± 0.36 22.77 ± 0.57 
HDL-Cholesterol (mg/dl) 56.91 ± 2.27 51.08 ± 2.36 55.19 ± 4.44 
LDL-Cholesterol (mg/dl) 113.09 ± 3.87 104.63 ± 4.95 101.96 ± 4.72 
Triglyceride (mg/dl) 115.02 ± 10.31 135.33 ± 13.06 139.88 ± 15.54 
GOT (IU/l) 69.5 ± 11.53 71.7 ± 9.19 52.54 ± 6.96 
GPT (IU/l) 40.93 ± 5.25 50.07 ± 8.66 34 ± 6.19 
γ-GTP (IU/l) 178.87 ± 45.33 205.07 ± 32.64 254.96 ± 67.99 
Clinical characteristics related to glucose tolerance    
Fasting Glucose (mg/dl) 86.09 ± 1.05 91.48 ± 1.45 124.19 ± 7.01** 
Fasting Insulin (μU/ml) 4.8 ± 0.84 4.73 ± 0.69 6.22 ± 1.4 
HemoglobinA1c (%Hb A1c) 5.5 ± 0.05 5.64 ± 0.08 7.13 ± 0.36** 
HOMA-IR 1.02 ± 0.17 1.05 ± 0.15 1.87 ± 0.36* 
HOMA-β 83.56 ± 18.56 66.13 ± 11.55 54.91 ± 14.87 
Table 1. Characteristics of subjects classified by oral glucose tolerance test among patients with alcohol 
dependence BMI, body mass index; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-
cholesterol, low density lipoprotein-cholesterol; GOT, glutamate oxaloacetate transaminase; GPT, 
glutamate pyruvate transaminase; γ-GTP, γ-glutamyl transferase; HOMA-IR, homeostasis model 
assessment-insulin resistance; HOMA-β, homeostasis model assessment-β-cell function (*, p<0.05 and 
**, p<0.01 compared with NGT). 
Moreover, this study demonstrated that leptin was significantly correlated with BMI, fasting 
insulin concentration and HOMA-IR reflecting insulin resistance (Table 2). The BMI was 
similar in the groups and the subjects were regarded as a non-obese group. The leptin 
produced by adipocytes increased in proportion to fat mass [79, 80]. The plasma leptin 
levels are highly correlated with BMI in both obese and normal weight subjects [81]. In spite 
of the correlation between BMI and leptin, covarying for BMI in our statistical analyses did 
not alter our findings. 
Leptin also has been shown to be correlated with insulin concentration and insulin 
sensitivity [82-84]. The direct relationship between leptin and insulin seemed to be 
mutual. Insulin also had a role in the regulation of leptin concentrations [85]. Among all 
patients with chronic alcoholism, significant quadratic association of leptin level with 
insulin concentration and HOMA-IR were observed using simple regression analysis (Fig. 2, 
Table 3).  
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Figure 2. Quadratic regression plots of plasma leptin levels with both insulin resistance index (a) and 
fasting insulin level (b) in chronic alcoholic subjects. The quadratic regression equation was y = 0.007x2 – 
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and insulin level (B). 
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Clinical characteristics NGT Pre-DM DM 
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glutamate pyruvate transaminase; γ-GTP, γ-glutamyl transferase; HOMA-IR, homeostasis model 
assessment-insulin resistance; HOMA-β, homeostasis model assessment-β-cell function (*, p<0.05 and 
**, p<0.01 compared with NGT). 
Moreover, this study demonstrated that leptin was significantly correlated with BMI, fasting 
insulin concentration and HOMA-IR reflecting insulin resistance (Table 2). The BMI was 
similar in the groups and the subjects were regarded as a non-obese group. The leptin 
produced by adipocytes increased in proportion to fat mass [79, 80]. The plasma leptin 
levels are highly correlated with BMI in both obese and normal weight subjects [81]. In spite 
of the correlation between BMI and leptin, covarying for BMI in our statistical analyses did 
not alter our findings. 
Leptin also has been shown to be correlated with insulin concentration and insulin 
sensitivity [82-84]. The direct relationship between leptin and insulin seemed to be 
mutual. Insulin also had a role in the regulation of leptin concentrations [85]. Among all 
patients with chronic alcoholism, significant quadratic association of leptin level with 
insulin concentration and HOMA-IR were observed using simple regression analysis (Fig. 2, 
Table 3).  
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Independent-Dependent Linear Quadratic 
Leptin-HOMA-IR 0.390** 0.437** 
Lepin-Insulin 0.363** 0.409** 
Table 3. Comparison of various kinds of regression models to find better model to fit the relationship 
of leptin with HOMA-IR and insulin level (**, p<0.01). 
In conclusion, leptin can play a role in the pathogenesis of T2DM in patients with alcohol 
dependence. Chronic alcohol consumption might produce leptin resistance, which produces 
a significant correlation between leptin and the fasting insulin concentration, β-cell function 
and insulin resistance. However, more study will be needed to determine the mechanism of 
the relationship between alcohol intake and leptin resistance. 
4. Role of the appetite regulating peptides in alcohol dependence and 
prevalence of T2DM 
The neuropeptide, ghrelin secreted from cells of the gastric oxyntic glands in stomach, and 
leptin excreted from white adipose cells, have received attention due their roles in the 
neurobiology of alcohol dependence [2, 6]. Many studies have suggested that ghrelin and 
leptin predominantly produce variations of glucose and insulin concentrations, which may 
initiate metabolic disorders [86, 87]. In addition, recent research regarding 
neuroendocrinological alterations of ghrelin and leptin in patients with alcohol dependence 
has showed that chronic use of alcohol represents a potentially crucial risk factor for T2DM 
prevalence as ghrelin reduces insulin secretion stimulated by the increased level of blood 
glucose in the β cells of pancreas, while in contrast, leptin increases insulin secretion and 
action [88-90]. In regards to the diabetogenic effects of chronic use of alcohol, development 
of pancreatic β-cell dysfunction, insulin resistance, obesity, impairment of liver function in 
glucose metabolism have been noted [35]. Indeed, alcoholic patients with T2DM have 
repeatedly been found to have deregulation of the ghrelin and leptin systems, as indicated 
by impaired insulin secretion, increased hepatic glucose production and decreased 
peripheral glucose utilization [38-40]. Moreover, these peptides are regarded to have an 
influence on T2DM-mediated alcohol cravings and relapses in alcoholism during alcohol 
abstinace [91-94]. Therefore, it is conceivable that alterations of appetite peptides provoked 
by chronic alcohol use might contribute to the development of T2DM, including defective 
glucose tolerance and impaired insulin resistance.  
The decreases in ghrelin are paralleled by increases in leptin and rises in insulin [87, 95]. 
Leptin, which is elevated in the plasma of obese subjects, controls fat cell secretary 
productions on ghrelin secretion due to leptin-related decreases in ghrelin levels. [96-98]. It 
has been suggested that leptin is significantly associated with BMI and alcohol 
consumption, influencing fasting insulin concentration and HOMA-IR, and the passible 
mechamism of alcohol leptin interaction may be attributable to a direct noxious effect of 
alcohol on the pancreatic islet cells, or may reflect a truncal fat pattern related to heavy use 
of alcohol [44]. Thus, the adverse effect of heavy use of alcohol on serum insulin 
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concentrations, a risk for DM, seems to be partially mediated through its effect on BMI. 
Interestingly, it has been proposed that elevated peripheral insulin resistance may produce 
increased leptin concentrations regardless of body fat profiles, suggesting that leptin 
released from fat tissue in alcohol dependence patients may be abundant irrespective of 
body fat content [6]. Therefore, altered leptin concentrations in alcoholic patients contribute 
to the incidence of T2DM mainly due to chronic alcohol consumption rather than body fat 
mass.  
In the clinical studies, increases of mean body weights and leptin concentrations resulted 
from therapeutic treatment of insulin for 1 year in T2DM patients. [99], suggesting that 
insulin prompted leptin secretion, which was believed to exert influence on the increased 
body weight. Further, decrease of insulin-stimulated glucose utilization in skeletal muscle 
was exibited by long periods of leptin exposure. This is to the fact that insulin-stimulated 
p38 mitogen-activated protein kinase (MAPK) activation was inhibited and GLUT4 
activation was decreased by leptin [100]. Leptin also can interfere with insulin signaling and 
induce gluconeogenesis in hepatocytes directly [83]. Insulin-stimulated glucose uptake into 
isolated adipocytes was inhibited by chronic alcohol feeding via vitiation of the fusion of 
GLUT4 vesicles at the plasma membrane of rats. Chronically fed with alcohol sustains 
insulin signaling through PI 3-kinase in adipocytes [101] but results in the disruption of 
insulin mediated Cbl/TC10 signaling pathway which leads to attenuated insulin-stimulated 
glucose transport [102]. Thus, a combination of decreased GLUT4 expression and impaired 
insulin-stimulated GLUT4 trafficking to the plasma membrane contributes to reduced 
glucose uptake in response to insulin in adipocytes. Hence, the possibility that ghrelin and 
leptin can be related with deteriorated pathophysiology of T2DM, aligned with defective 
insulin signaling pathway, including change in kinase activity, glucose transporter 
translocation and intracellular enzyme activity, in alcoholic patients exists. 
5. Ghrelin in glucose and insulin homeostasis 
Ghrelin was originally isolated from the stomach, but ghrelin has also been identified in 
other peripheral tissues, such as the gastrointestinal tract, pancreas, ovary and adrenal 
cortex [3, 103-105]. Regulation of ghrelin secretion, as well as its biological effects, appears to 
be opposite those of leptin and antagonize leptin’s effects in appetite regulation [95, 106-
108]. A suppressive role of ghrelin in insulin secretion from pancreatic islets is supported by 
the observation that ghrelin inhibits glucose-stimulated insulin secretion and disrupts 
glucose tolerance in normal subjects [109]. There is evidence that ghrelin may have 
proliferative or protective roles on β-cells [110] and stimulates insulin secretion, which 
primarily occurs in response to increased circulating glucose levels, whereas insulin reduces 
plasma ghrelin in normal controls and T2DM patients [111]. Moreover, ghrelin may be 
associated with β-cell hypofunction and first-phase insulin secretion defects in T2DM as 
well as regulates glucose homeostasis with glucagon and insulin [78]. Furthermore, it has 
been noted that deficiency of the genes encoding ghrelin and its receptor (GHS-R1a) 
enhances insulin levels, increases glucose-stimulated insulin secretion, improves peripheral 
insulin sensitivity and prevents high-fat diets from inducing obesity [112]. Similarly, ghrelin 
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by impaired insulin secretion, increased hepatic glucose production and decreased 
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influence on T2DM-mediated alcohol cravings and relapses in alcoholism during alcohol 
abstinace [91-94]. Therefore, it is conceivable that alterations of appetite peptides provoked 
by chronic alcohol use might contribute to the development of T2DM, including defective 
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The decreases in ghrelin are paralleled by increases in leptin and rises in insulin [87, 95]. 
Leptin, which is elevated in the plasma of obese subjects, controls fat cell secretary 
productions on ghrelin secretion due to leptin-related decreases in ghrelin levels. [96-98]. It 
has been suggested that leptin is significantly associated with BMI and alcohol 
consumption, influencing fasting insulin concentration and HOMA-IR, and the passible 
mechamism of alcohol leptin interaction may be attributable to a direct noxious effect of 
alcohol on the pancreatic islet cells, or may reflect a truncal fat pattern related to heavy use 
of alcohol [44]. Thus, the adverse effect of heavy use of alcohol on serum insulin 
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concentrations, a risk for DM, seems to be partially mediated through its effect on BMI. 
Interestingly, it has been proposed that elevated peripheral insulin resistance may produce 
increased leptin concentrations regardless of body fat profiles, suggesting that leptin 
released from fat tissue in alcohol dependence patients may be abundant irrespective of 
body fat content [6]. Therefore, altered leptin concentrations in alcoholic patients contribute 
to the incidence of T2DM mainly due to chronic alcohol consumption rather than body fat 
mass.  
In the clinical studies, increases of mean body weights and leptin concentrations resulted 
from therapeutic treatment of insulin for 1 year in T2DM patients. [99], suggesting that 
insulin prompted leptin secretion, which was believed to exert influence on the increased 
body weight. Further, decrease of insulin-stimulated glucose utilization in skeletal muscle 
was exibited by long periods of leptin exposure. This is to the fact that insulin-stimulated 
p38 mitogen-activated protein kinase (MAPK) activation was inhibited and GLUT4 
activation was decreased by leptin [100]. Leptin also can interfere with insulin signaling and 
induce gluconeogenesis in hepatocytes directly [83]. Insulin-stimulated glucose uptake into 
isolated adipocytes was inhibited by chronic alcohol feeding via vitiation of the fusion of 
GLUT4 vesicles at the plasma membrane of rats. Chronically fed with alcohol sustains 
insulin signaling through PI 3-kinase in adipocytes [101] but results in the disruption of 
insulin mediated Cbl/TC10 signaling pathway which leads to attenuated insulin-stimulated 
glucose transport [102]. Thus, a combination of decreased GLUT4 expression and impaired 
insulin-stimulated GLUT4 trafficking to the plasma membrane contributes to reduced 
glucose uptake in response to insulin in adipocytes. Hence, the possibility that ghrelin and 
leptin can be related with deteriorated pathophysiology of T2DM, aligned with defective 
insulin signaling pathway, including change in kinase activity, glucose transporter 
translocation and intracellular enzyme activity, in alcoholic patients exists. 
5. Ghrelin in glucose and insulin homeostasis 
Ghrelin was originally isolated from the stomach, but ghrelin has also been identified in 
other peripheral tissues, such as the gastrointestinal tract, pancreas, ovary and adrenal 
cortex [3, 103-105]. Regulation of ghrelin secretion, as well as its biological effects, appears to 
be opposite those of leptin and antagonize leptin’s effects in appetite regulation [95, 106-
108]. A suppressive role of ghrelin in insulin secretion from pancreatic islets is supported by 
the observation that ghrelin inhibits glucose-stimulated insulin secretion and disrupts 
glucose tolerance in normal subjects [109]. There is evidence that ghrelin may have 
proliferative or protective roles on β-cells [110] and stimulates insulin secretion, which 
primarily occurs in response to increased circulating glucose levels, whereas insulin reduces 
plasma ghrelin in normal controls and T2DM patients [111]. Moreover, ghrelin may be 
associated with β-cell hypofunction and first-phase insulin secretion defects in T2DM as 
well as regulates glucose homeostasis with glucagon and insulin [78]. Furthermore, it has 
been noted that deficiency of the genes encoding ghrelin and its receptor (GHS-R1a) 
enhances insulin levels, increases glucose-stimulated insulin secretion, improves peripheral 
insulin sensitivity and prevents high-fat diets from inducing obesity [112]. Similarly, ghrelin 
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receptor antagonists which inhibit ghrelin signaling have been shown to improve the 
diabetic condition by promoting glucose-dependent insulin secretion [113]. Ghrelin can also 
inhibit the activity of glucose-sensing neurons in the dorsal vagal complex of rats, indicating 
that ghrelin manipulates the sensitivity of glucose-sensing neurons [114, 115].  
The pathophysiological role of ghrelin in glucose homeostasis was strengthened by the fact 
that ghrelin may decline endogenous glucose production through suppression of insulin 
secretory capacity [116], while reinforcing insulin action on glucose disposal [112]. A recent 
study demonstrated that acylated ghrelin has a positive correlation with insulin resistance, 
as indicated by the increased insulin and glucose concentrations, whereas correlation 
between des-acylated ghrelin and HOMA-IR was shown to be negative [117]. On the other 
hand, it has been reported that fasting ghrelin levels at any other point might be impossible 
to use for predicting the development of impaired glucose regulation [118]. The reduction of 
ghrelin levels were shown to be associated independently with T2DM, agreeing with the 
results of studies demonstrating that ghrelin has an inverse correlation with insulin 
resistance evaluated by HOMA-IR [119]. Moreover, increases in ghrelin during chronic 
alcohol use suggested that a role of ghrelin may contribute significantly to the overall 
alcohol response. It has likewise been reported that ghrelin is not only a regulator of glucose 
and insulin metabolism in the central nervous system (CNS), but also a modulator of those 
in the periphery. In the periphery, ghrelin has been shown to stimulate hepatic glucose 
production [120] and inhibit insulin release from pancreatic islets [121, 122]. Peripheral 
ghrelin produced in the gastrointestinal tract [103, 123] reaches ghrelin-receptors in the 
anterior pituitary and potentially in the mediobasal and mediolateral hypothalamus 
through the general circulation to stimulate GH release and to regulate energy homeostasis 
[124]. Therefore, it can be postulated that decreases in ghrelin concentrations as well as 
facilitation of the development of perturbations in glucose metabolism resulting from 
deregulation of the CNS and the periphery might lead to perseverance of T2DM. Besides, 
low blood ghrelin concentrations appears to influence growth hormone/insulin like growth 
facor-1-axis which may, in turn, affect increased insulin resistance and ultimately manifest 
T2DM [125].  
6. Leptin in glucose and insulin homeostasis 
Leptin, an adipocyte-derived anorexic peptide plays a primary role in regulation of energy 
homeostasis including food intake and energy expenditure involved in obesity, regulating 
overall metabolism and particularly glucose metabolism. Leptin is transported across the 
blood brain barrier (BBB) by binding to its receptor in the arcuate nucleus of the 
hypothalamus to regulate glucose metabolism via central leptin signaling, which modulates 
sympathetic and neuroendocrine activities [126, 127], as well as though peripheral signaling 
in insulin-sensitive tissues such as liver and muscle [128, 129]. A previous study 
demonstrated that serum leptin was positively correlated with fasting blood glucose in 
obese patients with DM, suggesting that resistance to insulin and leptin may have 
participated in increasing food intake in T2DM. Additionally, leptin has to be considered as 
a possible regulator of the gastrohypothalamic axis involved in short-term feeding 
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regulation [130] and may have a central role in islet cell growth and insulin secretion [131]. 
In addition, several other appetite-related hormones such as anorexigenic neuropeptides, 
alpha-melanocyte-stimulating hormone (alpha-MSH), proopiomelanocortin (POMC), 
cocaine and amphetamine regulated transcript (CART) and corticotropin-releasing hormone 
(CRH) are stimulated by leptin. Conversely, orexigenic neuropeptides NPY, melanin-
concentrating hormone (MCH), orexins and agouti-related peptide (AgRP) are inhibited by 
leptin which suppresses food intake and enhances energy expenditure through these central 
interactions, which is associated with T2DM [132-135].  
In the brain, obesity and T2DM typified by both insulin and leptin resistance, on account of 
either reduced BBB transport or impaired neuronal capacity to sense peripheral signals, 
causes increased concentrations of anorexigenic neuropeptides and reduced concentrations 
of orexigenic ones [136]. It has been postulated that leptin resistance might be due to 
defective leptin transport across the BBB [137]. Leptin enters the brain by a satiable transport 
system and that capacity of leptin transport is lower in obese individuals, thereby providing 
a mechanism for leptin resistance [138]. The development leptin resistance most likely 
involves a period of excess caloric intake, resulting in a disturbance of the leptin system, 
leading to sustained defects. The hypothalamus exposed to high leptin levels becomes less 
sensitive to leptin, resulting in a sustained increase in leptin levels [139]. Leptin resistance 
may also have functional implications in peripheral tissues expressing leptin receptors, such 
as pancreatic β cells, where insulin is synthesized and secreted; leptin may also affect 
hepatocytes, muscle and adipose tissue, where insulin exerts its function [140]. In all these 
tissues, an effect of leptin has been demonstrated on insulin secretion and on insulin-
induced activities such as glucose utilization [83, 141]. Also, increased leptin levels, probably 
reflecting leptin resistance, was shown to be strongly related to insulin resistance [142]. 
Moreover, peripheral leptin inhibits insulin secretion in pancreatic β-cells [83], whereas 
insulin stimulates leptin production in adipocytes [85]. Therefore, reciprocal interaction of 
leptin and insulin called ‘adipo-insular axis’ is central under physiological conditions.  
However, in few studies, glucose and insulin levels were able to increase circulating leptin 
levels, indicating that the capacity of leptin to suppress insulin secretion in pancreatic β-cell 
might be a possible involvement of T2DM [143, 144]. Interestingly, reduced leptin sensitivity 
of the pancreatic β-cell occurs concurrently with hyperinsulinemia resulting from not only 
decreased insulin sensitivity, but also increased insulin secretion, and consequently 
hyperleptimia as part of a vicious cycle that promotes both and insulin resistance [145]). 
Leptin has been shown to increase whole-body glucose utilization, decrease glycogen stores 
and inhibit insulin-stimulated glucose uptake [146], implying that increased leptin levels 
contribute to increased glycemia and altered glucose homeostasis [147]. Therefore, the 
capacity of leptin to suppress insulin secretion in pancreatic β-cell suggests a possible 
involvement in T2DM. Moreover, obese (ob) gene depleted mice exhibited susceptibility to 
the development of obesity and diabetic disorders, indicating that leptin-(an ob gene 
product) induced insulin resistance may be considered a major influence in developing 
T2DM [148]. Thus, animal models that are used to elucidate mechanisms underlying obesity 
and T2DM often display an altered diabetogenic imbalance, involving leptin. This suggests 
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receptor antagonists which inhibit ghrelin signaling have been shown to improve the 
diabetic condition by promoting glucose-dependent insulin secretion [113]. Ghrelin can also 
inhibit the activity of glucose-sensing neurons in the dorsal vagal complex of rats, indicating 
that ghrelin manipulates the sensitivity of glucose-sensing neurons [114, 115].  
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as indicated by the increased insulin and glucose concentrations, whereas correlation 
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hand, it has been reported that fasting ghrelin levels at any other point might be impossible 
to use for predicting the development of impaired glucose regulation [118]. The reduction of 
ghrelin levels were shown to be associated independently with T2DM, agreeing with the 
results of studies demonstrating that ghrelin has an inverse correlation with insulin 
resistance evaluated by HOMA-IR [119]. Moreover, increases in ghrelin during chronic 
alcohol use suggested that a role of ghrelin may contribute significantly to the overall 
alcohol response. It has likewise been reported that ghrelin is not only a regulator of glucose 
and insulin metabolism in the central nervous system (CNS), but also a modulator of those 
in the periphery. In the periphery, ghrelin has been shown to stimulate hepatic glucose 
production [120] and inhibit insulin release from pancreatic islets [121, 122]. Peripheral 
ghrelin produced in the gastrointestinal tract [103, 123] reaches ghrelin-receptors in the 
anterior pituitary and potentially in the mediobasal and mediolateral hypothalamus 
through the general circulation to stimulate GH release and to regulate energy homeostasis 
[124]. Therefore, it can be postulated that decreases in ghrelin concentrations as well as 
facilitation of the development of perturbations in glucose metabolism resulting from 
deregulation of the CNS and the periphery might lead to perseverance of T2DM. Besides, 
low blood ghrelin concentrations appears to influence growth hormone/insulin like growth 
facor-1-axis which may, in turn, affect increased insulin resistance and ultimately manifest 
T2DM [125].  
6. Leptin in glucose and insulin homeostasis 
Leptin, an adipocyte-derived anorexic peptide plays a primary role in regulation of energy 
homeostasis including food intake and energy expenditure involved in obesity, regulating 
overall metabolism and particularly glucose metabolism. Leptin is transported across the 
blood brain barrier (BBB) by binding to its receptor in the arcuate nucleus of the 
hypothalamus to regulate glucose metabolism via central leptin signaling, which modulates 
sympathetic and neuroendocrine activities [126, 127], as well as though peripheral signaling 
in insulin-sensitive tissues such as liver and muscle [128, 129]. A previous study 
demonstrated that serum leptin was positively correlated with fasting blood glucose in 
obese patients with DM, suggesting that resistance to insulin and leptin may have 
participated in increasing food intake in T2DM. Additionally, leptin has to be considered as 
a possible regulator of the gastrohypothalamic axis involved in short-term feeding 
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regulation [130] and may have a central role in islet cell growth and insulin secretion [131]. 
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(CRH) are stimulated by leptin. Conversely, orexigenic neuropeptides NPY, melanin-
concentrating hormone (MCH), orexins and agouti-related peptide (AgRP) are inhibited by 
leptin which suppresses food intake and enhances energy expenditure through these central 
interactions, which is associated with T2DM [132-135].  
In the brain, obesity and T2DM typified by both insulin and leptin resistance, on account of 
either reduced BBB transport or impaired neuronal capacity to sense peripheral signals, 
causes increased concentrations of anorexigenic neuropeptides and reduced concentrations 
of orexigenic ones [136]. It has been postulated that leptin resistance might be due to 
defective leptin transport across the BBB [137]. Leptin enters the brain by a satiable transport 
system and that capacity of leptin transport is lower in obese individuals, thereby providing 
a mechanism for leptin resistance [138]. The development leptin resistance most likely 
involves a period of excess caloric intake, resulting in a disturbance of the leptin system, 
leading to sustained defects. The hypothalamus exposed to high leptin levels becomes less 
sensitive to leptin, resulting in a sustained increase in leptin levels [139]. Leptin resistance 
may also have functional implications in peripheral tissues expressing leptin receptors, such 
as pancreatic β cells, where insulin is synthesized and secreted; leptin may also affect 
hepatocytes, muscle and adipose tissue, where insulin exerts its function [140]. In all these 
tissues, an effect of leptin has been demonstrated on insulin secretion and on insulin-
induced activities such as glucose utilization [83, 141]. Also, increased leptin levels, probably 
reflecting leptin resistance, was shown to be strongly related to insulin resistance [142]. 
Moreover, peripheral leptin inhibits insulin secretion in pancreatic β-cells [83], whereas 
insulin stimulates leptin production in adipocytes [85]. Therefore, reciprocal interaction of 
leptin and insulin called ‘adipo-insular axis’ is central under physiological conditions.  
However, in few studies, glucose and insulin levels were able to increase circulating leptin 
levels, indicating that the capacity of leptin to suppress insulin secretion in pancreatic β-cell 
might be a possible involvement of T2DM [143, 144]. Interestingly, reduced leptin sensitivity 
of the pancreatic β-cell occurs concurrently with hyperinsulinemia resulting from not only 
decreased insulin sensitivity, but also increased insulin secretion, and consequently 
hyperleptimia as part of a vicious cycle that promotes both and insulin resistance [145]). 
Leptin has been shown to increase whole-body glucose utilization, decrease glycogen stores 
and inhibit insulin-stimulated glucose uptake [146], implying that increased leptin levels 
contribute to increased glycemia and altered glucose homeostasis [147]. Therefore, the 
capacity of leptin to suppress insulin secretion in pancreatic β-cell suggests a possible 
involvement in T2DM. Moreover, obese (ob) gene depleted mice exhibited susceptibility to 
the development of obesity and diabetic disorders, indicating that leptin-(an ob gene 
product) induced insulin resistance may be considered a major influence in developing 
T2DM [148]. Thus, animal models that are used to elucidate mechanisms underlying obesity 
and T2DM often display an altered diabetogenic imbalance, involving leptin. This suggests 
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that dysfunction of leptin’s ability in T2DM may not only represent a consequence of the 
disease, but also plays an important role in its cause.  
7. Inverse interactions between leptin and ghrelin  
Leptin is important for the negative feedback regulation of ghrelin in states of moderate 
body weight increase, whereas recombinant leptin administration is ineffective on altering 
ghrelin levels in healthy subjects [149]. There is currently evidence that ghrelin and leptin 
exert antagonistic effects via their specific receptors in the CNS and in peripheral tissues. 
Ghrelin increases appetite and food intake via centrally mediating actions but, peripherally 
it modulates pancreatic β-cells function as well as glucose and lipid metabolism [150]. The 
satiety inducing effects of leptin include the suppression of ghrelin secretion to induce 
anorexic effects [97]. Adipogenic as well as orexigenic effects of ghrelin are also most likely 
mediated by a specific central network of neurons that is also mediated by leptin [124, 151-
153].  
In the brain, ghrelin may transfort the BBB and bind to its receptors in the hypothalamus 
after secretion into the bloodstream from the stomach [105, 154, 155]. Ghrelin reaches the 
brain via the vagal nerve and nucleus tractus solitarus [154, 156] and is released locally in 
the hypothalamus, where it may directly affect various hypothalamic nuclei [154, 157]. In 
addition, central ghrelin may affect the energy centre in the hypothalamus and both ghrelin 
and leptin stimulate and suppress, respectively hypothalamic neurons containing various 
neuropeptides, resulting in anorexic or orexic effects on energy balance. Ghrelin thus 
stimulates the activity of neurons expressing NPY, AgRP and orexin [158-160] and inhibits 
POMC neurons and CRH-producing neurons [157]. The interaction between ghrelin and 
leptin in the hypothalamus indicates that these peptides have different effects in the 
hypothalamic neurons producing various orexigenic and anorexigenic peptides, presenting 
more or less opposing effects on energy balance.  
In hepatocytes, ghrelin reduces and leptin augments insulin signal transduction, resulting in 
increased and decreased glucose production, respectively [120]. In pancreatic β-cells, insulin 
release was stimulated by ghrelin but inhibited by leptin administration [3]. Insulin was 
postulated to act indirectly via ghrelin and leptin to suppress appetite [5]. However, 
attenuated suppressive action of insulin on ghrelin and particular association between 
insulin resistance and leptin resistance were shown in T2DM [5, 142]. Thus, leptin seems to 
the major determinant of ghrelin effects on progression of metabolic syndromes. 
8. Conclusion  
The studies discussed here demonstrate that the role of appetite regulating peptides, ghrelin 
and leptin, in alcohol patients with T2DM may be of high importance for clinical research 
and practice. The extensive functional interactions between these peptides, which may 
contribute significantly to the overall defecting glucose tolerance with regard to alcoholism, 
may have a new insight into mechanism of T2DM. Therefore, understanding of mechanisms 
The Relationship Between Chronic Alcohol Use and Type 2 Diabetes Mellitus:  
New Insights into Mechanisms of Appetite-Regulating Peptides 113 
underlying the pivotal relations between ghrelin, leptin and glucose homeostasis during 
chronic use of alcohol represents an additional therapeutic intervention for T2DM. 
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1. Introduction 
Obesity is currently regarded as one of the most alarming pandemic diseases worldwide as 
it is closely related to, and in many cases causative of, Type 2 Diabetes (T2D), coronary heart 
disease (CHD), cancer and other pathophysiological disturbances. A cluster of these 
disorders are linked together under the term Metabolic Syndrome (MetS). These factors 
include impaired glucose tolerance and/or insulin resistance, dyslipidemia (high plasma 
levels of triglycerides and low density lipoproteins), central obesity and hypertension [1]. In 
the USA a recent Health and Nutrition Examination Survey (NHANES) reported that 68.3% 
of study subjects were considered as overweight (BMI  25) and 33.9% obese (BMI  30) [2]. 
The rising incidence of childhood obesity and T2D, high blood pressure, hyperinsulinemia 
and dyslipidemia are particularly worrisome as these children often mature to be obese 
adults [3]. This risk of developing obesity and T2D has largely been blamed on the increased 
consumption of energy dense foods and fat intake, particularly saturated fat, but it is 
interesting to know that the mean fat intake of the human population has not increased 
much in the past 50 years [4]. It is true that the vast advancement in technological 
developments has led to a reduction in physical activity worldwide, but as obesity now 
involves infants and the populations of developing countries [5], this obesity pandemic 
cannot be attributed to this alone. In addition, laboratory and other domesticated animals 
have also been subject to the increased prevalence of obesity, despite having largely 
unchanged living conditions for many years [5]. 
Obesity and MetS have nevertheless been blamed on excess intake of fat leading to excess 
energy intake exceeding energy expenditure, which causes the deposition of this energy in 
the format of greater numbers of excessively enlarged fat cells. When this fat deposition 
occurs in the central trunk (visceral fat accumulation) it is highly causative and suggestive of 
 The Author(s). Lic nsee InTech. This cha ter is distributed under the terms of the Cr ative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 







© 2012 Krygsman, licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Importance of Dietary Fatty Acid Profile and 
Experimental Conditions in the Obese Insulin-
Resistant Rodent Model of Metabolic Syndrome 
Annadie Krygsman 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/53805 
1. Introduction 
Obesity is currently regarded as one of the most alarming pandemic diseases worldwide as 
it is closely related to, and in many cases causative of, Type 2 Diabetes (T2D), coronary heart 
disease (CHD), cancer and other pathophysiological disturbances. A cluster of these 
disorders are linked together under the term Metabolic Syndrome (MetS). These factors 
include impaired glucose tolerance and/or insulin resistance, dyslipidemia (high plasma 
levels of triglycerides and low density lipoproteins), central obesity and hypertension [1]. In 
the USA a recent Health and Nutrition Examination Survey (NHANES) reported that 68.3% 
of study subjects were considered as overweight (BMI  25) and 33.9% obese (BMI  30) [2]. 
The rising incidence of childhood obesity and T2D, high blood pressure, hyperinsulinemia 
and dyslipidemia are particularly worrisome as these children often mature to be obese 
adults [3]. This risk of developing obesity and T2D has largely been blamed on the increased 
consumption of energy dense foods and fat intake, particularly saturated fat, but it is 
interesting to know that the mean fat intake of the human population has not increased 
much in the past 50 years [4]. It is true that the vast advancement in technological 
developments has led to a reduction in physical activity worldwide, but as obesity now 
involves infants and the populations of developing countries [5], this obesity pandemic 
cannot be attributed to this alone. In addition, laboratory and other domesticated animals 
have also been subject to the increased prevalence of obesity, despite having largely 
unchanged living conditions for many years [5]. 
Obesity and MetS have nevertheless been blamed on excess intake of fat leading to excess 
energy intake exceeding energy expenditure, which causes the deposition of this energy in 
the format of greater numbers of excessively enlarged fat cells. When this fat deposition 
occurs in the central trunk (visceral fat accumulation) it is highly causative and suggestive of 
 The Author(s). Lic nsee InTech. This cha ter is distributed under the terms of the Cr ative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucose Tolerance 126 
the risk of developing MetS, due to associated high levels of blood cholesterol and 
triglycerides [6]. It is especially dietary saturated fat acid (SFA) consumption that has been 
thought to lead to the elevation of these blood factors which are highly indicative of CHD 
risk. Most recently, through meta-analyses of large international studies, the consumption of 
SFA has been de-vilified and the causal link between these parameters and CHD disproven 
[7-9]. The question thus arises which changes in the dietary composition in the past half-
century is causing this obesogenic outcome? Although the total fat content of the diet has 
not changed significantly, a growing number of reports are making it quite clear that the 
dietary fatty acid quality may be responsible for the differential influence on obesity and 
pathophysiological outcome.  
The main alteration within the fatty acid profile of the modern diet has been the increased 
use of vegetable oil, both as a cheaper and more accessible alternative to animal fats, but 
also as a substitute to animal fats to reduce the intake of SFAs. Vegetable oils, although 
higher in monounsaturated fatty acids, are very high in omega-6 fatty acids (100-fold larger) 
compared with animal fat [10]. These oils are also much lower in omega-3 fatty acids, 
leading to an increase in the ratio of dietary omega-6:omega-3 fatty acids. In the past few 
years a growing number of studies and meta-analyses have focused on the influence of 
dietary omega-6:omega-3 ratio, and the role of omega-3 fatty acids in the development of 
T2D and CHD [11-13] and a clear link between a high ratio of omega-6:omega-3 fatty acids 
and the development of these pathologies illustrated (Fig. 1). These effects are, to a large 
extent, believed to be due to the pro-inflammatory functions of the omega-6 arachidonic 
acid (AA) cascade which has deleterious effects in a variety of tissues due to chronic low-
grade systemic inflammation. This inflammatory environment is now considered a key 
component of MetS, as the enlarged adipocytes are known to secrete many relevant pre-
inflammatory adipokines [14]. These pro-inflammatory adipokines are to a great extent 
responsible for insulin resistance, hallmarked by decreased fatty acid oxidation and an 
increase in triglyceride and free fatty acid (FFA) synthesis. These FFAs are then deposited 
within the adipocytes, leading to and worsening obesity and the perpetual further effect on 
metabolic dysregulation of fat and glucose homeostasis. Conversely, the omega-3 fatty acids 
eicosapentanoic acid (EPA) and docohexanoic acid (DHA) have anti-inflammatory 
properties, and serve as protection against MetS and CHD [15]. In adipocytes, these omega-3 
fatty acids prevent insulin resistance mediated by the AA-induced increase in pro-
inflammatory eicosanoids, via modulation of adiponectin levels and function [16-18]. This 
positive effect can only occur when an excess of omega-6 fatty acids is not present, as high 
levels of omega-6 fatty acids prevent the synthesis of omega-3 fatty acids in tissues [19], and 
it is thus arguable whether supplementation or dietary increase of omega-3 fatty acids 
would effectively attenuate the deleterious effects of omega-6 mediated inflammatory 
mechanisms without a decrease in the intake of omega-6 fatty acids [20-22]. 
Close scrutiny of the modern Western diet in epidemiological studies have brought to 
attention the role of the fatty acid profile of certain native and regional diets in the 
prevention of the development of MetS and all of its associated symptoms [8, 9, 23, 24]. In 
populations consuming diets rich in omega-3 fatty acids, the prevalence of impaired glucose 
tolerance and CHD is much lower than those populations consuming the Western diet.  
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especially in the development of T2D, and animals exposed to pro-diabetic diets during 
pregnancy give rise to offspring with a higher propensity of developing metabolic 
perturbations [27]. The ‘control’ diet used in the majority of studies thus in fact may 
represent a high omega-6 treatment diet, which casts a degree of doubt on the accuracy of 
results obtained from such experiments. More careful scrutiny and transparency of rodent 
dietary composition is needed in order to make valid comparisons with other dietary 
interventions in the study of MetS components.  
Animal models of MetS are not only influenced by dietary fatty acid composition, and other 
husbandry-associated factors such as day/night cycle and time-of-day experimental 
procedures can also influence the outcome of such studies. Rodents, by nature, are 
nocturnally active animals, but sampling and experimental procedures commonly take 
place in the day time which is the inactive rest phase of these animals. The circadian clock, 
which is regulated by daylight exposure, plays a critical role in many physiological 
processes associated with insulin, fatty acid and glucose metabolism. In the rat, insulin 
levels are low during its inactive diurnal phase, and high during the nocturnal phase with 
high glucose utilization [28]. Sampling of blood and performance of glucose tolerance tests 
usually take place in the morning, as it represents the most convenient time for the scientist, 
following a 6-12 h overnight fast during the animal’s active phase. This causes a rapid fall in 
blood glucose levels, whereas fasting during the day in the animal’s rest phase causes a 
much less significant drop in blood glucose levels. In addition, stress induction due to this 
food deprivation, causes a rise in corticosteroid levels which mobilizes fatty acids from 
triglyceride stores [29] giving an inaccurate reflection of the blood levels of these 
compounds. This of course is not desirable in an experimental setting and undue bias is 
incorporated. A solution is to reverse the light-dark cycle, so that all animal procedures are 
carried out during the animal’s active phase. This creates the most effective scenario, but is 
critically dependent on the absence of dark-phase light contamination, as even dim light 
during the dark phase causes the inhibition of the circadian rhythms in blood glucose, lactic 
acid, insulin and corticosteroid levels [29] which would compromise or alter the outcome of 
scientific investigations.  
Creating and using accurate and comparable models for research into MetS and associated 
CHD is essential in providing relevant and applicable data that may be extended to human 
disease state research. Basic principles such as dietary composition and fatty acids profile, 
together with appropriate husbandry practices are thus of major importance in the design 
an execution of research studies using animal models. This chapter will endeavor to 
highlight some of the crucial aspects surrounding dietary fat composition and use of the 
rodent model of diet-induced obesity and metabolic syndrome.  
2. Role of omega-6 and omega-3 fatty acids in insulin resistance and CHD 
Fatty acids are important sources of fuel as they yield large quantities of ATP when 
metabolized and the heart and skeletal muscle prefer fatty acids to glucose as fuel [30]. Fatty 
acids consist of a long aliphatic chain with a carboxylic acid group at one end and may be 
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saturated or unsaturated (those that contain no double bonds are saturated, and those that 
have double bonds are unsaturated). The biological reactivity of these compounds are 
dependent on both the length of the fatty acid chains as well as the number and positional 
location of double bonds prevalent (n-3, n-6, n-7 and n-9). An 18-carbon fatty acid 
containing two or more double bonds is referred to as being polyunsaturated fatty acids 
(PUFA), whereas fatty acids consisting of 20 or 22 carbons are termed highly unsaturated 
fatty acids (HUFA). It is especially the n-3 and n-6 HUFA that are considered to be major 
role-players affecting diet-dependent disease. These fatty acids are responsible for 
maintaining correct cell membrane protein function and fluidity and cellular functioning. 
The more highly unsaturated fatty acids, such as the n-6 arachidonic acid, are converted to 
eicosanoid derivatives which have a hormone-like action and are involved inflammatory 
pathologies such as obesity, insulin resistance and atherosclerosis [31-33]. In contrast, the n-
3 fatty acid-derived eicosanoids have anti-inflammatory and anti-thrombotic activities [34, 
35]. It is this action of the n-6 derived eicosanoids that is of particular importance as they are 
major role-players in diet-associated pathologies through their pro-inflammatory actions 
(Fig. 2). 
A number of studies, including the Seven Countries Study, have shown the Mediterranean 
Diet to be preventative of insulin resistance and CHD and protective against certain cancers 
[19, 36, 37]. This diet is characterized by a high intake of unsaturated fatty acids in the form 
of virgin olive oil containing a very low ratio of omega-6:omega-3 fatty acids (2:1). In these 
 
Figure 2. The effects of omega-6 vs. omega-3 conversion pathways on inflammation in coronary heart 
disease (adapted from [45]) 
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studies, Western diets of non-Mediterranean countries (USA, Western Europe and 
Scandinavia), and containing omega-6:omega-3 fatty acid ratios in excess of 15:1, was 
associated with significant higher incidences of insulin resistance and CHD. More 
importantly, the lack of detrimental effect of SFA and cholesterol intake, in the presence of 
optimal omega-3 intake, was simultaneously indicated [38, 39], as was the failure to 
document a relationship between dietary cholesterol and CHD (reviewed by [9]). Reducing 
SFA intake or replacing SFA with MUFA was found to not improve cardiovascular risk [40, 
41]. Moreover, blood cholesterol levels alone do not predict absolute CHD mortality rates 
observed for different groups worldwide (Fig. 3) and these death rates differ at each 
cholesterol level. In fact, the elevations in blood cholesterol are fatal only to the magnitude 
that omega-6 exceeds omega-3 in tissue HUFA [19]. It is thus not surprising that it has 
recently been proposed that omega-6 HUFA blood levels are more indicative of heart 
disease risk than total cholesterol level, where high omega-6 HUFA levels inhibits omega-3 
synthesis [42, 43]. The authors of the 25-year follow-up of the Seven Countries Study 
considered factors affecting inflammatory oxidative processes and thrombosis to be of great 
importance [44].  
 
Figure 3. Dietary fatty acid imbalances which elevate blood cholesterol are fatal only to the magnitude 
that omega-6 exceeds omega-3 in tissue HUFA (From [19]). 
Omega-6 fatty acids are further known to amplify post-prandial oxidative stress leading to 
these elevations in inflammatory vascular lesions and atherosclerosis. High percentages of 
HUFA in plasma and adipose tissue of obese children have been reported, associated with 
higher concentrations of inflammatory markers [46]. In contrast, omega-3 HUFAs prevent 
and reverse high fat diet-induced insulin resistance, in part via modulation of adipose tissue 
inflammatory product secretion patterns [11, 20, 47]. The omega-3 HUFAs act via different 
pathways to establish this protective effect by, amongst others, inhibiting the pro-
inflammatory NFB pathway due to its inhibition of SFA-activation of Toll like receptors 
(TLR) 2 and -4, with DHA being the most potent inhibitor of this pathway. The omega-3 
HUFA EPA competes for cyclooxygenase and lipooxygenase enzymes in the AA cascade, 
and in this manner reduces the production of pro-inflammatory AA-derived eicosanoids. 
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Furthermore, EPA and DHA inhibits the release of AA by inhibiting phopholipase-A2, and 
thus also reduces activation of the pro-inflammatory AA-cascade [48]. Inflammation, 
mediated via AA-derived eicosanoids, also plays a critical role in the pathophysiology of 
atherosclerosis with coronary plaques being highly inflamed with a core rich in lipids [49]. 
Recently published studies reported that the blood plasma ratio of omega-6:omega-3 plays 
an important role in endothelial function and vascular tone, and that a high ratio is 
significantly associated with a high prevalence of coronary artery lesions [50]. The plasma 
EPA/AA ratio and high-sensitivity CRP levels were further found to be independent 
predictors of the presence of complex coronary lesion. In addition, the fact that omega-3 
fatty acid supplementation improves endothelium-dependent vasodilation further supports 
the recommendation that modulation of dietary omega-6 and omega-3 fatty acids is a safe 
and necessary approach to improving vascular health and reducing the risk of CHD [51, 52].  
3. Evolution of the omega-6:omega-3 fatty acid dietary ratio 
Studies in Paleolithic nutrition and modern-day hunter-gatherer populations estimate that 
humans evolved on a diet that was much lower in saturated fatty acids than is today's diet, 
and contained small but roughly equal amounts of omega 6 and omega 3 fats [10]. The 
Paleolithic diet, also known as the Cave Man or Hunter-Gatherer diet, prevailed for about 
2.5 million years and ended 10 000 years ago with the development of agriculture [53, 54]. 
These stone age humans centered their diet on foods that could be hunted and fished, such 
as meat, offal and seafood, and could be gathered, such as eggs, insects, fruit, nuts, seeds, 
vegetables, mushrooms, herbs and spices. The proportion of nutrients, although dependent 
on latitude and other influences, consisted of roughly 20-35% each protein and 
carbohydrates and 30-60% fat. Of the total food intake 45-65% came from animal products 
and 35-55% from plant products, but it is debatable whether any grains or tubers were 
consumed [54]. Omega-3 fatty acids were found in all of these foods, and a balance existed 
between omega-3 and omega-6 for this entire period. Hunters tended to target herbivores, 
and the total carcass fat of such animals averaged about 7% compared with domesticated 
beef cows 40%, and with 35% PUFA compared with the current 7% in grain-fed beef [55]. 
Carbohydrates nearly all came from fruit and vegetables, and a small proportion from 
honey [56], thus consisting overall of low glycemic load carbohydrates.  
The modern human inherited characteristics by genetic adaptation accrued over millions of 
years of the Paleolithic Period, and the vast majority of our biochemistry and physiology are 
adapted to life conditions that existed prior to the advent of agriculture about 10 000 years 
ago. At this time humans began to cultivate plants and later to domesticate animals 
constituting the Agricultural Revolution leading to the Neolithic Period. The gradual spread 
of agriculture throughout the Old and New Worlds generally led to an increase in 
population, and demand for foodstuffs which soon led to difficulties in exploitation of game 
and wild plant food. The main dietary innovation that accompanied agriculture involved 
the introduction of cereal grains. Crop cultivation became necessary to supply in the 
increased demand for foodstuffs, leading to cereal grains becoming staple food – a 
departure from native nutrition unparalleled and unseen in other free-living primates of 
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that period [57]. Before that time, early humans did recognize that grains could be 
consumed in times of shortage, but the labor involved in milling the grains discouraged 
frequent use. The almost 60% intake of fruits and vegetables soon declined to an estimated 
20% of daily caloric intake, with cereal grains consumed in place thereof. Grains are high in 
omega-6 fatty acids and low in omega-3, and this led to the increased dietary ratio of omega-
6:omega-3 (Fig 4).  
Since this major change in the human diet, natural selection has had too little time to make 
the optimal genetic adaptations to the new dietary composition, leading to physiological 
and metabolic maladaptation [58]. These incomplete genetic changes are not seen in modern 
hunter-gatherer populations it is thus reasonable to conclude that humans are maladapted 
to diets of domesticated and processed plant foods, contributing too many of the current 
diseases of civilization. What has compounded these maladaptive consequences of the 
agricultural age, is the fact that the demand for meat in the past 50 years has led to the 
implementation of large cattle and poultry feedlots in order to provide in the increased 
demand for meat. Prior to that time, animals were pasture-reared and consumed a diet of 
green leaves high in the omega-3 fatty acid -linolenic acid (ALA) resulting in a meat ratio 
of omega-6:omega-3 of 2:1, vs. 4:1 in grain-fed meat in beef and poultry as well as eggs. 
Cattle moved from pasture to feedlots for fattening prior to slaughter lose this valuable ALA 
store, as well as EPA and DHA with the supply diminishing each day the animal spends in 
the feedlot (Fig. 5 [59]). 
 
Figure 4. Change in dietary omega-6:omega-3 ratio from the Paleolithic Period to the current dietary 
composition [10]. 
In addition to the new emphasis on grain feeds for domestic livestock, the first part of the 
20th century marked the onset of the industrial vegetable oil industry [60]. Technological 
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advancements after World War I made large-scale production of vegetable oil more efficient 
and economic. With the advent of hydrogenation of oils to increase solidification, the ALA 
content was greatly reduced leaving a high concentration LA, and hence a high omega-
6:omega-3 ratio, with similar changes in the production of other oils such as cottonseed oil, 
safflower oil and sunflower seed oil. Soy bean meal/oil forms the main constituent of 
livestock and poultry feed, shortening and margarine and it thus forms a large proportion of 
the average daily fat intake in most countries. These changes in the consumption of essential 
fatty acids throughout the 20th century was recently (2011) reported for the first time as a 
detailed quantitative analysis (Fig. 6 [61]). They found that the estimated consumption of 
soy bean oil increased in excess of 1000-fold from 1909 to 1999. This consequently led to a 3-
fold increase in the intake of LA which was the primary determinant for the declining 
percentages of omega-3 HUFAs in tissue throughout the 20th century.  
Animals have not been spared the fate of this deleterious dietary transformation, as 
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similarly to humans. Although in this study it was speculated that certain viral pathogens 
and epigenetic factors possibly could have contributed to this obesogenic effect, it is also 
highly likely that it could be due to the deleterious transformation to a high omega-6 intake 
in chow. As in the human diet, the fat content of chow has remained constant during the 
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that period [57]. Before that time, early humans did recognize that grains could be 
consumed in times of shortage, but the labor involved in milling the grains discouraged 
frequent use. The almost 60% intake of fruits and vegetables soon declined to an estimated 
20% of daily caloric intake, with cereal grains consumed in place thereof. Grains are high in 
omega-6 fatty acids and low in omega-3, and this led to the increased dietary ratio of omega-
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store, as well as EPA and DHA with the supply diminishing each day the animal spends in 
the feedlot (Fig. 5 [59]). 
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Figure 6. Changes in the estimated per capita consumption (kg/person/year) in the USA between 1909 and 
1999 of A: of major food commodities; B: Major fat commodities; C: Vegetable and seed oils (from [61]) 
Indeed the fatty acid composition of standard rodent chow has changed similarly to that of 
humans, with comparable effects on the omega-6:omega-3 ratio [62-64]. Fifty years ago, 
laboratory chow fat content consisted of the lard of animals grazing on grass which had an 
omega-6:omega-3 of less than 6:1, but since then the omega6:omega-3 ratio in the control 
rodent diet has changed from 6:1 in 1998, to 9:1 in 2002, 12.5:1 in 2006 [26]. Standard high fat 
research diets now contain omega-6:omega-3 ratios in excess of 11:1 [51]. All maintenance 
diets contain soy bean oil as their main fat source with omega-6:omega-3 ratio of 8:1 which 
is much higher than lard produced from grass-reared beef at 2:1 used before the change to 
soy bean oil (Table 1). Hydrogenated soy bean oil produces severe insulin resistance [65], 
and is thus not suitable as a source of fat for rodent maintenance diets.  
 
Fat/Oil Omega-6:omega-3 




Soy Bean 8:1 
Beef Tallow (Grain-fed) 8:1 
Milk Fat (Grain-fed) 5:1 
Beef Tallow (Grass-finished) 2:1 
Canola 2:1 
Milk Fat (Grass-finished) 1:1 
Flax Seed 0.2:1 
 
Table 1. Omega-6:omega-3 ratios of commonly-consumed fat sources in the USA [66, 67] 
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Although the evidence is now mounting and the clear link between excessive omega-6 
intake and modern Western diseases of lifestyle established, formal dietary 
recommendations (Institute of Medicine, National Academies of Science), have not 
incorporated these alarming findings. Dietary Reference Intakes (Food and Nutrition Board) 
in 2006 recommended an adequate intake of omega-6:omega-3 of 10:1, a ratio now proven to 
be deleterious to especially cardiovascular health [67]. These recommended dietary intake 
guidelines are thus in urgent need of revision to include the levels and profiles based on the 
evidence now available in literature. 
4. Rodent models for the study of insulin resistance and CHD 
Model organisms have extensive value as sentinels informing us about environmental 
factors which may potentially have an impact on humans [68]. The severity of the obesity 
epidemic has created an urgent need to study the causes and progression of the pathologies 
associated therewith such as MetS. Animal models that sufficiently mimic all the aspects of 
this syndrome, including obesity, insulin resistance, dyslipidemia and hypertension are 
required for such studies.  
A large variety of animal species have been used as models to study MetS, with varying 
degrees of success. The ideal model should be small and economical, but large enough to 
perform the required experimental procedures. Non-human primates are in many respects 
the ideal models as they are phylogenetically close to humans, consume a comparable 
omnivorous diet, and develop MetS and CHD as they age [69], but in addition to important 
ethical issues, they have an extended lifespan, are expensive to house and carry viral 
zoonoses dangerous to humans. Other animals, such as the domestic pig, the dog and the 
rabbit all provide potential as models for MetS and CHD research, but cost, cultural status 
and species-specific vulnerabilities to dietary modulation [70], place doubt on their efficacy 
for this research field. The rat, in particular, resembles the human both in physiology and 
metabolism, and follows an omnivorous diet similar to humans with whom the rat has 
spread worldwide [71]. Since the development of the first defined rat strain at the Wistar 
Institute in the 1920s, the rat has been used regularly and to great effectivity for the study of 
diet-induced obesity, insulin resistance and the disease states associated therewith, such as 
CHD [70, 72].  
Standard laboratory rat species, such as the Wistar or Sprague-Dawley strains, are 
successfully utilized for diet-induced MetS models [73]. The diets aim at reproducing high 
fat diets (HFD) similar to what is ingested in the Westernized society, i.e. a high percentage 
total fat (of calories) with a high SFA content with or without high carbohydrate content. 
Varying combinations and amounts of carbohydrates and fats are used in different studies 
[72, 74, 75], with the carbohydrates fructose or sucrose standardly used, but the fat source 
varying. Long-term feeding of these diets induce obesity, increased abdominal fat 
deposition, hyperinsulinemia, hypertension and impaired glucose tolerance in most rat and 
mouse strains [76]. Fat fractions in these diets range between 20% and 60% of energy as fat 
as either animal-derived lard or beef tallow, or plant oils such as soy bean oil, coconut oil, 
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olive oil, safflower oil [73]. The problem is that in many cases, these constituents or profile of 
the fatty acid element in the diet are not available, not taken into account or not reported in 
published literature. In fact, standard chow prepared by commercial companies contains 
fats obtained from a variety of sources, both animal and vegetable, which, considering the 
variation in omega-6:omega-3 fatty acid ratio between such foodstuffs can have far-reaching 
implications for the outcomes of studies employing these diets. This complicates the study 
of the effects of dietary fats on obesity and insulin resistance and associated disease states, 
and makes comparison between studies almost impossible. A rodent high fat diet high in 
SFA content, in the presence of a low omega-6:omega-3 ratio would not give the same 
results as a diet similar in total fat and SFA content, but with a high omega-6:omega-3 ratio. 
Even with low to moderate fat percentages (20-30%) in the presence of the recommended 
SFA content (10%), high omega-6:omega-3 ratios can lead to glucose intolerance in rodents 
indicated by decreased insulin response to intravenous glucose tolerance tests [77].  
Rodent models share many traits with human diabetic cardiomyopathy, such as left 
ventricular hypertrophy, increased ventricular stiffness, ventricular dilatation, decreased 
fatty acid uptake, cardiac inflammation and fibrosis, decreased cardiac function and 
endothelial dysfunction [72]. In the Wistar rat the onset of cardiomyopathy occurs within 7 
weeks of receiving the diet, and leads to cardiac steatosis, impaired contractile function and 
mitochondrial degeneration with increased myocardial fatty acid uptake [78]. Simple high 
fat feeding with caloric excess is thus sufficient to induce metabolic defects that area 
associated with diabetic cardiomyopathy, but isocaloric high fat diets based on saturated 
fats alone do not induce insulin resistance and in fact improve cardiac function [79, 80]. This 
could point to both the deleterious role of hyperinsulinemia and impaired glucose 
homeostasis on the development of cardiac defects due to the consumption of the Western 
Diet, or could indicate the failure to take into account the PUFA profile of said diets used in 
these studies.  
It is worthy to note the normal rat is resistant to the development of atherosclerosis, and 
simple Western high fat diets do not induce atherosclerosis in these animals. Induction of 
atherosclerosis is less easily achieved, and generally requires addition of cholesterol to the 
animal’s diet. Atherosclerosis can be induced by increasing the oxidized form of LDL in the 
blood by either increasing the total LDL while maintaining the proportion of oxidized LDL, 
or by increasing the proportion of oxidized LDL. Linoleic acid may be a factor in the 
susceptibility of LDL to oxidation as LDL is rich in LA, but the dietary content of LA differs 
in its ability to cause LDL oxidation depending on its effect on the blood lipid profile which 
in turn varies according to species. Saturated fat feeding only exacerbates an increase in LDL 
when excessive cholesterol is consumed, and in the absence of cholesterol SFA does not 
cause a rise in LDL both in rats and humans and atherosclerosis does not result [81] 
(reviewed in [82]).  
Although rodent models play a very important role in, and indeed have advanced the 
understanding of the underlying pathological mechanisms of human MetS and CHD, these 
models do have limitation and none exist that exactly phenocopies the human MetS disease 
condition. By adding dietary inconsistencies these models cannot be used to their full 
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potential and clear and transparent dietary formulations, which include the fatty acid 
profile, are crucial for providing comparable studies and thus results. Maintenance and 
Control diets should consist of the correct recommended balance of omega-6:omega-3 fatty 
acids to provide a ‘healthy’ model and control group as reference with which to compare 
dietary interventions.  
5. The circadian clock in animal models of insulin resistance and fatty 
acid metabolism 
Nutrient homeostasis in many species of vertebrates is intricately controlled by coordinated 
interactions of daily rhythms of activity and rest, feeding behavior and energy expenditure 
and storage across the daily 24h light-and-dark cycles [83]. This circadian clock, under the 
control of molecular mechanisms cycling in the suprachiasmatic nuclei (SCN) of the 
hypothalamus, plays a critical role in a diverse group of physiological processes in different 
cell types associated with insulin, glucose and fatty acid metabolism. The main factor 
responsible for synchronization of the circadian rhythm is sun light, which determines the 
precise length of the day and night in the 24 h period. This serves to orient the human or 
animal in relation to the point of day, and light is thus one of the most powerful 
synchronizers of the circadian rhythm. In the absence of pronounced SCN signals the 
circadian rhythm in peripheral tissues becomes uncoupled, resulting in aberrant cellular 
metabolism and disease risk [29, 83]. The changes in lifestyle during the past 50 years has, in 
addition to an increased intake of inappropriate, energy-dense and poor fat- and nutrient-
quality foods, also led to increased time spent awake and hence disrupted pattern of eating, 
sleeping and physical activity. This causes an asynchrony with the circadian rhythm with 
profound effects on glucose and fatty acid metabolism, which is well-described in the 
human and linked to metabolic derangements associated with and leading to increased 
adiposity and BMI [84].  
The main synchronizers of the peripheral circadian clocks are food restriction, 
glucocorticoids and melatonin [85]. Of the peripheral tissues, the adipose tissue circadian 
clock plays a fundamental role in glucose and lipid metabolism [86, 87]. Any disturbances of 
the adipocyte circadian clock van alter adipocyte responsiveness to different stimuli, i.e. 
levels of glucose, insulin and fatty acids, and can alter the level of lipogenesis and lipolysis. 
The adipokine, adiponectin, which plays an important role in insulin sensitivity, 
inflammation and fatty acid oxidation, presents a circadian rhythm similar to insulin, with 
peak levels in the early active phase and low levels in the inactive phase (Table 2). The early 
hours of the active phase are characterized by higher glucose levels and thus higher insulin 
demand in anticipation of the onset of stimulus [88-90]. At the end of the active phase and 
the start of the rest phase, insulin levels and sensitivity are low and oral or intravenous 
glucose (or consumption of a meal) leads to a significantly higher plasma glucose response. 
Accordingly, rodents respond differently by day and night to insulin and 2-deoxy-D-glucose 
with a rapid fall in blood glucose levels occurring at the end of the active phase after a 6h 
overnight fast in contrast to delayed and diminished hypoglycemia following a day time 
(inactive phase) fast [89]. Furthermore, the circulating FFA levels follow the same circadian 
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pattern as glucose and are low in the active phase and high in the inactive phase in both 
humans and rats, with an increased turnover present in humans with T2D [90, 91]. The role 
of adiponectin in FFA, insulin and glucose metabolism in context of the circadian rhythm is 
shown in Figure 7. Under normal condition, i.e. healthy diet and daily sleep-wake cycle, 
adiponectin levels are high in the early active phase which stimulates AMPK, resulting in 
increased fatty acid oxidation and energy yield, with resultant low triglyceride levels. 
Adiponectin also upregulates PI3K which further downstream contributes to the 
improvement and optimization of insulin action, thus counteracting any pro-obesogenic and 
insulin-resistance inducing effects.  
 
 Active phase Inactive phase
Glucose Low High 
Insulin High Low 
FFAs Low High 
 - Omega-6 Low High 
 - Omega-3 High Low 
 - Eicosanoids High Low 
Adiponectin High Low 
O-GlcNAc High Low 
Table 2. Circadian pattern of compounds involved in the regulation metabolic processes linked with 
metabolic homeostasis related to the development of insulin resistance and CHD. [88, 92-94]. 
Both obesity and dysregulated circadian rhythms can profoundly modulate adiponectin 
from various perspectives, all which may have bearing on the application of the rodent 
model of insulin resistance. Peak levels of corticosteroids occur at the start of the active/dark 
phase, and then fall during the light/inactive phase, reaching the lowest level just before the 
dark/light transition. Any stressor experienced at this time, be it anxiety, starvation, fear or 
pain would cause an increase in corticosteroid levels and hence release of FFAs from fat 
stores. 
The circadian rhythm of specific PUFAs is largely lacking in literature, and to our 
knowledge, only one study has been published in which the daily variation of omega-6 and 
omega-3 fatty acid levels was reported [94]. In this study only preliminary evidence is 
presented, but the fact that a differential circadian rhythm for these fatty acids was 
identified is of great possible importance and deserves further exploration. This also 
supports earlier findings that a circadian rhythm for eicosanoid production exists, with low 
levels during the inactive phase and high levels present during the active phase [92]. In light 
of the fact the plasma FFA profile represents the dietary FFA profile [77], it is likely that the 
levels omega-6 HUFAs will be increased when a diet high in omega-6 fatty acids is 
followed. As arachidonic acid, via NFkB and eicosanoid conversions products, causes a 
suppression of adiponectin, this would exaggerate and amplify the pro-diabetic, insulin 
resistance and hyperglycemic propensity of the hormonal profile of the inactive phase. This 
further suppression of adiponectin, already low at the active/inactive phase transition, 
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Figure 7. A simplified representation of the interrelation of obesity, circadian rhythm disruption and 
dietary fatty acid intake on development of metabolic perturbations related to T2D and CHD. 
would lead to down regulation of AMPK and hence increased triglyceride levels due to 
decreased fatty acid oxidation and clearance. Furthermore, this would ultimately lead to 
hyperglycemia due to the increased fatty acid-induced flux through the hexosamine 
biosynthetic pathway (HBP) which further decreases adiponectin levels, and thus increases 
its stimulating effect on liver gluconeogenesis.  
It is known that a glucose-fatty acid cycle operates in the heart and diaphragm muscle by 
decreasing the rate of oxidation of the alternative substrate in the presence of increased 
availability of the other substrate [95, 96]. In the presence of high circulating levels of FFAs, 
a decrease in the rate of carbohydrate oxidation is seen, and vice versa when high 
circulating levels of glucose prevail. It is in this context that the HBP serves as a nutrient-
sensing mechanism and both excess FFA and glucose can lead to augmented flux through 
this pathway, which ultimately plays a role in causing insulin resistance in the adipocyte, 
liver, muscle and pancreatic β-cell via reduced recruitment and translocation of GLUT4 to 
the plasma membrane [97, 98]. In the presence of excess FFA, glycolysis is inhibited distal to 
fructose-6-phosphate by increased levels of acetyl-CoA, leading to inhibition of 
pyruvatedehydrogenase, which in turn increases fructose-6-phosphate availability and thus 
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adiponectin levels are high in the early active phase which stimulates AMPK, resulting in 
increased fatty acid oxidation and energy yield, with resultant low triglyceride levels. 
Adiponectin also upregulates PI3K which further downstream contributes to the 
improvement and optimization of insulin action, thus counteracting any pro-obesogenic and 
insulin-resistance inducing effects.  
 
 Active phase Inactive phase
Glucose Low High 
Insulin High Low 
FFAs Low High 
 - Omega-6 Low High 
 - Omega-3 High Low 
 - Eicosanoids High Low 
Adiponectin High Low 
O-GlcNAc High Low 
Table 2. Circadian pattern of compounds involved in the regulation metabolic processes linked with 
metabolic homeostasis related to the development of insulin resistance and CHD. [88, 92-94]. 
Both obesity and dysregulated circadian rhythms can profoundly modulate adiponectin 
from various perspectives, all which may have bearing on the application of the rodent 
model of insulin resistance. Peak levels of corticosteroids occur at the start of the active/dark 
phase, and then fall during the light/inactive phase, reaching the lowest level just before the 
dark/light transition. Any stressor experienced at this time, be it anxiety, starvation, fear or 
pain would cause an increase in corticosteroid levels and hence release of FFAs from fat 
stores. 
The circadian rhythm of specific PUFAs is largely lacking in literature, and to our 
knowledge, only one study has been published in which the daily variation of omega-6 and 
omega-3 fatty acid levels was reported [94]. In this study only preliminary evidence is 
presented, but the fact that a differential circadian rhythm for these fatty acids was 
identified is of great possible importance and deserves further exploration. This also 
supports earlier findings that a circadian rhythm for eicosanoid production exists, with low 
levels during the inactive phase and high levels present during the active phase [92]. In light 
of the fact the plasma FFA profile represents the dietary FFA profile [77], it is likely that the 
levels omega-6 HUFAs will be increased when a diet high in omega-6 fatty acids is 
followed. As arachidonic acid, via NFkB and eicosanoid conversions products, causes a 
suppression of adiponectin, this would exaggerate and amplify the pro-diabetic, insulin 
resistance and hyperglycemic propensity of the hormonal profile of the inactive phase. This 
further suppression of adiponectin, already low at the active/inactive phase transition, 
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Figure 7. A simplified representation of the interrelation of obesity, circadian rhythm disruption and 
dietary fatty acid intake on development of metabolic perturbations related to T2D and CHD. 
would lead to down regulation of AMPK and hence increased triglyceride levels due to 
decreased fatty acid oxidation and clearance. Furthermore, this would ultimately lead to 
hyperglycemia due to the increased fatty acid-induced flux through the hexosamine 
biosynthetic pathway (HBP) which further decreases adiponectin levels, and thus increases 
its stimulating effect on liver gluconeogenesis.  
It is known that a glucose-fatty acid cycle operates in the heart and diaphragm muscle by 
decreasing the rate of oxidation of the alternative substrate in the presence of increased 
availability of the other substrate [95, 96]. In the presence of high circulating levels of FFAs, 
a decrease in the rate of carbohydrate oxidation is seen, and vice versa when high 
circulating levels of glucose prevail. It is in this context that the HBP serves as a nutrient-
sensing mechanism and both excess FFA and glucose can lead to augmented flux through 
this pathway, which ultimately plays a role in causing insulin resistance in the adipocyte, 
liver, muscle and pancreatic β-cell via reduced recruitment and translocation of GLUT4 to 
the plasma membrane [97, 98]. In the presence of excess FFA, glycolysis is inhibited distal to 
fructose-6-phosphate by increased levels of acetyl-CoA, leading to inhibition of 
pyruvatedehydrogenase, which in turn increases fructose-6-phosphate availability and thus 
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increased flux via catalyzation of glutamine:fructose 6-phosphate amido transferase (GFAT). 
This ultimately leads to accumulation of uridine-5’-disphospho-N-acetylglucosamine (UDP-
GlcNAc) levels in tissues and this is directly correlated with the degree of insulin resistance. 
UDP-GlcNAc is the end product of the HBP, and serves as a substrate for O-linked 
glycosylation (O-GlcNAc) of proteins. It is thus regarded as the mediator of the HBP flux 
and thus insulin resistance by posttranslational protein modification of the insulin receptor 
proteins (IRS-1 and IRS-2) as well as GLUT4 (reviewed in [99]). There have, however, been 
conflicting reports in literature in which the lipid supplement Intralipid (a fat emulsion used 
intravenously as source of calories for patients requiring extended periods of parenteral 
nutrition regarded as ‘safe’ by the FDA) was found to induce insulin resistance without 
increasing HBP products [100], but as Intralipid consists mainly of soy bean oil with a ratio 
of omega-6:omega-3 of 7:1 [101] it is likely that insulin resistance was mediated mainly 
through the pro-inflammatory effects of the arachidonic acid cycle (Fig. 7) and to a lesser 
extent via flux through the HBP. Circulating FFAs also invoke insulin resistance via 
upregulation of PKC/PTEN which has an inhibitory effect on IRS-1 and IRS-2, which then 
further downstream prevents translocation of GLUT4 to the plasma membrane due to 
downregulation of PI3K [102]. This places increased emphasis on the critical need of clear 
definition of the profile of fats used in research studies, as it is probable that high levels of 
omega-6 fatty acids have a differential influence on these metabolic pathways in addition to 
being intricately involved in the circadian time structure of organisms.  
In the heart, the cardiomyocyte circadian clock, in a time-of-day-dependent manner, 
regulates metabolism and ischemic tolerance similar to the regulatory roles of that of protein 
O-GlcNAcylation [93]. These variations mediate the clock-dependent regulation of O-
GlcNAc transferase and O-GlcNAcase levels and nutrient metabolism and uptake. This 
would involve the coordinated regulation of the hexosamine biosynthetic pathway and play 
an important role in not only insulin resistance [103] but also myocardial apoptosis in the 
diet-induced insulin resistant rat [104] which in turn conversely depends critically on an 
adequate dark-phase. Any stress could increase flux through the HBP, leading to 
detrimental effects on the level of the cardiomyocyte [29, 104]. As the O-GlcNAcylation of 
proteins show clear circadian patterns and is high during the active phase and low during 
the inactive phase, it is thus proposed to have major consequences in the rat model of 
insulin resistance [93]. Any stress in the rodents during the inactive phase or at the 
transition from the active to inactive phase, as frequently is the case due to overnight 
starvation and early morning sampling, would lead to an increase in glucocorticoid levels 
which not only causes increased lipolysis and FFA levels, but also leads to inappropriately 
increased O-GlcNAcylation via direct recruitment of OGT [105]. Peak levels of 
corticosteroids occur at the start of the dark phase, and then fall during the light phase 
reaching the lowest level just before dark-light transition. Early morning sampling would 
thus possibly induce bias, due to the stress associated with starving and experimental 
procedures imposed on the animal. 
A remedy for the deleterious introduction of bias, due to researcher convenience-of-
sampling time, is to reverse the light-dark cycle, so that all animal handling and procedures 
are carried out during the animal’s active phase. This constitutes the most effective scenario, 
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but is exclusively dependent on the absence of dark-phase light contamination. Even dim 
light during the dark phase causes the inhibition of the circadian rhythms in blood glucose, 
lactic acid, insulin and corticosteroid levels [29] and would compromise or alter the outcome 
of scientific investigations.  
6. Conclusions 
In summary, this chapter described the importance of the dietary fatty acid profile, with 
particular reference to the ratio of omega-6:omega-3 essential fatty acids, and the role it plays 
in insulin-resistance with reference specifically to the utilization of animal research models. 
Fatty acids are well-known to play a cardinal role in lipid and glucose homeostasis, and there 
is now compelling evidence that a reduction in the intake of omega-6 fatty acids in the diet is 
crucial to prevent disease states such as insulin resistance, obesity and cardiovascular disease. 
The majority of studies in the field of diet-induced obesity are performed using the high fat 
rodent model, but consistency and comparability is severely lacking/compromised due to 
incomplete disclosure of dietary fat components, and in many cases uncontrolled variation in 
the diet due to rat chow manufacturers using different fat sources according to availability or 
personal preference. In addition, the importance of the circadian rhythm in fatty acid and 
glucose metabolism and metabolic disturbances in the rodent experimental model is 
underemphasized, and in many cases not taken into account. This too, is of concern in the 
accuracy of results expressed in such studies, especially those investigating dietary 
interventions in insulin resistance, as seen in the regulative role that the humoral factors and 
the hexosamine biosynthetic pathway plays the circadian clock of insulin, glucose and fatty 
acid metabolism. These points highlight some frequently overlooked aspects in the 
experimental use of the diet-induced rodent model for insulin resistance, T2D and CHD 
research. In order to utilize the model to its full potential, attention to the exact dietary 
composition and experimental conditions are of critical importance.  
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1. Introduction 
Postprandial hyperglycemia is now established as an independent risk factor for the 
development of at least macro vascular complications in diabetes mellitus (1), as it is a 
widely accepted experience that it is more difficult to normalize postprandial blood glucose 
than the fasting concentrations. Furthermore, it is well known that impaired glucose 
tolerance (IGT) is related to increased cardiovascular morbidity and mortality (2) and that 
postprandial hyperglycemia plays a central role in progression from IGT to type 2 diabetes 
(3). It is possible to delay the appearance of type 2 diabetes and cardiovascular diseases in 
IGT patients by good glycemic control (4-8). The glycemic load as well as peak 
concentrations of glucose in the blood depend on many factors including gastric emptying, 
the nature of ingested food, intraluminal glucose concentration, and enzymatic activity in 
the brush border. On top of this several gut hormones play a role as well as the ability of the 
liver to reduce endogenous glucose production, being a special problem in patients with 
type 2 diabetes. This phenomenon increases the importance of reducing postprandial 
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equal amounts of glucose and fructose molecules. The absorption and metabolism of the 
two molecules is different. The absorbed glucose is utilized in an insulin dependent manner 
primarily in the peripheral tissues. Fructose is utilized in the liver in the glycolytic pathway 
with products like glucose, glycogen, lactate and pyruvate. Fructose is more lipogenic than 
glucose, an effect that might contribute to the development of cardiovascular diseases 
(CVD), insulin resistance and type 2 diabetes (10). Fructose does not stimulate insulin 
secretion as glucose why a modest intake of fructose is recomended in diabetes and heart 
patients due to the lipogenicity (10;11). Recently, a metaanalysis stated that fructose intake 
at a level of ≤ 36g/d, which is equivalent to daily intake of fruit, could have beneficial effects 
by decreasing endogenous glucose production and increasing glycogen synthesis, and 
 The Author(s). License  InTech. This chapter is distributed und r the terms of the Creativ  Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucose Tolerance 148 
[104] Rajamani, U, et al., The hexosamine biosynthetic pathway can mediate myocardial 
apoptosis in a rat model of diet-induced insulin resistance. Acta Physiol (Oxf), 2011; 
202(2) p 151-7. 
[105] Li, MD, et al., O-GlcNAc transferase is involved in glucocorticoid receptor-mediated 






© 2012 Andersen et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Intestinal Disaccharidase Activity and Uptake of 
Glucose from Sucrose 
Kia Halschou Hansen, Klaus Bukhave and Jens Rikardt Andersen 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/53099 
1. Introduction 
Postprandial hyperglycemia is now established as an independent risk factor for the 
development of at least macro vascular complications in diabetes mellitus (1), as it is a 
widely accepted experience that it is more difficult to normalize postprandial blood glucose 
than the fasting concentrations. Furthermore, it is well known that impaired glucose 
tolerance (IGT) is related to increased cardiovascular morbidity and mortality (2) and that 
postprandial hyperglycemia plays a central role in progression from IGT to type 2 diabetes 
(3). It is possible to delay the appearance of type 2 diabetes and cardiovascular diseases in 
IGT patients by good glycemic control (4-8). The glycemic load as well as peak 
concentrations of glucose in the blood depend on many factors including gastric emptying, 
the nature of ingested food, intraluminal glucose concentration, and enzymatic activity in 
the brush border. On top of this several gut hormones play a role as well as the ability of the 
liver to reduce endogenous glucose production, being a special problem in patients with 
type 2 diabetes. This phenomenon increases the importance of reducing postprandial 
glucose uptake in type 2 diabetics. In addition, it seems possible to modify the insulin 
secretion after meals by addition of arabinose to the ingested sucrose (9). Sucrose contains 
equal amounts of glucose and fructose molecules. The absorption and metabolism of the 
two molecules is different. The absorbed glucose is utilized in an insulin dependent manner 
primarily in the peripheral tissues. Fructose is utilized in the liver in the glycolytic pathway 
with products like glucose, glycogen, lactate and pyruvate. Fructose is more lipogenic than 
glucose, an effect that might contribute to the development of cardiovascular diseases 
(CVD), insulin resistance and type 2 diabetes (10). Fructose does not stimulate insulin 
secretion as glucose why a modest intake of fructose is recomended in diabetes and heart 
patients due to the lipogenicity (10;11). Recently, a metaanalysis stated that fructose intake 
at a level of ≤ 36g/d, which is equivalent to daily intake of fruit, could have beneficial effects 
by decreasing endogenous glucose production and increasing glycogen synthesis, and 
 The Author(s). License  InTech. This chapter is distributed und r the terms of the Creativ  Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
 
Glucose Tolerance 150 
thereby improve glycaemic control. This benefit is seen without the adverse cardiometabolic 
effects reported when fructose is ingested in high doses or as excess energy (12).  
2. Disaccharidase activity in vitro 
The digestive enzymes, α-amylase and α-glucosidase are the key enzymes responsible for 
the digestion of carbohydrates to glucose. In search for modulators and/or inhibitors of 
disaccharidases various in vitro models for determination have been described in the 
literature. These represent quick and cheap screening procedures and include among others 
intestinal mucosa homogenates (13;14), intestinal brush border preparations (15) from 
different experimental animals, and homogenates of human intestinal cell line Caco-2 (9). 
The Caco-2 cells were originally derived from a human colon adenocarcinoma. In culture 
they proliferate and differentiate to cells resembling mature jejunocytes with high levels of 
brush-border enzyme activity including alkaline phosphatase, amino-peptidase, and 
sucrase-isomaltase (16). Although the Caco-2 cells are derived from colonic cells they 
represent human tissue and are thereby superior to animal tissue in relation to human 
studies. For kinetic studies on disaccharidase activity an in vitro model with homogenates of 
Caco-2 cells was established. Caco-2 cells from passage number 38 and 39 were seeded onto 
polycarbonate membranes (Fisher Scientific, Transwell®membrane, 75mm) and cultured at 
37°C and 5/95% CO2/air. At day 20-22, when the transepithelial electrical resistance (TEER) 
has reached a steady state level of 3-400 Ω*cm2, the Caco-2 cells were rinsed with phosphate 
buffered saline, scraped off the membranes, and homogenized by sonication. Homogenates  
 
 
Figure 1. Michaelis-Menten curves for the substrate (sucrose) concentrations 0 – 280 mM  with and 
without L-arabinose as inhibitor of sucrase (0.0mM (x), 0.84mM (□), 1.4mM (∆) and 2.8mM (○)). Data are 
mean±SEM (n=6). S is the substrate concentration and V is the velocity of the reaction. (Reproduced 
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corresponding to 2.2 mg protein/mL and disaccharide solutions at final concentrations of 7, 
14, 28, 140, and 280 mM in 0.1 M maleate buffer, pH=6.0 were used. The amount of glucose 
released by the enzymatic reaction was linear with time up to 60 min, so a 30 min reaction time 
was used and glucose measured with a Cobas Mira Plus Spectrophotometer (Roche Diagnostic 
Systems, F Hoffmann-La Roche, Basel, Switzerland). Pentoses like L-arabinose and D-xylose 
were used as inhibitors at final concentrations of 0.84, 1.4, and 2.8 mM as exemplified with 










Figure 2. Lineweaver-Burk plots with and without L-arabinose as inhibitor of sucrase (0.0mM (x), 
0.84mM (□), 1.4mM (∆) and 2.8mM (○)). Data are mean±SEM (n=6). (Reproduced from Krog-Mikkelsen 
et al (2) with permission.) 
Reaction velocity (v) plotted against substrate concentration (s) revealed classical Michaelis-
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arabinose (fig 1) Lineweaver-Burke analysis (fig 2) indicated uncompetitive inhibition since 
Vmax decreased from 19.8 over 14.7 and 14.1 to 12.2 nmol/(min*mg protein), and Km 
decreased from 9.8 over 7.3 and 6.1 to 5.3 mmol/L when the inhibitor concentrations 
increased from zero over 0.84 and 1.4 to 2.8 mM L-arabinose (data not shown). Thus, 
addition of 0.84, 1.4, and 2.8 mM L-arabinose resulted in 25, 29 and 38% inhibition of the 
sucrase activity, respectively at Vmax. The apparent Ki was calculated to 2.8±0.3 mM 
(mean±SEM, n=3) from the Lineweaver-Burke plots (2). 
Similar results were obtained with sucrose as substrate and D-xylose as inhibitor, and with 
maltose as substrate and L-arabinose as inhibitor (data not shown). 
The validity of the in vitro model was confirmed in a human intervention study with 15 
healthy volunteers in a randomized double-blinded cross-over study. Sucrose beverages (75 
g in 300 mL) supplemented with 0, 1, 2, or 3 g (0, 1.3, 2.7 and 4 w/w%, respectively) L-
arabinose were tested (2). Blood was collected fasting and for 3-h postprandial with 15 






Figure 3. Plasma glucose  in 15 normal male subjects after intake of sucrose drinks supplemented with 
0 (x), 1(□), 2 (∆), or 3 (○) grams of L-arabinose. Data are mean (± SEM). iAUC = incremental area under 
the curve. Statistical differences Peak, P=0.001. Time to peak, P=0.133. iAUC, P=0.245. (Reproduced from 
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The present in vivo results in man strongly indicate that the Caco-2 cell model is useful in 
screening procedures in search for compounds which may lower the glycemic and insulimic 
responses in man. Importantly, because the Caco-2 cell line is of human origin, the results 








Figure 4. Serum insulin  in 15 normal male subjects after intake of sucrose drinks supplemented with 0 
(x), 1 (□), 2 (∆), or 3 (○) grams of L-arabinose. Data are mean (± SEM). Statistical differences Peak, 
P<0.0001. Time to peak, P=0.002. iAUC, P=0.017. (Reproduced from Krog-Mikkelsen et al (9) with 
permission.) 
3. The inhibition of the uptake of maltose and sucrose by food 
components 
In addition to the pentoses L-arabinose and D-xylose growing evidence indicates that 
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made to identify new possible α-glucosidase inhibitors and interest in replacement of 
synthetic foods by natural ones has fostered research on vegetable sources and screening of 
raw materials to identify these α-glucosidase inhibitors (17-20). Polyphenols are abundant 
micronutrients in our diet, found in plants foods like fruits, vegetables, tea, coffee, red wine, 
and cacao. Studies with polyphenolic compounds, polyphenolic extracts of foods including 
berries, vegetables and colored grains such as black rice, green and black tea, and red wine 
have been shown to inhibit α-glucosidase activities and there by suppress the elevation of 
blood glucose concentrations when tested in especially small rodents (18). Additionally, 
different cell lines like Caco 2 cells mentioned above have been used in vitro. The inhibitory 
polyphenols includes flavonoids, phenolic acids, tannins (18). For example gallic acid and 
tannic acid have showed to be potential inhibitors of sucrase and other brush border 
enzymes in mice and rat (15;21;22). Extracts of acerola fruit have been studied and shows 
reduced plasma glucose level after oral administration of maltose or sucrose in mice, 
indicating inhibition of α-glucosidase effects on both sucrase and maltase in mice intestines 
(23-25). A hot water extract of leaves of Nerium Indicum, a bush from Pakistan, was found to 
reduce the rise in postprandial blood glucose when maltose and sucrose was given orally in 
rats. It was found that the extract inhibited α-glycosidase, suggesting the isolated polyphenols 
from the leaves extract, chlorogenic acid, to be the inhibitor of maltase and sucrose (26).  
4. Sugar beets 
The nutritional value of sucrose is to provide calories; nevertheless some studies have found 
that in the process of refining sugar from sugar beets and sugar cane some of the  by 
products like pulp and molasses  are important sources of bioactive compounds 
(polyphenols and pentoses). A study with sugar beet pulp revealed that the pulp contained 
polyphenolic compounds and had antioxidant properties (27;28). The same has been shown 
in studies with sugar cane products (29). The sugar beet molasses contains a variety of 
different phenolic acids mostly vanillic acid, syringic acid, p-coumaric acid, gallic acid, 
protocatechuic acid and ferulic acid the most abundant. 
For kinetic studies of sucrase activity, we used the aforementioned assay (2). As inhibitors 
two different polyphenol-rich fractions from chromatographic separation of molasses from 
sugar beets and pure ferulic acid were used. Results from the kinetic studies of EDC 
molasses, fraction III-2 molasses and pure ferulic acid (obtained from Nordic Sugar 
Denmark) are represented in figure 5-7. 
There were no inhibitory effects of EDC molasses or fraction III-2. Ferulic acid showed a 
week inhibition of 1.9 % for the concentration of 1 mM (Unpublished data). The variability 
of polyphenol content in foods is pronounced and in most cases, foods contain complex 
mixtures of polyphenols. The content is influenced by numerous factors such as variety, 
production practices at a particular processing plant, environmental factors and by storage 
variables. Even though, molasses contain a variety of different phenolic acids and pure 
ferulic acid inhibition of sucrose activity was weak at a relatively low concentration. This 
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indicates that there are still much to learn about the potential bioactivities and the 
bioavailabilities of polyphenolic compounds (30).  
 
Figure 5. Michaelis-Menten curves for the substrate (sucrose) concentrations 0 – 280 mM with and 
without fraction III-2 molasses as inhibitor of sucrose (n=4). [sucrose (◊)  Fraktion III-2 molasses (□)] 
 
 
Figure 6. Michaelis-Menten curves for the substrate (sucrose) concentrations 0 – 280 mM with and 
without 3 % EDC molasses as inhibitor of sucrose (n=4). Sucrose placebo represents the amount of 
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Figure 7. Michaelis-Menten curves for the substrate (sucrose) concentrations 0 – 280 mM with and 
without 1mM ferulic acid as inhibitor of sucrase and 5,6 mM arabinose as inhibitor of sucrase. [sucrose 
(◊) 1 mM ferulic acid  (□), 5,6 mM arabinose (∆)]  
5. Intraluminal factors related to uptake of glucose  
It has been known for many years that dietary fibers reduce postprandial glucose 
concentrations in the blood, insulin response and delay gastric emptying. These effects have 
been established for a variety of fibers, but most markedly for soluble fibers. The character 
of chemical binding to the fibers are not well elucidated, neither the questions of existing 
physical binding mechanisms. The different processing methods of carbohydrates such as 
parboiling have verified effects on the glycemic response.  
One could ask whether the fiber-effects are due to the fibers, or can be explained by 
compensatory effects on the diet. That means if intake of fibers in the relevant amounts 
decreases appetite for fat and short chain carbohydrates, and thereby induces early satiety 
or changes food preferences towards other kinds of nutrients. These questions have only 
been addressed in very few publications and deserve to be discussed further. It has been 
very difficult to show that changes by fibers on appetite and food intake last more than 
around three weeks. This could be due to adaptation both to the direct effect of fibers, but 
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An additional question is the significance of formation of resistant starch during the 
preparation and production of food items.  
During the 1980`s it was well documented that dietary fibers have beneficial effects on blood 
glucose levels, the postprandial values in particular. The mechanisms, however, were not 
clear, and chemical bindings of glucose to elements in the fibers were hypothesized. Such 
bindings have never been convincingly proven, and at an early point these hypothesis were 
questioned. A study  used pectin in the glucose solution and modulated gastric emptying 
with propantheline (31) which demonstrated  that pectin significantly reduced blood-
glucose, but propantheline had a more pronounced effect. In an additional investigation in 
the same paper they demonstrated that both gastric emptying and paracetamol absorption 
were slower after inclusion of gel fiber (guar gum and pectin), but the total absorption of the 
drug, reflected in urinary recovery, was not significantly reduced. These results indicated 
that gastric emptying could be the dominating factor in the delay of glucose absorption. 
Later a long list of authors has contributed. Lavin and Read (32) found no difference in 
gastric emptying time when comparing fluent meal of  30 % glucose with or without guar 
gum, and speculated in an unknown mucosal receptor mechanism to explain the  effects on 
postprandial blood glucose and insulin concentrations as well as satiety. In contradiction 
Horowitz et al (33) found convincing correlations between gastric emptying and peak 
plasma glucose as well as the total amount of glucose absorbed using a scintigraphic 
technique, but with almost twice the concentration of glucose in the fluent meal and a 40 % 
larger volume compared to Lavin and Read (32). Horowitz et al (33) calculated that gastric 
emptying accounts for about 34 % of the variance in postprandial peak plasma glucose. The 
difference between these results could be explained by the techniques used, but also by the 
concentrations of glucose in the test meals. A study investigated the rehydration ability of 2 
and 10 % glucose-electrolyte solutions with osmolality of 189 and 654 mOsm/kg, 
respectively. Gastric volumes were determined via gastric aspiration at 15 min intervals. 
They showed that the reduced overall rate of fluid uptake following ingestion of the 10 % 
glucose solution was due largely to a relatively slow rate of gastric emptying (34). Hence the 
influence of gastric emptying on glucose uptake may only be relevant for solutions with 
very high concentrations of glucose, which is not relevant in relation to the human diet 
neither in normal persons nor in diabetic patients. This is in accordance with the hypothesis, 
that gastric content is only allowed access to the duodenum when iso-osmotic. Part of the 
delay in gastric emptying may well to allow a dilution with secreted water and sodium. 
All these results indicate that gastric emptying is probably the dominating factor, but not the 
only one. Blackburn et al (35) had the same results as others concerning the lowering of 
blood glucose and insulin, but there was no correlation between the changes in the 
individual blood glucose responses and changes in gastric emptying rates induced by guar. 
By a steady-state perfusion technique, glucose absorption was found to be significantly 
reduced during perfusion of the jejunum with solutions containing guar. They estimated the 
thickness of unstirred layer in addition, and concluded that guar improves glucose tolerance 
predominantly by reducing glucose absorption in the small intestine. These were very 
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larger volume compared to Lavin and Read (32). Horowitz et al (33) calculated that gastric 
emptying accounts for about 34 % of the variance in postprandial peak plasma glucose. The 
difference between these results could be explained by the techniques used, but also by the 
concentrations of glucose in the test meals. A study investigated the rehydration ability of 2 
and 10 % glucose-electrolyte solutions with osmolality of 189 and 654 mOsm/kg, 
respectively. Gastric volumes were determined via gastric aspiration at 15 min intervals. 
They showed that the reduced overall rate of fluid uptake following ingestion of the 10 % 
glucose solution was due largely to a relatively slow rate of gastric emptying (34). Hence the 
influence of gastric emptying on glucose uptake may only be relevant for solutions with 
very high concentrations of glucose, which is not relevant in relation to the human diet 
neither in normal persons nor in diabetic patients. This is in accordance with the hypothesis, 
that gastric content is only allowed access to the duodenum when iso-osmotic. Part of the 
delay in gastric emptying may well to allow a dilution with secreted water and sodium. 
All these results indicate that gastric emptying is probably the dominating factor, but not the 
only one. Blackburn et al (35) had the same results as others concerning the lowering of 
blood glucose and insulin, but there was no correlation between the changes in the 
individual blood glucose responses and changes in gastric emptying rates induced by guar. 
By a steady-state perfusion technique, glucose absorption was found to be significantly 
reduced during perfusion of the jejunum with solutions containing guar. They estimated the 
thickness of unstirred layer in addition, and concluded that guar improves glucose tolerance 
predominantly by reducing glucose absorption in the small intestine. These were very 
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elegant experiments, but has not been reproduced. However, another important influence 
on glucose uptake may be the rate of perfusion of the small intestine which can be 
modulated both by hormonal effects and meal composition (36).  
After glucose meals it seems like gastric emptying is a dominant intraluminal factor for 
glucose absorption. However, glucose is rarely ingested as glucose, and production of 
glucose in the stomach due to acid hydrolysis is not a predominant mechanism of glucose 
production. For these reasons it would be valuable to look at starch and sucrose as well. 
the hypothesis was investigated In another study with focus on particle size and structural 
features of the food. An extract from barley was used to modify the granules and the 
particle size, and found a decrease in the in-vitro starch digestion and accordingly release of 
glucose (37). Also starch-entrapped microspheres have been used with similar beneficial 
effects on the postprandial blood glucose response for different starch fractions (38). In 
addition it would be relevant to investigate the effects on brush border sucrose activity 
related to the different forms of glucose suppliers. 
In animal studies promising results are emerging. Kett et al (39) found that starch 
gelatinized with α-casein resulted in lower postprandial glucose uptake than starch 
gelatinized with β-casein. In rats a study found indications of an effect of addition of 
resistant starch to bread, but different effects for maize and wheat based bread (40). 
Besides from the more or less well described factors mentioned above, we see an 
emerging and probably very important field of  intestinal sensing of nutrients, recently 
reviewed by Tolhurst et al (41). Of special interest in the glucose aspect are the 
documented effects of psyllium fibers in the diet prolonging pancreatic polypeptide 
(PYY) secretion and suppressing postprandial glucagon-like peptide-1(GLP-1) 
concentration (42). 
6. Conclusions 
All together, these findings imply that there must be many possible ways of modifying food 
components to reduce the postprandial glucose levels in the blood. These modifications can 
be made both by induction of physical changes in the carbohydrates (gelatinization), 
additives and addition of food components already existing in nature. Arabinose is present 
in considerable amounts in the sugar beet along with sucrose, but the components are 
separated during the manufacturing process. Modifications of food components generally 
cost money, so it will partly be the consciousness of the consumers that will determine 
whether such products have a future on the market.  
The simplest way of getting an effect is still to increase the amount of dietary fibers in the 
diet, and hypothetically the largest effects would result from a change in eating habits in the 
total population. The results presented are from normal volunteers, and the same effects can 
be measured in diabetics, whereas results are lacking from persons/patients with insulin 
resistance but not yet diabetic. 
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1. Introduction 
Diabetes is the world’s most common metabolic disease and one of the leading causes of 
morbidity and mortality. The medications currently in use are limited in their potency, have 
many side effects, and cannot be tolerated by many patients. As a result of the global 
epidemic of diabetes, the need for new diabetes therapies is expected to grow dramatically 
during the next decade. An intense research has been conducted to identify new therapeutic 
targets and pharmacologic compounds that might correct the impaired glucose tolerance. 
Materials that mimic insulin action or augment the effect of residual endogenous insulin are 
likely to be beneficial for both type 1 and 2 diabetic patients. During the recent years many 
investigators have shown that natural products are a potential source for new drug 
candidates for many diseases in general, and diabetes in particular. A research aimed at 
revealing new natural sources to treat diabetes is of high importance. 
A variety of traditional anti diabetic plants are known in the folk medicine. Although some 
of them have been studied for their anti diabetic effects, the knowledge on their efficacy and 
mechanism of action is very limited.  
The Glucose Tolerance Factor (GTF) is a dietary agent first extracted from Brewer’s yeast [1]. 
GTF reversed the impaired glucose tolerance of both diabetic rats and diabetic patients. In 
vitro studies with GTF showed remarkable increase in glucose transport into adipocytes, 
and cardiomyocytes. An increase in glucose incorporation into glycogen in rat hepatocytes 
was also found for GTF preparations [2].  
Despite the high anti diabetic activity of this natural compound, GTF has not been fully 
characterized or identified, mainly due to the instability of the purified fractions. Our 
laboratory succeeded in extraction and partial purification of an active and stable GTF 
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The Glucose Tolerance Factor (GTF) is a dietary agent first extracted from Brewer’s yeast [1]. 
GTF reversed the impaired glucose tolerance of both diabetic rats and diabetic patients. In 
vitro studies with GTF showed remarkable increase in glucose transport into adipocytes, 
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was also found for GTF preparations [2].  
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preparation from brewer’s yeast. We examined GTF effects in animal models for both types 
of diabetes, and found high and rapid anti diabetic activity. We also examined GTF effects 
on the cellular level and found high insulin mimetic and insulin potentiating activity for 
GTF. The mechanism of action of GTF along insulin signaling pathway was also studied. 
2. Prevalence of diabetes mellitus  
Diabetes is the world’s most common metabolic disease and one of the leading causes of 
morbidity and mortality. According to WHO (World Health Organization) report [3], 346 
million people worldwide are diabetic. The number is expected to grow to 438 million until 
2030 [8% of the world population!) [4]. Diabetes is the greatest healthcare threat in both 
developed countries and the third world: diabetes is the third leading cause of death in most 
developed countries; moreover, it is epidemic in many third world nations. Diabetes 
imposes an increasing economic burden on national health care systems worldwide [5]. The 
global health expenditure on diabetes in 2010 was 376$ billion and is expected to grow to 
490$ billion by 2030 [6].  
3. Diabetes mellitus and its complications  
Diabetes mellitus is a complex syndrome involving severe insulin dysfunction along with 
gross abnormalities in glucose homeostasis and lipid and protein metabolism. The disease is 
generally divided into two major types: Insulin Dependent Diabetes Mellitus (IDDM, or 
type 1], and Non Insulin Dependent Diabetes Mellitus (NIDDM, or type 2 DM). Both forms 
are devastating with respect to their latter complications. People with diabetes have a 25-
fold increase in the risk of blindness, a 20-fold increase in the risk of renal failure, a 20-fold 
increase in the risk of amputation as a result of gangrene and a 2 to 6-fold increase in the 
risk of coronary heart disease and ischemic brain damage. In general, life expectancy for a 
person with diabetes is decreased by one-third [5].  
4. Diabetes mellitus and oxidative stress  
Oxidative stress and non enzymatic glycation play a major role in the pathogenesis of 
diabetes mellitus [7, 8]. During diabetes, persistent high concentrations of blood glucose 
increase the production of oxygen free radicals – OFRs. through auto oxidation of glucose 
Hunt et al., 1990, and also by non enzymatic lipid and protein glycation [9]. OFRs react with 
membrane phospholipids forming malondialdehyde (MDA) [10, 11]. Lipid peroxide levels, 
and especially oxidized LDL, are significantly higher in diabetic patients than in healthy 
individuals. [12-14]. These Major changes in lipid metabolism cause lipid peroxidation in 
plasma and cellular membranes which lead to micro and macro vascular pathologies [15].  
The natural protective system of antioxidant enzymes like superoxide dismutase, 
glutathione peroxidase and catalase that provides the detoxification steps for the oxidative 
products, cannot overcome massive production of free radicals to prevent oxidative 
damage. [16]. It was shown that the activity of the antioxidant systems is decreased in 
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diabetic patients. [17, 18]. This leads to oxidative stress and to the development of diabetes 
complications.  
5. Diabetes mellitus and aldose reductase  
The reduction of glucose by the aldose reductase (AR) catalyzed polyol pathway has been 
linked to the development of secondary diabetic complications like cataract, nephropathy, 
retinopathy and neuropathy. Accumulation of sorbitol in the organs, due to AR-catalyzed 
reduction of glucose, causes osmotic swelling resulting in ionic imbalance and protein 
insolubilization leading to diabetes complications. [19]. Although treatment with AR 
inhibitors has been shown to prevent tissue injury in animal models of diabetes, the clinical 
efficacy of these drugs remains to be established. [20].  
6. Treatment of diabetes mellitus 
Daily injections of insulin are the only treatment for type 1 diabetes. The treatment for type 2 
ranges from diet, to classical oral drugs (Sulfonyl urea and biguanides), and to 
Thiazolidinediones and the new GLP1 analogues. About 40% of type 2 diabetics use insulin 
in addition to oral drugs.  
Although the pathogenesis of diabetes and its long-term complications are well known, 
optimal treatment remains elusive. The medications currently in use are limited in their 
potency, have many side effects, and cannot be tolerated by many patients. Only half of the 
patients achieve the recommended hemoglobin A1c target using conventional treatment 
[21]. As a result of the global epidemic of diabetes, the need for new diabetes therapies is 
expected to grow dramatically during the next years. [22]. Pharmaceutical research 
conducted over the past decades has shown that natural sources like herbs, medicinal plants 
and yeast extract, are potential sources for new drug candidates for many diseases in 
general [23], and diabetes in particular [24].  
7. Anti diabetic medicinal plants 
Several reviews published in recent years screen many plant sources with anti-diabetic 
properties [24, 25, 26, 27, 28, 29]. Among these plants: Trigonella foenum, graecum, Allium 
cepa. & Allim sativum, Silybum marianum, Mordica charantia, Camellia sinensis, Morus 
nigra, Gymnema sylvestre L., Ginkgo biloba L., and many others. Anti-diabetic health 
effects include increasing serum insulin, decreasing blood glucose, increasing glucose 
metabolism, and/or stimulating pancreatic function. Adverse effects, contraindications, and 
interactions between herbal medicines and synthetic drugs exist and may cause clinical 
consequences. 
We shall briefly screen here some of the most potent anti diabetic sources. 
Fenugreek (Trigonella Foenum Graecum), is one of the safest and most effective plants in 
treating diabetes. Clinical studies showed that fenugreek seeds have anti diabetic effects 
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[30]. "Bitter melon" (Momordica Charantia) fruit extract reduced blood glucose and was 
found effective in treating diabetes [31]. Garlic has been reported to possess a variety of 
medicinal properties including hypoglycemic, hypocholesterolemic and hypolipidemic 
activities [32]. Raw garlic extract reversed proteinuria in diabetic rats in addition to reducing 
blood glucose, cholesterol and triglyceride in diabetic rats [33]. Silybum Extract (Silybum 
Marianum) increases the cellular sensitivity to insulin and thus reduces blood glucose total 
cholesterol and LDL levels in diabetic patients [34]. Bitter cucumber plant fruit (Mamordica 
Charantia) reduced blood glucose in patients with type 1 diabetes [35]. Green tea (Camellia 
Sinensis) can reduce blood sugar in diabetic patients. Studies show that the consumption of 
one and a half gram dry powder of green tea, improved the metabolism of blood sugar in 
diabetic patients [36]. Ginkgo biloba plant is capable of lowering glucose, fat, and lipid 
peroxide in diabetic patients [37]. The ethanolic extract of Allium porrum leaves had 
hypoglycemic effects on diabetic animals probably through the increase of insulin release 
[38].  
Some nutritional factors, such as polyphenols, counteract insulin resistance and therefore 
may be beneficial for patients with type 2 diabetes mellitus through their insulin-
potentiating, antioxidant, and anti-inflammatory properties. The common cinnamon (CN) 
has a long history of use as a spice, preservative, and pharmacological agent; CN is also a 
source of polyphenols. Several studies demonstrated that in animals and humans, CN and 
aqueous extracts of cinnamon improved the level of blood glucose, lipids and insulin, and 
may be beneficial to counteract the features of insulin resistance, metabolic syndrome, and 
the onset of type 2 diabetes mellitus [39, 40, 41, 42].  
Although many medicinal plants have been traditionally used for treating diabetes [43, 44, 
45], the influence of most of them has only rarely been scientifically tested and validated, 
and the knowledge on their efficacy and mechanisms of action is very limited. 
7.1. Yeast as a natural source for anti diabetic material 
Brewers' yeast is also included among the anti diabetic natural sources [46, 47]. Schwartz 
and Mertz were the first to discover the natural anti diabetic agent present in yeast and 
called it "Glucose Tolerance Factor" (GTF) [1].  
8. Glucose Tolerance Factor (GTF) a natural anti diabetic agent  
The Glucose Tolerance Factor (GTF) is a dietary agent first extracted from Brewer’s yeast [1]. 
This natural compound reversed the impaired glucose tolerance of diabetic rats [48, 49], and 
of diabetic patients [50]. GTF can be extracted from several sources, among them: liver [51], 
black pepper, and kidneys. Especially rich source for GTF are brewers’ yeast [52, 53, 54, 55].  
Addition of partially purified GTF to the diet of glucose intolerant rats rapidly returned 
them to normal [56]. Doisy and his group found an improvement in glucose tolerance in 
elderly people who were treated for two months with GTF. In 50% of the patients, glucose 
tolerance was restored to normal values. [57].  
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Offenbacher and Pi Sunyer [46], examined 24 elderly subjects, who were fed daily for 8 
weeks with brewers’ yeast as a sorce for GTF. They found a considerable improvement in 
glucose tolerance and insulin sensitivity, and a reduction of total lipids in these patients.  
Grant and McMullen [50] treated 37 type 2 diabetics for 7 weeks, in a double blind study, 
with either brewers’ yeast as a source of GTF, or placebo. Supplementation of brewers’ yeast 
significantly decreased HbA1c and increased HDL cholesterol in the treated group. Elwood 
[58] supplemented 11 normolipidemic and 16 hyperlipidemic subjects with brewers’ yeast. 
They found that total circulating cholesterol was significantly reduced and the HDL levels 
were significantly increased in both the normo and hyperlipidemic subjects supplemented 
with brewers’ yeast. Riales [59] reported that human subjects receiving 7g of brewers’ yeast 
for 6 weeks had a significant decrease in serum LDL and an increase in HDL cholesterol.  
In vitro studies with partially purified preparations of GTF, showed stimulation of glucose 
metabolism in several tissues. GTF potentiated glucose oxidation to CO2 in adipose tissue 
[54, 60], or adipocytes [53, 61]. In those studies the enhancement was shown only in the 
presence of insulin, and the stimulation of CO2 production by GTF in the absence of insulin 
was negligible [53, 54, 60, 61].  
In contrast to the findings above, showing GTF activity only in the presence of insulin, other 
groups found an increase of glucose metabolism by adding GTF in the absence of insulin. 
Tokuda et al, [62] examined GTF obtained from yeast extract powder on glucose uptake in 
adipocytes. They found a stimulation of glucose uptake (5.6 times greater than the basal 
level) in the absence of insulin. Our group also showed an increase in glucose transport both 
to yeast cells [63, 64], and to animal cells [65]. 
Since GTF is supposed to be essential for normal glucose tolerance in mammals, and as 
muscle tissue consumes a major part of blood glucose in the post prandial state, it is most 
important to assess the effect of GTF on muscle tissue. Fischer and his group [66] examined 
the effect of GTF obtained by partial purification of yeast extract, on glucose transport in 
isolated cardiomyocytes. They found that GTF samples increased the rate of glucose 
transport in the isolated cells, 2 to 2.5 fold, in the absence of insulin. Hwang et al [67] 
showed enhancement of 14C -glucose oxidation into CO2 in rat adipocytes by the addition of 
several fractions extracted from yeast. The authors found only insulin like activity and not 
insulin potentiating activity for the fractions examined. 
The exact composition and structure of GTF are still obscure. Mertz and his group suggested 
that GTF is probably a small organic molecule comprising one trivalent chromium ion, two 
molecules of nicotinic acid, and three amino acids: glycine, cystein and glutamic acid [54, 68, 
69]. Its molecular weight is estimated to be around 500 daltons [54, 69], It is cationic, soluble 
in water, and stable in physiological solutions [54, 68].  
Several groups who tried to identify the active components present in brewers' yeast, 
claimed that they are quinoline derivatives [70], or phosphatidylinositol glycans [71]. Other 
investigators tried to further purify and identify the exact structure and composition of GTF. 
There is no standard accepted method to isolate GTF, and this fact can probably explain the 
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diversity of the results reported in the literature. In addition, a major problem related to GTF 
purification, is the instability of the partially purified fractions. This lability, can partially 
explain the complexity of the subject, and the fact that in spite of the long time since the 
material was discovered, its exact composition and structure have not been determined. 
Tuman [48] who presented the activity of GTF and several synthetic complexes on lowering 
blood glucose found that in 10 days both the natural compound and the synthetic complexes 
lost their activity. Mertz reported that highly purified preparations of GTF from yeast or 
pork kidney tend to be unstable, and lost their activity very quickly [52]. Yamamoto [51] 
found that GTF like activity of the purified LMCr (low molecular weight chromium binding 
substance) reduced gradually, and finally there could not be detected any activity. Even at -
20 °C, no recovery of the active material could be achieved. We can explain the instability of 
the purified fractions of GTF by a loss of a co-factor(s) which is probably responsible for the 
stability of the complex. 
Most of the groups who tried to purify GTF from brewers' yeast agree that the GTF is a 
cationic compound. Only several researchers claimed that the GTF is an anionic compound: 
Votava and his group [72] reported that GTF is an anionic chromium complex of molecular 
weight 400-600, containing at least six amino acids. Since the authors measured only the 
absorption of the complex by rats, and no biological activity assay was done on it, it is hard 
to compare Votava’s compound to other extracts exhibiting GTF activity. 
A low molecular weight chromium binding substance (LMCr), was isolated from mouse or 
rabbit liver and bovine colostrum by Yamamoto and his group [51, 73]. LMCr appears as 
anionic organic Cr compound, with a relative molecular mass of 1500 daltons. It is 
composed of glutamic acid, glycine, cysteine and aspartic acid in a ratio of Cr: Amino acid 
1:4. The purified LMCr enhanced glucose conversion to CO2 in rat epididymal adipocytes in 
the presence of insulin. The rate of glucose incorporation into lipid was stimulated by 30-
40% with insulin, or by 15-23% without insulin [51]. Yamamoto and his colleagues were not 
able to detect nicotinic acid in the extract of LMCr, but some UV absorption was present 
[73]. This substance appeared to posses properties similar to GTF extracted from yeast.  
Another question is related to the nature of the amino acids present in the GTF complex. 
Urumow & Wieland [74], suggested that GTF activity in stimulating 14C-glucose oxidation is 
attributable to the combined action of certain amino acids (aspartate, cystein) and 
nucleosides (adenosine). Fischer [66] came to a conclusion that GTF activity is attributed to 
the presence of alanine. Hwang and his group [70] suggested that the GTF obtained was a 
quinoline derivative, which easily binds chromium. 
While many research groups in the past agreed with the concept suggested by Mertz that 
GTF contains chromium [51, 55, 73, 75], accumulating data during the years indicates that 
there is no chromium present in the GTF preparation. Haylock and his group, who tried to 
purify and identify GTF for many years, did not find a correlation between chromium 
content and the biologic activity. They came to the conclusion that: "GTF from brewers' 
yeast can no longer be regarded as a chromium complex" [76] . Shepherd [77] also came to a 
similar conclusion.  
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Stearns [78] summarized the purification research that had been done on GTF and discussed 
the relation of the active component to chromium. She did not find a correlation between 
chromium and GTF activity. Stearns also investigated the issue of the essentiality of chromium 
to human health, and found that "no chromium-containing glucose tolerance factor has been 
characterized, the purpose of the low-molecular-weight chromium-binding protein is 
questionable, and no direct interaction between chromium and insulin has been found" [79]. 
Moreover, she criticized the dietary supplementation of chromium: "Chromium+3 may act 
clinically by decreasing the iron stores that are linked to diabetes and heart disease. This 
would make chromium+3 a pharmacological agent, not an essential metal" [79].  
Eddens and his colleagues [47], isolated three separate fractions by eluting yeast extract 
from C18 column and found diverse activities in increasing glucose metabolism and 
inhibiting lipolysis for the different fractions, not connected to their chromium content.  
Recently, our group also measured the chromium concentrations in the active fractions 
isolated from yeast extract and did not find any correlation between the chromium content 
and the biologic activity (Mirsky et al, unpublished data). 
To summarize the chromium issue: Although the active material isolated from yeast (GTF) 
has been known for years to be a chromium complex, accumulating evidence during recent 
years show that the active anti diabetic fractions in GTF do not contain chromium.  
Our laboratory succeeded in extraction and partial purification of an active and stable GTF 
preparation from brewer’s yeast. We used several separation techniques including 
membranes with different molecular cut off, ion exchange columns and reversed phase 
HPLC. Our GTF preparation has a molecular weight below 1000 dalton. It was found to be 
very stable: it is stable to high and low pH and it keeps its activity up to 12 months in 4°C. 
Moreover, GTF is also stable to proteolytic enzymes. This finding enables an oral treatment 
with GTF, in contrast to insulin, which is a protein and has to be injected [49, 80, 81].  
In the following paragraphs we shall present several of our findings on GTF both in vivo 
and in vitro. We examined GTF effects in animal models for both types of diabetes, and 
found high and rapid anti diabetic, hypolipidemic and antioxidant activity. We also found a 
remarkable reduction in the complications of diabetes: nephropathy and retinopathy, by 
treating the diabetic animals with oral doses of GTF [81].  
In vitro studies done in our laboratory showed insulin mimetic and insulin potentiating 
activity for GTF [65]. 
9. In vivo effects of GTF 
9.1. GTF decreases blood glucose in diabetic rat models 
A single oral dose of GTF, orally administered to both types of diabetic animals, decreased 
immediately and remarkably glucose and lipid levels in their blood [49, 80]. Glucose 
reduction appeared immediately after the administration of GTF, reached a maximum 
within 2 hours, and lasted for several hours. When GTF was administered in concert with 
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diversity of the results reported in the literature. In addition, a major problem related to GTF 
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material was discovered, its exact composition and structure have not been determined. 
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blood glucose found that in 10 days both the natural compound and the synthetic complexes 
lost their activity. Mertz reported that highly purified preparations of GTF from yeast or 
pork kidney tend to be unstable, and lost their activity very quickly [52]. Yamamoto [51] 
found that GTF like activity of the purified LMCr (low molecular weight chromium binding 
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stability of the complex. 
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purify and identify GTF for many years, did not find a correlation between chromium 
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yeast can no longer be regarded as a chromium complex" [76] . Shepherd [77] also came to a 
similar conclusion.  
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Stearns [78] summarized the purification research that had been done on GTF and discussed 
the relation of the active component to chromium. She did not find a correlation between 
chromium and GTF activity. Stearns also investigated the issue of the essentiality of chromium 
to human health, and found that "no chromium-containing glucose tolerance factor has been 
characterized, the purpose of the low-molecular-weight chromium-binding protein is 
questionable, and no direct interaction between chromium and insulin has been found" [79]. 
Moreover, she criticized the dietary supplementation of chromium: "Chromium+3 may act 
clinically by decreasing the iron stores that are linked to diabetes and heart disease. This 
would make chromium+3 a pharmacological agent, not an essential metal" [79].  
Eddens and his colleagues [47], isolated three separate fractions by eluting yeast extract 
from C18 column and found diverse activities in increasing glucose metabolism and 
inhibiting lipolysis for the different fractions, not connected to their chromium content.  
Recently, our group also measured the chromium concentrations in the active fractions 
isolated from yeast extract and did not find any correlation between the chromium content 
and the biologic activity (Mirsky et al, unpublished data). 
To summarize the chromium issue: Although the active material isolated from yeast (GTF) 
has been known for years to be a chromium complex, accumulating evidence during recent 
years show that the active anti diabetic fractions in GTF do not contain chromium.  
Our laboratory succeeded in extraction and partial purification of an active and stable GTF 
preparation from brewer’s yeast. We used several separation techniques including 
membranes with different molecular cut off, ion exchange columns and reversed phase 
HPLC. Our GTF preparation has a molecular weight below 1000 dalton. It was found to be 
very stable: it is stable to high and low pH and it keeps its activity up to 12 months in 4°C. 
Moreover, GTF is also stable to proteolytic enzymes. This finding enables an oral treatment 
with GTF, in contrast to insulin, which is a protein and has to be injected [49, 80, 81].  
In the following paragraphs we shall present several of our findings on GTF both in vivo 
and in vitro. We examined GTF effects in animal models for both types of diabetes, and 
found high and rapid anti diabetic, hypolipidemic and antioxidant activity. We also found a 
remarkable reduction in the complications of diabetes: nephropathy and retinopathy, by 
treating the diabetic animals with oral doses of GTF [81].  
In vitro studies done in our laboratory showed insulin mimetic and insulin potentiating 
activity for GTF [65]. 
9. In vivo effects of GTF 
9.1. GTF decreases blood glucose in diabetic rat models 
A single oral dose of GTF, orally administered to both types of diabetic animals, decreased 
immediately and remarkably glucose and lipid levels in their blood [49, 80]. Glucose 
reduction appeared immediately after the administration of GTF, reached a maximum 
within 2 hours, and lasted for several hours. When GTF was administered in concert with 
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marginal insulin doses, the reduction in blood glucose was much higher than for each agent 
alone, demonstrating a synergy between GTF and insulin [80].  
9.1.1. GTF improves oral glucose tolerance test (OGTT) in diabetic rats 
We examined GTF effects in two rat models exhibiting insulin deficiency: the streptozotocin 
(STZ) diabetic rat, which is characterized by the damage induced to beta cells by the drug, 
and the hyperglycemic Cohen diabetic-sensitive ((hyp-CDs) rat, which is characterized by 
beta cell dysfunction and decreased glucose stimulated insulin secretion (from Wexler-
Zangen et al, [65]. 
Control-vehicle treated hyp-CDs and STZ rats exhibited an abnormal glucose-tolerance 
curve, characterized by elevated blood glucose levels (Figs 1A and B) Administration of an 
oral dose of GTF (at zero time) lowered the blood glucose area under the curve (BG-AUC) of 
both hyp-CDs and STZ rats compared to vehicle treated rats. The decrease in BG-AUC 
depended on the dose of GTF administered. Insulin secretion in response to glucose 
stimulation did not change significantly in GTF treated hyp-CDs rats (From Wexler-Zangen et 
al, [65], indicating that the glucose lowering effect of GTF is not related to stimulation of 
insulin secretion.  
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A: OGTT profiles of diabetic untreated Hyp-CDs rats (black circles), GTF (0.6g/100g BW) treated Hyp-CDs rats (white 
circles) and GTF (1.2g/100g BW) treated Hyp-CDs rats (black squares). B: OGTT profiles of diabetic untreated STZ rats 
(black circles) and GTF (0.8g/100g BW) treated STZ rats (black squares). GTF was administered at time 0. BG levels 
were measured after an overnight fast [0], and at 30, 60 and 120 min period after glucose (3.5g/kg for Hyp-CDs and 
2g/kg for STZ rats) administration. Data are means ± SE for 5 or 6 rats per group. * P< 0.001, Diabetic vs. respective 
untreated control. (From Wexler-Zangen et al, [65] 
Figure 1. Oral Glucose Tolerance Test (OGTT) of GTF treated diabetic rats 
9.2. GTF reduces postprandial blood glucose concentration in diabetic rats 
Post prandial (PP) blood glucose level is very high in both hyp-CDs and STZ diabetic rats. In 
the vehicle treated hyp-CDs and STZ rats, the markedly elevated BG concentrations 
remained high for more than 120 min (Figs 2A and B). A single oral dose of GTF 
Glucose Tolerance Factor – Insulin Mimetic 
and Potentiating Agent – A Source for a Novel Anti Diabetic Medication 173 
administered at zero time significantly reduced (P<0.001) the high BG concentrations in both 
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A: PP glucose levels of control untreated Hyp-CDs rats (black circles), GTF treated (1.2g/100g BW) Hyp-CDs rats 
(white circles). At time 0 GTF was administered to the indicated groups. B: Postprandial glucose levels of untreated 
STZ rats (black circles) and GTF treated (0.8g/100g BW) STZ rats (white circles). At time 0 GTF was administered to the 
indicated groups. Data are means ± SE for 5 or 6 rats per group. * P< 0.001, Diabetic vs. respective untreated control. 
(From Wexler-Zangen et al, [65] 
Figure 2. GTF decreases Postprandial (PP) glucose levels in diabetic rats 
9.3. GTF decreases tri glyceride and LDL cholesterol and increases HDL 
cholesterol 
A remarkable decrease in triglyceride level was observed in diabetic animals administered 
with 5 daily oral doses of GTF (Figure 3). The treatment with GTF also remarkably 
decreased the level of LDL cholesterol (Figure 4A), and increased the level of HDL 
cholesterol (Figure 4B), (Ampel et al., unpublished data). The reduction in LDL cholesterol 
was also demonstrated in healthy animals treated with GTF, indicating a potential 
preventive effect of GTF in healthy subjects. 
9.4. GTF reduces lipid peroxidation in the plasma, both in vivo and in vitro 
GTF can inhibit the deleterious elevation in lipid peroxides induced by diabetes. Type 1 
diabetic rats were treated with 5 daily oral doses of GTF. The animals were killed and the 
levels of lipid peroxidation products - malondialdehyde (measured as TBARS – 
thiobarbituric acid reactive substances), in healthy, diabetic and diabetic rats treated with 
GTF were determined. Figure 5 demonstrates the level of lipid peroxidation products 
detected in the plasma of healthy, diabetic, and diabetic rats treated with GTF, showing a 
major decrease in the level of plasma peroxides in diabetic animals treated with GTF. These 
results indicate high antioxidant activity of the GTF preparation (From Ampel et al., 
unpublished data). 
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Figure 3. Effect of GTF on plasma triglycerides. Plasma triglyceride concentration in healthy rats, 
diabetic rats and diabetic rats treated with 5 daily oral doses of GTF [1,64g /rat). All animals were 15 




Figure 4. Effect of GTF on Plasma LDL and HDL concentrations. A. LDL composition: 
cholesterol/protein ratio in healthy rats, diabetic rats and diabetic rats treated with 5 daily oral doses of 
GTF [1,64g /rat). All animals were 15 weeks old, diabetic animals were 10 weeks after onset of diabetes. 
B. HDL composition: cholesterol/protein ratio in healthy rats, diabetic rats and diabetic rats treated with 
5 daily oral doses of GTF [1,64g /rat). All animals were 15 weeks old, diabetic animals were 10 weeks 
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Figure 5. Effect of GTF on plasma peroxides. Plasma oxidation level, measured as peroxide 
concentration, in healthy rats, diabetic rats and diabetic rats treated with 5 daily oral doses of GTF 
(1,64g /rat). All Animals were 15 weeks old, diabetic animals were 10 weeks after onset of diabetes 
(From Ampel et al., 2000). 
In vitro studies with GTF added to tubes containing human LDL, indicated a protective 
effect of GTF against LDL oxidation (Ampel et al., unpublished data).  
9.5. GTF reduces lipid peroxidation in the heart and kidneys of diabetic rats 
The levels of lipid peroxidation products, TBARS, in the kidneys and hearts removed from 
healthy, diabetic, and diabetic rats treated with GTF are shown in figures 6 & 7 (From 
Nakhoul et al., [81] Figure 6 presents the level of lipid peroxidation products determined in 
the hearts of the various experimental groups. The value of lipid peroxides in untreated 
diabetic rats was significantly higher than the value detected for healthy animals. The level 
of lipid peroxides in the hearts of diabetic rats treated with 5 oral doses of GTF was very low 
- a higher effect seen for the higher dose of GTF, similar to the level found in healthy 
animals. A remarkable decrease in lipid peroxidation level is shown also in kidneys 
removed from diabetic rats treated with GTF (Figure 7). Peroxide values found in the 
animals treated with GTF were very similar to those found in healthy controls. The above 
assays show the remarkable effect of GTF treatment on lipid peroxidation level in diabetic 
animals, both in plasma and in cardinal organs. 
9.6. GTF decreases aldose reductase activity 
Elevated activity of aldose reductase (AR) in the organs is one of the events occurring in 
hyperglycemic conditions. We measured aldose reductase activity in the hearts of healthy, 
diabetic and diabetic treated with GTF (Figure 8). AR activity in the hearts of diabetic rats 
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the activity of the enzyme in the hearts of the treated diabetic animals in a dose dependent 
mode, indicating a potent aldose reductase inhibition activity in GTF preparation. 
 
Effect of treatment with GTF on lipid peroxidation products measured as TBARS in the heart of control, untreated 
diabetic rats and diabetic rats treated with two different doses of GTF: 0,82 and 1,64 g/rat. The rats were treated with 
repeated doses for 5 days. The age of the rats was 9 weeks. Diabetes was induced with STZ injection (60mg/Kg BW) at 
the age of 5 weeks. Every group represents 8-11 animals. One way ANOVA test showed significant differences 
between groups (P<0,001). Different letters above bars indicate significant differences between groups. (From Nakhoul 
et al., [81]. 
Figure 6. Effect of GTF on lipid peroxidation in the heart 
 
GTF reduces the level of lipid peroxidation products in renal cortex of diabetic rats. Streptozotocin diabetic rats were 
administered with 5 repeated oral doses of GTF (1.64 g/rat).The level of lipid peroxidation products (TBARS nmole/g 
tissue) was determined in control rats (n=5], untreated diabetic rats (n=8], and diabetic rats treated with GTF (n=8). 
Products of lipid peroxidation were measured in the presence (induced) and absence (non-induced) of FeSO4. P < 0.01 
compared with untreated diabetic animals. ** P < 0.01 compared with healthy controls. From Nakhoul et al., [81] 
Figure 7. Effect of GTF on lipid peroxidation in renal cortex 
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Effect of treatment with GTF on aldose reductase activity in the hearts of control, untreated diabetic rats and diabetic 
rats treated with two different doses of GTF: 0,82 and 1,64 g/rat. The rats were treated with repeated doses for 5 days. 
The age of the rats was 9 weeks. Diabetes was induced with STZ injection (60mg/Kg BW) at the age of 5 weeks. Every 
group represents 8-11 animals. (From Mirsky et al unpublished data).  
Figure 8. Effect of GTF on aldose reductase activity in the heart 
9.7. GTF decreases nephropathy in diabetic rats 
9.7.1. Decreased urine volume and urine protein in diabetic rats treated with GTF 
We measured the urine volume and urine protein of healthy, diabetic, and diabetic rats 
treated for two weeks with oral doses of GTF. Diabetes was induced at zero time. The group 
of diabetic animals treated with GTF received daily doses of GTF mixed in their food 
immediately with the induction of diabetes. The animals were kept in metabolic cages, and 
urine was collected daily. Fig. 9 presents the urine volume and Fig 10 presents urine protein 
of the different groups, indicating a significant reduction both in urine volume and in urine 
protein of diabetic rats treated with GTF (from Nakhoul et al., [81]). 
9.8. GTF decreases retinopathy in diabetic rats  
9.8.1. GFAP expression in healthy, diabetic and Diabetic rats treated with GTF  
Glial Fibrillary Acidic Protein (GFAP) is normally expressed in retinal astrocytes. Under 
pathologic conditions like hyperglycemia or ischemia, GFAP can be detected in other 
retina's areas like Muller cells layer. GFAP has been widely used as a cellular marker for 
retinal pathology. 
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Daily urinary volume of healthy rats (n=5], diabetic rats (n=8] and diabetic rats treated with daily doses of GTF 
[4g/day) for 2 weeks. (From Nakhoul et al., [81]. 























Healthy Diabetic treated with GTF (4g/day)Diabetic untreated  
Urine protein (mg protein / day) excreted by healthy (N=5), diabetic (N=8) and diabetic rats treated with GTF (N=8) 
(4g/day) for 2 weeks. (From Nakhoul et al., [81]. 
Figure 10. Effect of GTF on urine protein 
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In a study done in our laboratory on healthy, diabetic, and diabetic rats treated for two 
weeks with GTF, a large amount of GFAP staining in Muller cell layer was demonstrated in 
diabetic untreated retinas (Fig. 11). (Mirsky et al., unpublished data). A remarkable 
reduction in GFAP expression was demonstrated in retinas derived from diabetic animals 
treated with GTF, where GFAP could be seen only in the glial astrocytes layer, very similar 
to what was found in the healthy retinas. 
 
GFAP Immuno histochemistry in neural retina of healthy, diabetic and diabetic rats treated with GTF (4g/day) for 2 
weeks (healthy, diabetic, and← diabetic treated with GTF). Magnication X400 (Mirsky et al., unpublished data) 
Figure 11. Effect of GTF on GFAP in the retina 
9.8.2. GTF prevents the diabetic damage to Na/K ATPase in retinas 
Sodium / Potassium ATPase is located in the pigment epithelial layer of the retina. In 
healthy retinas stained histochemically for Sodium / Potassium ATPase, the activity of the 
enzyme can easily be detected, whereas it was remarkably reduced in diabetic retinas. A 
prevention of the damage could be detected in retinas isolated from diabetic animals treated 
for two weeks with GTF, where the activity of the pump is similar to the activity shown for 
healthy controls. (Figure 12) (Mirsky et al., unpublished data). 
 
Histochemical localization of Sodium / Potassium ATPase in retinas of healthy, diabetic and diabetic rats treated for 
two weeks with GTF(4g/day) for 2 weeks. Magnification X400 (From Mirsky et al., unpublished data). 
Figure 12. Effect of GTF on Sodium/Potassium ATPase in the retina.  
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two weeks with GTF(4g/day) for 2 weeks. Magnification X400 (From Mirsky et al., unpublished data). 
Figure 12. Effect of GTF on Sodium/Potassium ATPase in the retina.  
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10. Mechanism of action of GTF: Insulin mimetic activity  
Binding of insulin to its receptor initiates a cascade of phosphorylations of several 
substrates, including insulin receptor substrate (IRS) proteins. IRS-1 is widely expressed in 
insulin-sensitive tissues, and it transmits the signal from insulin receptor to biological 
endpoints, such as glucose transport, protein, lipid, and glycogen synthesis. 
Phosphorylation of IRS-1 subsequently triggers the activation of downstream signal 
molecules such as phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT), 
several isoforms of protein kinase C (PKC), and mitogen-activated protein kinase (MAPK).  
Studies done in our laboratory on L6 myoblasts and 3T3-L1 adipocytes presented a marked 
increase in 2-deoxy-glucose [2-DG) uptake induced by GTF, in a rate similar to insulin, 
indicating a high positive effect on glucose uptake (Figure 13) (From Weksler-Zangen et al., 
[65].  
 
Glucose transport was measured in 3T3-L1 adipocytes in PBS (pH 7.4), at 37°C, with the addition of 0.05mmol/L (3H) 
2-deoxyglucose. Different concentrations of GTF (0-20mg/ml) were assayed. Incubation time was 1 hour. Cells were 
dissolved in 1N NaOH, and aliquots were taken for scintillation counting and protein determination. Data are means ± 
SE n=3-4 plates in all experiments (P<0.05). (From Weksler-Zangen et al., [65]. 
Figure 13. GTF increases 2-Deoxy glucose uptake to 3T3-L1 adipocytes.  
We also found that the increased glucose transport induced by GTF is dose dependent 
(Weksler-Zangen et al., [65]. A similar synergy between GTF and insulin that was 
demonstrated in diabetic animals in vivo was also found in vitro: The increase in 2-DG 
transport detected for the combination of GTF and insulin was much higher than for each 
agent alone. The rate of 2-DG transport found for the combined treatment exceeded the sum 
of the two separate treatments, indicating a synergy between GTF and insulin (Weksler-
Zangen et al., [65]. We also found increased phosphorylation of key proteins along insulin 
signaling pathway, like IRS1, AKT, ccbl and MAPK, by the addition of GTF to the medium 
(Figures 14-16). GTF induced phophorylation of key proteins was dose and time dependent. 
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did not find any augmented phosphorylation of the insulin receptor following GTF 
addition, indicating a possible "by pass" of the insulin receptor by GTF.  
 
Differentiated 3T3-L1 adipocytes were serum starved for 18 hr. Cells were treated with 100nM insulin for 1 min or 
with 20 mg/ml GTF for 15 min. Cells were lysed and western blot analysis was performed with antibodies for 
phosphotyrosine followed by stripping and reblotting with antibodies for total IRS1 as a loading control. 
Quantification of the bands of P-IRS1 (mean ± SE) based on scanning densitometry of three independent immunoblots 
is represented by the bar graph (From Weksler-Zangen et al., [65]. 
Figure 14. GTF stimulates tyrosine phosphorylation on IRS1.  
 
Differentiated 3T3-L1 adipocytes were serum starved for 18 hr. Cells were treated with 100nM insulin for 10 min or 
with 20 mg/ml GTF for 1, 5, 10 or 15 min. Cells were lysed and western blot analysis was performed with antibodies 
for phospho-Akt followed by stripping and reblotting with antibodies for total Akt as a loading control. Quantification 
of the bands of P-AKT (mean ± SE) based on scanning densitometry of three independent immunoblots is represented 
by the bar graph (From Weksler-Zangen et al., [65]. 
Figure 15. GTF stimulates AKT phosphorylation. 
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Differentiated 3T3-L1 adipocytes were serum starved for 18 hr. Cells were treated with 100nM insulin for 10 min or 
with 20 mg/ml GTF for 1, 5, 10 or 15 min. Cells were lysed and western blot analysis was performed with antibodies 
for phospho-p42/44 MAPK followed by stripping and reblotting with antibodies for total p42/44 MAPK as a loading 
control. Quantification of the bands of p42/44 MAPK (mean ± SE) based on scanning densitometry of three 
independent immunoblots is represented by the bar graph (From Weksler-Zangen et al., [65]. 
Figure 16. GTF stimulates MAPK phosphorylation. 
11. Conclusions 
In a search for new and effective medications for diabetes mellitus, there is a growing 
interest in natural derived hypoglycemic agents such as medicinal plants, herbs, and yeast. 
The Glucose Tolerance Factor (GTF), which is an active anti diabetic material extracted from 
yeast, is presented in the current manuscript. 
GTF effectively decreased the elevated blood glucose in diabetic animals and humans. It 
also decreased triglycerides and LDL cholestrerol and increased HDL cholesterol in diabetic 
subjects. GTF treatment also prevented diabetes complications like nephropathy and 
retinopathy. 
Not being a protein, GTF can be taken orally. GTF is both insulin mimicker and insulin 
potentiator: It can decrease glucose and lipids in the blood when given without any 
additional medication, but can also activate insulin effect: a small dose of insulin becomes 
more effective when administered with a dose of GTF. 
GTF exerts insulin-mimetic and insulin-potentiating activity also in-vitro: glucose transport 
is increased by the addition of GTF. When GTF is added with insulin - an augmented 
glucose transport is detected. 
In vitro studies shed light on the mechanism of action of GTF: GTF produces insulin-like 
effect by acting on cellular signals downstream of insulin receptor, regulating glucose 
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transport, glycogen, and protein synthesis and modulating nuclear activity in the same 
manner as insulin. These results demonstrate GTF as a potential natural source for a novel 
oral anti diabetic drug in the future.   
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1. Introduction 
Diabetes mellitus (DM) is a metabolic disorder resulting from defects in insulin secretion or 
reduced sensitivity of the tissues to insulin action or both [1]. It is characterized by chronic 
high blood glucose that causes glycation of body proteins which could lead to severe 
complications. These complications are classified into acute, sub-acute and chronic. 
Acute complications include hypoglycemia, diabetic ketoacidosis, hyperosmolar and 
hyperglycaemic non-ketotic syndrome while sub acute complications are thirst, polyuria, 
lack of energy, visual blurriness and weight loss. The chronic complications of diabetes 
mellitus include hypertension, neuropathy, nephropathy, retinopathy and diabetic foot 
ulcers which could result in amputation [2]. 
On the basis of aetiology and clinical presentation, diabetes mellitus can be grouped into 
type 1 known as insulin- dependent diabetes mellitus (IDDM) and type 2 also known as non 
insulin-dependent diabetes mellitus (NIDDM). The World Health Organization (WHO) 
recommends that the terms type 1 and type 2 should be reintroduced, because they classify 
the patients on the basis of the pathogenesis and not on the basis of treatment. Type 1 
diabetes mellitus is caused by immunological destruction of pancreatic β cells leading to 
insulin deficiency [3], whereas type 2 diabetes results from defects in insulin secretion or 
rather insulin resistance. It is the most common type of diabetes, afflicting 85-95% of all 
diabetic individuals. It is a prevalent form of the disease and common in individuals over 40 
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years of age. The increasing number of ageing population, consumption of calorie-rich diet, 
obesity and sedentary life style have led to a tremendous increase in the number of diabetes 
mellitus world wide [2]. About 173 million people suffer with this disease. The number of 
people with diabetes mellitus will be more than double over the next 25 years to reach a 
total of 366 million by 2030 [4]. 
The only therapy of type 1 diabetes is the substitution of insulin. Many and diverse 
therapeutic strategies for the treatment of type 2 diabetes are known. Conventional 
treatments include the reduction of the demand for insulin, stimulation of endogenous 
insulin secretion, enhancement of the action of insulin at the target tissues and the inhibition 
of degradation of oligo- and disaccharides. One group of drugs introduced in the 
management of type 2 diabetes is represented by the inhibitors of α-glycosidase [4]. 
In a general manner DM is a group of metabolic disorders characterized by hyperglycemia. 
These metabolic disorders include alterations in carbohydrate, fat and protein metabolisms 
associated with absolute and relative deficiencies in insulin secretion and/or insulin action 
[5]. Insulin is a hormone needed to convert sugar, starch and other food into energy needed 
for daily life. The cause of diabetes continues to be a mystery, although both genetic and 
environmental factors such as obesity and lack of exercise appear to play a part [6]. The 
control of DM normally involves exercise, diet and drug therapy. In the last years there has 
been an increasing demand for natural products with antidiabetic activity, mainly due to the 
side effects associated with the use of insulin and oral hypoglycemic agents [7]. The 
available therapies for diabetes include insulin and oral antidiabetic agents such as 
sulfonylureas, biguanides and α-glycosidase inhibitors. Many of these oral antiabetic agents 
have a number of serious adverse effects [8]. Thus, the management of diabetes without any 
side effects is still a challenge. 
Plants have always been an important source of drugs and many of the currently available 
drugs have been derived directly or indirectly from them. Ethnobotanical reports indicate 
about 1200 plants in the world with anti-diabetic potential [9], of which more than three 
hundred have been reported in the literature referring to a large variety of identified 
chemical substances. The discovery of the widely used hypoglycemic drug, metformin (N,N-
dimethylguanylguanidine) came from the traditional approach through the use of Galega 
officinalis [10]. 
In this regard, several medicinal plants among which are those belonging to the genus 
Morus have been reported to be used in traditional medicine for the treatment of DM. 
Medicinal plants are one of the few therapeutic resources available to most population. 
According to this reality it is essential to search new alternatives for the treatment of DM. 
Several plant species have been studied as potential antidiabetic agents. 
Considering the importance of species of the genus Morus in treatment of diabetes mellitus, 
this chapter is a review of medicinal plants and natural products with hypoglycaemic 
activity from genus Morus and the main methods used in the assessment of hypoglycemic 
potential of these plants. 
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2. Methods 
With the objective of contributing to these studies, a literature search on the ethnomedical 
information and use of natural products (crude plant extracts, semi-purified fractions and 
chemically defined molecules) from the genus Morus which have already been evaluated 
particularly for hypoglycemic activity was carried out. The keywords used for the literature 
search for this review were Morus, Moraceae, hypoglycemic activity, antidiabetic activity, 
medicinal plants and natural products. The search was carried out using Biological 
Abstracts, Chemical Abstracts, and the data bank of the University of Illinois in Chicago 
NAPRALERT (Acronym for NAtural PRoducts ALERT), updated to December 2011. The 
references found in the search were then studied in detail. Only those plants whose extracts 
and/or isolated constituents that showed clear pharmacological effects with hypoglycemic 
activity in animal models were included in this review. 
3. Results and discussion 
In this section we present some considerations about the Moraceae family, the main species 
from the genus Morus and chemical constituents isolated from species of this genus with 
hypoglycemic activity as well as important methods for assessing the hypoglycemic 
potential of natural products and plant extracts. 
Consultation of various literature sources resulted in the elaboration of a list of some 
active biomolecules of different Morus species and natural products evaluated for 
hypoglycemic activity (Tables 1, 2 and 3). It should be noted that most of the references 
cited are not first-hand observations, but compilations copied from other sources. For 
details on the models or mechanism-based bioassays utilized for selecting crude plant 
extracts, fractions and other preparations for hypoglycemic activity, the original 
references should be consulted. 
3.1. The family Moraceae and the genus Morus 
Moraceae is a family of flowering plants that comprises about 40 genera and over 1000 
species [11]. The genus Morus, is widely distributed in Asia, Europe, North America, South 
America, and Africa, and is cultivated extensively in the eastern, central, and southern Asia 
for silk production. Mulberry (Morus sp.) has been domesticated over thousands of years 
and has been adapted to a wide area of tropical, subtropical, and temperate zones of the 
world [12]. 
Morus is a genus with species of deciduous trees [11]. There are 24 species of Morus and one 
subspecie, with at least 100 known varieties. Mulberry is found from temperate to 
subtropical regions of the Northern hemisphere to the tropics of the Southern hemisphere 
and they can grow in a wide range of climatic, topographic and soil conditions [13]. Some 
species of this genus are widely cultived in many countries, in particular in China and 
Japan, where mulberry is used for its foliage to feed the silkworm [14]. 
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years of age. The increasing number of ageing population, consumption of calorie-rich diet, 
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According to this reality it is essential to search new alternatives for the treatment of DM. 
Several plant species have been studied as potential antidiabetic agents. 
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Japan, where mulberry is used for its foliage to feed the silkworm [14]. 
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Species of this genus has also been used in folk medicine (especially in Chinese traditional 
medicine) as antiphlogistic, hepatoprotective, hypotensive, antipyretic, analgesic, diuretic, 
expectorant, antidiabetic [14, 15] as well as to treat anemia and arthritis [12]. The leaves of 
mulberry species are consumed in Korea and Japan as anti-hyperglycemic nutraceutical 
food for patients with diabetes mellitus because the leaves are rich in alkaloid components, 
including 1-deoxynojirymicin (1), which is known to be one of the most potent α-







Figure 1. Chemical structure of compound (1) isolated from species of Morus. 
This genus contains a variety of phenolic compounds including isoprenylated flavonoids, 
stilbenes, 2-arylbenzopyrans, coumarins, chromones, xanthones and a variety of Diels-Alder 
adduct compounds [14, 17]. Some of these compounds exhibit interesting biological 
properties such as antiphlogistic, antiinflammatory, diuretic, hypotensive effects and some 
are known as phytoalexins [18]. The antioxidant potential of some phenolic compounds of 
Morus alba also been reported in the literature [19].  
The production of mulberry fruits in 2005 was 78,000 tonnes in Turkey and its cultivation in 
Turkey have been known for more than 400 years [20]. 
3.2. Morus alba L. 
Morus alba, known as white mulberry, is a species native to China and now widely 
cultivated in other countries. It has white and purple fruits with a very sweet taste and low 
acidity. Its fruits are perishable and mostly used for fresh consumption. The fruit of white 
mulberry (which is also found in the Eastern United States) is white to pinkish, unlike the 
red or black berries of most other Morus species. According to sources, white mulberry is the 
species that has been used exclusively in Chinese medicine since A.D- 659. The Chinese 
Pharmacopoeia (1985) lists the leaves, root bark, branches, and fruits as ingredients in 
medicinal preparations, but other parts, including the sap and wood ash, are also widely 
used [21]. 
The different parts of this plant have been used in the traditional Chinese medicine for 
many purposes. The white mulberry leaves, an important food for silkworm, are used to 
treat hypertension, arthritis, and the fruit is a diuretic and a tonic agent. The root bark of the 
plant is considered as an important medicine to treat cough, inflammation, diabetes, cancer, 
hepatitis and heart diseases. Previous studies showed that M. alba mainly contained 
polyphenolic constituents including prenylated flavonoids, benzofurans and Diels–Alder 
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type adducts with various biological activities such as cytotoxicity, antioxidant, inhibition of 
NF-κB, LOX-1, cancer cell invasion and migration, and hepatoprotection. The glycosidase 
inhibitory activity of several alkaloids in M. alba has also been reported [22]. The root is 
astringent and bark is anti-helmintic. Root is one of the constituents of the Chinese drug 
named “Sohaku-hi” which reduces the plasma sugar level in mice. Decorked bark is used 
against chronic bronchitis and emphysema [23]. 
The root bark also contain an alkaloid, 1-deoxynojirimycin (1) that inhibited glycogenolyses, 
glycoprotein, processing and saccharide hydrolysis enzymes whereas its derivatives have 
great therapeutic potential for the treatment of viral infections, diabetes, obesity and cancer 
[21]. Morus alba leaves containing many nutritional components are the best feed for 
silkworms and they have been used in traditional Chinese medicine as an 
antihyperglycemic to treat and to prevent diabetes mellitus. The components are flavones, 
steroids, triterpenes, amino acids, vitamins and other trace minerals. Among the 6 N-
containing sugars isolated, 2-O-α-D-galactopyranosyl-DNJ (GAL-DNJ) and fagomine have 
the most potent antihyperglycemic effects [24]. Table 1 lists some active biomolecules of 
different Morus species with their medicinal properties. 
3.3. Morus bombycis 
This plant is found in China, Japan, Korea and Southern Sakhaline. Root bark contains 
quinones named as Kwanons G and H with hypotensive activity, phytoalexins like Moracin 
A-Z and Albanins A-H with antimicrobial activity. The leaves also contain N-methyl-1-
deoxynojirimycin which is used against diabetes mellitus. This compound is also inhibits 
the infectivity of human immunodeficiency virus [21]. 
3.4. Morus indica L. 
Over the years, medicinal plants and their extracts are gaining importance in the treatment 
of hyperglycemia and diabetes. The extracts of Morus indica, commonly known as mulberry, 
have been reported to possess medicinal properties, including hypoglycemic, hypotensive 
and diuretic activities. The hypoglycemic effect of mulberry leaves or shoot culture extract 
has been demonstrated using streptozotocin-induced diabetic animals [25]. The ethanol 
extract from the leaves of Morus indica showed antiinflammatory activity on carragenan-
induced edema in rats and cotton pellet granuloma models [26]. 
3.5. Morus insignis 
Ethyl acetate and n-butanol-soluble fractions of the leaves of Morus insignis showed a 
significant hypoglycemic activity on streptozotocin (STZ)-induced hyperglycemic rats. From 
these hypoglycemic activity-showing fractions, two new compounds, mulberrofuran U and 
moracin M-3-O-β-D-glucopyranoside were isolated, along with six known compounds (β-
sitosterol, β-sitosterol-3-O-β-glucopyranoside, ursolic acid, moracin M, kaempferol-3-O-β-
glucopyranoside and quercetin-3-O-β-glucopyranoside) [27]. The fungicidal, bactericidal 
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inhibitory activity of several alkaloids in M. alba has also been reported [22]. The root is 
astringent and bark is anti-helmintic. Root is one of the constituents of the Chinese drug 
named “Sohaku-hi” which reduces the plasma sugar level in mice. Decorked bark is used 
against chronic bronchitis and emphysema [23]. 
The root bark also contain an alkaloid, 1-deoxynojirimycin (1) that inhibited glycogenolyses, 
glycoprotein, processing and saccharide hydrolysis enzymes whereas its derivatives have 
great therapeutic potential for the treatment of viral infections, diabetes, obesity and cancer 
[21]. Morus alba leaves containing many nutritional components are the best feed for 
silkworms and they have been used in traditional Chinese medicine as an 
antihyperglycemic to treat and to prevent diabetes mellitus. The components are flavones, 
steroids, triterpenes, amino acids, vitamins and other trace minerals. Among the 6 N-
containing sugars isolated, 2-O-α-D-galactopyranosyl-DNJ (GAL-DNJ) and fagomine have 
the most potent antihyperglycemic effects [24]. Table 1 lists some active biomolecules of 
different Morus species with their medicinal properties. 
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This plant is found in China, Japan, Korea and Southern Sakhaline. Root bark contains 
quinones named as Kwanons G and H with hypotensive activity, phytoalexins like Moracin 
A-Z and Albanins A-H with antimicrobial activity. The leaves also contain N-methyl-1-
deoxynojirimycin which is used against diabetes mellitus. This compound is also inhibits 
the infectivity of human immunodeficiency virus [21]. 
3.4. Morus indica L. 
Over the years, medicinal plants and their extracts are gaining importance in the treatment 
of hyperglycemia and diabetes. The extracts of Morus indica, commonly known as mulberry, 
have been reported to possess medicinal properties, including hypoglycemic, hypotensive 
and diuretic activities. The hypoglycemic effect of mulberry leaves or shoot culture extract 
has been demonstrated using streptozotocin-induced diabetic animals [25]. The ethanol 
extract from the leaves of Morus indica showed antiinflammatory activity on carragenan-
induced edema in rats and cotton pellet granuloma models [26]. 
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Ethyl acetate and n-butanol-soluble fractions of the leaves of Morus insignis showed a 
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these hypoglycemic activity-showing fractions, two new compounds, mulberrofuran U and 
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and hypoglycemic activities of leaves of M. insignis have been attributed to benzofurans 
Mulberrofuran U and Moracin M-3'-O-β-D-glucopyranoside [28].  
 
Name of Morus 
species 
Active constituents Plant part 
used 
Medicinal properties 
Morus alba Kwanon I; Kwanon I hexamethyl ether; 
Kwanon I octamethyl ether; 2’-
Hydroxy-2,4,4’-trimethoxychalcone; 2’-
Hydroxy-3’-prenyl-2,4,4’-
trimethoxychalcone III; Mulberrofuran 
T; Kwanon E; Morusin, Mulberrofuran 
D, G, K; Kwanon G, H; Mulberroside 
A; Cis-mulberrosideA; Oxyresveratrol; 
Isoquercetin; Kwanon G; Moracin E, F, 





helmintic, HIV, cough, 
antiinflammatory, 






Morus australis Australone A; triterpenoid 3β-[(m-
methoxybenzoyl) oxy]-urs-12-en-28-oic 
acid; morusin; Kwanon C; betulinic 
acid; β-amyrin; quercetin; ursolic acid; 






Morus bombycis N-methyl-1-Deoxynojirimycin; 
Kwanon G, H; Moracin A-Z; Albanins 
A-H; γ-aminobutyric acid; L-
asparagine; L-arginine; L- lysine; 
choline; Mulberrofuran I 




Morus laevigata Citrulline; hydroxyproline; free amino 
acids 
Fruit Plaster for sores, cools 
the blood 






Morus serrata β-Amyrin acetate; betulinic acid; 
cerylalcohol; quercetin; morin 
Root ----- 




Morus macroura Guangsangons A-N; albafuran C; 
Kwanon J, X, Y; Mulberrofuran G, K, J 
Stem Antiinflammatory, 
antioxidative 




Adapted from reference [21]. 
Table 1. Active biomolecules of different Morus species 
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3.6. Morus nigra L. 
Morus nigra, known as black mulberry, is one of the most important species of the genus 
Morus. It has juicy fruits with extraordinary color and a unique, slightly acidic flavor. The 
fruits are 2-3 cm long [12]. 
A medium or small sized tree 6-9 m high, native to West Asia. It is also cultivated in 
Kashmir, Darjeeling, leaves are ovate-cordate, flower dioecious or monoecious, fruits are 
syncarp, ovoid, purple to black, juicy, edible. The root bark is purgative and vermifuge. 
Root has and effect on pancreas and glycogenolysis while its juice reduces the blood sugar 
level in diabetic patient. The root bark extract contains deoxynojirimycin (DNJ), an alkaloid 
which said to be active against AIDS virus. An infusion of leaves causes a drop in blood 
sugar, sometimes diuresis and a reduction of arterial pressure [21]. 
DNJ is a potent source α-glycosidase inhibitor and helpful to establish greater glycemic 
control in type 2 diabetes. Young mulberry leaves taken from top part of branches in 
summer contains the highest amount of DNJ. In a human study, DNJ enriched powder of 
mulberry leaves significantly suppressed elevation of post-prandial glucose. Newly 
developed DNJ enriched powder can be used as a dietary supplement for preventing 
diabetes mellitus [21]. 
Morus nigra and other members of its genus can be grown without protection in many 
countries. The berries, bark and leaves of the black mulberry are all used medicinally, the 
berries for inflammation and to stop bleeding, the bark for toothache, and the leaves for 
snake bites and as an antidote to action poisoning. In Europe, black mulberry leaves have 
been used recently to stimulate insulin production in diabetes. Mulberry contains soluble 
plant chemicals known as bioflavonoids. These powerful antioxidants may be responsible 
for their medicinal properties [29]. 
Morus nigra has been used in folk medicine as an analgesic, diuretic, antitussive, sedative, 
anxiolytic and hypotensive, in addition to its uses in the treatment of a variety of ailments, 
including inflammatory disorders [17]. There are few studies involving the chemical 
composition and evaluation of biological and pharmacological properties of Morus nigra. 
Morusin, the main prenylflavonoid present in the root bark of this specie have been 
investigated in classical models of pain in mice and exhibits a promising antinociceptive or 
analgesic profile [30]. In recent studies, Naderi et al. [29] demonstrated that extracts of 
Morus nigra fruits have a protective action against peroxidative damage to biomembranes 
and biomolecules. Antiinflammatory properties of methylene chloride extract from leaves 
[31] as well as antinociceptive effects [32] were reported. Three new compounds including 
two flavonoids and a new 2-phenylbenzofuran, named morunigrols A-C, together with 
three known compounds albafuran A, albafuran B and mulberrofuran L were isolated from 
the barks of Morus nigra [33]. Two new prenylflavonoids, mornigrol E and mornigrol F 
were isolated from the barks of this specie [34], as well as germanicol, betulinic acid and β-
sitosterol [31]. Figure 2 shows the chemical structures of some chemical constituents isolated 
from species of the genus Morus. 
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and hypoglycemic activities of leaves of M. insignis have been attributed to benzofurans 
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Figure 2. Chemical structures of some natural compounds isolated from species of the genus Morus. 
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symptoms of menopause, particularly hot flashes, which are related to the sudden 
vasodilatation that causes the feeling of intense heat and redness of the skin, namely the face 
[35]. 
In Brazil, the cultivation of M. nigra began with the Japanese migration into the country, 
adapting well to conditions of climate and soil. In a recent study realized by our research 
group [36], we evaluated the hypoglycemic potential and acute toxicity of the crude ethanol 
extract of the leaves, and we observed that the extract may be considered of low toxicity since 
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B= barks; BR= branches; C= cortex; F= fruit; FL= flowers; L= leaf; NS= not specified; P= protoplasts; R= root; RB= 
rootbark; S= stem; SC= shoot culture 
Table 3. Biological activities for extracts of Morus. 
3.7. Methods for evaluation of hypoglycemic activity of medicinal plants 
3.7.1. Oral glucose tolerance test 
The oral glucose tolerance test is a fast and inexpensive technique and allows you to check 
the effects of drugs on glucose metabolism. In normoglycemic rats, the increase of post-
prandial glucose level, after glucose load, and the consequent standardization to baseline 
levels after about 2 h, characterizes a normal metabolism of glucose. The oral glucose 
tolerance test is an acute methodology for evaluating the resistance of the body to absorb 
glucose and reduce blood glucose levels. Therefore, it’s a method to perform a screening of 
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drugs with potential hypoglycemic action, but with a profile in the absorption of glucose 
(type 2 DM) and not in the production of insulin (type 1 DM) [37]. 
In this experiment, normal Wistar rats are fasted overnight. They are divided into three 
groups containing six animals each. 
Control rats (Group I) are given 1 ml distilled water orally. Extracts of plants in different 
concentrations (mg/kg body weight) are administered orally using a syringe to second and third 
groups. Glucose (2 g/kg b.wt.) is given orally using a syringe to all groups immediately after the 
extracts administration. Blood samples are collected from the tail vein just prior to and 30, 60, 
120 and 240 min after the glucose loading and serum glucose levels are measured [38]. 
3.7.2. Alloxan-induced diabetic rats 
Alloxan induces “chemical diabetes” in a wide variety of animal species by damaging the 
insulin secreting pancreatic β-cell, resulting in a decrease in endogenous insulin release [39]. 
Numerous studies demonstrated that a variety of plant extracts effectively lowered the 
glucose level in alloxan-induced diabetic animals. Alloxan produces oxygen radicals in the 
body, which cause pancreatic injury which is responsible for increased blood sugar seen in 
the animals. However, it is found that action is not specific to pancreas as other organs such 
as liver, kidney and haemopoietic system are also affected by alloxan administration as seen 
from the elevation of marker enzymes and reduction of hematological parameters [40]. 
In this experiment, diabetes is induced in male rats by single intraperitonial injection of 120 
mg/kg b.wt. of alloxan monohydrate. Serum glucose level is checked after 72 h. Animals 
with serum glucose levels >250 mg/dl are considered diabetic and are used for the study. 
The rats are divided into four groups of six rats each. Both group I control normal rats (no 
alloxan treatment) and group II diabetic animals are given 1 ml of distilled water. Group III 
and IV are given the extracts orally in different doses on 3rd day after alloxan treatment. 
Overnight fasted blood samples are collected from the tail vein on 3rd day of alloxan 
treatment prior to and at 2, 4, 6 and 8 h intervals after the administration of the extract 
orally. Serum is separated and glucose levels are estimated as before [38]. 
3.7.3. Streptozotocin-induced diabetic rats 
Streptozotocin (STZ) at low dose for Wistar rats induces light damage to islet cells, leading 
to glucose intolerance. Previous studies have showed that STZ-induced diabetic rats had 
low production of insulin and high levels of blood circulating glucose, which were similar to 
those found in diabetic humans. The precise mechanisms responsible for this defect remain 
unknown. 
Male rats weighing 150-200 g are used in the study and type 2 diabetes is induced. The rats 
are fed with high fat diet (diet containing 74% carbohydrate, 22% protein and 4% fat, 
formulated as 60% total energy is derived from fat) for 15 days except normal control rats 
and then injected with streptozotocin (40 mg/kg). Five days after injection, the rats are fasted 
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and the plasma glucose levels are estimated; rats having plasma glucose levels ≥300 mg/dl 
are taken for further studies with administration of plant extracts. The rats are fed with high 
fat diet throughout the experimental period [41]. 
4. Conclusion 
Diabetes mellitus is a public health problem worldwide. Ethnomedical informations and the 
scientific knowledge of the hypoglycemic activity of species of Morus demonstrate the 
potential of these species in the treatment of diabetes. In vivo testing has become an 
important tool in the search for new antidiabetic agents. The present work showed that 
therapy with species from the genus Morus traditionally used in many countries could be a 
possibility to treat diabetes. On the other hand, medicinal plants contain an enormous 
potential for the development of new antidiabetic drugs. In conclusion, the present study 
provides data which suggest that therapy with mulberry is capable of enhancing glycemic 
control in patients with diabetes. 
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1. Introduction 
1.1. Pharmacognosy of Diabetes Mellitus 
Diabetes mellitus type II (T2DM) is a global public health crisis that threatens the economies 
of all nations, particularly developing countries. Fueled by rapid urbanization, nutrition 
transition, and increasingly sedentary lifestyles, the epidemic has grown in parallel with the 
worldwide rise in obesity. According to the International Diabetes Federation [1], diabetes 
affects at least 285 million people worldwide, and that number is expected to reach 438 
million by the year 2030, with two-thirds of all diabetes cases occurring in low- to middle-
income countries. The number of adults with impaired glucose tolerance will rise from 344 
million in 2010 to an estimated 472 million by 2030. Several factors contribute to accelerated 
diabetes epidemic, including the “normal-weight metabolically obese” phenotype; high 
prevalence of smoking and heavy alcohol use; high intake of refined carbohydrates (e.g., 
white rice); and dramatically decreased physical activity levels [2]. 
In spite of the tremendous progress in the management of diabetes using synthetic drugs, 
potential new and inexpensive treatments should be used to reduce the global morbidity 
and mortality, as most of the people with T2DM lives in areas of the world, where existing 
treatments are unavailable or are too expensive. It is well documented that insulin sensitivity 
and glucose tolerance can be modulated by use of traditional medicines that are mainly 
derived from plants [3-5]. Natural antidiabetic agents with fewer side effects from readily 
available medicinal plants offer great potential in the discovery of new antidiabetic drugs. 
Pharmacognosy (the study of the medicinal properties of materials of natural origin) has 
played an important role in the management of diabetes mellitus since ancient times. 
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1. Introduction 
1.1. Pharmacognosy of Diabetes Mellitus 
Diabetes mellitus type II (T2DM) is a global public health crisis that threatens the economies 
of all nations, particularly developing countries. Fueled by rapid urbanization, nutrition 
transition, and increasingly sedentary lifestyles, the epidemic has grown in parallel with the 
worldwide rise in obesity. According to the International Diabetes Federation [1], diabetes 
affects at least 285 million people worldwide, and that number is expected to reach 438 
million by the year 2030, with two-thirds of all diabetes cases occurring in low- to middle-
income countries. The number of adults with impaired glucose tolerance will rise from 344 
million in 2010 to an estimated 472 million by 2030. Several factors contribute to accelerated 
diabetes epidemic, including the “normal-weight metabolically obese” phenotype; high 
prevalence of smoking and heavy alcohol use; high intake of refined carbohydrates (e.g., 
white rice); and dramatically decreased physical activity levels [2]. 
In spite of the tremendous progress in the management of diabetes using synthetic drugs, 
potential new and inexpensive treatments should be used to reduce the global morbidity 
and mortality, as most of the people with T2DM lives in areas of the world, where existing 
treatments are unavailable or are too expensive. It is well documented that insulin sensitivity 
and glucose tolerance can be modulated by use of traditional medicines that are mainly 
derived from plants [3-5]. Natural antidiabetic agents with fewer side effects from readily 
available medicinal plants offer great potential in the discovery of new antidiabetic drugs. 
Pharmacognosy (the study of the medicinal properties of materials of natural origin) has 
played an important role in the management of diabetes mellitus since ancient times. 
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Indeed, it has been estimated that more than 800 herbal or plant-derived products have been 
used for the management of T2DM across geographically and culturally diverse populations 
worldwide [6-9].  
World Health Organization (WHO) recommendations [10] on the use of alternative 
medicines for treating diabetes mellitus provide an impetus for research in this area. 
Currently, the focus of research includes discovering newer antidiabetic agents as well as 
isolating the active compounds from herbal sources that have been documented to have 
antidiabetic properties as have been described in ancient texts. The active components of a 
number of plant-derived antidiabetic compounds have been identified, and amongst these 
are flavonoids, alkaloids, glycosides, polysaccharides, peptidoglycans, hypoglycans, 
guanidine, steroids, carbohydrates, glycopeptides, terpenoids and amino acids. Potentially 
beneficial effects on the rate of food digestion, glucose transport, potentiation of insulin 
release, inhibition of insulin clearance, insulin-mimetic effects, reduced gluconeogenesis, 
and β-cell protection have been attributed to these agents [11].  
Type 2 diabetes (T2DM) is a disease characterized by a dual defect: 1) by insulin resistance 
which prevents cells from using insulin properly and 2) degrees of reduced pancreatic 
insulin secretion. It is a progressive disease that shows a consistent deterioration in glycemic 
control over time. While the pathophysiology and pathogenesis of the T2DM is not fully 
understood, it is clear that impaired glucose tolerance (IGT) often develops into T2DM.  
Interventions that may delay or prevent the progression of IGT to T2DM are desperately 
needed. Hyperlipidaemia is a secondary complication in diabetes and there is a growing 
interest in plants with both hypoglycaemic and hypolipidemic properties since they have a 
potential to be developed further for effective  treatment for diabetes specially associated 
with a hyperlipidaemic state. Since Artocarpus heterophyllus is traditionally used for 
management of diabetes mellitus, it may hold promise in this regard and warrants 
pharmacognostical, pharmacological and clinical studies to investigate the therapeutic 
potential of this plant in the treatment of T2DM. 
1.2. Overview of Artocarpus heterophyllus 
Artocarpus heterophyllus Lam (family Moraceae), commonly known as jakfruit is one of the 
most significant trees in tropical homegardens and perhaps the most widespread tree in the 
genus Artocarpus. It is a medium-size evergreen tree typically reaching 8–25 m (26–82 ft) in 
height with evergreen, alternate, glossy and leathery leaves to 22.5 cm (9 in) in length.  
Jackfruit's place of origin is believed to be indigenous to the rainforests of the Western 
Ghats. Today, it is cultivated at low elevations throughout India, Sri Lanka, Myanmar, 
southern China, Malaya, East Indies, Queensland, Mauritius, Kenya, Uganda and former 
Zanzibar, Pacific islands and Brazil [12]. 
Many parts of the plant including the bark, roots, leaves, and fruit are attributed with 
medicinal properties. It  is reported in Ayurveda (a traditional medicine system in Sri Lanka 
and India) to possess antibacterial, anti-inflammatory, antidiabetic, antioxidant and 
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immunomodulatory  properties. It is an important source of compounds like morin, 
dihydromorin, cynomacurin, artocarpin, isoartocarpin, cyloartocarpin, artocarpesin, 
oxydihydroartocarpesin, artocarpetin, norartocarpetin, cycloartinone, betulinic acid, 
artocarpanone and  heterophylol which have therapeutic properties [13]. 
The root is a remedy for skin diseases and asthma and the extract is taken in cases of fever 
and diarrhea. The ashes of the leaves, burned together with corn and coconut shells are used 
alone or mixed with coconut oil to heal ulcers. Mixed with vinegar, the latex promotes 
healing of abscesses, snakebite and glandular swellings. Heated leaves alone are placed on 
wounds and the bark is made into poultices. The seed starch is given to relieve biliousness 
and the roasted seeds are regarded as aphrodisiac. In Chinese medicine the pulp and seeds 
are considered tonic and nutritious [12]. 
 
Figure 1. Mature leaves of A. heterophyllus 
1.3. Aim of the chapter 
Alternative systems of medicine such as Ayurveda is widely used in Sri Lanka and India. 
In Ayurveda diabetes falls under the term Madhumeha [14]. Various types of herbal 
preparations such as decoctions (boiled extracts), Swaras (expressed juices), Asav-Arisht 
(fermented juices), and powders have been used for the treatment of Madhumeha [14]. 
Hot water extracts of A. heterophyllus leaves are used in the treatment of T2DM by 
traditional medical practioners in Sri lanka and India [15,16]. This traditional claim was first 
scientifically validated by the investigations carried out by Fernando et. al [17] which 
demonstrated the hypoglycaemic potential of the leaf extract. This preliminary work has 
been followed by many other studies which have provided insights into the efficacy, safety, 
mechanisms of action and the presence of other bioactivities of therapeutic potential in A. 
heterophyllus leaves. This chapter is based on the investigations carried out by 
Chackrewarthy et al [18] to evaluate the hypoglycaemic and hypolipidaemic potential of an 
ethylacetate fraction of A. heterophyllus leaves using a normal and streptozotocin induced 
diabetic rat models.   
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2. Phytochemical screening and standardized extraction 
Plant extracts used in traditional medicine are chemically complex and may contain one or 
more structurally related active compounds that produce a combined effect. Standardization 
and phytochemical screening are essential measurements of ensuring quality control of 
herbal drugs. 
Phytochemical screening of the aqueous extract of the leaves has revealed the presence of a 
range of polyphenols such as flavanoids, anthocyanins, tannins and polysaccharides as 
constituents [19].  In a more recent study of the aqueous extract of leaves, the presence of 
proteins, saponins, sterols, glycosides and lipids have been revealed in addition to the 
compounds mentioned [20]. A total ash value of  0.84%, acid insoluble ash value of 0.12% 
and water soluble ash value of 0.35% on dry weight basis have been reported for the 
aqueous extract of the leaves. 
The purpose of standardized extraction procedures of plant crude extracts  is to attain the 
therapeutically desired fractions and to eliminate unwanted material by treatment with  
selective solvents. In general, the solvent system used for the extraction plays a significant 
role in the solubility of the active principles of plant materials which in turn influence the 
bioactivities of the fractions [21].  
Plant crude extracts usually contain large amounts of carbohydrates and/or lipoidal material 
and the concentration of the phenolics in the crude extract may be low [22]. To concentrate 
and obtain polyphenol rich fractions before analysis, strategies including sequential 
extraction is commonly used. Sequential extraction with solvents of increasing polarity; eg: 
hexane, dichloromethane (DCM), ethyl acetate, methanol and water leads to initial 
fractionation of constituents of plant materials based mainly on their nature of polarity and 
with minimal chemical damage [23]. Based on this procedure an initial fractionation of the 
constituents of  A. heterophyllus leaves was carried out in the present study. Generally, waxy 
and lipoid substances are extracted into hexane and DCM and polyphenols are extracted 
into more polar solvents such as ethylacetate, methanol and water. In particular, methanol 
has been generally found to be more efficient in extraction of sugars, organic acids and 
lower molecular weight polyphenols while the higher molecular weight flavanols are better 
extracted with ethylacetate [24-27]. In recent studies, the phytochemical screening of the 
ethylactate fraction of A. heterophyllus leaves and bark has revealed the presence of 
flavanoids in high content. [28,29]. All fractions were evaporated to dryness and the 
residues stored at -40C until use.    
3. Hypoglycaemic activity of A.heterophyllus leaves 
3.1. Effects on fasting blood glucose levels 
The hypoglycemic potential of fractions separated from A. heterophyllus leaves by sequential 
fractionation, were tested using a normoglycaemic rat model. Male Wistar rats were fasted 
overnight, devided into groups and each group was treated with a different fraction by oral 
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administration at a dose equivalent to 50 mg/kg body weight. The ethylacetate (EA) fraction 
and the water fraction were found to exert the highest hypoglycemic effects compared to the 
controls treated with distilled water (Fig 2). The reduction in fasting blood glucose levels at 
+2 hr mediated by ethylacetate and water fractions were 42.5% and 28.7% respectively. This 
demonstrates that both these fractions contain the active principals mediating the 
hypoglycaemic effect in varying proportions.  Methanol fraction also had significant activity 
similar to the aqueous fraction, but the initial hypoglycaemic effect (+1 hr) was more 
prominent in the aqueous fraction (30% vs 16%). In experiments carried out by Fernando et 
al [17] with the crude extract of A. heterophyllus leaves, the fasting blood glucose levels of 
normoglycaemic rats were reduced by 24% at +3hr. However, this reduction was obtained 
with a higher dose of 10g/kg body weight of A. hetertophyllus starting material. Further, 
purification and fractionation results in an enhancement of bioactivity by eliminating the 
unwanted material which could exert inhibitory effects on the bioactivity of interest. Since 
the ethylacetate fraction has been shown to contain a high content of flavanoids by 
phyotochemical screening [19,28,29], the hypoglycaemic activity of this fraction could be 
attributed to a high molecular weight flavanoid which has a higher solubility in ethylacetate 
than in water.  
 
Figure 2. The effects of ethylacetate (EtAc), methanol and water fractions of A.heterophyllus leaves on 
fasting blood glucose levels of normoglycaemic rats. Data expressed as % change in blood glucose level. 
Each point is the mean of six determinations. 
3.2. Effects on glucose tolerance  
Impaired glucose tolerance is a pre-diabetic state which may precede T2DM. The oral 
glucose tolerance test (OGTT) was used as a screening method for acute antihyperglycemic 
activity since the results give the overall effect of the test material on the handling of an 
external glucose load [30]. 
Glucose tolerance studies with normoglycaemic rats, receiving the ethylacetate fraction 
showed a significant improvement in their ability to utilize the external glucose load 
compared to the control group (Fig. 3). This was dose dependant, and a dosage of 20mg/kg 
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was found to be more effective than 10 mg/kg. Compared with the controls, the reduction in 
blood glucose concentration at 2 hr post glucose administration was 18.9% and 26.4% for 
dosages of 10 mg/kg and 20 mg/kg respectively (Table 1). Reductions in blood glucose levels 
were statistically significant between the control curve and test curves at all time intervals. 
In similar experiments a higher dose of 150mg/kg of the ethylacetate fraction had resulted in 
a 36.9% reduction in blood glucose at 2 hr post glucose administration [28].  
Effects of the hot water extract of A. heterophyllus leaves on glucose tolerance of healthy 
individuals and maturity onset diabetic patients have been investigated by Fernando et al 
[31]. Oral administration of the hot water extract equivalent to a dose of 20g/kg starting 
material, one hour before the glucose load of 50 g, resulted in a significant improvement in 
the glucose tolerance of normal subjects and in the diabetic patients compared to the 
controls receiving distilled water. These data provide confirmatory evidence for the 
presence of antidiabetic principals in the leaf extract and validate its use in the treatment of 
diabetes by traditional medical practitioners.   
 
 
Mean serum glucose concentration 
(mg/dl) % reduction in serum 
glucose compared to control 
Fasting 2 hrs post glucose
Control 95.1  ±  4.4 169.5 ±  3.6  
EA fraction (10 mg/kg) 96.5  ±  2.3 137.3 ±  2.7 18.9* 
EA fraction (20 mg/kg) 98.6  ±  3.5 124.8 ±  4.2 26.4* 
Gibenclamide (0.6 mg/kg) 98.3  ±  1.9 108.5  ± 2.9 35.9* 
*Significantly different (p<0.05) compared to control 
Table 1. Effect of ethylacetate fraction on glucose tolerance 
 
Figure 3. The effects of ethylacetate (EtAc) fraction of A.heterophyllus leaves at doses of 10 mg/kg and 20 
mg/kg bodyweight, on glucose tolerance of normoglycaemic rats. Data expressed as % change in blood 
glucose level. Each point is the mean of six determinations. 
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3.3. Animal models of diabetes mellitus 
Non-insulin-dependent forms of diabetes can be produced by administration of a low dose 
of Streptozotocin (STZ) or alloxan [32]. These kinds of models of diabetes are considered a 
screening step in the search for drugs for the treatment of diabetes [33].  
Streptozotocin (STZ) is an antibiotic derived from Streptomyces achromogenes and structurally 
is a glucosamine derivative of nitrosourea. Its structural similarity to glucose allows it to 
enter the pancreatic beta-cell via a glucose transporter-GLUT-2 and causes alkylation of 
deoxyribonucleic acid (DNA). Furthermore, STZ induces activation of poly-adenosine 
diphosphate  ribosylation and nitric oxide release. As a result of STZ action, pancreatic beta-
cells are destroyed by necrosis [34]. The diabetes induced by STZ is associated with 
polydipsia and loss in body weight [35]. Although high-dose STZ severely impairs insulin 
secretion mimicking type 1 diabetes, low-dose STZ has been known to induce a mild 
impairment of insulin secretion which generate an impairment in glucose metabolism 
leading to glucose intolerance and mild, moderate or severe hyperglycaemia [36, 37]. 
Further, it also affects the lipid metabolism which leads to hyperlipidaemia which closely 
mimic the natural course of pathogenesis of T2DM [36-39]. The potential problem with STZ 
is that its toxic effects are not restricted to pancreatic beta-cells since it may cause renal 
injury [40], oxidative stress, inflammation and endothelial dysfunction [41]. Despite its 
widespread use, there is a wide variability in the extent of diabetes depending on species, 
strain and age limiting the predictability of its effects and precautions should be taken when 
trying to extrapolate the findings to the clinical practice [42,43]. 
3.4. Effect of chronic administration of ethylacetate extract on fasting blood 
glucose levels of sterptozotocin-induced diabetic rats  
Diabetes was induced in male Wistar rats by a single intravenous injection of freshly 
prepared STZ solution (in 0.1 M citrate buffer pH = 4.5) at a dose of 60 mg/kg body weight. 
The efficacy of antidiabetic plant materials may vary with time and investigating the effects 
of sub chronic or chronic administration is a necessary requirement in evaluating the profile 
of long term effects of herbal extracts [44]. 
Chronic administration (Table 2) of the EA fraction to rats at dose of 20 mg/kg for five 
consecutive weeks  caused a significant fall (P < 0.05) in the fasting blood sugar levels of 
diabetic rats when compared with diabetic controls which did not receive the ethylacetate 
fraction. This is evident in the second week itself and the reduction in the fasting blood 
sugar in the ethylacetate fraction treated rats (22.8%) was fairly comparable to that produced 
by the reference drug glibenclamide (32.2%) during the same time period. As in the 
glibenclamide-treated rats, in rats receiving the ethylacetate fraction also, the fall in the 
blood sugar level continued progressively till the end of the fifth week. A maximum fall of 
39.1%  and 55.7% were seen for for the ethylacetate fraction and glibenclamide respectively 
at the end of the fifth week. In a more recent study, chronic administration of the aqueous 
extract of A. heterophyllus leaves to streptozotocin induced diabetic rats has shown similar 
results [20]. There was a 51% decrease in fasting blood sugar level for a dose of 250 mg/kg in 
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glucose compared to control 
Fasting 2 hrs post glucose
Control 95.1  ±  4.4 169.5 ±  3.6  
EA fraction (10 mg/kg) 96.5  ±  2.3 137.3 ±  2.7 18.9* 
EA fraction (20 mg/kg) 98.6  ±  3.5 124.8 ±  4.2 26.4* 
Gibenclamide (0.6 mg/kg) 98.3  ±  1.9 108.5  ± 2.9 35.9* 
*Significantly different (p<0.05) compared to control 
Table 1. Effect of ethylacetate fraction on glucose tolerance 
 
Figure 3. The effects of ethylacetate (EtAc) fraction of A.heterophyllus leaves at doses of 10 mg/kg and 20 
mg/kg bodyweight, on glucose tolerance of normoglycaemic rats. Data expressed as % change in blood 
glucose level. Each point is the mean of six determinations. 
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3.3. Animal models of diabetes mellitus 
Non-insulin-dependent forms of diabetes can be produced by administration of a low dose 
of Streptozotocin (STZ) or alloxan [32]. These kinds of models of diabetes are considered a 
screening step in the search for drugs for the treatment of diabetes [33].  
Streptozotocin (STZ) is an antibiotic derived from Streptomyces achromogenes and structurally 
is a glucosamine derivative of nitrosourea. Its structural similarity to glucose allows it to 
enter the pancreatic beta-cell via a glucose transporter-GLUT-2 and causes alkylation of 
deoxyribonucleic acid (DNA). Furthermore, STZ induces activation of poly-adenosine 
diphosphate  ribosylation and nitric oxide release. As a result of STZ action, pancreatic beta-
cells are destroyed by necrosis [34]. The diabetes induced by STZ is associated with 
polydipsia and loss in body weight [35]. Although high-dose STZ severely impairs insulin 
secretion mimicking type 1 diabetes, low-dose STZ has been known to induce a mild 
impairment of insulin secretion which generate an impairment in glucose metabolism 
leading to glucose intolerance and mild, moderate or severe hyperglycaemia [36, 37]. 
Further, it also affects the lipid metabolism which leads to hyperlipidaemia which closely 
mimic the natural course of pathogenesis of T2DM [36-39]. The potential problem with STZ 
is that its toxic effects are not restricted to pancreatic beta-cells since it may cause renal 
injury [40], oxidative stress, inflammation and endothelial dysfunction [41]. Despite its 
widespread use, there is a wide variability in the extent of diabetes depending on species, 
strain and age limiting the predictability of its effects and precautions should be taken when 
trying to extrapolate the findings to the clinical practice [42,43]. 
3.4. Effect of chronic administration of ethylacetate extract on fasting blood 
glucose levels of sterptozotocin-induced diabetic rats  
Diabetes was induced in male Wistar rats by a single intravenous injection of freshly 
prepared STZ solution (in 0.1 M citrate buffer pH = 4.5) at a dose of 60 mg/kg body weight. 
The efficacy of antidiabetic plant materials may vary with time and investigating the effects 
of sub chronic or chronic administration is a necessary requirement in evaluating the profile 
of long term effects of herbal extracts [44]. 
Chronic administration (Table 2) of the EA fraction to rats at dose of 20 mg/kg for five 
consecutive weeks  caused a significant fall (P < 0.05) in the fasting blood sugar levels of 
diabetic rats when compared with diabetic controls which did not receive the ethylacetate 
fraction. This is evident in the second week itself and the reduction in the fasting blood 
sugar in the ethylacetate fraction treated rats (22.8%) was fairly comparable to that produced 
by the reference drug glibenclamide (32.2%) during the same time period. As in the 
glibenclamide-treated rats, in rats receiving the ethylacetate fraction also, the fall in the 
blood sugar level continued progressively till the end of the fifth week. A maximum fall of 
39.1%  and 55.7% were seen for for the ethylacetate fraction and glibenclamide respectively 
at the end of the fifth week. In a more recent study, chronic administration of the aqueous 
extract of A. heterophyllus leaves to streptozotocin induced diabetic rats has shown similar 
results [20]. There was a 51% decrease in fasting blood sugar level for a dose of 250 mg/kg in 
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diabetic rats at the end of the first week when compared with diabetic controls. The fall in 
fasting blood sugar has continued progressively during the period of treatment with the 
extract. In another study conducted by Mohana Priya et al [29] using a similar protocol, 
chronic administration of an ethylacetate fraction of the A. heterophyllus bark extract has 
resulted in a maximum fall of fasting blood glucose level by 27.5% for a dose of 400mg/kg 
body weight.   
Glibenclamide being a standard drug for the treatment of T2DM, stimulates insulin 
secretion from pancreatic β-cells.[45] Therefore, it may be suggested that stimulation of 
insulin release from the still functioning β-cells by active principles in ethylacetate fraction 
may be one of the mechanisms by which this fraction mediates its hypoglycemic effect, as 
proposed for some other plant extracts.[46,47] Further, components of the ethylacetate 
fraction as proposed by Gomes et al.[48] with reference to Camellia sinensis (black tea), may 
be able to generate β-cells of the pancreas or protect the intact β-cells from further 
deterioration so that they may remain active and continue to produce insulin. 
Histopathological analysis of pancreas of streptozotocin induced diabetic rats chronically 
treated with an ethylacetate fraction of A. heterophyllus bark extract has revealed initial 
stages of regenerating islet cells with loss of degenerative features when compared with 
diabetic controls in which progressive β cell vacuolation, occasional apoptotic cells with 
vascular congestion and fibrous tissue infilteration was observed in the pancreas. All the 
above findings provide the biochemical basis for the use of A. heterophyllus leaves in the 
management of patients with diabetes and confirms its role as a traditional antidiabetic 
remedy.  
 
Groups Post STZ 2 weeks 4 weeks 5 weeks 
Normal control 98.4± 2.9 90.6± 5.7 91.6 ± 4.8 92.7 ± 6.6 
Diabetic control 254.3± 2.5 245.5± 6.6a 250.0 ± 3.9a 253.4 ± 6.3 a 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
252.8±11.9 189.4± 5.1b 160.1±11.0 b 154.2± 11.1 b 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
235.2 ± 8.3 166.4 ± 4.8 c 126.6 ± 9.2 c 112.3 ± 7.5 c 
Serum glucose levels in mg dl-1. Significantly different (p<0.05) compared to normal controls a , compared to diabetic 
controls b  , EA treated diabetic rats c 
Table 2. Serum glucose levels in STZ-induced diabetic rats after prolonged treatment with ethylacetate 
fraction  
4. Effect of chronic administration of ethylacetate extract on body 
weights and hyperlipidaemia associated with diabetes  
Hyperlipidemia is a metabolic complication of both clinical and experimental diabetes.[49] 
Insulin plays a major role in lipid metabolism apart from its regulation of carbohydrate 
metabolism. Insulin increases the receptor mediated removal of LDL cholesterol and 
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activates lipoprotein lipase for the hydrolysis of triacylglycerols in lipoproteins. Therefore, 
reduced activity if insulin in diabetes causes hypercholesterolaemia and 
hypertriglyceridaemia. This is cleary demonstrated in the diabetic controls of the present 
study by the increased levels of serum total cholesterol (TC) and triacylglycerols (TG) in 









Normal control 78.2 ± 3.8 102.2 ± 2.3 201.0 ± 8.5 
Diabetic control 127.9 ± 3.2 a 199.8 ± 6.2 a 172.1± 5.5 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
98.5 ± 4.3 b 119.0 ± 2.5 b 190.4 ± 1.2 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
87.4 ± 3.2 c 116.8 ± 1.3 c 196.5 ± 3.3 
Significantly different (p<0.05) compared to normal controls a ,compared to diabetic controls b ,EA treated diabetic 
ratsc  
Table 3. Serum total cholesterol, triglyceride levels and body weight in STZ-induced diabetic rats after 
five weeks of treatment with ethylacetate fraction 
Alterations in the lipid profiles and body weights of STZ-induced diabetic rats are 
summarized in Table 3. Treatment of diabetic rats with the ethylacetate fraction resulted in a 
significant fall (P <0.05) in the levels of both total cholesterol (TC) and TGs compared to 
diabetic controls. The fall in serum TG levels (40%) was more marked than that of 
cholesterol levels (23%).  This effect on diabetic hypertriglyceridemia in ethylacetate fraction 
treated rats could be due to improved glycemic control. The improved glycemic control by 
sulfonylureas accompanied by decreased serum very low density lipoprotein (VLDL) and 
TG levels has already been reported.[50] The reduction in cholesterol levels in diabetic test 
rats could be due to an inhibitory effect of the active principles on enzymes of cholesterol 
biosynthesis[51,52] and/or due to the enhanced activity of enzymes involved in bile acid 
synthesis and its excretion [53]. Further, stimulation of insulin secretion in response to the 
treatment with the extract could increase the uptake of low density lipoprotein (LDL) 
cholesterol by extrahepatic tissues contributing to the cholesterol lowering effects of the 
ethylacetate fraction. However, to obtain confirmatory evidence of these views, further 
studies on the effects of the ethylacetate fraction on LDL and high density lipoprotein (HDL) 
cholesterol levels and their clearance need to be investigated. A high fat intake and 
increased levels of free fatty acids in circulation have been implicated in the development of 
insulin resistance.[54,55] Based on these observations, it could be speculated that the EA 
fraction mediated reduction in circulating levels of TGs may also help to ameliorate insulin 
resistance in diabetic rats and thereby stimulate glucose utilization by peripheral tissues.[56] 
In a more recent study the chronic administration of  aqueous extract of A. heterophyllus 
leaves have been shown to reduce the serum total cholesterol level and improve the HDL 
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diabetic rats at the end of the first week when compared with diabetic controls. The fall in 
fasting blood sugar has continued progressively during the period of treatment with the 
extract. In another study conducted by Mohana Priya et al [29] using a similar protocol, 
chronic administration of an ethylacetate fraction of the A. heterophyllus bark extract has 
resulted in a maximum fall of fasting blood glucose level by 27.5% for a dose of 400mg/kg 
body weight.   
Glibenclamide being a standard drug for the treatment of T2DM, stimulates insulin 
secretion from pancreatic β-cells.[45] Therefore, it may be suggested that stimulation of 
insulin release from the still functioning β-cells by active principles in ethylacetate fraction 
may be one of the mechanisms by which this fraction mediates its hypoglycemic effect, as 
proposed for some other plant extracts.[46,47] Further, components of the ethylacetate 
fraction as proposed by Gomes et al.[48] with reference to Camellia sinensis (black tea), may 
be able to generate β-cells of the pancreas or protect the intact β-cells from further 
deterioration so that they may remain active and continue to produce insulin. 
Histopathological analysis of pancreas of streptozotocin induced diabetic rats chronically 
treated with an ethylacetate fraction of A. heterophyllus bark extract has revealed initial 
stages of regenerating islet cells with loss of degenerative features when compared with 
diabetic controls in which progressive β cell vacuolation, occasional apoptotic cells with 
vascular congestion and fibrous tissue infilteration was observed in the pancreas. All the 
above findings provide the biochemical basis for the use of A. heterophyllus leaves in the 
management of patients with diabetes and confirms its role as a traditional antidiabetic 
remedy.  
 
Groups Post STZ 2 weeks 4 weeks 5 weeks 
Normal control 98.4± 2.9 90.6± 5.7 91.6 ± 4.8 92.7 ± 6.6 
Diabetic control 254.3± 2.5 245.5± 6.6a 250.0 ± 3.9a 253.4 ± 6.3 a 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
252.8±11.9 189.4± 5.1b 160.1±11.0 b 154.2± 11.1 b 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
235.2 ± 8.3 166.4 ± 4.8 c 126.6 ± 9.2 c 112.3 ± 7.5 c 
Serum glucose levels in mg dl-1. Significantly different (p<0.05) compared to normal controls a , compared to diabetic 
controls b  , EA treated diabetic rats c 
Table 2. Serum glucose levels in STZ-induced diabetic rats after prolonged treatment with ethylacetate 
fraction  
4. Effect of chronic administration of ethylacetate extract on body 
weights and hyperlipidaemia associated with diabetes  
Hyperlipidemia is a metabolic complication of both clinical and experimental diabetes.[49] 
Insulin plays a major role in lipid metabolism apart from its regulation of carbohydrate 
metabolism. Insulin increases the receptor mediated removal of LDL cholesterol and 
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activates lipoprotein lipase for the hydrolysis of triacylglycerols in lipoproteins. Therefore, 
reduced activity if insulin in diabetes causes hypercholesterolaemia and 
hypertriglyceridaemia. This is cleary demonstrated in the diabetic controls of the present 
study by the increased levels of serum total cholesterol (TC) and triacylglycerols (TG) in 









Normal control 78.2 ± 3.8 102.2 ± 2.3 201.0 ± 8.5 
Diabetic control 127.9 ± 3.2 a 199.8 ± 6.2 a 172.1± 5.5 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
98.5 ± 4.3 b 119.0 ± 2.5 b 190.4 ± 1.2 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
87.4 ± 3.2 c 116.8 ± 1.3 c 196.5 ± 3.3 
Significantly different (p<0.05) compared to normal controls a ,compared to diabetic controls b ,EA treated diabetic 
ratsc  
Table 3. Serum total cholesterol, triglyceride levels and body weight in STZ-induced diabetic rats after 
five weeks of treatment with ethylacetate fraction 
Alterations in the lipid profiles and body weights of STZ-induced diabetic rats are 
summarized in Table 3. Treatment of diabetic rats with the ethylacetate fraction resulted in a 
significant fall (P <0.05) in the levels of both total cholesterol (TC) and TGs compared to 
diabetic controls. The fall in serum TG levels (40%) was more marked than that of 
cholesterol levels (23%).  This effect on diabetic hypertriglyceridemia in ethylacetate fraction 
treated rats could be due to improved glycemic control. The improved glycemic control by 
sulfonylureas accompanied by decreased serum very low density lipoprotein (VLDL) and 
TG levels has already been reported.[50] The reduction in cholesterol levels in diabetic test 
rats could be due to an inhibitory effect of the active principles on enzymes of cholesterol 
biosynthesis[51,52] and/or due to the enhanced activity of enzymes involved in bile acid 
synthesis and its excretion [53]. Further, stimulation of insulin secretion in response to the 
treatment with the extract could increase the uptake of low density lipoprotein (LDL) 
cholesterol by extrahepatic tissues contributing to the cholesterol lowering effects of the 
ethylacetate fraction. However, to obtain confirmatory evidence of these views, further 
studies on the effects of the ethylacetate fraction on LDL and high density lipoprotein (HDL) 
cholesterol levels and their clearance need to be investigated. A high fat intake and 
increased levels of free fatty acids in circulation have been implicated in the development of 
insulin resistance.[54,55] Based on these observations, it could be speculated that the EA 
fraction mediated reduction in circulating levels of TGs may also help to ameliorate insulin 
resistance in diabetic rats and thereby stimulate glucose utilization by peripheral tissues.[56] 
In a more recent study the chronic administration of  aqueous extract of A. heterophyllus 
leaves have been shown to reduce the serum total cholesterol level and improve the HDL 
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levels and the body weight in streptozotocin induced diabetic rats [20]. Similar effects have 
been shown for the ethyacetate fraction of A. heterophyllus bark on diabetic rats [29].  
Loss of body weight in diabetic rats is due to increased muscle wasting and loss of tissue 
proteins [57]. As evident from Table 3, the ethylacetate fraction had an improving effect on the 
BW (11%) of diabetic rats, which was restored to near normal levels.  This may be a reflection 
of improved health resulting from the effects of the ethylacetate fraction on insulin release. 
5. Toxicity 
The use of herbal medicines for the treatment or prevention of a variety of diseases has 
increased markedly. Herbal medicines are believed to be benign and  not cause severe 
toxicity. This coupled with lower costs compared with conventional medications is the 
major attraction  to these treatments. The active ingredients of plant extracts are chemicals 
similar to those in purified medications, and they have the same potential to cause serious 
side effects. The usefulness of any drug depends not only on its therapeutic efficacy but also 
on its lack of toxicity or adverse side effects. Therefore, toxicological investigations have to 
be carried out before any drug can be considered as safe. This is specially important in the 
case of antidiabetic drugs, which have to be administered over a relatively long period of 
time to obtain their pharmacological potency.  
Hot water extracts of A. heterophyllus leaves have been used from ancient times as a 
treatment for diabetes in traditional medicine in Sri Lanka and no evidence has been 
reported of any toxicity or adverse side effects. However, this requires scientific validation 
with toxicological studies. An in vivo study using Sprague Dawley rats carried out by 
Fernando and Thabrew [58] has demonstrated that an aqueous extract of  mature leaves of 
A. heterophyllus exerted no adverse effects even after daily administration for 30 days, as 
assessed by effects on (a) liver function, (b) haematological parameters such as haemoglobin 
concentration, red blood cell count, white blood cell count and packed cell volume, (c) 
reproductive ability of experimental animals and (d) histology of body organs (heart, liver, 
lung,kidney, intestine and pancreas). Investigations carried out by Chandrika et al [28] also 
have revealed that the chronic administration of the ethylacetate fraction of A. heterophyllus 
leaves to normoglycaemic rats over a period of twelve weeks at a dose of 50 mg/kg body 
weight failed to bring any overt signs of toxicity such as salivation, diarrhea, lacrymation, 
postural abnormalities or behavioural changes. No significant differences had been 
observed in the liver function tests and the histology of various body organs between the 
test and the control groups. A. heterophyllus leaf extract can therefore be considered to be free 
of any major toxic compounds or adverse effects.  
6. Mechanism of action 
Antidiabetic activity of plant extracts is mainly due to their ability to restore the function of 
the pancreatic tissue by causing an increase in insulin secretion or inhibit the intestinal 
absorption of glucose or by facilitation of the insulin dependant process. 
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In investigations carried out by Fernando & Thabrew [59] to investigate the mechanism of 
action, the hypoglycaemic activity of the aqueous extract of A. heterophyllus leaves has been 
attributed to an extra pancreatic effect, resulting from the inhibition or destruction of 
insulinase by the constituents of the leaf extract. Improved glycaemic control is achieved by 
prolonging the half life of insulin. Further, no effects of the extract have been observed on 
the intestinal glucose absorption in experimental rats. 
In vitro investigations carried out by Kotowaroo et al [60], on the mechanism of action have 
revealed that aqueous leaf extract of A. heterophyllus significantly (p < 0.05) inhibited α-
amylase activity in rat plasma. Further, enzyme kinetic studies using the Michaelis-Menten 
and Lineweaver-Burk equations have established that the aqueous leaf extract of A. 
heterophyllus behaved as a competitive inhibitor. Results from this study  indicated that A. 
heterophyllus could act as a ‘starch blocker’ thereby reducing post-prandial glucose peaks. 
However, this finding does not agree with the fact that the leaf extract significantly 
improves the glucose tolerance by improving the ability to handle an external glucose load, 
which has been consistently demonstrated in both animal and human studies conducted so 
far. However, the possibility exists, that the leaf extract could exert its hypoglycaemic effects 
through more than one mechanism.  
Furthermore, avialable evidence indicates that the active principals mediating the 
antidiabetic effect in A. heterophyllus leaves to be flavanoids. There is evidence that 
flavonoids, can increase the viability of beta-cells exposed to STZ or other oxidative stress 
conditions and improve beta-cell function [61-64]. Increased oxidative stress due either to 
fasting or postprandial hyperglycemia is accepted as a participant in increased beta-cell 
damage contributing to the development and progression of diabetes [65]. There is also 
evidence that the antioxidant defense system is under-expressed in pancreatic cells [66] and 
flavonoid-rich extracts administration to diabetic animal models has been shown to increase 
expression of enzymes like catalase and superoxide dismutase as well as glutathione 
peroxidase system [67, 68]. Therefore, there is a strong possibility of a pancreatic mechanism 
either by induction of insulin secretion or by recovery of beta-cell mass through which the 
hypoglycaemic activity of the leaf extract could be exerted. However, further research is 
necessary to elucidate the mechanism(s) of action. 
7. Conclusions 
An ethylacetate fraction of A. heterophyllus leaf extract exerts stong hypoglycaemic activity in 
both normoglycaemic and diabetic rats. Chronic administration of the ethylacetate fraction 
to STZ-induced diabetic rats resulted in a significant improvement in the hyperlipidaemia 
associated with diabetes leading to a significant lowering of serum total cholesterol and 
triglycerides. The effects of the improved glycaemic control was evident in the improvement 
of body weights in diabetic rats under chronic treatment with the ethylacetate fraction. 
Isolation and characterization of the active principals in the ethylacetate fraction followed by 
further pharmacological and clinical studies would provide with a novel herbal drug for 
T2DM therapy.     
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been shown for the ethyacetate fraction of A. heterophyllus bark on diabetic rats [29].  
Loss of body weight in diabetic rats is due to increased muscle wasting and loss of tissue 
proteins [57]. As evident from Table 3, the ethylacetate fraction had an improving effect on the 
BW (11%) of diabetic rats, which was restored to near normal levels.  This may be a reflection 
of improved health resulting from the effects of the ethylacetate fraction on insulin release. 
5. Toxicity 
The use of herbal medicines for the treatment or prevention of a variety of diseases has 
increased markedly. Herbal medicines are believed to be benign and  not cause severe 
toxicity. This coupled with lower costs compared with conventional medications is the 
major attraction  to these treatments. The active ingredients of plant extracts are chemicals 
similar to those in purified medications, and they have the same potential to cause serious 
side effects. The usefulness of any drug depends not only on its therapeutic efficacy but also 
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case of antidiabetic drugs, which have to be administered over a relatively long period of 
time to obtain their pharmacological potency.  
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reported of any toxicity or adverse side effects. However, this requires scientific validation 
with toxicological studies. An in vivo study using Sprague Dawley rats carried out by 
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A. heterophyllus exerted no adverse effects even after daily administration for 30 days, as 
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concentration, red blood cell count, white blood cell count and packed cell volume, (c) 
reproductive ability of experimental animals and (d) histology of body organs (heart, liver, 
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have revealed that the chronic administration of the ethylacetate fraction of A. heterophyllus 
leaves to normoglycaemic rats over a period of twelve weeks at a dose of 50 mg/kg body 
weight failed to bring any overt signs of toxicity such as salivation, diarrhea, lacrymation, 
postural abnormalities or behavioural changes. No significant differences had been 
observed in the liver function tests and the histology of various body organs between the 
test and the control groups. A. heterophyllus leaf extract can therefore be considered to be free 
of any major toxic compounds or adverse effects.  
6. Mechanism of action 
Antidiabetic activity of plant extracts is mainly due to their ability to restore the function of 
the pancreatic tissue by causing an increase in insulin secretion or inhibit the intestinal 
absorption of glucose or by facilitation of the insulin dependant process. 
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heterophyllus could act as a ‘starch blocker’ thereby reducing post-prandial glucose peaks. 
However, this finding does not agree with the fact that the leaf extract significantly 
improves the glucose tolerance by improving the ability to handle an external glucose load, 
which has been consistently demonstrated in both animal and human studies conducted so 
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through more than one mechanism.  
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1. Introduction 
Diabetes mellitus has become a global health problem, and the incidence of the disease is 
increasing rapidly in all regions of the world. Furthermore, the prevalence of diabetes is 
increasing worldwide at an alarming rate. For example, prevalence of diabetes across the 
world is forecast to increase from 171 million in 2000 to 366 million in 2030 [1]. 
Diabetes mellitus is classified into two categories, type 1 and type 2. Type 1 diabetes 
mellitus (T1D or IDDM; Insulin Dependent Diabetes Mellitus) is characterized by a loss of 
insulin secretion due to pancreatic β-cell degeneration, leading to autoimmune attack. Type 
2 diabetes mellitus (T2D or NIDDM; Non Insulin Dependent Diabetes Mellitus) is 
metabolic disorder that is caused by insufficient insulin secretion and/or insulin resistance in 
peripheral and liver tissues. It is known that 90-95% of diabetes is diagnosed as T2D [2]. 
Development of T2D is usually caused by several factors, which are combined with lifestyle, 
genetic defects, virus infection, and drugs [3, 4]. Sustained hyperglycemia causes severe 
diabetic microvascular complications, such as retinopathy, peripheral neuropathy, and 
nephropathy. In the diabetic states, multiple mechanisms have been implicated in glucose-
mediated vascular damage and contribute to diabetic microvascular complications. In 
addition, postprandial state is also an important factor in the development of 
macroangiopathy. In diabetes, the postprandial phase is characterized by an exaggerated 
rise in blood glucose levels. It has recently been shown that postprandial hyperglycemia is 
relevant to onset of cardiovascular complications. From this evidence, treatment of diabetes 
has become a part of the strategies for the prevention of diabetic vascular complications. 
To help develop new diabetic treatments, it is important to reveal the complex mechanisms 
of diabetes. In particular, studies using diabetic animal models are essential to aid in 
clarification of the pathogenesis and progression in human disease course. Types of T2D 
animal models are classified into three groups, non-obese T2D, obese T2D, and new T2D 
models. In this chapter, we review these three types of T2D animal models with respect to 
characteristic features, including impaired glucose tolerance. 
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2. Non-obese type 2 diabetic animal models 
Certain non-obese diabetic models are used in the investigation of T2D in humans. 
Spontaneous models are well known in this category, e.g., Goto-Kakizaki (GK) rats, 
Spontaneously Diabetic Torii (SDT) rats, Cohen diabetic rats, Wistar Bonn/Kobori 
(WBN/Kob) rats, Akita mice, Horino-Niki diabetic (HND) mice, Diabetes Mellitus Saitama 
(DMS) mice, and Chinese hamsters with spontaneous diabetes (CHAD). Chemically-
induced diabetes models such as neonatally streptozotocin-induced (nSTZ) diabetic rats are 
also used. 
2.1. Goto-Kakizaki (GK) rat 
2.1.1. Background 
Goto-Kakizaki (GK) rat is a non-obese animal with mild T2D [5, 6]. Glucose intolerance is 
developed early, at 2 weeks of age. Since the GK rat is generally considered as one of the 
best models of T2D, many researchers have used this animal model to study the physiology 
of diabetes and its complications, and to evaluate anti-diabetes drugs. In 1973, Goto and 
Kakizaki of Tohoku University (Japan) started selection of this substrain from Wistar rats by 
mating pairs with glucose intolerance. Since F8, sister-brother mating has been repeated, 
and were established as an SPF animal at F29. Today, many colonies of the GK rat exist and 
the rats are available for purchase from several breeders. 
The major quantitative trait locus (QTL) for impaired glucose tolerance is Niddm1, identified 
in chromosome 1. Several loci linked to pathophysiologic characteristics was observed on 
chromosomes 2, 4, 5, 8, 10, and 17, indicating that the diabetic features in GK rats are 
inherited as polygenic traits and that GK rats would provide insights into genetics of human 
T2D [7].  
2.1.2. Glucose tolerance and insulin sensitivity 
Non-fasting blood insulin levels in GK rats are slightly higher than in age-matched Wistar 
rats. Impaired glucose-stimulated insulin secretion has been reported in GK rat in vivo [8], in 
the isolated pancreas [9], and in isolated pancreatic islets [10]. Perfusion experiments using 
isolated pancreas showed that the first phase of insulin secretion by glucose stimulation was 
impaired in GK rats, although the response to arginine was preserved [9]. 
“Starfish-shaped” islets are a morphological feature of GK rat. The number of enlarged islets 
with irregular shape, ill-defined borders, and fibrous strands of endocrine cells is increased 
in aged GK rats. These islets showed similar or moderately decreased insulin content 
compared with control rats. Pancreatic glucagon content is at almost the same level as in 
Wistar rats, and somatostatin content is slightly higher in GK rats [11]. The defective insulin 
response to glucose in β-cells is due to abnormalities in the function of K+ATP channels and L-
type Ca2+ channels [12]. 
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The GK rats show mild insulin resistance, mainly considered to be due to increased hepatic 
glucose production [8]. Decreased glycogen synthesis from glucose, and glucose uptake in 
skeletal muscle and adipose tissue are also observed in GK rat. 
2.1.3. Drug treatment and diabetic complications 
GK rats have been widely used for evaluating anti-diabetic drugs. Almost all types of such 
drugs have been tested with GK rats, including sulfonylureas [13], an α-glucosidase 
inhibitor [14], a thiazolidinedione derivative (troglitazone) [15], a biguanide (metformin) 
and a gluconeogenesis inhibitor [16], a GLP-1 analog and a dipeptidyl peptidase-4 inhibitor 
(DPPIV-i) [17], and an SGLT2 inhibitor [18]. 
In addition to its useful features as a T2D model, GK rat has been used as model of diabetic 
complications. Reduced motor nerve conduction velocity (MNCV) in the caudal nerve is 
reported in 2-month-old GK rats [19]. Increase of glomerular basal membrane was observed 
at 3 months [8]. Electroretinogram (ERG) showed functional abnormalities of photoreceptors 
in GK rats [20]. Aged GK rats at eight months showed higher endothelial/pericyte ratio than 
in normal rats, indicating retinopathy [21]. 
2.2. Neonatally streptozotocin-induced (nSTZ) diabetic rat 
2.2.1. Background 
Streptozotocin (STZ) is an antibiotic derived from Streptomyces achromogenes that has 
selective toxicity to pancreatic β-cells. STZ induces DNA strand breaks and a consequent 
excess activation of poly (ADP-ribose) synthetase, an enzyme that repairs DNA, depleting 
NAD in cells, which leads to energy depletion and finally causes β-cell death [22]. Therefore, 
STZ is widely used as an agent to induce IDDM (or T1D) experimentally: injection of a 
single high dose of STZ causes T1D in adult rats. 
On the other hand, when the STZ is injected neonatally, rats develop T2D in adulthood. 
Neonatal rats treated with STZ at birth (nSTZ rat) revealed acute insulin deficient diabetes at 
3-5 days after birth [23]. Their pancreatic insulin contents reduced to 7% that of normal rats, 
and showed hyperglycemia in this period. However, after this period, blood glucose and 
insulin levels in nSTZ rats were almost the same as in control rats at 3 weeks of age. At eight 
weeks of age, nSTZ rats showed mild hyperglycemia and impaired glucose tolerance with a 
50% decrease in pancreatic insulin content [24]. 
Recently, Masiello et al. have reported a new method of inducing T2D in rat by 
administration of STZ combination with nicotinaminde (NA) [25]. Adult (3 months old) 
Wistar rats treated with NA intraperitoneally 15 min before STZ administration (STZ/NA 
rat) have shown moderate and stable hyperglycemia with 40% preservation of pancreatic 
insulin stores. When given a calorie-controlled high fat diet, hyperlipidemia and insulin 
resistance without obesity were observed [26]. These models of T2D similar to human T2D 
may provide a particularly advantageous tool for pharmacological investigations of new 
insulinotropic agents. 
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2.2.2. Glucose tolerance 
The reduction of β-cell number and insulin content in the pancreas leads to defective insulin 
response in vivo. An isolated pancreas perfusion study using adult nSTZ rats showed lack of 
insulin response to glucose stimulation, indicating loss of β-cell function [27]. Both the first 
and the second phase of insulin response were severely impaired. Reduction of GLUT2 
expression in β-cells may attribute to impaired glucose entry into β-cells and the following 
insulin secretion [28]. Reduced sensitivity of KATP channel to extracellular glucose has also 
been suggested by the patch-clamp technique [29]. Furthermore, an in vivo study has 
indicated that the hepatic glucose production (HGP) in the basal state is higher in adult 
nSTZ rats than in control animals [30]. From these observations, a lack of insulin response to 
glucose in pancreas and an increased insulin action upon HGP in vivo are major causes of 
mild basal hyperglycemia and impaired glucose tolerance in nSTZ rats. 
2.2.3. Drug treatment 
The features of nSTZ rats as a T2D model make this model valuable for evaluation of many 
hypoglycemic drugs, including a sulfonylurea [31], a thiazolidinedione (pioglitazone) [32], a 
biguanide (metformin) [33], a glucose sensor enhancer [34], a DPPIV-i [35], and an SGLT2 
inhibitor [36]. nSTZ rats are also a useful model for assessment of therapeutic drugs that 
enhance β-cell regeneration. Tourrel et al. reported improved beneficial effects of GLP-1 and 
its analog exendin-4 on β-cell mass recovery and glucose homeostasis [37]. Ghrelin, the 
hunger-stimulating peptide produced in stomach, also promotes regeneration of β-cells in 
nSTZ rats. Treatment with ghrelin increased pancreatic expression of insulin and Pdx1 
mRNA with a consequent improvement of hyperglycemia in nSTZ rats [38]. 
3. Obese type 2 diabetes animal models 
Obesity is a well-established risk factor for many chronic disorders, such as T2D [39]. To 
understand the complicated features of the disease, spontaneously T2D models provide 
important knowledge. In particular, the development of diabetic animal models and 
pathophysiological analyses of the models are very important to aid in clarification of the 
pathogenesis and the patterns of progression in the human disease course. Genetic models 
of obesity and diabetes, such as db/db mice, ob/ob mice, Zucker diabetic fatty (ZDF) rats, 
Otsuka Long-Evans Tokushima Fatty (OLETF) rats, and Wistar fatty rats are most 
commonly used in such studies. 
3.1. Zucker diabetic fatty (ZDF) rat 
3.1.1. Background 
Zucker diabetic fatty (ZDF) rat is an obese animal associated with hyperphagia, 
hyperglycemia, hyperinsulinemia, and hyperlipidemia. Insulin resistance is caused by age-
dependent degeneration in pancreatic β-cells that trigger hyperglycemia. Thus, ZDF rat is a 
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widely studied model of obesity and insulin resistance and is used for evaluation of anti-
diabetic drugs. ZDF rat was discovered in a colony of outbred Zucker fatty (ZF) rat in the 
laboratory of Dr. Walter Shaw at Eli Lilly Research laboratories during the 1980’s. ZF rat, 
discovered in crosses between Sherman and Merck stock M rats (13M strain) in 1961 [40], 
was identified as carrying a mutation in fa gene, and exhibits hyperphagia/obesity. Dr. 
Richard Peterson at Indiana University Medical School (IUMS) started selection of this 
rederivation, and established an inbred line of ZDF rat in 1985. It is well known that sexual 
differences exist in the incidence and progression of diabetes mellitus in ZDF rat [41]. 
Diabetes mellitus has developed in more 90% of the males, whereas the blood glucose level 
remains normal in most females. However, female ZDF rat became diabetic on high-fat diet, 
and it was shown that the dietary fat content affected development of diabetes in females 
[41]. Today, ZDF rat is available for purchase from Charles River. 
3.1.2. Glucose tolerance and insulin sensitivity 
Serum glucose levels in ZDF rat are usually elevated from 7-10 weeks of age. The increase 
was sustained until about 14 weeks of age. ZDF rats showed hyperinsulinemia from 6 to 12 
weeks, but after about 14 weeks of age their insulin levels showed a tendency to decrease. 
Impaired glucose tolerance has been reported in ZDF rat at 5-7 weeks of age. Glucose 
intolerance at 12 weeks becomes more severe than that at 5-7 weeks of age [42, 43]. Age-
dependent degenerative changes of pancreatic islets showed decreased production and 
secretion of insulin, and atrophy of islets. Early pathological changes of the pancreatic islets, 
such as hypertrophy, disarray of islet architecture, and irregular islet boundaries, were 
observed by 10-12 weeks of age [44, 45]. The specific factor that causes deterioration of 
pancreatic β-cells has not been identified, but changes in β-cell structure and function have 
been well studied. It was reported that lipotoxicity based on high plasma free fatty acid 
could attribute to β-cell dysfunction [46]. Reduction of islet mRNAs in β-cells, such as those 
for insulin, GLUT2, and glucokinase, contributes to the β-cell deterioration [42]. 
Furthermore, decrease in GLUT4 expression is also observed in skeletal muscle and adipose 
tissue of ZDF rat [47].  
3.1.3. Drug treatment and diabetic complications 
It is well known that ZDF rat is a useful model for evaluating anti-diabetic compounds. 
Some studies have shown that DPPIV-i improve the diabetic condition in ZDF rat. Other 
compounds also have been evaluated in ZDF rat, including a sulfonylurea [48], α-
glucosidase inhibitors [49], a thiazolidinedione (pioglitazone) [50], a biguanide (metformin) 
[51], a GLP-1 analog [52], an SGLT2 inhibitor [53], a β3-andrenergic receptor agonist [54], 
and a variety of other compounds [55-58]. 
A number of studies demonstrated that ZDF rat can be used as model of diabetic 
complications. Blood urea nitrogen (BUN) levels and urinary protein excretion in ZDF rat 
were elevated from about 40-50 weeks of age. Renal morphologic changes were observed at 
40 weeks of age [59]. It is shown that ZDF rat exhibits renal hypertrophy. Reduced MNCV 
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in the sciatic nerve is observed from 12–14 weeks of age in ZDF rats, and endoneurial blood 
flow (EBF) in the sciatic nerve is also decreased after 24 weeks of age [60]. It is suggested 
that ZDF rat develops neural dysfunction. The degeneration and swelling of fibrae lentis, 
formation of Morgagnian globules, and stratification of epithelium lentis cells is observed in 
ZDF rat at 21 weeks of age [61, 62]. It is shown that diabetic cataract is observed in ZDF rat. 
3.2. Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rat 
3.2.1. Background 
Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rat is a mildly obese animal associated with 
polydipsia, polyuria, polyphagia, hyperglycemia, and hyperlipidemia. The incidence of 
diabetes mellitus in this rat might be related to weakness of β-cells. OLETF rat is considered 
to be a suitable model for understanding the properties of T2D with mild obesity. The 
spontaneously obese rat with T2D was obtained from a colony of outbred Long-Evans rat, 
available for purchase from Charles River, in 1984 at laboratory of Otsuka pharmaceuticals, 
Tokushima [63]. A strain of this rat was established by sister-brother mating with obesity 
and glucose intolerance. According to the results of a study by Takiguchi [64, 65], a 
disrupted cholecystokinin-A (CCK-A)  receptor gene in peripheral tissues and central nervous 
system is found in the OLETF rats [64]. The function of CCK-A in central nervous system is to 
regulate food intake directly [66]. Meanwhile, in peripheral tissues, CCK-A also controls 
satiety signals through the vagal afferent neurons [67]. Thus, dysfunctional signal of CCK may 
cause obese T2D, leading to hyperphagia in OLETF rats. Today, OLETF rats are available for 
purchase from Japan SLC, Inc., but this rat is limited in use to non-profit purposes. 
3.2.2. Glucose tolerance and insulin sensitivity 
Non-fasting plasma glucose levels in OLETF rats were elevated from 18 weeks of age, and 
the increase was sustained until 40 weeks of age. Diabetes mellitus developed in about 90% 
of OLETF rats at 30 weeks of age, whereas the plasma glucose level remained normal in 
most females at 24 weeks of age [63, 68]. Sexual differences exit in the incidence and 
progression of diabetes mellitus in OLETF rats [69]. In glucose tolerance test, marked 
elevation of plasma glucose and insulin level responses to glucose are observed at 24 weeks 
of age [63]. Impaired glucose tolerance becomes more severe after 24 weeks of age. Age-
dependent degenerative changes of pancreatic islets are observed from 16 weeks of age [70]. 
The pathological changes of the pancreatic islets, such as hypertrophy, atrophy of insulin 
positive-β-cells, fibrosis, and indistinct, irregular islet boundaries, were observed by 30 
weeks of age [71]. These dysfunctions of β-cells seem to cause the development of glucose 
intolerance in OLETF rats. Insulin resistance has been reported in OLETF rats at 16 weeks of 
age, as measured by hyperinsulinemic euglycemic clamp technique [70]. In adipocytes, the 
GLUT4 protein expression considerably decreased in OLETF rats at 30 weeks of age. The 
decrease in GLUT4 protein in muscles is also observed in OLETF rats at 30 weeks of age 
[72]. These abnormalities of GLUT4 protein expression lead to insulin resistance in the 
peripheral tissues of OLETF rats. 
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3.2.3. Drug treatment and diabetic complications 
OLETF rats have been widely used for pharmacological evaluation while testing for many 
anti-diabetic drugs, including a Ca2+ antagonist [73], sulfonylureas [74], an α-glucosidase 
inhibitor [75], a thiazolidinedione [76], a biguanide (metformin) and a gluconeogenesis 
inhibitor [77], and a GLP-1 analog [78]. 
OLETF rats are also used as a model for assessment of diabetic complications. It was 
reported that histopathological changes in the kidney were observed after 23 weeks of age. 
OLETF rats at 55 weeks of age showed an expansion of the mesangial matrix and 
aneurismal dilatation of intraglomerular vessels [63]. Development of diabetic nephropathy 
was also observed in OLETF rats. It is known that lenticular sorbitol level increases in 
OLETF rats from 40 weeks of age [79]. OLETF rats show swelling and liquefaction of lens 
fibers in the subcapsular and supranuclear region at 60 weeks of age. It is suggested that 
diabetic cataract is observed in OLETF rats. 
3.3. Wistar fatty rat 
3.3.1. Background 
Wistar fatty rat develops obesity with hyperphagia, hyperglycemia, hyperinsulinemia, 
hyperlipidemia, and glucose intolerance. Wistar fatty rat is a good model for studying 
obesity and insulin resistance, and for evaluation of anti-diabetic drugs. Wistar fatty rat was 
established as a congenic line of the insulin resistance of the Wistar Kyoto strain (WKY) rat 
by introducing the fa allele of the ZF rat for obesity into the WKY rat genome in the 
laboratory of Dr. Hitoshi Ikeda at Takeda Chemical Industries [80]. At 5th generation of 
backcrossing, male obese animals exhibit hyperglycemia, and were established as Wistar 
fatty rat at 10th generation. Sex differences in diabetes have been reported in Wistar fatty 
rat. The female Wistar fatty rat sustained the euglycemia until 22 weeks of age [81]. The 
molecular basis for this sex difference has not been identified. 
3.3.2. Glucose tolerance and insulin sensitivity 
Nonfasting plasma glucose levels in Wistar fatty rats were elevated until 8 weeks of age, and 
this level was sustained until 24 weeks of age. Wistar fatty rats also exhibited 
hyperinsulinemia and hypertriglyceridemia. Wistar fatty rat is a widely studied model used 
to investigate the pathogenesis of obesity and insulin resistance, and for evaluation of anti-
diabetic drugs. In glucose tolerance test conducted at 12 weeks of age, Wistar fatty rat 
showed higher serum glucose and insulin levels after glucose loading compared with WKY 
rat, and glucose intolerance became more severe age-dependently. Pronounced glucose 
intolerance was observed in Wistar fatty rat. Hypertrophied pancreatic islets in Wistar fatty 
rat were increased in pancreas compared with WKY rat [80]. Insulin resistance has been 
reported in Wistar fatty rats, confirmed by glucose clamp technique [82]. Decreased insulin-
stimulated glycogen synthesis and glycolysis in the isolated soleus muscles, and insulin-
stimulated glucose oxidation and lipogenesis in adipocytes were observed in Wistar fatty 
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in the sciatic nerve is observed from 12–14 weeks of age in ZDF rats, and endoneurial blood 
flow (EBF) in the sciatic nerve is also decreased after 24 weeks of age [60]. It is suggested 
that ZDF rat develops neural dysfunction. The degeneration and swelling of fibrae lentis, 
formation of Morgagnian globules, and stratification of epithelium lentis cells is observed in 
ZDF rat at 21 weeks of age [61, 62]. It is shown that diabetic cataract is observed in ZDF rat. 
3.2. Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rat 
3.2.1. Background 
Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rat is a mildly obese animal associated with 
polydipsia, polyuria, polyphagia, hyperglycemia, and hyperlipidemia. The incidence of 
diabetes mellitus in this rat might be related to weakness of β-cells. OLETF rat is considered 
to be a suitable model for understanding the properties of T2D with mild obesity. The 
spontaneously obese rat with T2D was obtained from a colony of outbred Long-Evans rat, 
available for purchase from Charles River, in 1984 at laboratory of Otsuka pharmaceuticals, 
Tokushima [63]. A strain of this rat was established by sister-brother mating with obesity 
and glucose intolerance. According to the results of a study by Takiguchi [64, 65], a 
disrupted cholecystokinin-A (CCK-A)  receptor gene in peripheral tissues and central nervous 
system is found in the OLETF rats [64]. The function of CCK-A in central nervous system is to 
regulate food intake directly [66]. Meanwhile, in peripheral tissues, CCK-A also controls 
satiety signals through the vagal afferent neurons [67]. Thus, dysfunctional signal of CCK may 
cause obese T2D, leading to hyperphagia in OLETF rats. Today, OLETF rats are available for 
purchase from Japan SLC, Inc., but this rat is limited in use to non-profit purposes. 
3.2.2. Glucose tolerance and insulin sensitivity 
Non-fasting plasma glucose levels in OLETF rats were elevated from 18 weeks of age, and 
the increase was sustained until 40 weeks of age. Diabetes mellitus developed in about 90% 
of OLETF rats at 30 weeks of age, whereas the plasma glucose level remained normal in 
most females at 24 weeks of age [63, 68]. Sexual differences exit in the incidence and 
progression of diabetes mellitus in OLETF rats [69]. In glucose tolerance test, marked 
elevation of plasma glucose and insulin level responses to glucose are observed at 24 weeks 
of age [63]. Impaired glucose tolerance becomes more severe after 24 weeks of age. Age-
dependent degenerative changes of pancreatic islets are observed from 16 weeks of age [70]. 
The pathological changes of the pancreatic islets, such as hypertrophy, atrophy of insulin 
positive-β-cells, fibrosis, and indistinct, irregular islet boundaries, were observed by 30 
weeks of age [71]. These dysfunctions of β-cells seem to cause the development of glucose 
intolerance in OLETF rats. Insulin resistance has been reported in OLETF rats at 16 weeks of 
age, as measured by hyperinsulinemic euglycemic clamp technique [70]. In adipocytes, the 
GLUT4 protein expression considerably decreased in OLETF rats at 30 weeks of age. The 
decrease in GLUT4 protein in muscles is also observed in OLETF rats at 30 weeks of age 
[72]. These abnormalities of GLUT4 protein expression lead to insulin resistance in the 
peripheral tissues of OLETF rats. 
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3.2.3. Drug treatment and diabetic complications 
OLETF rats have been widely used for pharmacological evaluation while testing for many 
anti-diabetic drugs, including a Ca2+ antagonist [73], sulfonylureas [74], an α-glucosidase 
inhibitor [75], a thiazolidinedione [76], a biguanide (metformin) and a gluconeogenesis 
inhibitor [77], and a GLP-1 analog [78]. 
OLETF rats are also used as a model for assessment of diabetic complications. It was 
reported that histopathological changes in the kidney were observed after 23 weeks of age. 
OLETF rats at 55 weeks of age showed an expansion of the mesangial matrix and 
aneurismal dilatation of intraglomerular vessels [63]. Development of diabetic nephropathy 
was also observed in OLETF rats. It is known that lenticular sorbitol level increases in 
OLETF rats from 40 weeks of age [79]. OLETF rats show swelling and liquefaction of lens 
fibers in the subcapsular and supranuclear region at 60 weeks of age. It is suggested that 
diabetic cataract is observed in OLETF rats. 
3.3. Wistar fatty rat 
3.3.1. Background 
Wistar fatty rat develops obesity with hyperphagia, hyperglycemia, hyperinsulinemia, 
hyperlipidemia, and glucose intolerance. Wistar fatty rat is a good model for studying 
obesity and insulin resistance, and for evaluation of anti-diabetic drugs. Wistar fatty rat was 
established as a congenic line of the insulin resistance of the Wistar Kyoto strain (WKY) rat 
by introducing the fa allele of the ZF rat for obesity into the WKY rat genome in the 
laboratory of Dr. Hitoshi Ikeda at Takeda Chemical Industries [80]. At 5th generation of 
backcrossing, male obese animals exhibit hyperglycemia, and were established as Wistar 
fatty rat at 10th generation. Sex differences in diabetes have been reported in Wistar fatty 
rat. The female Wistar fatty rat sustained the euglycemia until 22 weeks of age [81]. The 
molecular basis for this sex difference has not been identified. 
3.3.2. Glucose tolerance and insulin sensitivity 
Nonfasting plasma glucose levels in Wistar fatty rats were elevated until 8 weeks of age, and 
this level was sustained until 24 weeks of age. Wistar fatty rats also exhibited 
hyperinsulinemia and hypertriglyceridemia. Wistar fatty rat is a widely studied model used 
to investigate the pathogenesis of obesity and insulin resistance, and for evaluation of anti-
diabetic drugs. In glucose tolerance test conducted at 12 weeks of age, Wistar fatty rat 
showed higher serum glucose and insulin levels after glucose loading compared with WKY 
rat, and glucose intolerance became more severe age-dependently. Pronounced glucose 
intolerance was observed in Wistar fatty rat. Hypertrophied pancreatic islets in Wistar fatty 
rat were increased in pancreas compared with WKY rat [80]. Insulin resistance has been 
reported in Wistar fatty rats, confirmed by glucose clamp technique [82]. Decreased insulin-
stimulated glycogen synthesis and glycolysis in the isolated soleus muscles, and insulin-
stimulated glucose oxidation and lipogenesis in adipocytes were observed in Wistar fatty 
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rats [83]. It is considered that these abnormalities in the peripheral tissues lead to insulin 
resistance in Wistar fatty rats. 
3.3.3. Drug treatment and diabetic complications 
Wistar fatty rats have been used as a good model for evaluation of a number of anti-diabetic 
drugs, including a biguanide [84], an α-glucosidase inhibitor [75], a thiazolidinedione [85], 
and an DPPIV-i [86]. 
Wistar fatty rats are also used as a model of diabetic complications. It was reported that age-
related increases in urinary NAG (N-acetyl-beta-D-glucosaminidase) and urinary protein 
and albumin excretion in Wistar fatty rat were elevated from 5-11 weeks of age. Wistar fatty 
rats at 26 weeks of age showed an expansion of the glomerular mesangial matrix and local 
formation of a nodular-like lesion. The development of diabetic nephropathy was observed 
in Wistar fatty rats [87]. Reduced MNCV in the fibula nerve and histopathological changes, 
such as demyelination and axonal degeneration, were observed in Wistar fatty rats [88]. It is 
suggested that Wistar fatty rat develops neural dysfunction. 
4. New type 2 diabetes animal models 
4.1. Spontaneously Diabetic Torii (SDT) rat 
4.1.1. Background 
The Spontaneously Diabetic Torii (SDT) rat is a new inbred strain of Sprague-Dawley (SD) 
rat established as a non-obese model of type 2 diabetes mellitus. Glucosuria appeared at 
approximately 20 weeks in male SDT rats. The cumulative incidence of diabetes was 100% 
by 32 weeks in male SDT rats, while it was only 33% in females even at 65 weeks. A clear sex 
difference is observed in the onset of diabetes in SDT rats. Male SDT rats showed high 
plasma glucose levels (over 700 mg/dL) by 20 weeks [89]. As a result of chronic severe 
hyperglycemia, the SDT rats developed severe complications in eyes, peripheral nerves, and 
kidneys. Especially, ocular complications including the diabetic retinopathy in SDT rats is 
noteworthy [90]. Of many diabetic ocular complications, cataract, retinopathy, and 
neovascular glaucoma (hemorrhagic glaucoma) are the most important clinically. SDT rats 
are the first diabetic model with all of these complications [89, 90]. 
4.1.2. Glucose tolerance and insulin sensitivity 
In SDT rats, development of hyperglycemia may be more dependent on decreased insulin 
secretion than insulin resistance, as shown by the fact that the blood insulin concentration 
tended to be lower than in normal SD rats even before the onset of diabetes, and marked 
hypoinsulinemia developed after the onset of hyperglycemia [91-93], indicating that this 
strain of rat is a model of non-obese T2D associated with impaired insulin secretion. It is 
clinically known that glucose tolerance decreases before the onset of T2D. In oral glucose 
tolerance test in SDT rats, glucose tolerance markedly decreased at least 3 months before 
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manifestation of hyperglycemia (around 16 weeks old), and the rate of rise in blood glucose 
level after glucose-loading increased with age. We examined the glucose tolerance 
periodically at 5, 9, and 13 weeks of age in SDT rats (Figure 1.).  
 
Figure 1. Glucose tolerance test (GTT) at 5, 9, and 13 weeks of age in SD rats and SDT rats. Glucose 
solution (2g glucose/kg) were administered to SD rats and SDT rats. The glucose and the insulin levels 
were examined at immediately before glucose-loading, 30, 60, and 120 min after glucose-loading. (A), 
(B) 5 weeks of age, (C), (D) 9 weeks of age, (E), (F) 13 weeks of age. The data are shown as the mean ± 
standard deviation (n=4-6). * P<0.05, ** P<0.01 significantly different from SD rats. 
At 5 weeks of age, blood glucose level at 30 min after glucose-loading in SDT rats tended to 
increase as compared with that in SD rats (Figure 1A.). The blood glucose level before 
glucose-loading and the level at 120 min after glucose-loading in SDT rats significantly 
decreased as compared with those in SD rats. The blood insulin level at 30 min after glucose-
loading was not different from that in SD rats, but the insulin levels at the other points 
significantly decreased as compared with those in SD rats (Figure 1B.). Also, the 
insulinogenic index at 5 weeks of age in SDT rats was comparable with that in SD rats 
(Figure 2.). 
At 9 weeks of age, the blood glucose levels after glucose-loading in SDT rats were more 
elevated as compared with those in the rats at 5 weeks of age, suggesting that the glucose 
tolerance was deteriorated with age (Figure 1C.). The insulin levels at points except for 120 
min after glucose-loading in SDT rats was comparable with those in SD rats (Figure 1D.), 
but the insulinogenic index showed a lower level than SD rats (Figure. 2). At 13 weeks of 
age, the impaired glucose tolerance (IGT) in SDT rats was accelerated and a peak value in 
the blood glucose level reached to about 300 mg/dl (Figure 1E.). The insulin level at 30 min 
after glucose-loading did not increase in SDT rats (Figure 1F.), suggesting that the glucose 
stimulated insulin secretion (GSIS) was almost deleted in the rats at 13 weeks of age (Figure 
2.). In male rats, the severity of impaired glucose tolerance before the onset of diabetes was 
closely correlated with the age. Impaired glucose tolerance was related to decreased insulin 
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rats [83]. It is considered that these abnormalities in the peripheral tissues lead to insulin 
resistance in Wistar fatty rats. 
3.3.3. Drug treatment and diabetic complications 
Wistar fatty rats have been used as a good model for evaluation of a number of anti-diabetic 
drugs, including a biguanide [84], an α-glucosidase inhibitor [75], a thiazolidinedione [85], 
and an DPPIV-i [86]. 
Wistar fatty rats are also used as a model of diabetic complications. It was reported that age-
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formation of a nodular-like lesion. The development of diabetic nephropathy was observed 
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such as demyelination and axonal degeneration, were observed in Wistar fatty rats [88]. It is 
suggested that Wistar fatty rat develops neural dysfunction. 
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4.1. Spontaneously Diabetic Torii (SDT) rat 
4.1.1. Background 
The Spontaneously Diabetic Torii (SDT) rat is a new inbred strain of Sprague-Dawley (SD) 
rat established as a non-obese model of type 2 diabetes mellitus. Glucosuria appeared at 
approximately 20 weeks in male SDT rats. The cumulative incidence of diabetes was 100% 
by 32 weeks in male SDT rats, while it was only 33% in females even at 65 weeks. A clear sex 
difference is observed in the onset of diabetes in SDT rats. Male SDT rats showed high 
plasma glucose levels (over 700 mg/dL) by 20 weeks [89]. As a result of chronic severe 
hyperglycemia, the SDT rats developed severe complications in eyes, peripheral nerves, and 
kidneys. Especially, ocular complications including the diabetic retinopathy in SDT rats is 
noteworthy [90]. Of many diabetic ocular complications, cataract, retinopathy, and 
neovascular glaucoma (hemorrhagic glaucoma) are the most important clinically. SDT rats 
are the first diabetic model with all of these complications [89, 90]. 
4.1.2. Glucose tolerance and insulin sensitivity 
In SDT rats, development of hyperglycemia may be more dependent on decreased insulin 
secretion than insulin resistance, as shown by the fact that the blood insulin concentration 
tended to be lower than in normal SD rats even before the onset of diabetes, and marked 
hypoinsulinemia developed after the onset of hyperglycemia [91-93], indicating that this 
strain of rat is a model of non-obese T2D associated with impaired insulin secretion. It is 
clinically known that glucose tolerance decreases before the onset of T2D. In oral glucose 
tolerance test in SDT rats, glucose tolerance markedly decreased at least 3 months before 
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manifestation of hyperglycemia (around 16 weeks old), and the rate of rise in blood glucose 
level after glucose-loading increased with age. We examined the glucose tolerance 
periodically at 5, 9, and 13 weeks of age in SDT rats (Figure 1.).  
 
Figure 1. Glucose tolerance test (GTT) at 5, 9, and 13 weeks of age in SD rats and SDT rats. Glucose 
solution (2g glucose/kg) were administered to SD rats and SDT rats. The glucose and the insulin levels 
were examined at immediately before glucose-loading, 30, 60, and 120 min after glucose-loading. (A), 
(B) 5 weeks of age, (C), (D) 9 weeks of age, (E), (F) 13 weeks of age. The data are shown as the mean ± 
standard deviation (n=4-6). * P<0.05, ** P<0.01 significantly different from SD rats. 
At 5 weeks of age, blood glucose level at 30 min after glucose-loading in SDT rats tended to 
increase as compared with that in SD rats (Figure 1A.). The blood glucose level before 
glucose-loading and the level at 120 min after glucose-loading in SDT rats significantly 
decreased as compared with those in SD rats. The blood insulin level at 30 min after glucose-
loading was not different from that in SD rats, but the insulin levels at the other points 
significantly decreased as compared with those in SD rats (Figure 1B.). Also, the 
insulinogenic index at 5 weeks of age in SDT rats was comparable with that in SD rats 
(Figure 2.). 
At 9 weeks of age, the blood glucose levels after glucose-loading in SDT rats were more 
elevated as compared with those in the rats at 5 weeks of age, suggesting that the glucose 
tolerance was deteriorated with age (Figure 1C.). The insulin levels at points except for 120 
min after glucose-loading in SDT rats was comparable with those in SD rats (Figure 1D.), 
but the insulinogenic index showed a lower level than SD rats (Figure. 2). At 13 weeks of 
age, the impaired glucose tolerance (IGT) in SDT rats was accelerated and a peak value in 
the blood glucose level reached to about 300 mg/dl (Figure 1E.). The insulin level at 30 min 
after glucose-loading did not increase in SDT rats (Figure 1F.), suggesting that the glucose 
stimulated insulin secretion (GSIS) was almost deleted in the rats at 13 weeks of age (Figure 
2.). In male rats, the severity of impaired glucose tolerance before the onset of diabetes was 
closely correlated with the age. Impaired glucose tolerance was related to decreased insulin 
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secretory response after glucose-loading, and decrease in the fasting plasma insulin 
concentration (lower than 1 ng/ml) and loss of insulin secretory response after glucose-
loading were also observed after the onset of diabetes (Figure 3.). 
 
Figure 2. Insulinogenic index at 5, 9, and 13 weeks of age in SD rats and SDT rats. Insulinogenic index 
(∆Insulin/∆Glucose) was calculated using incremental blood insulin and glucose levels for 0 to 30 min 
after glucose-loading. The data are shown as the mean ± standard deviation (n=4-6). 
 
Figure 3. Glucose tolerance test (GTT) at 17 and 27 weeks of age in SDT rats. Glucose solution (2g 
glucose/kg) were administered to SDT rats. The glucose (A) and the insulin (B) levels were examined at 
immediately before glucose-loading, 30, 60, and 120 min after glucose-loading. The data are shown as 
the mean ± standard deviation (n=5).  
In addition, the insulin secretion level in pancreatic islets of Langerhans from SDT rats after 
glucose treatment markedly decreased at 12 weeks of age and thereafter compared with 
normal SD rats. Likewise, the mRNA expression levels for GLUT2 and glucokinase (GK) in 
the isolated pancreatic islets of Langerhans markedly decreased at 12 weeks and thereafter 
in SDT rats [94]. In female rats, glucose tolerance also decreased, at 25 weeks and thereafter, 
but insulin was secreted after glucose-loading, indicating that some factors cause insulin 
resistance or insulin requirement in the females, unlike in the males [95]. 
It is reported that the pancreatic insulin content in SDT rats at 7 weeks of age decreased as 
compared with that in SD rats [96]. In human, β cell mass in impaired fasting glucose (IFG) 
subjects significantly decreased as compared with that in nondiabetic subjects [97]. In 
further study, the change of β-cell mass in pre-diabetic SDT rats should be elucidated.  
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Other non-obese type 2 diabetic models, such as GK rats and the nSTZ rats, did not show a 
pre-diabetic state. Since the SDT rat shows a pre-diabetic state for a long term, the rat is 
valuable as IGT model as well as a type 2 diabetic model. 
4.1.3. Drug treatment 
In previous study, α-glucosidase inhibitor voglibose was administered to male SDT rats in a 
pre-diabetic stage, and the effects of voglibose on the glucose intolerance and the 
development of diabetes were investigated [98]. In SDT rats at 10 weeks of age, a single dose 
of voglibose (0.03, 0.1, 0.3 mg/kg) improved the glucose tolerance dose-dependently. 
Moreover, voglibose was administered as a dietary mixture to SDT rats from 10 to 20 weeks of 
age. As a result, voglibose suppressed the incidence of diabetes in SDT rats. In clinical study, 
α-glucosidase inhibitor, such as voglibose and acarbose, showed a prevention of type 2 
diabetes mellitus [99, 100]. The pharmacological intervention delayed progression of IGT to 
diabetes. The results showed that pharmacological intervention with voglibose in SDT rats 
with IGT can delay progression to T2D. SDT rat is considered to be useful for development of 
a preventive drug on T2D. SDT rat is available for purchace from CLEA Japan.  
4.2. Spontaneously Diabetic Torii Leprfa (SDT fatty) rat 
4.2.1. Background 
Type 2 diabetes mellitus is a polygenic disorder that is caused by a metabolic and/or 
hormonal imbalance between insulin secretion from β cells and insulin sensitivity in 
peripheral tissues, both of which might be modified by genetic and environmental factors 
[101]. The decreased sensitivity to insulin leads to an increased requirement for insulin, and 
is often associated with obesity in which metabolic disturbances are marked in insulin-target 
organs, such as the liver, muscle and adipose tissues [102]. Obesity plays key roles in the 
pathophysiology of several metabolic diseases and is a risk factor for diabetes mellitus and 
dyslipidemia. Based on the above concept, a novel model of obesity-related diabetes was 
established by Masuyama et al. [103]. They established a congenic line of the Spontaneously 
Diabetic Torii (SDT) rat by introducing the fa allele of the ZF rat into the SDT rat genome via 
the Speed Congenic Method using a PCR technique with DNA markers. This congenic strain 
has been maintained by inter-crossing between fa-heterozygous littermates.  
4.2.2. Glucose tolerance, insulin sensitivity and drug treatment 
Metabolic disorder in SDT fatty rats was obviously promoted as compared with SDT rats 
[104, 105]. Serum glucose levels in SDT fatty rats of both sexes were elevated from 6 weeks, 
and lipid parameters such as serum triglyceride and total cholesterol levels in the rats were 
elevated from 4 weeks of age. The hyperglycemia and hyperlipidemia were sustained for a 
long time afterwards. With early incidence of diabetes mellitus, diabetes-associated 
complications in SDT fatty rats were seen at younger ages than those in the SDT rats. SDT 
fatty rats did not almost show a pre-diabetic state, since the rats showed a hyperglycemia 
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secretory response after glucose-loading, and decrease in the fasting plasma insulin 
concentration (lower than 1 ng/ml) and loss of insulin secretory response after glucose-
loading were also observed after the onset of diabetes (Figure 3.). 
 
Figure 2. Insulinogenic index at 5, 9, and 13 weeks of age in SD rats and SDT rats. Insulinogenic index 
(∆Insulin/∆Glucose) was calculated using incremental blood insulin and glucose levels for 0 to 30 min 
after glucose-loading. The data are shown as the mean ± standard deviation (n=4-6). 
 
Figure 3. Glucose tolerance test (GTT) at 17 and 27 weeks of age in SDT rats. Glucose solution (2g 
glucose/kg) were administered to SDT rats. The glucose (A) and the insulin (B) levels were examined at 
immediately before glucose-loading, 30, 60, and 120 min after glucose-loading. The data are shown as 
the mean ± standard deviation (n=5).  
In addition, the insulin secretion level in pancreatic islets of Langerhans from SDT rats after 
glucose treatment markedly decreased at 12 weeks of age and thereafter compared with 
normal SD rats. Likewise, the mRNA expression levels for GLUT2 and glucokinase (GK) in 
the isolated pancreatic islets of Langerhans markedly decreased at 12 weeks and thereafter 
in SDT rats [94]. In female rats, glucose tolerance also decreased, at 25 weeks and thereafter, 
but insulin was secreted after glucose-loading, indicating that some factors cause insulin 
resistance or insulin requirement in the females, unlike in the males [95]. 
It is reported that the pancreatic insulin content in SDT rats at 7 weeks of age decreased as 
compared with that in SD rats [96]. In human, β cell mass in impaired fasting glucose (IFG) 
subjects significantly decreased as compared with that in nondiabetic subjects [97]. In 
further study, the change of β-cell mass in pre-diabetic SDT rats should be elucidated.  
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Other non-obese type 2 diabetic models, such as GK rats and the nSTZ rats, did not show a 
pre-diabetic state. Since the SDT rat shows a pre-diabetic state for a long term, the rat is 
valuable as IGT model as well as a type 2 diabetic model. 
4.1.3. Drug treatment 
In previous study, α-glucosidase inhibitor voglibose was administered to male SDT rats in a 
pre-diabetic stage, and the effects of voglibose on the glucose intolerance and the 
development of diabetes were investigated [98]. In SDT rats at 10 weeks of age, a single dose 
of voglibose (0.03, 0.1, 0.3 mg/kg) improved the glucose tolerance dose-dependently. 
Moreover, voglibose was administered as a dietary mixture to SDT rats from 10 to 20 weeks of 
age. As a result, voglibose suppressed the incidence of diabetes in SDT rats. In clinical study, 
α-glucosidase inhibitor, such as voglibose and acarbose, showed a prevention of type 2 
diabetes mellitus [99, 100]. The pharmacological intervention delayed progression of IGT to 
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a preventive drug on T2D. SDT rat is available for purchace from CLEA Japan.  
4.2. Spontaneously Diabetic Torii Leprfa (SDT fatty) rat 
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long time afterwards. With early incidence of diabetes mellitus, diabetes-associated 
complications in SDT fatty rats were seen at younger ages than those in the SDT rats. SDT 
fatty rats did not almost show a pre-diabetic state, since the rats showed a hyperglycemia 
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from a young age. However, the glucose intolerance in SDT fatty rats is considered to exist 
with the progression of diabetes mellitus. 
We evaluated the pharmacological effects of an anti-diabetic drug, DPPIV-i on SDT fatty 
rats. Male SDT fatty rats at 9 weeks of age were used after overnight fasting. The effect of 
drug on blood glucose and insulin levels in glucose-loaded animals was examined by means 
of an oral glucose tolerance test (1g glucose/kg) 30 min after single oral administration of 
DPPIV-i. When DPPIV-i was administered at doses of 1 and 10 mg/kg, the impaired 
glucose tolerance was improved dose dependently and insulin secretion was enhanced 
(Figure 4.). 
 
Figure 4. Effect of DPPIV-i on blood glucose (A) and insulin (B) levels in glucose-loaded SDT fatty rats. 
DPPIV-i was administered orally 30 min before glucose-loading (1g glucose/kg). The data are shown as 
the mean ± standard deviation (n=5). * P<0.05, ** P<0.01 significantly different from the control. #P<0.05, 
## P<0.01 significantly different from SD rat. 
Furthermore, we investigated the chronic effect of DPPIV-i in male SDT fatty rats. DPPIV-i 
(1, 10 mg/kg) was given as a dietary admixture in the powder diet for 4 weeks. Non-fasted 
blood glucose levels decreased dose-dependently after 3 weeks of administration with 
DPPIV-i, and the hemoglobin A1c (HbA1c) levels at 4 weeks after the administration tended 
to decrease (HbA1c level, control: 7.31 ± 0.22%, DPPIV-i 1 mg/kg: 6.99 ± 0.24%, DPPIV-i 10 
mg/kg: 7.03 ± 0.17%). There was no change in body weights during the experimental period. 
DPPIV-i is expected to control postprandial hyperglycemia in patients with type 2 diabetes 
mellitus without increasing body weight. SDT fatty rats at 9 weeks of age showed a prominent 
hyperglycemia after glucose-loading (Figure 4A.). The glucose levels at 30 and 60 min after 
glucose-loading in the SDT fatty rats significantly increased as compared with those in SD rats. 
Moreover, the insulin levels at 30 and 120 min after glucose-loading in the SDT fatty rats 
increased as compared with those in SD rats (Figure 4B.). The GSIS in SDT fatty rats was 
accelerated as compared with SD rats, suggesting that hyperinsulinemia (insulin resistance) 
exists in the SDT fatty rats at 9 weeks of age. In the other hand, the insulinogenic index in SDT 
fatty rats was lower than that in SD rats (SDT fatty rat, 0.021 ± 0.010, and SD rat, 0.112 ± 0.087, 
respectively). Glucose intolerance in SDT fatty rats is considered to be related with both the 
insulin resistance and the impaired insulin secretion. SDT fatty rat is available for purchace 
from CLEA Japan. 
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5. Conclusion 
There are many type 2 diabetic animal models, and they can be classified into the following 
three groups: non-obese T2D, obese T2D, and new type 2 diabetic models.  
Each of these models has different features as described above (Table 1.), and each model 
acts as an important tool for revealing the complex mechanisms of diabetes and developing 
new anti-diabetic drugs. Studies using diabetic animal models are especially essential to aid 
in clarification of the pathogenetic development in human T2D. On the other hand, these 
animal models do not exhibit the human characteristics perfectly. New T2D animal models 
that more closely resemble the human conditions are required for further investigation of 
the disease mechanisms in the future. 
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